3.4.21.78	Abortion, Spontaneous	https://pubmed.ncbi.nlm.nih.gov/19239428/	The role of TSP-1 on decidual macrophages involved in the susceptibility to unexplained recurrent spontaneous abortion.	causal interaction	1	
3.4.21.78	Abortion, Spontaneous	https://pubmed.ncbi.nlm.nih.gov/19239428/	The role of TSP-1 on decidual macrophages involved in the susceptibility to unexplained recurrent spontaneous abortion.	ongoing research	2	
3.4.21.78	Abortion, Spontaneous	https://pubmed.ncbi.nlm.nih.gov/19239428/	The role of TSP-1 on decidual macrophages involved in the susceptibility to unexplained recurrent spontaneous abortion.	unassigned	-	
3.4.21.78	Acquired Immunodeficiency Syndrome	https://pubmed.ncbi.nlm.nih.gov/24045574/	Thrombospondin-1 triggers macrophage IL-10 production and promotes resolution of experimental lung injury.	causal interaction	1	
3.4.21.78	Acquired Immunodeficiency Syndrome	https://pubmed.ncbi.nlm.nih.gov/24045574/	Thrombospondin-1 triggers macrophage IL-10 production and promotes resolution of experimental lung injury.	unassigned	-	
3.4.21.78	Acute Chest Syndrome	https://pubmed.ncbi.nlm.nih.gov/28609750/	Association of plasma CD40L with acute chest syndrome in sickle cell anemia.	causal interaction	3	
3.4.21.78	Acute Chest Syndrome	https://pubmed.ncbi.nlm.nih.gov/28609750/	Association of plasma CD40L with acute chest syndrome in sickle cell anemia.	diagnostic usage	2	
3.4.21.78	Acute Chest Syndrome	https://pubmed.ncbi.nlm.nih.gov/28609750/	Association of plasma CD40L with acute chest syndrome in sickle cell anemia.	unassigned	-	
3.4.21.78	Acute Kidney Injury	https://pubmed.ncbi.nlm.nih.gov/26155102/	Evaluation of complement regulatory components in patients with atypical hemolytic uremic syndrome.	diagnostic usage	1	
3.4.21.78	Acute Kidney Injury	https://pubmed.ncbi.nlm.nih.gov/33088624/	Heparin-binding protein as a novel biomarker for sepsis-related acute kidney injury.	diagnostic usage	3	
3.4.21.78	Acute Kidney Injury	https://pubmed.ncbi.nlm.nih.gov/21557788/	Reduction of natural killer and natural killer T cells is not protective in cisplatin-induced acute renal failure in mice.	ongoing research	1	
3.4.21.78	Acute Kidney Injury	https://pubmed.ncbi.nlm.nih.gov/26155102/	Evaluation of complement regulatory components in patients with atypical hemolytic uremic syndrome.	ongoing research	2	
3.4.21.78	Acute Kidney Injury	https://pubmed.ncbi.nlm.nih.gov/21557788/	Reduction of natural killer and natural killer T cells is not protective in cisplatin-induced acute renal failure in mice.	unassigned	-	
3.4.21.78	Acute Kidney Injury	https://pubmed.ncbi.nlm.nih.gov/26155102/	Evaluation of complement regulatory components in patients with atypical hemolytic uremic syndrome.	unassigned	-	
3.4.21.78	Acute Kidney Injury	https://pubmed.ncbi.nlm.nih.gov/33088624/	Heparin-binding protein as a novel biomarker for sepsis-related acute kidney injury.	unassigned	-	
3.4.21.78	Acute Lung Injury	https://pubmed.ncbi.nlm.nih.gov/11254536/	Fas/FasL-dependent apoptosis of alveolar cells after lipopolysaccharide-induced lung injury in mice.	therapeutic application	1	
3.4.21.78	Acute Lung Injury	https://pubmed.ncbi.nlm.nih.gov/11254536/	Fas/FasL-dependent apoptosis of alveolar cells after lipopolysaccharide-induced lung injury in mice.	ongoing research	4	
3.4.21.78	Acute Lung Injury	https://pubmed.ncbi.nlm.nih.gov/11254536/	Fas/FasL-dependent apoptosis of alveolar cells after lipopolysaccharide-induced lung injury in mice.	unassigned	-	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/9695745/	The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.	causal interaction	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/10719053/	Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma.	causal interaction	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/11253112/	Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density.	causal interaction	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	causal interaction	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/11882904/	Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production.	causal interaction	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/12429967/	Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma.	causal interaction	3	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/12443715/	Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer.	causal interaction	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/15172186/	Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.	causal interaction	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/18067717/	[Relationship between changes of serum concentrations of antiangiogenic factors and disease progression in patients of pancreatic carcinoma]	causal interaction	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	causal interaction	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/19747478/	Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: Exploring the functional significance in tumor cell invasion.	causal interaction	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/20631908/	Thrombospondin-1 (TSP-1) Stimulates Expression of Integrin alpha6 in Human Breast Carcinoma Cells: A Downstream Modulator of TSP-1-Induced Cellular Adhesion.	causal interaction	3	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/20950544/	[Expression of thrombospondin-1 and CD44 in human lung cancer tissues and their prognostic significance.]	causal interaction	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/25943461/	Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.	causal interaction	3	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/9695745/	The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.	diagnostic usage	3	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/10719053/	Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma.	diagnostic usage	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/11253112/	Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density.	diagnostic usage	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	diagnostic usage	3	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/11882904/	Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production.	diagnostic usage	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/11955648/	Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer.	diagnostic usage	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/12429967/	Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma.	diagnostic usage	3	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/12443715/	Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer.	diagnostic usage	3	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/15172186/	Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.	diagnostic usage	3	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/18067717/	[Relationship between changes of serum concentrations of antiangiogenic factors and disease progression in patients of pancreatic carcinoma]	diagnostic usage	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	diagnostic usage	3	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/19747478/	Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: Exploring the functional significance in tumor cell invasion.	diagnostic usage	1	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/20950544/	[Expression of thrombospondin-1 and CD44 in human lung cancer tissues and their prognostic significance.]	diagnostic usage	3	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/25943461/	Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.	diagnostic usage	2	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/10719053/	Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma.	therapeutic application	1	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/11253112/	Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density.	therapeutic application	1	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	therapeutic application	2	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/11882904/	Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production.	therapeutic application	1	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/12443715/	Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer.	therapeutic application	2	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/15172186/	Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.	therapeutic application	1	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	therapeutic application	1	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/20631908/	Thrombospondin-1 (TSP-1) Stimulates Expression of Integrin alpha6 in Human Breast Carcinoma Cells: A Downstream Modulator of TSP-1-Induced Cellular Adhesion.	therapeutic application	1	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/9695745/	The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.	ongoing research	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/10719053/	Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma.	ongoing research	2	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/11253112/	Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density.	ongoing research	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	ongoing research	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/11882904/	Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production.	ongoing research	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/11955648/	Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer.	ongoing research	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/12429967/	Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma.	ongoing research	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/12443715/	Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer.	ongoing research	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/15172186/	Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.	ongoing research	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/18067717/	[Relationship between changes of serum concentrations of antiangiogenic factors and disease progression in patients of pancreatic carcinoma]	ongoing research	2	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/19747478/	Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: Exploring the functional significance in tumor cell invasion.	ongoing research	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/20631908/	Thrombospondin-1 (TSP-1) Stimulates Expression of Integrin alpha6 in Human Breast Carcinoma Cells: A Downstream Modulator of TSP-1-Induced Cellular Adhesion.	ongoing research	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/20950544/	[Expression of thrombospondin-1 and CD44 in human lung cancer tissues and their prognostic significance.]	ongoing research	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/25943461/	Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.	ongoing research	4	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/11955648/	Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer.	unassigned	-	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/26222671/	Differential role of gene hypermethylation in adenocarcinomas, squamous cell carcinomas and cervical intraepithelial lesions of the uterine cervix.	unassigned	-	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/20631908/	Thrombospondin-1 (TSP-1) Stimulates Expression of Integrin alpha6 in Human Breast Carcinoma Cells: A Downstream Modulator of TSP-1-Induced Cellular Adhesion.	unassigned	-	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/9695745/	The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.	unassigned	-	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/12429967/	Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma.	unassigned	-	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/18067717/	[Relationship between changes of serum concentrations of antiangiogenic factors and disease progression in patients of pancreatic carcinoma]	unassigned	-	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/19747478/	Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: Exploring the functional significance in tumor cell invasion.	unassigned	-	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/20950544/	[Expression of thrombospondin-1 and CD44 in human lung cancer tissues and their prognostic significance.]	unassigned	-	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/25943461/	Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.	unassigned	-	
3.4.21.78	Adenocarcinoma	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	unassigned	-	
3.4.21.78	Adenocarcinoma of Lung	https://pubmed.ncbi.nlm.nih.gov/20950544/	[Expression of thrombospondin-1 and CD44 in human lung cancer tissues and their prognostic significance.]	causal interaction	4	
3.4.21.78	Adenocarcinoma of Lung	https://pubmed.ncbi.nlm.nih.gov/20950544/	[Expression of thrombospondin-1 and CD44 in human lung cancer tissues and their prognostic significance.]	diagnostic usage	3	
3.4.21.78	Adenocarcinoma of Lung	https://pubmed.ncbi.nlm.nih.gov/20950544/	[Expression of thrombospondin-1 and CD44 in human lung cancer tissues and their prognostic significance.]	ongoing research	4	
3.4.21.78	Adenocarcinoma of Lung	https://pubmed.ncbi.nlm.nih.gov/20950544/	[Expression of thrombospondin-1 and CD44 in human lung cancer tissues and their prognostic significance.]	unassigned	-	
3.4.21.78	Adenocarcinoma, Follicular	https://pubmed.ncbi.nlm.nih.gov/18321763/	Thrombospondin-1 enhances human thyroid carcinoma cell invasion through urokinase activity.	diagnostic usage	2	
3.4.21.78	Adenocarcinoma, Follicular	https://pubmed.ncbi.nlm.nih.gov/18321763/	Thrombospondin-1 enhances human thyroid carcinoma cell invasion through urokinase activity.	ongoing research	4	
3.4.21.78	Adenocarcinoma, Follicular	https://pubmed.ncbi.nlm.nih.gov/18321763/	Thrombospondin-1 enhances human thyroid carcinoma cell invasion through urokinase activity.	unassigned	-	
3.4.21.78	Adenoma	https://pubmed.ncbi.nlm.nih.gov/12584168/	Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model.	causal interaction	4	
3.4.21.78	Adenoma	https://pubmed.ncbi.nlm.nih.gov/16258261/	Wnt signaling can repress thrombospondin-1 expression in colonic tumorigenesis.	causal interaction	4	
3.4.21.78	Adenoma	https://pubmed.ncbi.nlm.nih.gov/12584168/	Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model.	diagnostic usage	2	
3.4.21.78	Adenoma	https://pubmed.ncbi.nlm.nih.gov/12584168/	Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model.	therapeutic application	1	
3.4.21.78	Adenoma	https://pubmed.ncbi.nlm.nih.gov/16258261/	Wnt signaling can repress thrombospondin-1 expression in colonic tumorigenesis.	therapeutic application	4	
3.4.21.78	Adenoma	https://pubmed.ncbi.nlm.nih.gov/12584168/	Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model.	ongoing research	3	
3.4.21.78	Adenoma	https://pubmed.ncbi.nlm.nih.gov/16258261/	Wnt signaling can repress thrombospondin-1 expression in colonic tumorigenesis.	ongoing research	3	
3.4.21.78	Adenoma	https://pubmed.ncbi.nlm.nih.gov/16258261/	Wnt signaling can repress thrombospondin-1 expression in colonic tumorigenesis.	unassigned	-	
3.4.21.78	Airway Obstruction	https://pubmed.ncbi.nlm.nih.gov/34323115/	Low Dose Hyperoxia Primes Airways for Fibrosis in Mice after Influenza A Infection.	causal interaction	4	
3.4.21.78	Airway Obstruction	https://pubmed.ncbi.nlm.nih.gov/34323115/	Low Dose Hyperoxia Primes Airways for Fibrosis in Mice after Influenza A Infection.	diagnostic usage	3	
3.4.21.78	Airway Obstruction	https://pubmed.ncbi.nlm.nih.gov/34323115/	Low Dose Hyperoxia Primes Airways for Fibrosis in Mice after Influenza A Infection.	therapeutic application	1	
3.4.21.78	Airway Obstruction	https://pubmed.ncbi.nlm.nih.gov/34323115/	Low Dose Hyperoxia Primes Airways for Fibrosis in Mice after Influenza A Infection.	unassigned	-	
3.4.21.78	Alzheimer Disease	https://pubmed.ncbi.nlm.nih.gov/23860027/	Amyloid-? inhibits thrombospondin 1 release from cultured astrocytes: effects on synaptic protein expression.	therapeutic application	4	
3.4.21.78	Alzheimer Disease	https://pubmed.ncbi.nlm.nih.gov/23860027/	Amyloid-? inhibits thrombospondin 1 release from cultured astrocytes: effects on synaptic protein expression.	unassigned	-	
3.4.21.78	Anemia	https://pubmed.ncbi.nlm.nih.gov/8602630/	Disturbance of plasma and platelet thrombospondin levels in sickle cell disease.	causal interaction	2	
3.4.21.78	Anemia	https://pubmed.ncbi.nlm.nih.gov/8602630/	Disturbance of plasma and platelet thrombospondin levels in sickle cell disease.	diagnostic usage	4	
3.4.21.78	Anemia	https://pubmed.ncbi.nlm.nih.gov/8602630/	Disturbance of plasma and platelet thrombospondin levels in sickle cell disease.	ongoing research	2	
3.4.21.78	Anemia	https://pubmed.ncbi.nlm.nih.gov/8602630/	Disturbance of plasma and platelet thrombospondin levels in sickle cell disease.	unassigned	-	
3.4.21.78	Anemia, Hemolytic	https://pubmed.ncbi.nlm.nih.gov/26155102/	Evaluation of complement regulatory components in patients with atypical hemolytic uremic syndrome.	diagnostic usage	1	
3.4.21.78	Anemia, Hemolytic	https://pubmed.ncbi.nlm.nih.gov/26155102/	Evaluation of complement regulatory components in patients with atypical hemolytic uremic syndrome.	ongoing research	2	
3.4.21.78	Anemia, Hemolytic	https://pubmed.ncbi.nlm.nih.gov/26155102/	Evaluation of complement regulatory components in patients with atypical hemolytic uremic syndrome.	unassigned	-	
3.4.21.78	Anemia, Sickle Cell	https://pubmed.ncbi.nlm.nih.gov/8602630/	Disturbance of plasma and platelet thrombospondin levels in sickle cell disease.	causal interaction	2	
3.4.21.78	Anemia, Sickle Cell	https://pubmed.ncbi.nlm.nih.gov/8602630/	Disturbance of plasma and platelet thrombospondin levels in sickle cell disease.	diagnostic usage	4	
3.4.21.78	Anemia, Sickle Cell	https://pubmed.ncbi.nlm.nih.gov/32987383/	Relationship of Thrombospondin 1 to von Willebrand Factor and ADAMTS-13 in Sickle Cell Disease Patients of Arab Ethnicity.	diagnostic usage	3	
3.4.21.78	Anemia, Sickle Cell	https://pubmed.ncbi.nlm.nih.gov/8602630/	Disturbance of plasma and platelet thrombospondin levels in sickle cell disease.	ongoing research	2	
3.4.21.78	Anemia, Sickle Cell	https://pubmed.ncbi.nlm.nih.gov/32987383/	Relationship of Thrombospondin 1 to von Willebrand Factor and ADAMTS-13 in Sickle Cell Disease Patients of Arab Ethnicity.	unassigned	-	
3.4.21.78	Anemia, Sickle Cell	https://pubmed.ncbi.nlm.nih.gov/8602630/	Disturbance of plasma and platelet thrombospondin levels in sickle cell disease.	unassigned	-	
3.4.21.78	Aneurysm, Dissecting	https://pubmed.ncbi.nlm.nih.gov/30595182/	Thrombospondin 1 Is Increased in the Aorta and Plasma of Patients With Acute Aortic Dissection.	ongoing research	1	
3.4.21.78	Aneurysm, Dissecting	https://pubmed.ncbi.nlm.nih.gov/30595182/	Thrombospondin 1 Is Increased in the Aorta and Plasma of Patients With Acute Aortic Dissection.	unassigned	-	
3.4.21.78	Aortic Aneurysm	https://pubmed.ncbi.nlm.nih.gov/28592701/	Thrombospondin-1 contributes to slower aortic aneurysm growth by inhibiting maladaptive remodeling of extracellular matrix.	causal interaction	4	
3.4.21.78	Aortic Aneurysm	https://pubmed.ncbi.nlm.nih.gov/28592701/	Thrombospondin-1 contributes to slower aortic aneurysm growth by inhibiting maladaptive remodeling of extracellular matrix.	therapeutic application	1	
3.4.21.78	Aortic Aneurysm	https://pubmed.ncbi.nlm.nih.gov/28592701/	Thrombospondin-1 contributes to slower aortic aneurysm growth by inhibiting maladaptive remodeling of extracellular matrix.	ongoing research	3	
3.4.21.78	Aortic Aneurysm	https://pubmed.ncbi.nlm.nih.gov/28592701/	Thrombospondin-1 contributes to slower aortic aneurysm growth by inhibiting maladaptive remodeling of extracellular matrix.	unassigned	-	
3.4.21.78	Aortic Valve Stenosis	https://pubmed.ncbi.nlm.nih.gov/23074998/	Thrombospondins, potential drug targets for cardiovascular diseases.	causal interaction	3	
3.4.21.78	Aortic Valve Stenosis	https://pubmed.ncbi.nlm.nih.gov/23074998/	Thrombospondins, potential drug targets for cardiovascular diseases.	therapeutic application	4	
3.4.21.78	Aortic Valve Stenosis	https://pubmed.ncbi.nlm.nih.gov/23074998/	Thrombospondins, potential drug targets for cardiovascular diseases.	unassigned	-	
3.4.21.78	Arteriovenous Malformations	https://pubmed.ncbi.nlm.nih.gov/32723034/	Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.	causal interaction	1	
3.4.21.78	Arteriovenous Malformations	https://pubmed.ncbi.nlm.nih.gov/32723034/	Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.	ongoing research	1	
3.4.21.78	Arteriovenous Malformations	https://pubmed.ncbi.nlm.nih.gov/32723034/	Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.	unassigned	-	
3.4.21.78	Arthritis	https://pubmed.ncbi.nlm.nih.gov/27598995/	Granzyme A contributes to inflammatory arthritis through stimulation of osteoclastogenesis.	causal interaction	3	
3.4.21.78	Arthritis	https://pubmed.ncbi.nlm.nih.gov/27598995/	Granzyme A contributes to inflammatory arthritis through stimulation of osteoclastogenesis.	therapeutic application	1	
3.4.21.78	Arthritis	https://pubmed.ncbi.nlm.nih.gov/9473383/	Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis.	ongoing research	4	
3.4.21.78	Arthritis	https://pubmed.ncbi.nlm.nih.gov/9473383/	Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis.	unassigned	-	
3.4.21.78	Arthritis	https://pubmed.ncbi.nlm.nih.gov/27598995/	Granzyme A contributes to inflammatory arthritis through stimulation of osteoclastogenesis.	unassigned	-	
3.4.21.78	Arthritis, Experimental	https://pubmed.ncbi.nlm.nih.gov/15641039/	Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis.	causal interaction	4	
3.4.21.78	Arthritis, Experimental	https://pubmed.ncbi.nlm.nih.gov/15641039/	Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis.	therapeutic application	4	
3.4.21.78	Arthritis, Experimental	https://pubmed.ncbi.nlm.nih.gov/15641039/	Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis.	ongoing research	4	
3.4.21.78	Arthritis, Experimental	https://pubmed.ncbi.nlm.nih.gov/15641039/	Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis.	unassigned	-	
3.4.21.78	Arthritis, Rheumatoid	https://pubmed.ncbi.nlm.nih.gov/7536415/	Demonstration of granzyme A and perforin messenger RNA in the synovium of patients with rheumatoid arthritis.	causal interaction	4	
3.4.21.78	Arthritis, Rheumatoid	https://pubmed.ncbi.nlm.nih.gov/10337032/	The levels of soluble granzyme A and B are elevated in plasma and synovial fluid of patients with rheumatoid arthritis (RA).	causal interaction	3	
3.4.21.78	Arthritis, Rheumatoid	https://pubmed.ncbi.nlm.nih.gov/15641039/	Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis.	causal interaction	4	
3.4.21.78	Arthritis, Rheumatoid	https://pubmed.ncbi.nlm.nih.gov/25501558/	Thrombospondin-1 production is enhanced by Porphyromonas gingivalis lipopolysaccharide in THP-1 cells.	causal interaction	4	
3.4.21.78	Arthritis, Rheumatoid	https://pubmed.ncbi.nlm.nih.gov/1731326/	Perforin and granzyme A expression identifying cytolytic lymphocytes in rheumatoid arthritis.	diagnostic usage	3	
3.4.21.78	Arthritis, Rheumatoid	https://pubmed.ncbi.nlm.nih.gov/7536415/	Demonstration of granzyme A and perforin messenger RNA in the synovium of patients with rheumatoid arthritis.	diagnostic usage	1	
3.4.21.78	Arthritis, Rheumatoid	https://pubmed.ncbi.nlm.nih.gov/10337032/	The levels of soluble granzyme A and B are elevated in plasma and synovial fluid of patients with rheumatoid arthritis (RA).	diagnostic usage	4	
3.4.21.78	Arthritis, Rheumatoid	https://pubmed.ncbi.nlm.nih.gov/23933487/	Tumor Necrosis Factor Inhibition Modulates Thrombospondin-1 Expression in Human Inflammatory Joint Disease through Altered NR4A2 Activity.	diagnostic usage	3	
3.4.21.78	Arthritis, Rheumatoid	https://pubmed.ncbi.nlm.nih.gov/25501558/	Thrombospondin-1 production is enhanced by Porphyromonas gingivalis lipopolysaccharide in THP-1 cells.	diagnostic usage	3	
3.4.21.78	Arthritis, Rheumatoid	https://pubmed.ncbi.nlm.nih.gov/15641039/	Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis.	therapeutic application	4	
3.4.21.78	Arthritis, Rheumatoid	https://pubmed.ncbi.nlm.nih.gov/25501558/	Thrombospondin-1 production is enhanced by Porphyromonas gingivalis lipopolysaccharide in THP-1 cells.	therapeutic application	1	
3.4.21.78	Arthritis, Rheumatoid	https://pubmed.ncbi.nlm.nih.gov/1731326/	Perforin and granzyme A expression identifying cytolytic lymphocytes in rheumatoid arthritis.	ongoing research	2	
3.4.21.78	Arthritis, Rheumatoid	https://pubmed.ncbi.nlm.nih.gov/7536415/	Demonstration of granzyme A and perforin messenger RNA in the synovium of patients with rheumatoid arthritis.	ongoing research	2	
3.4.21.78	Arthritis, Rheumatoid	https://pubmed.ncbi.nlm.nih.gov/15641039/	Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis.	ongoing research	4	
3.4.21.78	Arthritis, Rheumatoid	https://pubmed.ncbi.nlm.nih.gov/23933487/	Tumor Necrosis Factor Inhibition Modulates Thrombospondin-1 Expression in Human Inflammatory Joint Disease through Altered NR4A2 Activity.	ongoing research	3	
3.4.21.78	Arthritis, Rheumatoid	https://pubmed.ncbi.nlm.nih.gov/25501558/	Thrombospondin-1 production is enhanced by Porphyromonas gingivalis lipopolysaccharide in THP-1 cells.	ongoing research	4	
3.4.21.78	Arthritis, Rheumatoid	https://pubmed.ncbi.nlm.nih.gov/1731326/	Perforin and granzyme A expression identifying cytolytic lymphocytes in rheumatoid arthritis.	unassigned	-	
3.4.21.78	Arthritis, Rheumatoid	https://pubmed.ncbi.nlm.nih.gov/23933487/	Tumor Necrosis Factor Inhibition Modulates Thrombospondin-1 Expression in Human Inflammatory Joint Disease through Altered NR4A2 Activity.	unassigned	-	
3.4.21.78	Arthritis, Rheumatoid	https://pubmed.ncbi.nlm.nih.gov/15641039/	Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis.	unassigned	-	
3.4.21.78	Arthritis, Rheumatoid	https://pubmed.ncbi.nlm.nih.gov/7536415/	Demonstration of granzyme A and perforin messenger RNA in the synovium of patients with rheumatoid arthritis.	unassigned	-	
3.4.21.78	Arthritis, Rheumatoid	https://pubmed.ncbi.nlm.nih.gov/10337032/	The levels of soluble granzyme A and B are elevated in plasma and synovial fluid of patients with rheumatoid arthritis (RA).	unassigned	-	
3.4.21.78	Asbestosis	https://pubmed.ncbi.nlm.nih.gov/33197421/	Exploration of identifying novel serum biomarkers for malignant mesothelioma using iTRAQ combined with 2D-LC-MS/MS.	causal interaction	3	
3.4.21.78	Asbestosis	https://pubmed.ncbi.nlm.nih.gov/33197421/	Exploration of identifying novel serum biomarkers for malignant mesothelioma using iTRAQ combined with 2D-LC-MS/MS.	diagnostic usage	4	
3.4.21.78	Asbestosis	https://pubmed.ncbi.nlm.nih.gov/33197421/	Exploration of identifying novel serum biomarkers for malignant mesothelioma using iTRAQ combined with 2D-LC-MS/MS.	ongoing research	2	
3.4.21.78	Asbestosis	https://pubmed.ncbi.nlm.nih.gov/33197421/	Exploration of identifying novel serum biomarkers for malignant mesothelioma using iTRAQ combined with 2D-LC-MS/MS.	unassigned	-	
3.4.21.78	Asthma	https://pubmed.ncbi.nlm.nih.gov/27578480/	Increased angiogenic factors in exhaled breath condensate of children with severe asthma - New markers of disease progression?	causal interaction	4	
3.4.21.78	Asthma	https://pubmed.ncbi.nlm.nih.gov/29545867/	TIPE2 is negatively correlated with tissue factor and thrombospondin-1 expression in patients with bronchial asthma.	causal interaction	4	
3.4.21.78	Asthma	https://pubmed.ncbi.nlm.nih.gov/23702636/	Granule Cytotoxic Activity and Oxidative DNA Damage in Smoking and Nonsmoking Patients With Asthma.	diagnostic usage	3	
3.4.21.78	Asthma	https://pubmed.ncbi.nlm.nih.gov/29545867/	TIPE2 is negatively correlated with tissue factor and thrombospondin-1 expression in patients with bronchial asthma.	diagnostic usage	4	
3.4.21.78	Asthma	https://pubmed.ncbi.nlm.nih.gov/23702636/	Granule Cytotoxic Activity and Oxidative DNA Damage in Smoking and Nonsmoking Patients With Asthma.	ongoing research	2	
3.4.21.78	Asthma	https://pubmed.ncbi.nlm.nih.gov/27578480/	Increased angiogenic factors in exhaled breath condensate of children with severe asthma - New markers of disease progression?	ongoing research	2	
3.4.21.78	Asthma	https://pubmed.ncbi.nlm.nih.gov/29545867/	TIPE2 is negatively correlated with tissue factor and thrombospondin-1 expression in patients with bronchial asthma.	ongoing research	2	
3.4.21.78	Asthma	https://pubmed.ncbi.nlm.nih.gov/23702636/	Granule Cytotoxic Activity and Oxidative DNA Damage in Smoking and Nonsmoking Patients With Asthma.	unassigned	-	
3.4.21.78	Asthma	https://pubmed.ncbi.nlm.nih.gov/28783702/	Natural killer cell-mediated inflammation resolution is disabled in severe asthma.	unassigned	-	
3.4.21.78	Asthma	https://pubmed.ncbi.nlm.nih.gov/27578480/	Increased angiogenic factors in exhaled breath condensate of children with severe asthma - New markers of disease progression?	unassigned	-	
3.4.21.78	Asthma	https://pubmed.ncbi.nlm.nih.gov/29545867/	TIPE2 is negatively correlated with tissue factor and thrombospondin-1 expression in patients with bronchial asthma.	unassigned	-	
3.4.21.78	Astrocytoma	https://pubmed.ncbi.nlm.nih.gov/10328956/	Retinoic acid alters the mechanism of attachment of malignant astrocytoma and neuroblastoma cells to thrombospondin-1.	causal interaction	1	
3.4.21.78	Astrocytoma	https://pubmed.ncbi.nlm.nih.gov/10393860/	Human cytomegalovirus infection decreases expression of thrombospondin-1 independent of the tumor suppressor protein p53.	causal interaction	4	
3.4.21.78	Astrocytoma	https://pubmed.ncbi.nlm.nih.gov/11132930/	Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma.	causal interaction	4	
3.4.21.78	Astrocytoma	https://pubmed.ncbi.nlm.nih.gov/10393860/	Human cytomegalovirus infection decreases expression of thrombospondin-1 independent of the tumor suppressor protein p53.	diagnostic usage	3	
3.4.21.78	Astrocytoma	https://pubmed.ncbi.nlm.nih.gov/11132930/	Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma.	diagnostic usage	3	
3.4.21.78	Astrocytoma	https://pubmed.ncbi.nlm.nih.gov/10393860/	Human cytomegalovirus infection decreases expression of thrombospondin-1 independent of the tumor suppressor protein p53.	therapeutic application	1	
3.4.21.78	Astrocytoma	https://pubmed.ncbi.nlm.nih.gov/11132930/	Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma.	therapeutic application	1	
3.4.21.78	Astrocytoma	https://pubmed.ncbi.nlm.nih.gov/10328956/	Retinoic acid alters the mechanism of attachment of malignant astrocytoma and neuroblastoma cells to thrombospondin-1.	ongoing research	4	
3.4.21.78	Astrocytoma	https://pubmed.ncbi.nlm.nih.gov/10393860/	Human cytomegalovirus infection decreases expression of thrombospondin-1 independent of the tumor suppressor protein p53.	ongoing research	4	
3.4.21.78	Astrocytoma	https://pubmed.ncbi.nlm.nih.gov/11132930/	Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma.	ongoing research	4	
3.4.21.78	Astrocytoma	https://pubmed.ncbi.nlm.nih.gov/10328956/	Retinoic acid alters the mechanism of attachment of malignant astrocytoma and neuroblastoma cells to thrombospondin-1.	unassigned	-	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/28345659/	Oral chromium picolinate impedes hyperglycemia-induced atherosclerosis and inhibits proatherogenic protein TSP-1 expression in STZ-induced type 1 diabetic ApoE(-/-) mice.	causal interaction	4	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/33327743/	TSP-1 (Thrombospondin-1) Deficiency Protects ApoE-/- Mice Against Leptin-Induced Atherosclerosis.	causal interaction	4	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/12810612/	Increased expression of thrombospondin-1 in vessel wall of diabetic Zucker rat.	causal interaction	4	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/18311056/	[The role of thrombospondin-1 in hypoxia-induced migration of human vascular smooth muscle cells]	causal interaction	3	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/20233213/	Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase.	causal interaction	4	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/20299182/	Thrombospondin-1: a proatherosclerotic protein augmented by hyperglycemia.	causal interaction	4	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/23074998/	Thrombospondins, potential drug targets for cardiovascular diseases.	causal interaction	3	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/32733941/	Recent Advancements in CD47 Signal Transduction Pathways Involved in Vascular Diseases.	causal interaction	3	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/20299182/	Thrombospondin-1: a proatherosclerotic protein augmented by hyperglycemia.	diagnostic usage	3	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/22396697/	Higher plasma thrombospondin-1 levels in patients with coronary artery disease and diabetes mellitus.	diagnostic usage	3	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/33612457/	C3 and alternative pathway components are associated with an adverse lipoprotein subclass profile: The CODAM study.	diagnostic usage	1	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/28345659/	Oral chromium picolinate impedes hyperglycemia-induced atherosclerosis and inhibits proatherogenic protein TSP-1 expression in STZ-induced type 1 diabetic ApoE(-/-) mice.	therapeutic application	4	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/33327743/	TSP-1 (Thrombospondin-1) Deficiency Protects ApoE-/- Mice Against Leptin-Induced Atherosclerosis.	therapeutic application	2	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/20233213/	Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase.	therapeutic application	3	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/20299182/	Thrombospondin-1: a proatherosclerotic protein augmented by hyperglycemia.	therapeutic application	3	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/23074998/	Thrombospondins, potential drug targets for cardiovascular diseases.	therapeutic application	4	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/28345659/	Oral chromium picolinate impedes hyperglycemia-induced atherosclerosis and inhibits proatherogenic protein TSP-1 expression in STZ-induced type 1 diabetic ApoE(-/-) mice.	ongoing research	2	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/33327743/	TSP-1 (Thrombospondin-1) Deficiency Protects ApoE-/- Mice Against Leptin-Induced Atherosclerosis.	ongoing research	3	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/9489988/	Immunolocalization of thrombospondin-1 in human atherosclerotic and restenotic arteries.	ongoing research	1	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/9536966/	Thrombospondin-1 is elevated with both intimal hyperplasia and hypercholesterolemia.	ongoing research	3	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/20299182/	Thrombospondin-1: a proatherosclerotic protein augmented by hyperglycemia.	ongoing research	2	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/22396697/	Higher plasma thrombospondin-1 levels in patients with coronary artery disease and diabetes mellitus.	ongoing research	4	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/33612457/	C3 and alternative pathway components are associated with an adverse lipoprotein subclass profile: The CODAM study.	ongoing research	2	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/9489988/	Immunolocalization of thrombospondin-1 in human atherosclerotic and restenotic arteries.	unassigned	-	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/9536966/	Thrombospondin-1 is elevated with both intimal hyperplasia and hypercholesterolemia.	unassigned	-	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/18178577/	Polymorphisms in thrombospondin genes and myocardial infarction: a case-control study and a meta-analysis of available evidence.	unassigned	-	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/22396697/	Higher plasma thrombospondin-1 levels in patients with coronary artery disease and diabetes mellitus.	unassigned	-	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/33612457/	C3 and alternative pathway components are associated with an adverse lipoprotein subclass profile: The CODAM study.	unassigned	-	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/28345659/	Oral chromium picolinate impedes hyperglycemia-induced atherosclerosis and inhibits proatherogenic protein TSP-1 expression in STZ-induced type 1 diabetic ApoE(-/-) mice.	unassigned	-	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/33327743/	TSP-1 (Thrombospondin-1) Deficiency Protects ApoE-/- Mice Against Leptin-Induced Atherosclerosis.	unassigned	-	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/12810612/	Increased expression of thrombospondin-1 in vessel wall of diabetic Zucker rat.	unassigned	-	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/18311056/	[The role of thrombospondin-1 in hypoxia-induced migration of human vascular smooth muscle cells]	unassigned	-	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/20233213/	Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase.	unassigned	-	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/23074998/	Thrombospondins, potential drug targets for cardiovascular diseases.	unassigned	-	
3.4.21.78	Atherosclerosis	https://pubmed.ncbi.nlm.nih.gov/32733941/	Recent Advancements in CD47 Signal Transduction Pathways Involved in Vascular Diseases.	unassigned	-	
3.4.21.78	Atypical Hemolytic Uremic Syndrome	https://pubmed.ncbi.nlm.nih.gov/21496552/	Postoperative thrombotic thrombocytopenic purpura in an infant: case report and literature review.	causal interaction	1	
3.4.21.78	Atypical Hemolytic Uremic Syndrome	https://pubmed.ncbi.nlm.nih.gov/24824395/	[Clinical characteristies of atypical hemolytie uremic syndrome associated with H factor antibody in children].	causal interaction	1	
3.4.21.78	Atypical Hemolytic Uremic Syndrome	https://pubmed.ncbi.nlm.nih.gov/25037634/	Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach.	causal interaction	4	
3.4.21.78	Atypical Hemolytic Uremic Syndrome	https://pubmed.ncbi.nlm.nih.gov/24824395/	[Clinical characteristies of atypical hemolytie uremic syndrome associated with H factor antibody in children].	diagnostic usage	3	
3.4.21.78	Atypical Hemolytic Uremic Syndrome	https://pubmed.ncbi.nlm.nih.gov/26155102/	Evaluation of complement regulatory components in patients with atypical hemolytic uremic syndrome.	diagnostic usage	1	
3.4.21.78	Atypical Hemolytic Uremic Syndrome	https://pubmed.ncbi.nlm.nih.gov/24824395/	[Clinical characteristies of atypical hemolytie uremic syndrome associated with H factor antibody in children].	therapeutic application	4	
3.4.21.78	Atypical Hemolytic Uremic Syndrome	https://pubmed.ncbi.nlm.nih.gov/24824395/	[Clinical characteristies of atypical hemolytie uremic syndrome associated with H factor antibody in children].	ongoing research	2	
3.4.21.78	Atypical Hemolytic Uremic Syndrome	https://pubmed.ncbi.nlm.nih.gov/26155102/	Evaluation of complement regulatory components in patients with atypical hemolytic uremic syndrome.	ongoing research	2	
3.4.21.78	Atypical Hemolytic Uremic Syndrome	https://pubmed.ncbi.nlm.nih.gov/16575691/	A user's guide to the interactive Web database of factor H-associated hemolytic uremic syndrome.	unassigned	-	
3.4.21.78	Atypical Hemolytic Uremic Syndrome	https://pubmed.ncbi.nlm.nih.gov/18423815/	Mutations in proteins of the alternative pathway of complement and the pathogenesis of atypical hemolytic uremic syndrome.	unassigned	-	
3.4.21.78	Atypical Hemolytic Uremic Syndrome	https://pubmed.ncbi.nlm.nih.gov/26155102/	Evaluation of complement regulatory components in patients with atypical hemolytic uremic syndrome.	unassigned	-	
3.4.21.78	Atypical Hemolytic Uremic Syndrome	https://pubmed.ncbi.nlm.nih.gov/21496552/	Postoperative thrombotic thrombocytopenic purpura in an infant: case report and literature review.	unassigned	-	
3.4.21.78	Atypical Hemolytic Uremic Syndrome	https://pubmed.ncbi.nlm.nih.gov/25037634/	Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach.	unassigned	-	
3.4.21.78	Brain Diseases	https://pubmed.ncbi.nlm.nih.gov/31709864/	Granzyme A Participates in the Pathogenesis of Infection-Associated Acute Encephalopathy.	causal interaction	3	
3.4.21.78	Brain Diseases	https://pubmed.ncbi.nlm.nih.gov/31709864/	Granzyme A Participates in the Pathogenesis of Infection-Associated Acute Encephalopathy.	diagnostic usage	1	
3.4.21.78	Brain Diseases	https://pubmed.ncbi.nlm.nih.gov/31709864/	Granzyme A Participates in the Pathogenesis of Infection-Associated Acute Encephalopathy.	therapeutic application	1	
3.4.21.78	Brain Diseases	https://pubmed.ncbi.nlm.nih.gov/31709864/	Granzyme A Participates in the Pathogenesis of Infection-Associated Acute Encephalopathy.	unassigned	-	
3.4.21.78	Brain Injuries	https://pubmed.ncbi.nlm.nih.gov/20091789/	Type IV collagen induces expression of thrombospondin-1 that is mediated by integrin alpha1beta1 in astrocytes.	diagnostic usage	1	
3.4.21.78	Brain Injuries	https://pubmed.ncbi.nlm.nih.gov/20091789/	Type IV collagen induces expression of thrombospondin-1 that is mediated by integrin alpha1beta1 in astrocytes.	ongoing research	2	
3.4.21.78	Brain Injuries	https://pubmed.ncbi.nlm.nih.gov/20091789/	Type IV collagen induces expression of thrombospondin-1 that is mediated by integrin alpha1beta1 in astrocytes.	unassigned	-	
3.4.21.78	Brain Injuries	https://pubmed.ncbi.nlm.nih.gov/22776902/	Trauma-induced expression of astrocytic thrombospondin-1 is regulated by P2 receptors coupled to protein kinase cascades.	unassigned	-	
3.4.21.78	Brain Injuries, Traumatic	https://pubmed.ncbi.nlm.nih.gov/26521864/	Plasma thrombospondin-1 and clinical outcomes in traumatic brain injury.	causal interaction	4	
3.4.21.78	Brain Injuries, Traumatic	https://pubmed.ncbi.nlm.nih.gov/26521864/	Plasma thrombospondin-1 and clinical outcomes in traumatic brain injury.	diagnostic usage	4	
3.4.21.78	Brain Injuries, Traumatic	https://pubmed.ncbi.nlm.nih.gov/26521864/	Plasma thrombospondin-1 and clinical outcomes in traumatic brain injury.	ongoing research	4	
3.4.21.78	Brain Injuries, Traumatic	https://pubmed.ncbi.nlm.nih.gov/22776902/	Trauma-induced expression of astrocytic thrombospondin-1 is regulated by P2 receptors coupled to protein kinase cascades.	unassigned	-	
3.4.21.78	Brain Injuries, Traumatic	https://pubmed.ncbi.nlm.nih.gov/28924363/	Thrombospondin-1 Gene Deficiency Worsens the Neurological Outcomes of Traumatic Brain Injury in Mice.	unassigned	-	
3.4.21.78	Brain Injuries, Traumatic	https://pubmed.ncbi.nlm.nih.gov/26521864/	Plasma thrombospondin-1 and clinical outcomes in traumatic brain injury.	unassigned	-	
3.4.21.78	Brain Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20305695/	Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors.	ongoing research	4	
3.4.21.78	Brain Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20305695/	Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/29212212/	ADAMTS1-mediated targeting of TSP-1 by PPAR? suppresses migration and invasion of breast cancer cells.	causal interaction	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/8661169/	Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer.	causal interaction	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/8751617/	Inhibition of breast cancer progression by an antibody to a thrombospondin-1 receptor.	causal interaction	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9288157/	Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system.	causal interaction	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9302563/	Histopathology and clinical assessment correlate with the cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) receptor of thrombospondin-1 in breast tumors.	causal interaction	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10090848/	Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.	causal interaction	2	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12219015/	Fibroblasts promote breast cancer cell invasion by upregulating tumor matrix metalloproteinase-9 production.	causal interaction	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12814189/	Evidence of a bi-phasic effect of thrombospondin-1 on angiogenesis.	causal interaction	1	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	causal interaction	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15838828/	Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo.	causal interaction	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17912439/	Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer.	causal interaction	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17912446/	Effects of alpha-difluoromethylornithine on thrombospondin-1 production by human breast cancer cells.	causal interaction	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19391135/	Estrogen regulation of thrombospondin-1 in human breast cancer cells.	causal interaction	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19570906/	Regulation of thrombospondin-1 by natural and synthetic progestins in human breast cancer cells.	causal interaction	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19747478/	Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: Exploring the functional significance in tumor cell invasion.	causal interaction	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20370578/	Fibroblast growth factor 8 induced downregulation of thrombospondin 1 is mediated by the MEK/ERK and PI3K pathways in breast cancer cells.	causal interaction	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20631908/	Thrombospondin-1 (TSP-1) Stimulates Expression of Integrin alpha6 in Human Breast Carcinoma Cells: A Downstream Modulator of TSP-1-Induced Cellular Adhesion.	causal interaction	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21155598/	Differential proteomic analysis of late-stage and recurrent breast cancer from formalin-fixed paraffin-embedded tissues.	causal interaction	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22207555/	Thrombospondin-1 expression in breast cancer: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.	causal interaction	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24120914/	Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: Implications for tumor angiogenesis.	causal interaction	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25552929/	Decrease of let-7f in low-dose metronomic Paclitaxel chemotherapy contributed to upregulation of thrombospondin-1 in breast cancer.	causal interaction	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26273699/	Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro.	causal interaction	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/28274095/	Sphingosylphosphorylcholine Induces Thrombospondin-1 Secretion in MCF10A Cells via ERK2.	causal interaction	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31750826/	[The poor prognosis is correlated with the high expression of vascular endothelial growth factor (VEGF) and low expression of thrombospondin 1 (TSP-1) in patients with breast cancer].	causal interaction	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32600280/	Role of TSP-1 as prognostic marker in various cancers: a systematic review and meta-analysis.	causal interaction	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32723034/	Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.	causal interaction	1	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/8751617/	Inhibition of breast cancer progression by an antibody to a thrombospondin-1 receptor.	diagnostic usage	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9288157/	Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system.	diagnostic usage	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9302563/	Histopathology and clinical assessment correlate with the cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) receptor of thrombospondin-1 in breast tumors.	diagnostic usage	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10090848/	Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.	diagnostic usage	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12219015/	Fibroblasts promote breast cancer cell invasion by upregulating tumor matrix metalloproteinase-9 production.	diagnostic usage	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12814189/	Evidence of a bi-phasic effect of thrombospondin-1 on angiogenesis.	diagnostic usage	2	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	diagnostic usage	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15838828/	Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo.	diagnostic usage	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17912439/	Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer.	diagnostic usage	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19747478/	Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: Exploring the functional significance in tumor cell invasion.	diagnostic usage	1	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20370578/	Fibroblast growth factor 8 induced downregulation of thrombospondin 1 is mediated by the MEK/ERK and PI3K pathways in breast cancer cells.	diagnostic usage	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21155598/	Differential proteomic analysis of late-stage and recurrent breast cancer from formalin-fixed paraffin-embedded tissues.	diagnostic usage	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22207555/	Thrombospondin-1 expression in breast cancer: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.	diagnostic usage	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24120914/	Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: Implications for tumor angiogenesis.	diagnostic usage	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25521357/	Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.	diagnostic usage	2	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/28274095/	Sphingosylphosphorylcholine Induces Thrombospondin-1 Secretion in MCF10A Cells via ERK2.	diagnostic usage	2	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31750826/	[The poor prognosis is correlated with the high expression of vascular endothelial growth factor (VEGF) and low expression of thrombospondin 1 (TSP-1) in patients with breast cancer].	diagnostic usage	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32600280/	Role of TSP-1 as prognostic marker in various cancers: a systematic review and meta-analysis.	diagnostic usage	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/29212212/	ADAMTS1-mediated targeting of TSP-1 by PPAR? suppresses migration and invasion of breast cancer cells.	therapeutic application	1	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/8661169/	Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer.	therapeutic application	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/8751617/	Inhibition of breast cancer progression by an antibody to a thrombospondin-1 receptor.	therapeutic application	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9302563/	Histopathology and clinical assessment correlate with the cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) receptor of thrombospondin-1 in breast tumors.	therapeutic application	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10090848/	Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.	therapeutic application	2	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11134179/	Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1.	therapeutic application	1	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12219015/	Fibroblasts promote breast cancer cell invasion by upregulating tumor matrix metalloproteinase-9 production.	therapeutic application	1	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14871834/	CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A.	therapeutic application	1	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15838828/	Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo.	therapeutic application	1	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16715132/	HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy.	therapeutic application	1	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17912446/	Effects of alpha-difluoromethylornithine on thrombospondin-1 production by human breast cancer cells.	therapeutic application	1	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19391135/	Estrogen regulation of thrombospondin-1 in human breast cancer cells.	therapeutic application	1	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19570906/	Regulation of thrombospondin-1 by natural and synthetic progestins in human breast cancer cells.	therapeutic application	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20631908/	Thrombospondin-1 (TSP-1) Stimulates Expression of Integrin alpha6 in Human Breast Carcinoma Cells: A Downstream Modulator of TSP-1-Induced Cellular Adhesion.	therapeutic application	1	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22207555/	Thrombospondin-1 expression in breast cancer: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.	therapeutic application	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25521357/	Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.	therapeutic application	2	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25552929/	Decrease of let-7f in low-dose metronomic Paclitaxel chemotherapy contributed to upregulation of thrombospondin-1 in breast cancer.	therapeutic application	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26273699/	Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro.	therapeutic application	1	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/28274095/	Sphingosylphosphorylcholine Induces Thrombospondin-1 Secretion in MCF10A Cells via ERK2.	therapeutic application	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32600280/	Role of TSP-1 as prognostic marker in various cancers: a systematic review and meta-analysis.	therapeutic application	1	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/29212212/	ADAMTS1-mediated targeting of TSP-1 by PPAR? suppresses migration and invasion of breast cancer cells.	ongoing research	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/8661169/	Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer.	ongoing research	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/8751617/	Inhibition of breast cancer progression by an antibody to a thrombospondin-1 receptor.	ongoing research	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9288157/	Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system.	ongoing research	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9302563/	Histopathology and clinical assessment correlate with the cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) receptor of thrombospondin-1 in breast tumors.	ongoing research	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10090848/	Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.	ongoing research	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11134179/	Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1.	ongoing research	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12219015/	Fibroblasts promote breast cancer cell invasion by upregulating tumor matrix metalloproteinase-9 production.	ongoing research	2	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	ongoing research	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14871834/	CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A.	ongoing research	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15050739/	Estradiol down-regulates CD36 expression in human breast cancer cells.	ongoing research	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15838828/	Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo.	ongoing research	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17912439/	Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer.	ongoing research	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19391135/	Estrogen regulation of thrombospondin-1 in human breast cancer cells.	ongoing research	1	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19570906/	Regulation of thrombospondin-1 by natural and synthetic progestins in human breast cancer cells.	ongoing research	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19747478/	Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: Exploring the functional significance in tumor cell invasion.	ongoing research	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20631908/	Thrombospondin-1 (TSP-1) Stimulates Expression of Integrin alpha6 in Human Breast Carcinoma Cells: A Downstream Modulator of TSP-1-Induced Cellular Adhesion.	ongoing research	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22207555/	Thrombospondin-1 expression in breast cancer: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.	ongoing research	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24120914/	Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: Implications for tumor angiogenesis.	ongoing research	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25521357/	Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.	ongoing research	3	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26273699/	Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro.	ongoing research	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31750826/	[The poor prognosis is correlated with the high expression of vascular endothelial growth factor (VEGF) and low expression of thrombospondin 1 (TSP-1) in patients with breast cancer].	ongoing research	4	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32723034/	Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.	ongoing research	1	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9032471/	Identification of cell adhesive active sites in the N-terminal domain of thrombospondin-1.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11134179/	Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14871834/	CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15050739/	Estradiol down-regulates CD36 expression in human breast cancer cells.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16715132/	HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25521357/	Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/29212212/	ADAMTS1-mediated targeting of TSP-1 by PPAR? suppresses migration and invasion of breast cancer cells.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/8661169/	Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17912446/	Effects of alpha-difluoromethylornithine on thrombospondin-1 production by human breast cancer cells.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19391135/	Estrogen regulation of thrombospondin-1 in human breast cancer cells.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19570906/	Regulation of thrombospondin-1 by natural and synthetic progestins in human breast cancer cells.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20631908/	Thrombospondin-1 (TSP-1) Stimulates Expression of Integrin alpha6 in Human Breast Carcinoma Cells: A Downstream Modulator of TSP-1-Induced Cellular Adhesion.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25552929/	Decrease of let-7f in low-dose metronomic Paclitaxel chemotherapy contributed to upregulation of thrombospondin-1 in breast cancer.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26273699/	Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32723034/	Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9288157/	Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12814189/	Evidence of a bi-phasic effect of thrombospondin-1 on angiogenesis.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17912439/	Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19747478/	Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: Exploring the functional significance in tumor cell invasion.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20370578/	Fibroblast growth factor 8 induced downregulation of thrombospondin 1 is mediated by the MEK/ERK and PI3K pathways in breast cancer cells.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21155598/	Differential proteomic analysis of late-stage and recurrent breast cancer from formalin-fixed paraffin-embedded tissues.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24120914/	Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: Implications for tumor angiogenesis.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31750826/	[The poor prognosis is correlated with the high expression of vascular endothelial growth factor (VEGF) and low expression of thrombospondin 1 (TSP-1) in patients with breast cancer].	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/28274095/	Sphingosylphosphorylcholine Induces Thrombospondin-1 Secretion in MCF10A Cells via ERK2.	unassigned	-	
3.4.21.78	Breast Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32600280/	Role of TSP-1 as prognostic marker in various cancers: a systematic review and meta-analysis.	unassigned	-	
3.4.21.78	Bronchopulmonary Dysplasia	https://pubmed.ncbi.nlm.nih.gov/34323115/	Low Dose Hyperoxia Primes Airways for Fibrosis in Mice after Influenza A Infection.	causal interaction	4	
3.4.21.78	Bronchopulmonary Dysplasia	https://pubmed.ncbi.nlm.nih.gov/34323115/	Low Dose Hyperoxia Primes Airways for Fibrosis in Mice after Influenza A Infection.	diagnostic usage	3	
3.4.21.78	Bronchopulmonary Dysplasia	https://pubmed.ncbi.nlm.nih.gov/34323115/	Low Dose Hyperoxia Primes Airways for Fibrosis in Mice after Influenza A Infection.	therapeutic application	1	
3.4.21.78	Bronchopulmonary Dysplasia	https://pubmed.ncbi.nlm.nih.gov/34323115/	Low Dose Hyperoxia Primes Airways for Fibrosis in Mice after Influenza A Infection.	unassigned	-	
3.4.21.78	Calcinosis	https://pubmed.ncbi.nlm.nih.gov/11793375/	The involvement of matrix glycoproteins in vascular calcification and fibrosis: an immunohistochemical study.	causal interaction	1	
3.4.21.78	Calcinosis	https://pubmed.ncbi.nlm.nih.gov/11793375/	The involvement of matrix glycoproteins in vascular calcification and fibrosis: an immunohistochemical study.	ongoing research	3	
3.4.21.78	Calcinosis	https://pubmed.ncbi.nlm.nih.gov/11793375/	The involvement of matrix glycoproteins in vascular calcification and fibrosis: an immunohistochemical study.	unassigned	-	
3.4.21.78	Calciphylaxis	https://pubmed.ncbi.nlm.nih.gov/11793375/	The involvement of matrix glycoproteins in vascular calcification and fibrosis: an immunohistochemical study.	causal interaction	1	
3.4.21.78	Calciphylaxis	https://pubmed.ncbi.nlm.nih.gov/11793375/	The involvement of matrix glycoproteins in vascular calcification and fibrosis: an immunohistochemical study.	ongoing research	3	
3.4.21.78	Calciphylaxis	https://pubmed.ncbi.nlm.nih.gov/11793375/	The involvement of matrix glycoproteins in vascular calcification and fibrosis: an immunohistochemical study.	unassigned	-	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/17198740/	The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.	causal interaction	4	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/11920636/	Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.	causal interaction	4	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/12439745/	Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice.	causal interaction	2	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/12534338/	Further characterization of BC3H1 myogenic cells reveals lack of p53 activity and underexpression of several p53 regulated and extracellular matrix-associated gene products.	causal interaction	1	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/12584168/	Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model.	causal interaction	4	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/15000492/	Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis.	causal interaction	4	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/15838828/	Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo.	causal interaction	4	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/16009408/	Immunohistochemical expression of thrombospondin-1 in invasive vulvar squamous cell carcinoma.	causal interaction	4	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/17180440/	Microvessel density and regulators of angiogenesis in malignant and nonmalignant prostate tissue.	causal interaction	4	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/18413367/	A novel role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer.	causal interaction	1	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/19805200/	Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer.	causal interaction	4	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/20458281/	Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation.	causal interaction	3	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/24018559/	Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors.	causal interaction	3	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/26461935/	Thrombospondin-1 in a Murine Model of Colorectal Carcinogenesis.	causal interaction	4	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/29434970/	The expression and underlying angiogenesis effect of DPC4 and VEGF on the progression of cervical carcinoma.	causal interaction	4	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/31016850/	TSP-1 is downregulated and inversely correlates with miR-449c expression in Cushing's disease.	causal interaction	4	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/17198740/	The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.	diagnostic usage	1	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/12439745/	Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice.	diagnostic usage	1	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/12584168/	Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model.	diagnostic usage	2	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/15000492/	Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis.	diagnostic usage	4	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/15838828/	Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo.	diagnostic usage	3	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/16009408/	Immunohistochemical expression of thrombospondin-1 in invasive vulvar squamous cell carcinoma.	diagnostic usage	4	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/19805200/	Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer.	diagnostic usage	3	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/20458281/	Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation.	diagnostic usage	3	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/29434970/	The expression and underlying angiogenesis effect of DPC4 and VEGF on the progression of cervical carcinoma.	diagnostic usage	1	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/31016850/	TSP-1 is downregulated and inversely correlates with miR-449c expression in Cushing's disease.	diagnostic usage	4	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/12439745/	Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice.	therapeutic application	1	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/12534338/	Further characterization of BC3H1 myogenic cells reveals lack of p53 activity and underexpression of several p53 regulated and extracellular matrix-associated gene products.	therapeutic application	1	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/12584168/	Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model.	therapeutic application	1	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/15000492/	Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis.	therapeutic application	1	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/15838828/	Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo.	therapeutic application	1	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/16009408/	Immunohistochemical expression of thrombospondin-1 in invasive vulvar squamous cell carcinoma.	therapeutic application	1	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/17180440/	Microvessel density and regulators of angiogenesis in malignant and nonmalignant prostate tissue.	therapeutic application	2	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/18413367/	A novel role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer.	therapeutic application	1	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/19805200/	Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer.	therapeutic application	1	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/20458281/	Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation.	therapeutic application	1	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/24018559/	Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors.	therapeutic application	2	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/29434970/	The expression and underlying angiogenesis effect of DPC4 and VEGF on the progression of cervical carcinoma.	therapeutic application	3	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/17198740/	The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.	ongoing research	1	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/11920636/	Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.	ongoing research	2	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/12439745/	Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice.	ongoing research	4	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/12534338/	Further characterization of BC3H1 myogenic cells reveals lack of p53 activity and underexpression of several p53 regulated and extracellular matrix-associated gene products.	ongoing research	1	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/12584168/	Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model.	ongoing research	3	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/15000492/	Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis.	ongoing research	4	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/15838828/	Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo.	ongoing research	4	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/16009408/	Immunohistochemical expression of thrombospondin-1 in invasive vulvar squamous cell carcinoma.	ongoing research	4	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/18413367/	A novel role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer.	ongoing research	2	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/19805200/	Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer.	ongoing research	3	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/20458281/	Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation.	ongoing research	2	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/24018559/	Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors.	ongoing research	2	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/26461935/	Thrombospondin-1 in a Murine Model of Colorectal Carcinogenesis.	ongoing research	4	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/29434970/	The expression and underlying angiogenesis effect of DPC4 and VEGF on the progression of cervical carcinoma.	ongoing research	4	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/31016850/	TSP-1 is downregulated and inversely correlates with miR-449c expression in Cushing's disease.	ongoing research	4	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/11920636/	Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.	unassigned	-	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/12534338/	Further characterization of BC3H1 myogenic cells reveals lack of p53 activity and underexpression of several p53 regulated and extracellular matrix-associated gene products.	unassigned	-	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/17180440/	Microvessel density and regulators of angiogenesis in malignant and nonmalignant prostate tissue.	unassigned	-	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/18413367/	A novel role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer.	unassigned	-	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/24018559/	Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors.	unassigned	-	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/26461935/	Thrombospondin-1 in a Murine Model of Colorectal Carcinogenesis.	unassigned	-	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/17198740/	The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.	unassigned	-	
3.4.21.78	Carcinogenesis	https://pubmed.ncbi.nlm.nih.gov/31016850/	TSP-1 is downregulated and inversely correlates with miR-449c expression in Cushing's disease.	unassigned	-	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/22136730/	Alteration of HGF and TSP-1 expression in ovarian carcinoma associated with clinical features.	causal interaction	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/32194708/	TSP-1 as a novel biological marker of tumor vasculature normalization in colon carcinoma induced by Endostar.	causal interaction	3	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/9833775/	Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes.	causal interaction	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/10433937/	Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas.	causal interaction	1	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11036248/	Thrombospondin-1 expression in oral squamous cell carcinomas: correlations with tumor vascularity, clinicopathological features and survival.	causal interaction	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11253112/	Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density.	causal interaction	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	causal interaction	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11531279/	Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.	causal interaction	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11882904/	Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production.	causal interaction	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11927969/	The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma.	causal interaction	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/12439745/	Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice.	causal interaction	2	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/12492491/	Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells.	causal interaction	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/12719977/	Expression of thrombospondin-1 is correlated with microvessel density in gastric carcinoma.	causal interaction	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	causal interaction	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/15000492/	Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis.	causal interaction	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/15172186/	Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.	causal interaction	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/15908066/	Extraction of RNA from archival tissues and measurement of thrombospondin-1 mRNA in normal, dysplastic, and malignant oral tissues.	causal interaction	3	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/16009408/	Immunohistochemical expression of thrombospondin-1 in invasive vulvar squamous cell carcinoma.	causal interaction	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/16732887/	Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.	causal interaction	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/17198740/	The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.	causal interaction	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	causal interaction	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/19762163/	Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas.	causal interaction	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/20498063/	B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.	causal interaction	1	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/23749112/	Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.	causal interaction	3	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/26273699/	Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro.	causal interaction	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/29434970/	The expression and underlying angiogenesis effect of DPC4 and VEGF on the progression of cervical carcinoma.	causal interaction	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/31237113/	High immune cytolytic activity in tumor-free tongue tissue confers better prognosis in patients with squamous cell carcinoma of the oral tongue.	causal interaction	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/31980715/	pVHL-mediated regulation of the anti-angiogenic protein thrombospondin-1 decreases migration of Clear Cell Renal Carcinoma Cell Lines.	causal interaction	3	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/22136730/	Alteration of HGF and TSP-1 expression in ovarian carcinoma associated with clinical features.	diagnostic usage	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/32194708/	TSP-1 as a novel biological marker of tumor vasculature normalization in colon carcinoma induced by Endostar.	diagnostic usage	1	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/9833775/	Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes.	diagnostic usage	3	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/10433937/	Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas.	diagnostic usage	3	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11036248/	Thrombospondin-1 expression in oral squamous cell carcinomas: correlations with tumor vascularity, clinicopathological features and survival.	diagnostic usage	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11253112/	Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density.	diagnostic usage	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	diagnostic usage	3	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11531279/	Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.	diagnostic usage	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11882904/	Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production.	diagnostic usage	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11927969/	The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma.	diagnostic usage	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11955648/	Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer.	diagnostic usage	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/12439745/	Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice.	diagnostic usage	1	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/12719977/	Expression of thrombospondin-1 is correlated with microvessel density in gastric carcinoma.	diagnostic usage	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	diagnostic usage	3	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/15000492/	Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis.	diagnostic usage	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/15172186/	Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.	diagnostic usage	3	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/16009408/	Immunohistochemical expression of thrombospondin-1 in invasive vulvar squamous cell carcinoma.	diagnostic usage	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/16732887/	Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.	diagnostic usage	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/17198740/	The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.	diagnostic usage	1	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	diagnostic usage	3	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/19762163/	Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas.	diagnostic usage	1	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/20734389/	Differential hypermethylation of genes in vulvar cancer and lichen sclerosus coexisting or not with vulvar cancer.	diagnostic usage	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/23749112/	Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.	diagnostic usage	3	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/29434970/	The expression and underlying angiogenesis effect of DPC4 and VEGF on the progression of cervical carcinoma.	diagnostic usage	1	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/31237113/	High immune cytolytic activity in tumor-free tongue tissue confers better prognosis in patients with squamous cell carcinoma of the oral tongue.	diagnostic usage	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/32194708/	TSP-1 as a novel biological marker of tumor vasculature normalization in colon carcinoma induced by Endostar.	therapeutic application	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/9833775/	Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes.	therapeutic application	1	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/10433937/	Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas.	therapeutic application	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11036248/	Thrombospondin-1 expression in oral squamous cell carcinomas: correlations with tumor vascularity, clinicopathological features and survival.	therapeutic application	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11253112/	Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density.	therapeutic application	1	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	therapeutic application	2	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11531279/	Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.	therapeutic application	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11882904/	Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production.	therapeutic application	1	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/12439745/	Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice.	therapeutic application	1	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/12492491/	Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells.	therapeutic application	2	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/12719977/	Expression of thrombospondin-1 is correlated with microvessel density in gastric carcinoma.	therapeutic application	3	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/15000492/	Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis.	therapeutic application	1	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/15172186/	Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.	therapeutic application	1	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/16009408/	Immunohistochemical expression of thrombospondin-1 in invasive vulvar squamous cell carcinoma.	therapeutic application	1	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/16732887/	Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.	therapeutic application	1	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	therapeutic application	1	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/26273699/	Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro.	therapeutic application	1	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/29434970/	The expression and underlying angiogenesis effect of DPC4 and VEGF on the progression of cervical carcinoma.	therapeutic application	3	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/20008890/	c-MYC depletion potentiates cisplatin-induced apoptosis in head and neck squamous cell carcinoma: involvement of TSP-1 up-regulation.	ongoing research	2	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/22136730/	Alteration of HGF and TSP-1 expression in ovarian carcinoma associated with clinical features.	ongoing research	3	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/9833775/	Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes.	ongoing research	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/10433937/	Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas.	ongoing research	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11036248/	Thrombospondin-1 expression in oral squamous cell carcinomas: correlations with tumor vascularity, clinicopathological features and survival.	ongoing research	3	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11253112/	Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density.	ongoing research	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	ongoing research	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11531279/	Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.	ongoing research	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11882904/	Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production.	ongoing research	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11927969/	The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma.	ongoing research	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11955648/	Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer.	ongoing research	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/12439745/	Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice.	ongoing research	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/12492491/	Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells.	ongoing research	2	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/12719977/	Expression of thrombospondin-1 is correlated with microvessel density in gastric carcinoma.	ongoing research	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	ongoing research	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/15000492/	Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis.	ongoing research	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/15095410/	Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1.	ongoing research	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/15172186/	Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.	ongoing research	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/16009408/	Immunohistochemical expression of thrombospondin-1 in invasive vulvar squamous cell carcinoma.	ongoing research	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/16204059/	Oncogenes and Angiogenesis: down-regulation of thrombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras.	ongoing research	3	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/16732887/	Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.	ongoing research	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/17198740/	The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.	ongoing research	1	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/19762163/	Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas.	ongoing research	3	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/20498063/	B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.	ongoing research	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/20734389/	Differential hypermethylation of genes in vulvar cancer and lichen sclerosus coexisting or not with vulvar cancer.	ongoing research	3	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/23749112/	Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.	ongoing research	2	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/26273699/	Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro.	ongoing research	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/29434970/	The expression and underlying angiogenesis effect of DPC4 and VEGF on the progression of cervical carcinoma.	ongoing research	4	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/31237113/	High immune cytolytic activity in tumor-free tongue tissue confers better prognosis in patients with squamous cell carcinoma of the oral tongue.	ongoing research	3	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/20008890/	c-MYC depletion potentiates cisplatin-induced apoptosis in head and neck squamous cell carcinoma: involvement of TSP-1 up-regulation.	unassigned	-	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11955648/	Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer.	unassigned	-	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/15095410/	Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1.	unassigned	-	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/16204059/	Oncogenes and Angiogenesis: down-regulation of thrombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras.	unassigned	-	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/20734389/	Differential hypermethylation of genes in vulvar cancer and lichen sclerosus coexisting or not with vulvar cancer.	unassigned	-	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/26222671/	Differential role of gene hypermethylation in adenocarcinomas, squamous cell carcinomas and cervical intraepithelial lesions of the uterine cervix.	unassigned	-	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/12492491/	Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells.	unassigned	-	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/15908066/	Extraction of RNA from archival tissues and measurement of thrombospondin-1 mRNA in normal, dysplastic, and malignant oral tissues.	unassigned	-	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/20498063/	B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.	unassigned	-	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/26273699/	Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro.	unassigned	-	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/31980715/	pVHL-mediated regulation of the anti-angiogenic protein thrombospondin-1 decreases migration of Clear Cell Renal Carcinoma Cell Lines.	unassigned	-	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/22136730/	Alteration of HGF and TSP-1 expression in ovarian carcinoma associated with clinical features.	unassigned	-	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/11927969/	The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma.	unassigned	-	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	unassigned	-	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/17198740/	The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.	unassigned	-	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/19762163/	Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas.	unassigned	-	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/23749112/	Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.	unassigned	-	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/31237113/	High immune cytolytic activity in tumor-free tongue tissue confers better prognosis in patients with squamous cell carcinoma of the oral tongue.	unassigned	-	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/32194708/	TSP-1 as a novel biological marker of tumor vasculature normalization in colon carcinoma induced by Endostar.	unassigned	-	
3.4.21.78	Carcinoma	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	unassigned	-	
3.4.21.78	Carcinoma in Situ	https://pubmed.ncbi.nlm.nih.gov/15000492/	Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis.	causal interaction	4	
3.4.21.78	Carcinoma in Situ	https://pubmed.ncbi.nlm.nih.gov/15000492/	Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis.	diagnostic usage	4	
3.4.21.78	Carcinoma in Situ	https://pubmed.ncbi.nlm.nih.gov/15000492/	Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis.	therapeutic application	1	
3.4.21.78	Carcinoma in Situ	https://pubmed.ncbi.nlm.nih.gov/15000492/	Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis.	ongoing research	4	
3.4.21.78	Carcinoma, Ductal	https://pubmed.ncbi.nlm.nih.gov/12461058/	Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast.	causal interaction	3	
3.4.21.78	Carcinoma, Ductal	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	causal interaction	4	
3.4.21.78	Carcinoma, Ductal	https://pubmed.ncbi.nlm.nih.gov/23614916/	Thrombospondin-1 is highly expressed in desmoplastic components of invasive ductal carcinoma of the breast and associated with lymph node metastasis.	causal interaction	4	
3.4.21.78	Carcinoma, Ductal	https://pubmed.ncbi.nlm.nih.gov/12461058/	Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast.	diagnostic usage	2	
3.4.21.78	Carcinoma, Ductal	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	diagnostic usage	3	
3.4.21.78	Carcinoma, Ductal	https://pubmed.ncbi.nlm.nih.gov/23614916/	Thrombospondin-1 is highly expressed in desmoplastic components of invasive ductal carcinoma of the breast and associated with lymph node metastasis.	diagnostic usage	4	
3.4.21.78	Carcinoma, Ductal	https://pubmed.ncbi.nlm.nih.gov/12461058/	Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast.	therapeutic application	1	
3.4.21.78	Carcinoma, Ductal	https://pubmed.ncbi.nlm.nih.gov/23614916/	Thrombospondin-1 is highly expressed in desmoplastic components of invasive ductal carcinoma of the breast and associated with lymph node metastasis.	therapeutic application	1	
3.4.21.78	Carcinoma, Ductal	https://pubmed.ncbi.nlm.nih.gov/12461058/	Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast.	ongoing research	4	
3.4.21.78	Carcinoma, Ductal	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	ongoing research	4	
3.4.21.78	Carcinoma, Ductal	https://pubmed.ncbi.nlm.nih.gov/23614916/	Thrombospondin-1 is highly expressed in desmoplastic components of invasive ductal carcinoma of the breast and associated with lymph node metastasis.	ongoing research	4	
3.4.21.78	Carcinoma, Ductal	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	unassigned	-	
3.4.21.78	Carcinoma, Hepatocellular	https://pubmed.ncbi.nlm.nih.gov/11216860/	Expression of thrombospondin-1 in human hepatocarcinoma cell lines and its regulation by transcription factor Jun/AP-1.	causal interaction	4	
3.4.21.78	Carcinoma, Hepatocellular	https://pubmed.ncbi.nlm.nih.gov/17827686/	Induction of Egr-1 is associated with anti-metastatic and anti-invasive ability of beta-lapachone in human hepatocarcinoma cells.	causal interaction	3	
3.4.21.78	Carcinoma, Hepatocellular	https://pubmed.ncbi.nlm.nih.gov/11216860/	Expression of thrombospondin-1 in human hepatocarcinoma cell lines and its regulation by transcription factor Jun/AP-1.	diagnostic usage	3	
3.4.21.78	Carcinoma, Hepatocellular	https://pubmed.ncbi.nlm.nih.gov/17827686/	Induction of Egr-1 is associated with anti-metastatic and anti-invasive ability of beta-lapachone in human hepatocarcinoma cells.	therapeutic application	1	
3.4.21.78	Carcinoma, Hepatocellular	https://pubmed.ncbi.nlm.nih.gov/11216860/	Expression of thrombospondin-1 in human hepatocarcinoma cell lines and its regulation by transcription factor Jun/AP-1.	ongoing research	4	
3.4.21.78	Carcinoma, Hepatocellular	https://pubmed.ncbi.nlm.nih.gov/17827686/	Induction of Egr-1 is associated with anti-metastatic and anti-invasive ability of beta-lapachone in human hepatocarcinoma cells.	unassigned	-	
3.4.21.78	Carcinoma, Hepatocellular	https://pubmed.ncbi.nlm.nih.gov/11216860/	Expression of thrombospondin-1 in human hepatocarcinoma cell lines and its regulation by transcription factor Jun/AP-1.	unassigned	-	
3.4.21.78	Carcinoma, Intraductal, Noninfiltrating	https://pubmed.ncbi.nlm.nih.gov/12461058/	Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast.	causal interaction	3	
3.4.21.78	Carcinoma, Intraductal, Noninfiltrating	https://pubmed.ncbi.nlm.nih.gov/12461058/	Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast.	diagnostic usage	2	
3.4.21.78	Carcinoma, Intraductal, Noninfiltrating	https://pubmed.ncbi.nlm.nih.gov/12461058/	Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast.	therapeutic application	1	
3.4.21.78	Carcinoma, Intraductal, Noninfiltrating	https://pubmed.ncbi.nlm.nih.gov/12461058/	Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast.	ongoing research	4	
3.4.21.78	Carcinoma, Mucoepidermoid	https://pubmed.ncbi.nlm.nih.gov/19906510/	The alteration of Id-1 and TSP-1 expression in mucoepidermoid carcinoma associated with its clinical features and prognosis.	causal interaction	1	
3.4.21.78	Carcinoma, Mucoepidermoid	https://pubmed.ncbi.nlm.nih.gov/18780507/	[The expression of inhibitor-1 of DNA binding/differentiation-1 and thrombospondin-1 in mucoepidermoid carcinoma of different malignant degree]	causal interaction	3	
3.4.21.78	Carcinoma, Mucoepidermoid	https://pubmed.ncbi.nlm.nih.gov/19024308/	[Correlation between the expression of thrombospondin-1 and the angiogenesis in mucoepidermoid carcinoma]	causal interaction	3	
3.4.21.78	Carcinoma, Mucoepidermoid	https://pubmed.ncbi.nlm.nih.gov/19080117/	Correlation between the expression of thrombospondin-1 and neovascularization in mucoepidermoid carcinoma.	causal interaction	3	
3.4.21.78	Carcinoma, Mucoepidermoid	https://pubmed.ncbi.nlm.nih.gov/19906510/	The alteration of Id-1 and TSP-1 expression in mucoepidermoid carcinoma associated with its clinical features and prognosis.	diagnostic usage	4	
3.4.21.78	Carcinoma, Mucoepidermoid	https://pubmed.ncbi.nlm.nih.gov/18780507/	[The expression of inhibitor-1 of DNA binding/differentiation-1 and thrombospondin-1 in mucoepidermoid carcinoma of different malignant degree]	diagnostic usage	3	
3.4.21.78	Carcinoma, Mucoepidermoid	https://pubmed.ncbi.nlm.nih.gov/19024308/	[Correlation between the expression of thrombospondin-1 and the angiogenesis in mucoepidermoid carcinoma]	diagnostic usage	4	
3.4.21.78	Carcinoma, Mucoepidermoid	https://pubmed.ncbi.nlm.nih.gov/19080117/	Correlation between the expression of thrombospondin-1 and neovascularization in mucoepidermoid carcinoma.	diagnostic usage	3	
3.4.21.78	Carcinoma, Mucoepidermoid	https://pubmed.ncbi.nlm.nih.gov/19080117/	Correlation between the expression of thrombospondin-1 and neovascularization in mucoepidermoid carcinoma.	therapeutic application	4	
3.4.21.78	Carcinoma, Mucoepidermoid	https://pubmed.ncbi.nlm.nih.gov/19906510/	The alteration of Id-1 and TSP-1 expression in mucoepidermoid carcinoma associated with its clinical features and prognosis.	ongoing research	2	
3.4.21.78	Carcinoma, Mucoepidermoid	https://pubmed.ncbi.nlm.nih.gov/18780507/	[The expression of inhibitor-1 of DNA binding/differentiation-1 and thrombospondin-1 in mucoepidermoid carcinoma of different malignant degree]	ongoing research	4	
3.4.21.78	Carcinoma, Mucoepidermoid	https://pubmed.ncbi.nlm.nih.gov/19024308/	[Correlation between the expression of thrombospondin-1 and the angiogenesis in mucoepidermoid carcinoma]	ongoing research	3	
3.4.21.78	Carcinoma, Mucoepidermoid	https://pubmed.ncbi.nlm.nih.gov/19080117/	Correlation between the expression of thrombospondin-1 and neovascularization in mucoepidermoid carcinoma.	ongoing research	4	
3.4.21.78	Carcinoma, Mucoepidermoid	https://pubmed.ncbi.nlm.nih.gov/19906510/	The alteration of Id-1 and TSP-1 expression in mucoepidermoid carcinoma associated with its clinical features and prognosis.	unassigned	-	
3.4.21.78	Carcinoma, Mucoepidermoid	https://pubmed.ncbi.nlm.nih.gov/18780507/	[The expression of inhibitor-1 of DNA binding/differentiation-1 and thrombospondin-1 in mucoepidermoid carcinoma of different malignant degree]	unassigned	-	
3.4.21.78	Carcinoma, Mucoepidermoid	https://pubmed.ncbi.nlm.nih.gov/19024308/	[Correlation between the expression of thrombospondin-1 and the angiogenesis in mucoepidermoid carcinoma]	unassigned	-	
3.4.21.78	Carcinoma, Non-Small-Cell Lung	https://pubmed.ncbi.nlm.nih.gov/24788022/	Net platelet angiogenic activity (NPAA) correlates with progression and prognosis of non-small cell lung cancer.	diagnostic usage	4	
3.4.21.78	Carcinoma, Non-Small-Cell Lung	https://pubmed.ncbi.nlm.nih.gov/24788022/	Net platelet angiogenic activity (NPAA) correlates with progression and prognosis of non-small cell lung cancer.	therapeutic application	1	
3.4.21.78	Carcinoma, Non-Small-Cell Lung	https://pubmed.ncbi.nlm.nih.gov/24788022/	Net platelet angiogenic activity (NPAA) correlates with progression and prognosis of non-small cell lung cancer.	ongoing research	2	
3.4.21.78	Carcinoma, Non-Small-Cell Lung	https://pubmed.ncbi.nlm.nih.gov/24788022/	Net platelet angiogenic activity (NPAA) correlates with progression and prognosis of non-small cell lung cancer.	unassigned	-	
3.4.21.78	Carcinoma, Ovarian Epithelial	https://pubmed.ncbi.nlm.nih.gov/11531279/	Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.	causal interaction	4	
3.4.21.78	Carcinoma, Ovarian Epithelial	https://pubmed.ncbi.nlm.nih.gov/11531279/	Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.	diagnostic usage	4	
3.4.21.78	Carcinoma, Ovarian Epithelial	https://pubmed.ncbi.nlm.nih.gov/11531279/	Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.	therapeutic application	4	
3.4.21.78	Carcinoma, Ovarian Epithelial	https://pubmed.ncbi.nlm.nih.gov/11531279/	Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.	ongoing research	4	
3.4.21.78	Carcinoma, Papillary	https://pubmed.ncbi.nlm.nih.gov/15526350/	Hepatocyte growth factor (HGF) downregulates thrombospondin 1 (TSP-1) expression in thyroid papillary carcinoma cells.	causal interaction	4	
3.4.21.78	Carcinoma, Papillary	https://pubmed.ncbi.nlm.nih.gov/15526350/	Hepatocyte growth factor (HGF) downregulates thrombospondin 1 (TSP-1) expression in thyroid papillary carcinoma cells.	diagnostic usage	4	
3.4.21.78	Carcinoma, Papillary	https://pubmed.ncbi.nlm.nih.gov/17409099/	Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion.	diagnostic usage	3	
3.4.21.78	Carcinoma, Papillary	https://pubmed.ncbi.nlm.nih.gov/15526350/	Hepatocyte growth factor (HGF) downregulates thrombospondin 1 (TSP-1) expression in thyroid papillary carcinoma cells.	ongoing research	2	
3.4.21.78	Carcinoma, Papillary	https://pubmed.ncbi.nlm.nih.gov/17409099/	Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion.	ongoing research	4	
3.4.21.78	Carcinoma, Papillary	https://pubmed.ncbi.nlm.nih.gov/17409099/	Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion.	unassigned	-	
3.4.21.78	Carcinoma, Papillary	https://pubmed.ncbi.nlm.nih.gov/15526350/	Hepatocyte growth factor (HGF) downregulates thrombospondin 1 (TSP-1) expression in thyroid papillary carcinoma cells.	unassigned	-	
3.4.21.78	Carcinoma, Renal Cell	https://pubmed.ncbi.nlm.nih.gov/23749112/	Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.	causal interaction	3	
3.4.21.78	Carcinoma, Renal Cell	https://pubmed.ncbi.nlm.nih.gov/31980715/	pVHL-mediated regulation of the anti-angiogenic protein thrombospondin-1 decreases migration of Clear Cell Renal Carcinoma Cell Lines.	causal interaction	3	
3.4.21.78	Carcinoma, Renal Cell	https://pubmed.ncbi.nlm.nih.gov/23749112/	Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.	diagnostic usage	3	
3.4.21.78	Carcinoma, Renal Cell	https://pubmed.ncbi.nlm.nih.gov/23749112/	Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.	ongoing research	2	
3.4.21.78	Carcinoma, Renal Cell	https://pubmed.ncbi.nlm.nih.gov/31980715/	pVHL-mediated regulation of the anti-angiogenic protein thrombospondin-1 decreases migration of Clear Cell Renal Carcinoma Cell Lines.	unassigned	-	
3.4.21.78	Carcinoma, Renal Cell	https://pubmed.ncbi.nlm.nih.gov/23749112/	Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.	unassigned	-	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/10433937/	Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas.	causal interaction	1	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	causal interaction	4	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/12439745/	Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice.	causal interaction	2	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/15000492/	Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis.	causal interaction	4	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/15172186/	Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.	causal interaction	4	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/16009408/	Immunohistochemical expression of thrombospondin-1 in invasive vulvar squamous cell carcinoma.	causal interaction	4	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/17198740/	The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.	causal interaction	4	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	causal interaction	4	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/31237113/	High immune cytolytic activity in tumor-free tongue tissue confers better prognosis in patients with squamous cell carcinoma of the oral tongue.	causal interaction	4	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/10433937/	Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas.	diagnostic usage	3	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	diagnostic usage	3	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/11955648/	Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer.	diagnostic usage	4	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/12439745/	Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice.	diagnostic usage	1	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/15000492/	Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis.	diagnostic usage	4	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/15172186/	Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.	diagnostic usage	3	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/16009408/	Immunohistochemical expression of thrombospondin-1 in invasive vulvar squamous cell carcinoma.	diagnostic usage	4	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/17198740/	The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.	diagnostic usage	1	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	diagnostic usage	3	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/20734389/	Differential hypermethylation of genes in vulvar cancer and lichen sclerosus coexisting or not with vulvar cancer.	diagnostic usage	4	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/31237113/	High immune cytolytic activity in tumor-free tongue tissue confers better prognosis in patients with squamous cell carcinoma of the oral tongue.	diagnostic usage	4	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/10433937/	Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas.	therapeutic application	4	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	therapeutic application	2	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/12439745/	Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice.	therapeutic application	1	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/15000492/	Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis.	therapeutic application	1	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/15172186/	Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.	therapeutic application	1	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/16009408/	Immunohistochemical expression of thrombospondin-1 in invasive vulvar squamous cell carcinoma.	therapeutic application	1	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	therapeutic application	1	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/20008890/	c-MYC depletion potentiates cisplatin-induced apoptosis in head and neck squamous cell carcinoma: involvement of TSP-1 up-regulation.	ongoing research	2	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/10433937/	Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas.	ongoing research	4	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	ongoing research	4	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/11955648/	Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer.	ongoing research	4	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/12439745/	Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice.	ongoing research	4	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/15000492/	Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis.	ongoing research	4	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/15172186/	Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.	ongoing research	4	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/16009408/	Immunohistochemical expression of thrombospondin-1 in invasive vulvar squamous cell carcinoma.	ongoing research	4	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/17198740/	The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.	ongoing research	1	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/20734389/	Differential hypermethylation of genes in vulvar cancer and lichen sclerosus coexisting or not with vulvar cancer.	ongoing research	3	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/31237113/	High immune cytolytic activity in tumor-free tongue tissue confers better prognosis in patients with squamous cell carcinoma of the oral tongue.	ongoing research	3	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/20008890/	c-MYC depletion potentiates cisplatin-induced apoptosis in head and neck squamous cell carcinoma: involvement of TSP-1 up-regulation.	unassigned	-	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/11955648/	Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer.	unassigned	-	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/20734389/	Differential hypermethylation of genes in vulvar cancer and lichen sclerosus coexisting or not with vulvar cancer.	unassigned	-	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/26222671/	Differential role of gene hypermethylation in adenocarcinomas, squamous cell carcinomas and cervical intraepithelial lesions of the uterine cervix.	unassigned	-	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/17198740/	The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.	unassigned	-	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/31237113/	High immune cytolytic activity in tumor-free tongue tissue confers better prognosis in patients with squamous cell carcinoma of the oral tongue.	unassigned	-	
3.4.21.78	Carcinoma, Squamous Cell	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	unassigned	-	
3.4.21.78	Cardiomegaly	https://pubmed.ncbi.nlm.nih.gov/18541142/	Thrombospondin-4 expression is rapidly upregulated by cardiac overload.	causal interaction	3	
3.4.21.78	Cardiomegaly	https://pubmed.ncbi.nlm.nih.gov/23074998/	Thrombospondins, potential drug targets for cardiovascular diseases.	causal interaction	3	
3.4.21.78	Cardiomegaly	https://pubmed.ncbi.nlm.nih.gov/23074998/	Thrombospondins, potential drug targets for cardiovascular diseases.	therapeutic application	4	
3.4.21.78	Cardiomegaly	https://pubmed.ncbi.nlm.nih.gov/18541142/	Thrombospondin-4 expression is rapidly upregulated by cardiac overload.	unassigned	-	
3.4.21.78	Cardiomegaly	https://pubmed.ncbi.nlm.nih.gov/23074998/	Thrombospondins, potential drug targets for cardiovascular diseases.	unassigned	-	
3.4.21.78	Cardiovascular Diseases	https://pubmed.ncbi.nlm.nih.gov/22750995/	Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction.	causal interaction	3	
3.4.21.78	Cardiovascular Diseases	https://pubmed.ncbi.nlm.nih.gov/27122857/	Association of Plasma Thrombospondin-1 Level with Cardiovascular Disease and Mortality in Hemodialysis Patients.	causal interaction	4	
3.4.21.78	Cardiovascular Diseases	https://pubmed.ncbi.nlm.nih.gov/29441713/	Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.	causal interaction	4	
3.4.21.78	Cardiovascular Diseases	https://pubmed.ncbi.nlm.nih.gov/22750995/	Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction.	diagnostic usage	4	
3.4.21.78	Cardiovascular Diseases	https://pubmed.ncbi.nlm.nih.gov/27122857/	Association of Plasma Thrombospondin-1 Level with Cardiovascular Disease and Mortality in Hemodialysis Patients.	diagnostic usage	4	
3.4.21.78	Cardiovascular Diseases	https://pubmed.ncbi.nlm.nih.gov/29441713/	Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.	diagnostic usage	4	
3.4.21.78	Cardiovascular Diseases	https://pubmed.ncbi.nlm.nih.gov/22750995/	Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction.	therapeutic application	4	
3.4.21.78	Cardiovascular Diseases	https://pubmed.ncbi.nlm.nih.gov/29441713/	Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.	therapeutic application	4	
3.4.21.78	Cardiovascular Diseases	https://pubmed.ncbi.nlm.nih.gov/22750995/	Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction.	ongoing research	3	
3.4.21.78	Cardiovascular Diseases	https://pubmed.ncbi.nlm.nih.gov/29441713/	Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.	ongoing research	4	
3.4.21.78	Cardiovascular Diseases	https://pubmed.ncbi.nlm.nih.gov/27122857/	Association of Plasma Thrombospondin-1 Level with Cardiovascular Disease and Mortality in Hemodialysis Patients.	unassigned	-	
3.4.21.78	Cataract	https://pubmed.ncbi.nlm.nih.gov/24135756/	Collagen XVIII short isoform is critical for retinal vascularization, and overexpression of the Tsp-1 domain affects eye growth and cataract formation.	unassigned	-	
3.4.21.78	Cerebral Hemorrhage	https://pubmed.ncbi.nlm.nih.gov/27653877/	Elevated cerebrospinal fluid levels of thrombospondin-1 correlate with adverse clinical outcome in patients with aneurysmal subarachnoid hemorrhage.	causal interaction	4	
3.4.21.78	Cerebral Hemorrhage	https://pubmed.ncbi.nlm.nih.gov/27653877/	Elevated cerebrospinal fluid levels of thrombospondin-1 correlate with adverse clinical outcome in patients with aneurysmal subarachnoid hemorrhage.	diagnostic usage	4	
3.4.21.78	Cerebral Hemorrhage	https://pubmed.ncbi.nlm.nih.gov/27653877/	Elevated cerebrospinal fluid levels of thrombospondin-1 correlate with adverse clinical outcome in patients with aneurysmal subarachnoid hemorrhage.	ongoing research	3	
3.4.21.78	Cerebral Hemorrhage	https://pubmed.ncbi.nlm.nih.gov/27653877/	Elevated cerebrospinal fluid levels of thrombospondin-1 correlate with adverse clinical outcome in patients with aneurysmal subarachnoid hemorrhage.	unassigned	-	
3.4.21.78	Cervical Intraepithelial Neoplasia	https://pubmed.ncbi.nlm.nih.gov/15000492/	Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis.	causal interaction	4	
3.4.21.78	Cervical Intraepithelial Neoplasia	https://pubmed.ncbi.nlm.nih.gov/15000492/	Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis.	diagnostic usage	4	
3.4.21.78	Cervical Intraepithelial Neoplasia	https://pubmed.ncbi.nlm.nih.gov/15000492/	Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis.	therapeutic application	1	
3.4.21.78	Cervical Intraepithelial Neoplasia	https://pubmed.ncbi.nlm.nih.gov/15000492/	Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis.	ongoing research	4	
3.4.21.78	Chikungunya Fever	https://pubmed.ncbi.nlm.nih.gov/28207896/	RNA-Seq analysis of chikungunya virus infection and identification of granzyme A as a major promoter of arthritic inflammation.	causal interaction	3	
3.4.21.78	Chikungunya Fever	https://pubmed.ncbi.nlm.nih.gov/28207896/	RNA-Seq analysis of chikungunya virus infection and identification of granzyme A as a major promoter of arthritic inflammation.	diagnostic usage	1	
3.4.21.78	Chikungunya Fever	https://pubmed.ncbi.nlm.nih.gov/28207896/	RNA-Seq analysis of chikungunya virus infection and identification of granzyme A as a major promoter of arthritic inflammation.	unassigned	-	
3.4.21.78	Cholangiocarcinoma	https://pubmed.ncbi.nlm.nih.gov/11927969/	The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma.	causal interaction	4	
3.4.21.78	Cholangiocarcinoma	https://pubmed.ncbi.nlm.nih.gov/11927969/	The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma.	diagnostic usage	4	
3.4.21.78	Cholangiocarcinoma	https://pubmed.ncbi.nlm.nih.gov/11927969/	The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma.	ongoing research	4	
3.4.21.78	Cholangiocarcinoma	https://pubmed.ncbi.nlm.nih.gov/11927969/	The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma.	unassigned	-	
3.4.21.78	Cholera	https://pubmed.ncbi.nlm.nih.gov/18571589/	The role of G proteins in thromospondin-1-induced vascular smooth muscle cell migration.	therapeutic application	1	
3.4.21.78	Cholera	https://pubmed.ncbi.nlm.nih.gov/18571589/	The role of G proteins in thromospondin-1-induced vascular smooth muscle cell migration.	ongoing research	2	
3.4.21.78	Cholera	https://pubmed.ncbi.nlm.nih.gov/18571589/	The role of G proteins in thromospondin-1-induced vascular smooth muscle cell migration.	unassigned	-	
3.4.21.78	Choroidal Neovascularization	https://pubmed.ncbi.nlm.nih.gov/10670489/	Production and accumulation of thrombospondin-1 in human retinal pigment epithelial cells.	unassigned	-	
3.4.21.78	Choroidal Neovascularization	https://pubmed.ncbi.nlm.nih.gov/17378161/	Thrombospondin-1 expression in RPE and choroidal neovascular membranes.	unassigned	-	
3.4.21.78	Chronic Periodontitis	https://pubmed.ncbi.nlm.nih.gov/34015597/	Targeting TSP-1 decreased periodontitis by attenuating extracellular matrix degradation and alveolar bone destruction.	causal interaction	4	
3.4.21.78	Chronic Periodontitis	https://pubmed.ncbi.nlm.nih.gov/34015597/	Targeting TSP-1 decreased periodontitis by attenuating extracellular matrix degradation and alveolar bone destruction.	therapeutic application	3	
3.4.21.78	Chronic Periodontitis	https://pubmed.ncbi.nlm.nih.gov/34015597/	Targeting TSP-1 decreased periodontitis by attenuating extracellular matrix degradation and alveolar bone destruction.	ongoing research	1	
3.4.21.78	Chronic Periodontitis	https://pubmed.ncbi.nlm.nih.gov/34015597/	Targeting TSP-1 decreased periodontitis by attenuating extracellular matrix degradation and alveolar bone destruction.	unassigned	-	
3.4.21.78	Chronic Urticaria	https://pubmed.ncbi.nlm.nih.gov/23995607/	Endostatin and Thrombospondin-1 levels are increased in the sera of patients with chronic spontaneous urticaria.	causal interaction	2	
3.4.21.78	Chronic Urticaria	https://pubmed.ncbi.nlm.nih.gov/23995607/	Endostatin and Thrombospondin-1 levels are increased in the sera of patients with chronic spontaneous urticaria.	diagnostic usage	3	
3.4.21.78	Chronic Urticaria	https://pubmed.ncbi.nlm.nih.gov/23995607/	Endostatin and Thrombospondin-1 levels are increased in the sera of patients with chronic spontaneous urticaria.	therapeutic application	1	
3.4.21.78	Chronic Urticaria	https://pubmed.ncbi.nlm.nih.gov/23995607/	Endostatin and Thrombospondin-1 levels are increased in the sera of patients with chronic spontaneous urticaria.	unassigned	-	
3.4.21.78	Colitis	https://pubmed.ncbi.nlm.nih.gov/26034351/	Thrombospondin peptide ABT-898 inhibits inflammation and angiogenesis in a colitis model.	ongoing research	3	
3.4.21.78	Colitis	https://pubmed.ncbi.nlm.nih.gov/26034351/	Thrombospondin peptide ABT-898 inhibits inflammation and angiogenesis in a colitis model.	unassigned	-	
3.4.21.78	Colitis, Ulcerative	https://pubmed.ncbi.nlm.nih.gov/26522261/	Association Between Response to Etrolizumab and Expression of Integrin ?E and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.	causal interaction	1	
3.4.21.78	Colitis, Ulcerative	https://pubmed.ncbi.nlm.nih.gov/17213646/	A role of a lymphocyte tryptase, granzyme A, in experimental ulcerative colitis.	therapeutic application	2	
3.4.21.78	Colitis, Ulcerative	https://pubmed.ncbi.nlm.nih.gov/17213646/	A role of a lymphocyte tryptase, granzyme A, in experimental ulcerative colitis.	ongoing research	2	
3.4.21.78	Colitis, Ulcerative	https://pubmed.ncbi.nlm.nih.gov/26522261/	Association Between Response to Etrolizumab and Expression of Integrin ?E and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.	ongoing research	2	
3.4.21.78	Colitis, Ulcerative	https://pubmed.ncbi.nlm.nih.gov/17213646/	A role of a lymphocyte tryptase, granzyme A, in experimental ulcerative colitis.	unassigned	-	
3.4.21.78	Colitis, Ulcerative	https://pubmed.ncbi.nlm.nih.gov/26522261/	Association Between Response to Etrolizumab and Expression of Integrin ?E and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.	unassigned	-	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24053448/	Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense?	causal interaction	4	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9888480/	Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer.	causal interaction	4	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11410779/	Expression of thrombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer.	causal interaction	4	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14658007/	Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.	causal interaction	3	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16258261/	Wnt signaling can repress thrombospondin-1 expression in colonic tumorigenesis.	causal interaction	4	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18583030/	Down regulation of c-Myc and induction of an angiogenesis inhibitor, thrombospondin-1, by 5-FU in human colon cancer KM12C cells.	causal interaction	1	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24085798/	Mechanisms of Platelet-Stimulated Colon Cancer Invasion: Role of Clusterin and Thrombospondin-1 in Regulation of the P38MAPK-MMP-9 Pathway.	causal interaction	3	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32194708/	TSP-1 as a novel biological marker of tumor vasculature normalization in colon carcinoma induced by Endostar.	causal interaction	3	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9888480/	Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer.	diagnostic usage	3	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11410779/	Expression of thrombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer.	diagnostic usage	4	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32194708/	TSP-1 as a novel biological marker of tumor vasculature normalization in colon carcinoma induced by Endostar.	diagnostic usage	1	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24053448/	Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense?	therapeutic application	1	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9888480/	Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer.	therapeutic application	1	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11410779/	Expression of thrombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer.	therapeutic application	3	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14658007/	Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.	therapeutic application	2	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16258261/	Wnt signaling can repress thrombospondin-1 expression in colonic tumorigenesis.	therapeutic application	4	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24085798/	Mechanisms of Platelet-Stimulated Colon Cancer Invasion: Role of Clusterin and Thrombospondin-1 in Regulation of the P38MAPK-MMP-9 Pathway.	therapeutic application	2	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32194708/	TSP-1 as a novel biological marker of tumor vasculature normalization in colon carcinoma induced by Endostar.	therapeutic application	4	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24053448/	Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense?	ongoing research	3	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9888480/	Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer.	ongoing research	3	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11410779/	Expression of thrombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer.	ongoing research	4	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16258261/	Wnt signaling can repress thrombospondin-1 expression in colonic tumorigenesis.	ongoing research	3	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18583030/	Down regulation of c-Myc and induction of an angiogenesis inhibitor, thrombospondin-1, by 5-FU in human colon cancer KM12C cells.	ongoing research	4	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24085798/	Mechanisms of Platelet-Stimulated Colon Cancer Invasion: Role of Clusterin and Thrombospondin-1 in Regulation of the P38MAPK-MMP-9 Pathway.	ongoing research	4	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24053448/	Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense?	unassigned	-	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14658007/	Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.	unassigned	-	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16258261/	Wnt signaling can repress thrombospondin-1 expression in colonic tumorigenesis.	unassigned	-	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18583030/	Down regulation of c-Myc and induction of an angiogenesis inhibitor, thrombospondin-1, by 5-FU in human colon cancer KM12C cells.	unassigned	-	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24085798/	Mechanisms of Platelet-Stimulated Colon Cancer Invasion: Role of Clusterin and Thrombospondin-1 in Regulation of the P38MAPK-MMP-9 Pathway.	unassigned	-	
3.4.21.78	Colonic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32194708/	TSP-1 as a novel biological marker of tumor vasculature normalization in colon carcinoma induced by Endostar.	unassigned	-	
3.4.21.78	Colorectal Neoplasms	https://pubmed.ncbi.nlm.nih.gov/28757355/	15-Lipoxygenase-1 re-expression in colorectal cancer alters endothelial cell features through enhanced expression of TSP-1 and ICAM-1.	causal interaction	2	
3.4.21.78	Colorectal Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	causal interaction	4	
3.4.21.78	Colorectal Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12963968/	Clinical significance of thrombospondin-1 expression in relation to vascular endothelial growth factor and interleukin-10 expression at the deepest invasive tumor site of advanced colorectal carcinoma.	causal interaction	4	
3.4.21.78	Colorectal Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17709727/	Association of angiogenesis markers with lymph node metastasis in early colorectal cancer.	causal interaction	4	
3.4.21.78	Colorectal Neoplasms	https://pubmed.ncbi.nlm.nih.gov/28757355/	15-Lipoxygenase-1 re-expression in colorectal cancer alters endothelial cell features through enhanced expression of TSP-1 and ICAM-1.	diagnostic usage	3	
3.4.21.78	Colorectal Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	diagnostic usage	3	
3.4.21.78	Colorectal Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12963968/	Clinical significance of thrombospondin-1 expression in relation to vascular endothelial growth factor and interleukin-10 expression at the deepest invasive tumor site of advanced colorectal carcinoma.	diagnostic usage	4	
3.4.21.78	Colorectal Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17709727/	Association of angiogenesis markers with lymph node metastasis in early colorectal cancer.	diagnostic usage	4	
3.4.21.78	Colorectal Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27526615/	Thrombospondin-1 Mimetic Agonist Peptides Induce Selective Death in Tumor Cells: Design, Synthesis, and Structure-Activity Relationship Studies.	diagnostic usage	3	
3.4.21.78	Colorectal Neoplasms	https://pubmed.ncbi.nlm.nih.gov/28757355/	15-Lipoxygenase-1 re-expression in colorectal cancer alters endothelial cell features through enhanced expression of TSP-1 and ICAM-1.	therapeutic application	4	
3.4.21.78	Colorectal Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32640217/	Extracellular Granzyme A Promotes Colorectal Cancer Development by Enhancing Gut Inflammation.	therapeutic application	3	
3.4.21.78	Colorectal Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	therapeutic application	2	
3.4.21.78	Colorectal Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17709727/	Association of angiogenesis markers with lymph node metastasis in early colorectal cancer.	therapeutic application	1	
3.4.21.78	Colorectal Neoplasms	https://pubmed.ncbi.nlm.nih.gov/28757355/	15-Lipoxygenase-1 re-expression in colorectal cancer alters endothelial cell features through enhanced expression of TSP-1 and ICAM-1.	ongoing research	3	
3.4.21.78	Colorectal Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	ongoing research	4	
3.4.21.78	Colorectal Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12963968/	Clinical significance of thrombospondin-1 expression in relation to vascular endothelial growth factor and interleukin-10 expression at the deepest invasive tumor site of advanced colorectal carcinoma.	ongoing research	2	
3.4.21.78	Colorectal Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17709727/	Association of angiogenesis markers with lymph node metastasis in early colorectal cancer.	ongoing research	3	
3.4.21.78	Colorectal Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27526615/	Thrombospondin-1 Mimetic Agonist Peptides Induce Selective Death in Tumor Cells: Design, Synthesis, and Structure-Activity Relationship Studies.	ongoing research	2	
3.4.21.78	Colorectal Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32640217/	Extracellular Granzyme A Promotes Colorectal Cancer Development by Enhancing Gut Inflammation.	unassigned	-	
3.4.21.78	Colorectal Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27526615/	Thrombospondin-1 Mimetic Agonist Peptides Induce Selective Death in Tumor Cells: Design, Synthesis, and Structure-Activity Relationship Studies.	unassigned	-	
3.4.21.78	Colorectal Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12963968/	Clinical significance of thrombospondin-1 expression in relation to vascular endothelial growth factor and interleukin-10 expression at the deepest invasive tumor site of advanced colorectal carcinoma.	unassigned	-	
3.4.21.78	Coma	https://pubmed.ncbi.nlm.nih.gov/26521864/	Plasma thrombospondin-1 and clinical outcomes in traumatic brain injury.	causal interaction	4	
3.4.21.78	Coma	https://pubmed.ncbi.nlm.nih.gov/26521864/	Plasma thrombospondin-1 and clinical outcomes in traumatic brain injury.	diagnostic usage	4	
3.4.21.78	Coma	https://pubmed.ncbi.nlm.nih.gov/26521864/	Plasma thrombospondin-1 and clinical outcomes in traumatic brain injury.	ongoing research	4	
3.4.21.78	Coma	https://pubmed.ncbi.nlm.nih.gov/26521864/	Plasma thrombospondin-1 and clinical outcomes in traumatic brain injury.	unassigned	-	
3.4.21.78	Corneal Injuries	https://pubmed.ncbi.nlm.nih.gov/32636307/	BMP-1 disrupts cell adhesion and enhances TGF-? activation through cleavage of the matricellular protein thrombospondin-1.	causal interaction	4	
3.4.21.78	Corneal Injuries	https://pubmed.ncbi.nlm.nih.gov/32636307/	BMP-1 disrupts cell adhesion and enhances TGF-? activation through cleavage of the matricellular protein thrombospondin-1.	therapeutic application	3	
3.4.21.78	Corneal Injuries	https://pubmed.ncbi.nlm.nih.gov/32636307/	BMP-1 disrupts cell adhesion and enhances TGF-? activation through cleavage of the matricellular protein thrombospondin-1.	unassigned	-	
3.4.21.78	Corneal Neovascularization	https://pubmed.ncbi.nlm.nih.gov/11134179/	Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1.	therapeutic application	1	
3.4.21.78	Corneal Neovascularization	https://pubmed.ncbi.nlm.nih.gov/11423995/	c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1.	therapeutic application	2	
3.4.21.78	Corneal Neovascularization	https://pubmed.ncbi.nlm.nih.gov/18322241/	Protective Roles of the Fractalkine/CX3CL1-CX3CR1 Interactions in Alkali-Induced Corneal Neovascularization through Enhanced Antiangiogenic Factor Expression.	therapeutic application	4	
3.4.21.78	Corneal Neovascularization	https://pubmed.ncbi.nlm.nih.gov/21536744/	Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes.	therapeutic application	1	
3.4.21.78	Corneal Neovascularization	https://pubmed.ncbi.nlm.nih.gov/11134179/	Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1.	ongoing research	4	
3.4.21.78	Corneal Neovascularization	https://pubmed.ncbi.nlm.nih.gov/21536744/	Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes.	ongoing research	3	
3.4.21.78	Corneal Neovascularization	https://pubmed.ncbi.nlm.nih.gov/11134179/	Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1.	unassigned	-	
3.4.21.78	Corneal Neovascularization	https://pubmed.ncbi.nlm.nih.gov/11423995/	c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1.	unassigned	-	
3.4.21.78	Corneal Neovascularization	https://pubmed.ncbi.nlm.nih.gov/15037577/	Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis.	unassigned	-	
3.4.21.78	Corneal Neovascularization	https://pubmed.ncbi.nlm.nih.gov/18199835/	PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition.	unassigned	-	
3.4.21.78	Corneal Neovascularization	https://pubmed.ncbi.nlm.nih.gov/18322241/	Protective Roles of the Fractalkine/CX3CL1-CX3CR1 Interactions in Alkali-Induced Corneal Neovascularization through Enhanced Antiangiogenic Factor Expression.	unassigned	-	
3.4.21.78	Corneal Neovascularization	https://pubmed.ncbi.nlm.nih.gov/21536744/	Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes.	unassigned	-	
3.4.21.78	Coronary Artery Disease	https://pubmed.ncbi.nlm.nih.gov/22396697/	Higher plasma thrombospondin-1 levels in patients with coronary artery disease and diabetes mellitus.	diagnostic usage	3	
3.4.21.78	Coronary Artery Disease	https://pubmed.ncbi.nlm.nih.gov/22396697/	Higher plasma thrombospondin-1 levels in patients with coronary artery disease and diabetes mellitus.	ongoing research	4	
3.4.21.78	Coronary Artery Disease	https://pubmed.ncbi.nlm.nih.gov/22396697/	Higher plasma thrombospondin-1 levels in patients with coronary artery disease and diabetes mellitus.	unassigned	-	
3.4.21.78	COVID-19	https://pubmed.ncbi.nlm.nih.gov/32948688/	Impaired Cytotoxic CD8+ T Cell Response in Elderly COVID-19 Patients.	diagnostic usage	3	
3.4.21.78	COVID-19	https://pubmed.ncbi.nlm.nih.gov/33154753/	Elevated Exhaustion Levels of NK and CD8+ T Cells as Indicators for Progression and Prognosis of COVID-19 Disease.	diagnostic usage	4	
3.4.21.78	COVID-19	https://pubmed.ncbi.nlm.nih.gov/32948688/	Impaired Cytotoxic CD8+ T Cell Response in Elderly COVID-19 Patients.	therapeutic application	1	
3.4.21.78	COVID-19	https://pubmed.ncbi.nlm.nih.gov/32948688/	Impaired Cytotoxic CD8+ T Cell Response in Elderly COVID-19 Patients.	unassigned	-	
3.4.21.78	COVID-19	https://pubmed.ncbi.nlm.nih.gov/33154753/	Elevated Exhaustion Levels of NK and CD8+ T Cells as Indicators for Progression and Prognosis of COVID-19 Disease.	unassigned	-	
3.4.21.78	Cowpox	https://pubmed.ncbi.nlm.nih.gov/9882377/	Perforin is essential for control of ectromelia virus but not related poxviruses in mice.	unassigned	-	
3.4.21.78	Craniocerebral Trauma	https://pubmed.ncbi.nlm.nih.gov/26521864/	Plasma thrombospondin-1 and clinical outcomes in traumatic brain injury.	causal interaction	4	
3.4.21.78	Craniocerebral Trauma	https://pubmed.ncbi.nlm.nih.gov/26521864/	Plasma thrombospondin-1 and clinical outcomes in traumatic brain injury.	diagnostic usage	4	
3.4.21.78	Craniocerebral Trauma	https://pubmed.ncbi.nlm.nih.gov/26521864/	Plasma thrombospondin-1 and clinical outcomes in traumatic brain injury.	ongoing research	4	
3.4.21.78	Craniocerebral Trauma	https://pubmed.ncbi.nlm.nih.gov/26521864/	Plasma thrombospondin-1 and clinical outcomes in traumatic brain injury.	unassigned	-	
3.4.21.78	Crohn Disease	https://pubmed.ncbi.nlm.nih.gov/22870271/	CD47(Low) Status on CD4 Effectors Is Necessary for the Contraction/Resolution of the Immune Response in Humans and Mice.	diagnostic usage	1	
3.4.21.78	Crohn Disease	https://pubmed.ncbi.nlm.nih.gov/22870271/	CD47(Low) Status on CD4 Effectors Is Necessary for the Contraction/Resolution of the Immune Response in Humans and Mice.	unassigned	-	
3.4.21.78	Cysts	https://pubmed.ncbi.nlm.nih.gov/10051595/	Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization.	causal interaction	4	
3.4.21.78	Cysts	https://pubmed.ncbi.nlm.nih.gov/10051595/	Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization.	ongoing research	1	
3.4.21.78	Cysts	https://pubmed.ncbi.nlm.nih.gov/10051595/	Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization.	unassigned	-	
3.4.21.78	Dermatitis, Contact	https://pubmed.ncbi.nlm.nih.gov/19194474/	The Angiogenesis Inhibitor Thrombospondin-1 Inhibits Acute Cutaneous Hypersensitivity Reactions.	causal interaction	2	
3.4.21.78	Dermatitis, Contact	https://pubmed.ncbi.nlm.nih.gov/19194474/	The Angiogenesis Inhibitor Thrombospondin-1 Inhibits Acute Cutaneous Hypersensitivity Reactions.	therapeutic application	1	
3.4.21.78	Dermatitis, Contact	https://pubmed.ncbi.nlm.nih.gov/19194474/	The Angiogenesis Inhibitor Thrombospondin-1 Inhibits Acute Cutaneous Hypersensitivity Reactions.	ongoing research	4	
3.4.21.78	Dermatitis, Contact	https://pubmed.ncbi.nlm.nih.gov/19194474/	The Angiogenesis Inhibitor Thrombospondin-1 Inhibits Acute Cutaneous Hypersensitivity Reactions.	unassigned	-	
3.4.21.78	Dermatomyositis	https://pubmed.ncbi.nlm.nih.gov/32810267/	Biomarker profiles of endothelial activation and dysfunction in rare systemic autoimmune diseases: implications for cardiovascular risk.	unassigned	-	
3.4.21.78	Diabetes Complications	https://pubmed.ncbi.nlm.nih.gov/18096704/	Cell type-specific post-transcriptional regulation of production of the potent antiangiogenic and proatherogenic protein thrombospondin-1 by high glucose.	causal interaction	3	
3.4.21.78	Diabetes Complications	https://pubmed.ncbi.nlm.nih.gov/32626782/	Thrombospondin-1: A Key Protein That Induces Fibrosis in Diabetic Complications.	causal interaction	4	
3.4.21.78	Diabetes Complications	https://pubmed.ncbi.nlm.nih.gov/18096704/	Cell type-specific post-transcriptional regulation of production of the potent antiangiogenic and proatherogenic protein thrombospondin-1 by high glucose.	unassigned	-	
3.4.21.78	Diabetes Complications	https://pubmed.ncbi.nlm.nih.gov/32626782/	Thrombospondin-1: A Key Protein That Induces Fibrosis in Diabetic Complications.	unassigned	-	
3.4.21.78	Diabetes Mellitus	https://pubmed.ncbi.nlm.nih.gov/2179951/	Genes encoding tumor necrosis factor alpha and granzyme A are expressed during development of autoimmune diabetes.	causal interaction	4	
3.4.21.78	Diabetes Mellitus	https://pubmed.ncbi.nlm.nih.gov/25501558/	Thrombospondin-1 production is enhanced by Porphyromonas gingivalis lipopolysaccharide in THP-1 cells.	causal interaction	4	
3.4.21.78	Diabetes Mellitus	https://pubmed.ncbi.nlm.nih.gov/26573598/	Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus.	causal interaction	3	
3.4.21.78	Diabetes Mellitus	https://pubmed.ncbi.nlm.nih.gov/25501558/	Thrombospondin-1 production is enhanced by Porphyromonas gingivalis lipopolysaccharide in THP-1 cells.	diagnostic usage	3	
3.4.21.78	Diabetes Mellitus	https://pubmed.ncbi.nlm.nih.gov/26573598/	Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus.	diagnostic usage	3	
3.4.21.78	Diabetes Mellitus	https://pubmed.ncbi.nlm.nih.gov/25501558/	Thrombospondin-1 production is enhanced by Porphyromonas gingivalis lipopolysaccharide in THP-1 cells.	therapeutic application	1	
3.4.21.78	Diabetes Mellitus	https://pubmed.ncbi.nlm.nih.gov/2179951/	Genes encoding tumor necrosis factor alpha and granzyme A are expressed during development of autoimmune diabetes.	ongoing research	2	
3.4.21.78	Diabetes Mellitus	https://pubmed.ncbi.nlm.nih.gov/25501558/	Thrombospondin-1 production is enhanced by Porphyromonas gingivalis lipopolysaccharide in THP-1 cells.	ongoing research	4	
3.4.21.78	Diabetes Mellitus	https://pubmed.ncbi.nlm.nih.gov/2179951/	Genes encoding tumor necrosis factor alpha and granzyme A are expressed during development of autoimmune diabetes.	unassigned	-	
3.4.21.78	Diabetes Mellitus	https://pubmed.ncbi.nlm.nih.gov/26573598/	Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus.	unassigned	-	
3.4.21.78	Diabetes Mellitus, Type 1	https://pubmed.ncbi.nlm.nih.gov/2179951/	Genes encoding tumor necrosis factor alpha and granzyme A are expressed during development of autoimmune diabetes.	causal interaction	4	
3.4.21.78	Diabetes Mellitus, Type 1	https://pubmed.ncbi.nlm.nih.gov/7813805/	Accelerated beta-cell destruction in adoptively transferred autoimmune diabetes correlates with an increased expression of the genes coding for TNF-alpha and granzyme A in the intra-islet infiltrates.	causal interaction	2	
3.4.21.78	Diabetes Mellitus, Type 1	https://pubmed.ncbi.nlm.nih.gov/29162734/	Granzyme A in the Pathogenesis of Type 1 Diabetes: The Yes and the No.	causal interaction	3	
3.4.21.78	Diabetes Mellitus, Type 1	https://pubmed.ncbi.nlm.nih.gov/28733313/	Granzyme A-deficiency breaks immune tolerance and promotes Autoimmune Diabetes Through a Type I Interferon-Dependent Pathway.	causal interaction	4	
3.4.21.78	Diabetes Mellitus, Type 1	https://pubmed.ncbi.nlm.nih.gov/7813805/	Accelerated beta-cell destruction in adoptively transferred autoimmune diabetes correlates with an increased expression of the genes coding for TNF-alpha and granzyme A in the intra-islet infiltrates.	diagnostic usage	1	
3.4.21.78	Diabetes Mellitus, Type 1	https://pubmed.ncbi.nlm.nih.gov/28733313/	Granzyme A-deficiency breaks immune tolerance and promotes Autoimmune Diabetes Through a Type I Interferon-Dependent Pathway.	therapeutic application	4	
3.4.21.78	Diabetes Mellitus, Type 1	https://pubmed.ncbi.nlm.nih.gov/2179951/	Genes encoding tumor necrosis factor alpha and granzyme A are expressed during development of autoimmune diabetes.	ongoing research	2	
3.4.21.78	Diabetes Mellitus, Type 1	https://pubmed.ncbi.nlm.nih.gov/7813805/	Accelerated beta-cell destruction in adoptively transferred autoimmune diabetes correlates with an increased expression of the genes coding for TNF-alpha and granzyme A in the intra-islet infiltrates.	ongoing research	3	
3.4.21.78	Diabetes Mellitus, Type 1	https://pubmed.ncbi.nlm.nih.gov/28733313/	Granzyme A-deficiency breaks immune tolerance and promotes Autoimmune Diabetes Through a Type I Interferon-Dependent Pathway.	ongoing research	2	
3.4.21.78	Diabetes Mellitus, Type 1	https://pubmed.ncbi.nlm.nih.gov/8420039/	The use of granzyme A as a marker of heart transplant rejection in cyclosporine or anti-CD4 monoclonal antibody-treated rats.	unassigned	-	
3.4.21.78	Diabetes Mellitus, Type 1	https://pubmed.ncbi.nlm.nih.gov/2179951/	Genes encoding tumor necrosis factor alpha and granzyme A are expressed during development of autoimmune diabetes.	unassigned	-	
3.4.21.78	Diabetes Mellitus, Type 1	https://pubmed.ncbi.nlm.nih.gov/29162734/	Granzyme A in the Pathogenesis of Type 1 Diabetes: The Yes and the No.	unassigned	-	
3.4.21.78	Diabetes Mellitus, Type 1	https://pubmed.ncbi.nlm.nih.gov/28733313/	Granzyme A-deficiency breaks immune tolerance and promotes Autoimmune Diabetes Through a Type I Interferon-Dependent Pathway.	unassigned	-	
3.4.21.78	Diabetes Mellitus, Type 1	https://pubmed.ncbi.nlm.nih.gov/7813805/	Accelerated beta-cell destruction in adoptively transferred autoimmune diabetes correlates with an increased expression of the genes coding for TNF-alpha and granzyme A in the intra-islet infiltrates.	unassigned	-	
3.4.21.78	Diabetic Angiopathies	https://pubmed.ncbi.nlm.nih.gov/20299182/	Thrombospondin-1: a proatherosclerotic protein augmented by hyperglycemia.	causal interaction	4	
3.4.21.78	Diabetic Angiopathies	https://pubmed.ncbi.nlm.nih.gov/28345659/	Oral chromium picolinate impedes hyperglycemia-induced atherosclerosis and inhibits proatherogenic protein TSP-1 expression in STZ-induced type 1 diabetic ApoE(-/-) mice.	causal interaction	4	
3.4.21.78	Diabetic Angiopathies	https://pubmed.ncbi.nlm.nih.gov/20299182/	Thrombospondin-1: a proatherosclerotic protein augmented by hyperglycemia.	diagnostic usage	3	
3.4.21.78	Diabetic Angiopathies	https://pubmed.ncbi.nlm.nih.gov/20299182/	Thrombospondin-1: a proatherosclerotic protein augmented by hyperglycemia.	therapeutic application	3	
3.4.21.78	Diabetic Angiopathies	https://pubmed.ncbi.nlm.nih.gov/28345659/	Oral chromium picolinate impedes hyperglycemia-induced atherosclerosis and inhibits proatherogenic protein TSP-1 expression in STZ-induced type 1 diabetic ApoE(-/-) mice.	therapeutic application	4	
3.4.21.78	Diabetic Angiopathies	https://pubmed.ncbi.nlm.nih.gov/20299182/	Thrombospondin-1: a proatherosclerotic protein augmented by hyperglycemia.	ongoing research	2	
3.4.21.78	Diabetic Angiopathies	https://pubmed.ncbi.nlm.nih.gov/28345659/	Oral chromium picolinate impedes hyperglycemia-induced atherosclerosis and inhibits proatherogenic protein TSP-1 expression in STZ-induced type 1 diabetic ApoE(-/-) mice.	ongoing research	2	
3.4.21.78	Diabetic Angiopathies	https://pubmed.ncbi.nlm.nih.gov/28345659/	Oral chromium picolinate impedes hyperglycemia-induced atherosclerosis and inhibits proatherogenic protein TSP-1 expression in STZ-induced type 1 diabetic ApoE(-/-) mice.	unassigned	-	
3.4.21.78	Diabetic Cardiomyopathies	https://pubmed.ncbi.nlm.nih.gov/20878350/	The role of thrombospondin-1-mediated TGF-?1 on collagen type III synthesis induced by high glucose.	causal interaction	4	
3.4.21.78	Diabetic Cardiomyopathies	https://pubmed.ncbi.nlm.nih.gov/20878350/	The role of thrombospondin-1-mediated TGF-?1 on collagen type III synthesis induced by high glucose.	therapeutic application	4	
3.4.21.78	Diabetic Cardiomyopathies	https://pubmed.ncbi.nlm.nih.gov/20878350/	The role of thrombospondin-1-mediated TGF-?1 on collagen type III synthesis induced by high glucose.	unassigned	-	
3.4.21.78	Diabetic Nephropathies	https://pubmed.ncbi.nlm.nih.gov/16495290/	Elevated glucose induction of thrombospondin-1 up-regulates fibronectin synthesis in proximal renal tubular epithelial cells through TGF-beta1 dependent and TGF-beta1 independent pathways.	causal interaction	3	
3.4.21.78	Diabetic Nephropathies	https://pubmed.ncbi.nlm.nih.gov/17878288/	Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo.	causal interaction	3	
3.4.21.78	Diabetic Nephropathies	https://pubmed.ncbi.nlm.nih.gov/18676351/	Correlation of enhanced thrombospondin-1 expression, TGF-beta signalling and proteinuria in human type-2 diabetic nephropathy.	causal interaction	4	
3.4.21.78	Diabetic Nephropathies	https://pubmed.ncbi.nlm.nih.gov/17878288/	Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo.	therapeutic application	1	
3.4.21.78	Diabetic Nephropathies	https://pubmed.ncbi.nlm.nih.gov/18676351/	Correlation of enhanced thrombospondin-1 expression, TGF-beta signalling and proteinuria in human type-2 diabetic nephropathy.	therapeutic application	2	
3.4.21.78	Diabetic Nephropathies	https://pubmed.ncbi.nlm.nih.gov/16495290/	Elevated glucose induction of thrombospondin-1 up-regulates fibronectin synthesis in proximal renal tubular epithelial cells through TGF-beta1 dependent and TGF-beta1 independent pathways.	unassigned	-	
3.4.21.78	Diabetic Nephropathies	https://pubmed.ncbi.nlm.nih.gov/17878288/	Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo.	unassigned	-	
3.4.21.78	Diabetic Nephropathies	https://pubmed.ncbi.nlm.nih.gov/18676351/	Correlation of enhanced thrombospondin-1 expression, TGF-beta signalling and proteinuria in human type-2 diabetic nephropathy.	unassigned	-	
3.4.21.78	Diabetic Neuropathies	https://pubmed.ncbi.nlm.nih.gov/32053260/	Exercise and IGF-1 supplementation improve angiogenesis and angiogenic cytokines in a rat model of diabetes-induced neuropathy.	causal interaction	3	
3.4.21.78	Diabetic Neuropathies	https://pubmed.ncbi.nlm.nih.gov/32053260/	Exercise and IGF-1 supplementation improve angiogenesis and angiogenic cytokines in a rat model of diabetes-induced neuropathy.	unassigned	-	
3.4.21.78	Diabetic Retinopathy	https://pubmed.ncbi.nlm.nih.gov/19365032/	Modulation of thrombospondin 1 and pigment epithelium-derived factor levels in vitreous fluid of patients with diabetes.	causal interaction	4	
3.4.21.78	Diabetic Retinopathy	https://pubmed.ncbi.nlm.nih.gov/17063547/	[Effects of pioglitazone on MKP-1 and TSP-1 expression in early stages of diabetic retinopathy induced by streptozotocin]	diagnostic usage	2	
3.4.21.78	Diabetic Retinopathy	https://pubmed.ncbi.nlm.nih.gov/25138030/	Thrombospondin-1 is produced by retinal glial cells and inhibits the growth of vascular endothelial cells.	diagnostic usage	3	
3.4.21.78	Diabetic Retinopathy	https://pubmed.ncbi.nlm.nih.gov/17063547/	[Effects of pioglitazone on MKP-1 and TSP-1 expression in early stages of diabetic retinopathy induced by streptozotocin]	ongoing research	2	
3.4.21.78	Diabetic Retinopathy	https://pubmed.ncbi.nlm.nih.gov/17966456/	[The changes of TSP-1 expression in the retina of STZ-induced rat diabetic mellitus model with pioglitazone]	ongoing research	2	
3.4.21.78	Diabetic Retinopathy	https://pubmed.ncbi.nlm.nih.gov/25138030/	Thrombospondin-1 is produced by retinal glial cells and inhibits the growth of vascular endothelial cells.	ongoing research	2	
3.4.21.78	Diabetic Retinopathy	https://pubmed.ncbi.nlm.nih.gov/17063547/	[Effects of pioglitazone on MKP-1 and TSP-1 expression in early stages of diabetic retinopathy induced by streptozotocin]	unassigned	-	
3.4.21.78	Diabetic Retinopathy	https://pubmed.ncbi.nlm.nih.gov/17966456/	[The changes of TSP-1 expression in the retina of STZ-induced rat diabetic mellitus model with pioglitazone]	unassigned	-	
3.4.21.78	Diabetic Retinopathy	https://pubmed.ncbi.nlm.nih.gov/25138030/	Thrombospondin-1 is produced by retinal glial cells and inhibits the growth of vascular endothelial cells.	unassigned	-	
3.4.21.78	Diabetic Retinopathy	https://pubmed.ncbi.nlm.nih.gov/19365032/	Modulation of thrombospondin 1 and pigment epithelium-derived factor levels in vitreous fluid of patients with diabetes.	unassigned	-	
3.4.21.78	Diphtheria	https://pubmed.ncbi.nlm.nih.gov/7479752/	Transgenic mice carrying the diphtheria toxin A chain gene under the control of the granzyme A promoter: expected depletion of cytotoxic cells and unexpected depletion of CD8 T cells.	ongoing research	4	
3.4.21.78	Diphtheria	https://pubmed.ncbi.nlm.nih.gov/8608208/	Hematopoietic stem cells are not direct cytotoxic targets of natural killer cells.	ongoing research	2	
3.4.21.78	Diphtheria	https://pubmed.ncbi.nlm.nih.gov/7479752/	Transgenic mice carrying the diphtheria toxin A chain gene under the control of the granzyme A promoter: expected depletion of cytotoxic cells and unexpected depletion of CD8 T cells.	unassigned	-	
3.4.21.78	Diphtheria	https://pubmed.ncbi.nlm.nih.gov/8608208/	Hematopoietic stem cells are not direct cytotoxic targets of natural killer cells.	unassigned	-	
3.4.21.78	Down Syndrome	https://pubmed.ncbi.nlm.nih.gov/15385927/	Identification of novel direct transcriptional targets of glucocorticoid receptor.	unassigned	-	
3.4.21.78	Dry Eye Syndromes	https://pubmed.ncbi.nlm.nih.gov/19700744/	Sjögren's syndrome-like ocular surface disease in thrombospondin-1 deficient mice.	causal interaction	4	
3.4.21.78	Dry Eye Syndromes	https://pubmed.ncbi.nlm.nih.gov/26154823/	Thrombospondin-1 as a Regulator of Corneal Inflammation and Lymphangiogenesis: Effects on Dry Eye Disease and Corneal Graft Immunology.	causal interaction	1	
3.4.21.78	Dry Eye Syndromes	https://pubmed.ncbi.nlm.nih.gov/31173926/	Thrombospondin-1 in ocular surface health and disease.	therapeutic application	2	
3.4.21.78	Dry Eye Syndromes	https://pubmed.ncbi.nlm.nih.gov/26154823/	Thrombospondin-1 as a Regulator of Corneal Inflammation and Lymphangiogenesis: Effects on Dry Eye Disease and Corneal Graft Immunology.	ongoing research	2	
3.4.21.78	Dry Eye Syndromes	https://pubmed.ncbi.nlm.nih.gov/31173926/	Thrombospondin-1 in ocular surface health and disease.	unassigned	-	
3.4.21.78	Dry Eye Syndromes	https://pubmed.ncbi.nlm.nih.gov/19700744/	Sjögren's syndrome-like ocular surface disease in thrombospondin-1 deficient mice.	unassigned	-	
3.4.21.78	Dry Eye Syndromes	https://pubmed.ncbi.nlm.nih.gov/26154823/	Thrombospondin-1 as a Regulator of Corneal Inflammation and Lymphangiogenesis: Effects on Dry Eye Disease and Corneal Graft Immunology.	unassigned	-	
3.4.21.78	Dysentery	https://pubmed.ncbi.nlm.nih.gov/12011015/	Apoptosis in acute shigellosis is associated with increased production of Fas/Fas ligand, perforin, caspase-1, and caspase-3 but reduced production of Bcl-2 and interleukin-2.	causal interaction	3	
3.4.21.78	Dysentery	https://pubmed.ncbi.nlm.nih.gov/12011015/	Apoptosis in acute shigellosis is associated with increased production of Fas/Fas ligand, perforin, caspase-1, and caspase-3 but reduced production of Bcl-2 and interleukin-2.	diagnostic usage	1	
3.4.21.78	Dysentery	https://pubmed.ncbi.nlm.nih.gov/12011015/	Apoptosis in acute shigellosis is associated with increased production of Fas/Fas ligand, perforin, caspase-1, and caspase-3 but reduced production of Bcl-2 and interleukin-2.	therapeutic application	1	
3.4.21.78	Dysentery	https://pubmed.ncbi.nlm.nih.gov/12011015/	Apoptosis in acute shigellosis is associated with increased production of Fas/Fas ligand, perforin, caspase-1, and caspase-3 but reduced production of Bcl-2 and interleukin-2.	unassigned	-	
3.4.21.78	Dysplastic Nevus Syndrome	https://pubmed.ncbi.nlm.nih.gov/25256553/	Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2.	causal interaction	2	
3.4.21.78	Dysplastic Nevus Syndrome	https://pubmed.ncbi.nlm.nih.gov/25256553/	Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2.	diagnostic usage	3	
3.4.21.78	Dysplastic Nevus Syndrome	https://pubmed.ncbi.nlm.nih.gov/25256553/	Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2.	therapeutic application	1	
3.4.21.78	Dysplastic Nevus Syndrome	https://pubmed.ncbi.nlm.nih.gov/25256553/	Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2.	ongoing research	4	
3.4.21.78	Ectromelia	https://pubmed.ncbi.nlm.nih.gov/10570179/	Granzymes are the essential downstream effector molecules for the control of primary virus infections by cytolytic leukocytes.	therapeutic application	2	
3.4.21.78	Ectromelia	https://pubmed.ncbi.nlm.nih.gov/19838298/	Caspase-dependent inhibition of mousepox replication by gzmB.	therapeutic application	1	
3.4.21.78	Ectromelia	https://pubmed.ncbi.nlm.nih.gov/8650169/	Granzyme A is critical for recovery of mice from infection with the natural cytopathic viral pathogen, ectromelia.	ongoing research	2	
3.4.21.78	Ectromelia	https://pubmed.ncbi.nlm.nih.gov/19838298/	Caspase-dependent inhibition of mousepox replication by gzmB.	ongoing research	3	
3.4.21.78	Ectromelia	https://pubmed.ncbi.nlm.nih.gov/8650169/	Granzyme A is critical for recovery of mice from infection with the natural cytopathic viral pathogen, ectromelia.	unassigned	-	
3.4.21.78	Ectromelia	https://pubmed.ncbi.nlm.nih.gov/10570179/	Granzymes are the essential downstream effector molecules for the control of primary virus infections by cytolytic leukocytes.	unassigned	-	
3.4.21.78	Ectromelia	https://pubmed.ncbi.nlm.nih.gov/19838298/	Caspase-dependent inhibition of mousepox replication by gzmB.	unassigned	-	
3.4.21.78	Encephalomyelitis, Autoimmune, Experimental	https://pubmed.ncbi.nlm.nih.gov/8058766/	Granzyme A released upon stimulation of cytotoxic T lymphocytes activates the thrombin receptor on neuronal cells and astrocytes.	unassigned	-	
3.4.21.78	Endometrial Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10502735/	Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas.	causal interaction	4	
3.4.21.78	Endometrial Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11445843/	Thrombospondin-1 and -2 messenger RNA expression in normal and neoplastic endometrial tissues: correlation with angiogenesis and prognosis.	causal interaction	4	
3.4.21.78	Endometrial Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19690133/	Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis.	causal interaction	4	
3.4.21.78	Endometrial Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22904162/	microRNAs related to angiogenesis are dysregulated in endometrioid endometrial cancer.	causal interaction	1	
3.4.21.78	Endometrial Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10502735/	Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas.	diagnostic usage	3	
3.4.21.78	Endometrial Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11445843/	Thrombospondin-1 and -2 messenger RNA expression in normal and neoplastic endometrial tissues: correlation with angiogenesis and prognosis.	diagnostic usage	4	
3.4.21.78	Endometrial Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19690133/	Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis.	diagnostic usage	3	
3.4.21.78	Endometrial Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10502735/	Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas.	therapeutic application	1	
3.4.21.78	Endometrial Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19690133/	Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis.	therapeutic application	4	
3.4.21.78	Endometrial Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10502735/	Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas.	ongoing research	2	
3.4.21.78	Endometrial Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19690133/	Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis.	ongoing research	2	
3.4.21.78	Endometrial Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22904162/	microRNAs related to angiogenesis are dysregulated in endometrioid endometrial cancer.	unassigned	-	
3.4.21.78	Endometrial Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11445843/	Thrombospondin-1 and -2 messenger RNA expression in normal and neoplastic endometrial tissues: correlation with angiogenesis and prognosis.	unassigned	-	
3.4.21.78	Endometriosis	https://pubmed.ncbi.nlm.nih.gov/12095505/	Expression of vascular endothelial growth factor and thrombospondin-1 mRNA in patients with endometriosis.	causal interaction	3	
3.4.21.78	Endometriosis	https://pubmed.ncbi.nlm.nih.gov/16136892/	[Expression of vascular endothelial growth factor and thrombospondin-1 in the ectopic and eutopic endometrium of women with endometriosis]	causal interaction	4	
3.4.21.78	Endometriosis	https://pubmed.ncbi.nlm.nih.gov/21335415/	microRNAs expression in endometriosis and their relation to angiogenic factors.	causal interaction	1	
3.4.21.78	Endometriosis	https://pubmed.ncbi.nlm.nih.gov/23749764/	Influence of Ovarian Endometrioma on Expression of Steroid Receptor RNA Activator, Estrogen Receptors, Vascular Endothelial Growth Factor, and Thrombospondin 1 in the Surrounding Ovarian Tissues.	causal interaction	4	
3.4.21.78	Endometriosis	https://pubmed.ncbi.nlm.nih.gov/12095505/	Expression of vascular endothelial growth factor and thrombospondin-1 mRNA in patients with endometriosis.	diagnostic usage	4	
3.4.21.78	Endometriosis	https://pubmed.ncbi.nlm.nih.gov/16136892/	[Expression of vascular endothelial growth factor and thrombospondin-1 in the ectopic and eutopic endometrium of women with endometriosis]	diagnostic usage	4	
3.4.21.78	Endometriosis	https://pubmed.ncbi.nlm.nih.gov/21335415/	microRNAs expression in endometriosis and their relation to angiogenic factors.	diagnostic usage	1	
3.4.21.78	Endometriosis	https://pubmed.ncbi.nlm.nih.gov/23749764/	Influence of Ovarian Endometrioma on Expression of Steroid Receptor RNA Activator, Estrogen Receptors, Vascular Endothelial Growth Factor, and Thrombospondin 1 in the Surrounding Ovarian Tissues.	diagnostic usage	2	
3.4.21.78	Endometriosis	https://pubmed.ncbi.nlm.nih.gov/16136892/	[Expression of vascular endothelial growth factor and thrombospondin-1 in the ectopic and eutopic endometrium of women with endometriosis]	therapeutic application	1	
3.4.21.78	Endometriosis	https://pubmed.ncbi.nlm.nih.gov/12095505/	Expression of vascular endothelial growth factor and thrombospondin-1 mRNA in patients with endometriosis.	ongoing research	3	
3.4.21.78	Endometriosis	https://pubmed.ncbi.nlm.nih.gov/16136892/	[Expression of vascular endothelial growth factor and thrombospondin-1 in the ectopic and eutopic endometrium of women with endometriosis]	ongoing research	3	
3.4.21.78	Endometriosis	https://pubmed.ncbi.nlm.nih.gov/23749764/	Influence of Ovarian Endometrioma on Expression of Steroid Receptor RNA Activator, Estrogen Receptors, Vascular Endothelial Growth Factor, and Thrombospondin 1 in the Surrounding Ovarian Tissues.	ongoing research	3	
3.4.21.78	Endometriosis	https://pubmed.ncbi.nlm.nih.gov/12095505/	Expression of vascular endothelial growth factor and thrombospondin-1 mRNA in patients with endometriosis.	unassigned	-	
3.4.21.78	Endometriosis	https://pubmed.ncbi.nlm.nih.gov/21335415/	microRNAs expression in endometriosis and their relation to angiogenic factors.	unassigned	-	
3.4.21.78	Endometriosis	https://pubmed.ncbi.nlm.nih.gov/23749764/	Influence of Ovarian Endometrioma on Expression of Steroid Receptor RNA Activator, Estrogen Receptors, Vascular Endothelial Growth Factor, and Thrombospondin 1 in the Surrounding Ovarian Tissues.	unassigned	-	
3.4.21.78	Enteritis	https://pubmed.ncbi.nlm.nih.gov/17213646/	A role of a lymphocyte tryptase, granzyme A, in experimental ulcerative colitis.	therapeutic application	2	
3.4.21.78	Enteritis	https://pubmed.ncbi.nlm.nih.gov/17213646/	A role of a lymphocyte tryptase, granzyme A, in experimental ulcerative colitis.	ongoing research	2	
3.4.21.78	Enteritis	https://pubmed.ncbi.nlm.nih.gov/17213646/	A role of a lymphocyte tryptase, granzyme A, in experimental ulcerative colitis.	unassigned	-	
3.4.21.78	Epilepsies, Partial	https://pubmed.ncbi.nlm.nih.gov/30386206/	A Purinergic P2 Receptor Family-Mediated Increase in Thrombospondin-1 Bolsters Synaptic Density and Epileptic Seizure Activity in the Amygdala-Kindling Rat Model.	causal interaction	2	
3.4.21.78	Epilepsies, Partial	https://pubmed.ncbi.nlm.nih.gov/30386206/	A Purinergic P2 Receptor Family-Mediated Increase in Thrombospondin-1 Bolsters Synaptic Density and Epileptic Seizure Activity in the Amygdala-Kindling Rat Model.	diagnostic usage	2	
3.4.21.78	Epilepsies, Partial	https://pubmed.ncbi.nlm.nih.gov/30386206/	A Purinergic P2 Receptor Family-Mediated Increase in Thrombospondin-1 Bolsters Synaptic Density and Epileptic Seizure Activity in the Amygdala-Kindling Rat Model.	therapeutic application	1	
3.4.21.78	Epilepsies, Partial	https://pubmed.ncbi.nlm.nih.gov/30386206/	A Purinergic P2 Receptor Family-Mediated Increase in Thrombospondin-1 Bolsters Synaptic Density and Epileptic Seizure Activity in the Amygdala-Kindling Rat Model.	ongoing research	4	
3.4.21.78	Epilepsy	https://pubmed.ncbi.nlm.nih.gov/32848539/	Serum Exosomal Proteins F9 and TSP-1 as Potential Diagnostic Biomarkers for Newly Diagnosed Epilepsy.	causal interaction	1	
3.4.21.78	Epilepsy	https://pubmed.ncbi.nlm.nih.gov/31664678/	Role of Elevated Thrombospondin-1 in Kainic Acid-Induced Status Epilepticus.	causal interaction	4	
3.4.21.78	Epilepsy	https://pubmed.ncbi.nlm.nih.gov/32848539/	Serum Exosomal Proteins F9 and TSP-1 as Potential Diagnostic Biomarkers for Newly Diagnosed Epilepsy.	diagnostic usage	4	
3.4.21.78	Epilepsy	https://pubmed.ncbi.nlm.nih.gov/32848539/	Serum Exosomal Proteins F9 and TSP-1 as Potential Diagnostic Biomarkers for Newly Diagnosed Epilepsy.	therapeutic application	1	
3.4.21.78	Epilepsy	https://pubmed.ncbi.nlm.nih.gov/31664678/	Role of Elevated Thrombospondin-1 in Kainic Acid-Induced Status Epilepticus.	therapeutic application	1	
3.4.21.78	Epilepsy	https://pubmed.ncbi.nlm.nih.gov/31664678/	Role of Elevated Thrombospondin-1 in Kainic Acid-Induced Status Epilepticus.	unassigned	-	
3.4.21.78	Epilepsy	https://pubmed.ncbi.nlm.nih.gov/32848539/	Serum Exosomal Proteins F9 and TSP-1 as Potential Diagnostic Biomarkers for Newly Diagnosed Epilepsy.	unassigned	-	
3.4.21.78	Epiretinal Membrane	https://pubmed.ncbi.nlm.nih.gov/25138030/	Thrombospondin-1 is produced by retinal glial cells and inhibits the growth of vascular endothelial cells.	diagnostic usage	3	
3.4.21.78	Epiretinal Membrane	https://pubmed.ncbi.nlm.nih.gov/25138030/	Thrombospondin-1 is produced by retinal glial cells and inhibits the growth of vascular endothelial cells.	ongoing research	2	
3.4.21.78	Epiretinal Membrane	https://pubmed.ncbi.nlm.nih.gov/25138030/	Thrombospondin-1 is produced by retinal glial cells and inhibits the growth of vascular endothelial cells.	unassigned	-	
3.4.21.78	Erectile Dysfunction	https://pubmed.ncbi.nlm.nih.gov/20215829/	Expression changes of transforming growth factor-beta1 and thrombospondin-1 in cavernous tissues of diabetic rats.	causal interaction	4	
3.4.21.78	Erectile Dysfunction	https://pubmed.ncbi.nlm.nih.gov/20215829/	Expression changes of transforming growth factor-beta1 and thrombospondin-1 in cavernous tissues of diabetic rats.	unassigned	-	
3.4.21.78	Fatty Liver	https://pubmed.ncbi.nlm.nih.gov/31891606/	Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).	causal interaction	4	
3.4.21.78	Fatty Liver	https://pubmed.ncbi.nlm.nih.gov/31891606/	Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).	ongoing research	4	
3.4.21.78	Fatty Liver	https://pubmed.ncbi.nlm.nih.gov/31891606/	Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).	unassigned	-	
3.4.21.78	Fibroadenoma	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	causal interaction	4	
3.4.21.78	Fibroadenoma	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	diagnostic usage	3	
3.4.21.78	Fibroadenoma	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	ongoing research	4	
3.4.21.78	Fibroadenoma	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	unassigned	-	
3.4.21.78	Fibrosarcoma	https://pubmed.ncbi.nlm.nih.gov/14511656/	Restoration of thrombospondin 1 expression in tumor cells harbouring mutant ras oncogene by treatment with low doses of doxycycline.	causal interaction	3	
3.4.21.78	Fibrosarcoma	https://pubmed.ncbi.nlm.nih.gov/14511656/	Restoration of thrombospondin 1 expression in tumor cells harbouring mutant ras oncogene by treatment with low doses of doxycycline.	diagnostic usage	2	
3.4.21.78	Fibrosarcoma	https://pubmed.ncbi.nlm.nih.gov/15321749/	[Inhibition of fibrosarcoma growth in mice by antibody against B cell epitope on mouse Toll-like receptor-2 extracellular domain]	diagnostic usage	1	
3.4.21.78	Fibrosarcoma	https://pubmed.ncbi.nlm.nih.gov/15321749/	[Inhibition of fibrosarcoma growth in mice by antibody against B cell epitope on mouse Toll-like receptor-2 extracellular domain]	therapeutic application	1	
3.4.21.78	Fibrosarcoma	https://pubmed.ncbi.nlm.nih.gov/14511656/	Restoration of thrombospondin 1 expression in tumor cells harbouring mutant ras oncogene by treatment with low doses of doxycycline.	ongoing research	2	
3.4.21.78	Fibrosarcoma	https://pubmed.ncbi.nlm.nih.gov/15321749/	[Inhibition of fibrosarcoma growth in mice by antibody against B cell epitope on mouse Toll-like receptor-2 extracellular domain]	ongoing research	3	
3.4.21.78	Fibrosarcoma	https://pubmed.ncbi.nlm.nih.gov/16204059/	Oncogenes and Angiogenesis: down-regulation of thrombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras.	ongoing research	3	
3.4.21.78	Fibrosarcoma	https://pubmed.ncbi.nlm.nih.gov/15321749/	[Inhibition of fibrosarcoma growth in mice by antibody against B cell epitope on mouse Toll-like receptor-2 extracellular domain]	unassigned	-	
3.4.21.78	Fibrosarcoma	https://pubmed.ncbi.nlm.nih.gov/16204059/	Oncogenes and Angiogenesis: down-regulation of thrombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras.	unassigned	-	
3.4.21.78	Fibrosarcoma	https://pubmed.ncbi.nlm.nih.gov/14511656/	Restoration of thrombospondin 1 expression in tumor cells harbouring mutant ras oncogene by treatment with low doses of doxycycline.	unassigned	-	
3.4.21.78	Fragile X Syndrome	https://pubmed.ncbi.nlm.nih.gov/27485117/	Astrocyte-secreted thrombospondin-1 modulates synapse and spine defects in the fragile X mouse model.	causal interaction	1	
3.4.21.78	Fragile X Syndrome	https://pubmed.ncbi.nlm.nih.gov/27485117/	Astrocyte-secreted thrombospondin-1 modulates synapse and spine defects in the fragile X mouse model.	therapeutic application	4	
3.4.21.78	Fragile X Syndrome	https://pubmed.ncbi.nlm.nih.gov/27485117/	Astrocyte-secreted thrombospondin-1 modulates synapse and spine defects in the fragile X mouse model.	unassigned	-	
3.4.21.78	Ganglioneuroma	https://pubmed.ncbi.nlm.nih.gov/15623630/	Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.	diagnostic usage	4	
3.4.21.78	Ganglioneuroma	https://pubmed.ncbi.nlm.nih.gov/15623630/	Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.	ongoing research	4	
3.4.21.78	Ganglioneuroma	https://pubmed.ncbi.nlm.nih.gov/15623630/	Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.	unassigned	-	
3.4.21.78	Genetic Diseases, Inborn	https://pubmed.ncbi.nlm.nih.gov/15094109/	The thrombospondins.	unassigned	-	
3.4.21.78	Glaucoma	https://pubmed.ncbi.nlm.nih.gov/15500824/	Thrombospondin-1 in the trabecular meshwork: localization in normal and glaucomatous eyes, and induction by TGF-beta1 and dexamethasone in vitro.	diagnostic usage	3	
3.4.21.78	Glaucoma	https://pubmed.ncbi.nlm.nih.gov/15500824/	Thrombospondin-1 in the trabecular meshwork: localization in normal and glaucomatous eyes, and induction by TGF-beta1 and dexamethasone in vitro.	unassigned	-	
3.4.21.78	Glioblastoma	https://pubmed.ncbi.nlm.nih.gov/25358253/	Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas.	causal interaction	3	
3.4.21.78	Glioblastoma	https://pubmed.ncbi.nlm.nih.gov/10811871/	Thrombospondin-1 is downregulated by anoxia and suppresses tumorigenicity of human glioblastoma cells.	causal interaction	4	
3.4.21.78	Glioblastoma	https://pubmed.ncbi.nlm.nih.gov/11132930/	Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma.	causal interaction	4	
3.4.21.78	Glioblastoma	https://pubmed.ncbi.nlm.nih.gov/11745436/	Antisense-mediated reduction in thrombospondin-1 expression reduces cell motility in malignant glioma cells.	causal interaction	4	
3.4.21.78	Glioblastoma	https://pubmed.ncbi.nlm.nih.gov/12825818/	Cell density regulates thrombospondin-1 production in malignant glioma cells.	causal interaction	3	
3.4.21.78	Glioblastoma	https://pubmed.ncbi.nlm.nih.gov/11132930/	Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma.	diagnostic usage	3	
3.4.21.78	Glioblastoma	https://pubmed.ncbi.nlm.nih.gov/11132930/	Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma.	therapeutic application	1	
3.4.21.78	Glioblastoma	https://pubmed.ncbi.nlm.nih.gov/29856660/	Reverting the molecular fingerprint of tumor dormancy as a therapeutic strategy for glioblastoma.	therapeutic application	3	
3.4.21.78	Glioblastoma	https://pubmed.ncbi.nlm.nih.gov/15779089/	Downregulation of GFAP, TSP-1, and p53 in human glioblastoma cell line, U373MG, by IE1 protein from human cytomegalovirus.	ongoing research	4	
3.4.21.78	Glioblastoma	https://pubmed.ncbi.nlm.nih.gov/25358253/	Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas.	ongoing research	2	
3.4.21.78	Glioblastoma	https://pubmed.ncbi.nlm.nih.gov/11132930/	Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma.	ongoing research	4	
3.4.21.78	Glioblastoma	https://pubmed.ncbi.nlm.nih.gov/11745436/	Antisense-mediated reduction in thrombospondin-1 expression reduces cell motility in malignant glioma cells.	ongoing research	3	
3.4.21.78	Glioblastoma	https://pubmed.ncbi.nlm.nih.gov/12825818/	Cell density regulates thrombospondin-1 production in malignant glioma cells.	ongoing research	4	
3.4.21.78	Glioblastoma	https://pubmed.ncbi.nlm.nih.gov/29856660/	Reverting the molecular fingerprint of tumor dormancy as a therapeutic strategy for glioblastoma.	ongoing research	4	
3.4.21.78	Glioblastoma	https://pubmed.ncbi.nlm.nih.gov/15779089/	Downregulation of GFAP, TSP-1, and p53 in human glioblastoma cell line, U373MG, by IE1 protein from human cytomegalovirus.	unassigned	-	
3.4.21.78	Glioblastoma	https://pubmed.ncbi.nlm.nih.gov/29856660/	Reverting the molecular fingerprint of tumor dormancy as a therapeutic strategy for glioblastoma.	unassigned	-	
3.4.21.78	Glioblastoma	https://pubmed.ncbi.nlm.nih.gov/25358253/	Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas.	unassigned	-	
3.4.21.78	Glioblastoma	https://pubmed.ncbi.nlm.nih.gov/10811871/	Thrombospondin-1 is downregulated by anoxia and suppresses tumorigenicity of human glioblastoma cells.	unassigned	-	
3.4.21.78	Glioblastoma	https://pubmed.ncbi.nlm.nih.gov/11745436/	Antisense-mediated reduction in thrombospondin-1 expression reduces cell motility in malignant glioma cells.	unassigned	-	
3.4.21.78	Glioblastoma	https://pubmed.ncbi.nlm.nih.gov/12825818/	Cell density regulates thrombospondin-1 production in malignant glioma cells.	unassigned	-	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/24348828/	Correlation between TSP-1, TGF-? and PPAR-? expression levels and glioma microvascular density.	causal interaction	4	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/25621889/	EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas.	causal interaction	4	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/11132930/	Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma.	causal interaction	4	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/11396305/	Participation of thrombospondin-1 in the activation of latent transforming growth factor-beta in malignant glioma cells.	causal interaction	4	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/11745436/	Antisense-mediated reduction in thrombospondin-1 expression reduces cell motility in malignant glioma cells.	causal interaction	4	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/11861403/	Overexpression of thrombospondin-1 reduces growth and vascular index but not perfusion in glioblastoma.	causal interaction	4	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/15662972/	Quantification of thrombospondin-1 secretion and expression of alphavbeta3 and alpha3beta1 integrins and syndecan-1 as cell-surface receptors for thrombospondin-1 in malignant glioma cells.	causal interaction	4	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/27167139/	Cytotoxic CD4(+) T cells are correlated with better prognosis in Han Chinese grade II and grade III glioma subjects and are suppressed by PD-1 signaling.	causal interaction	1	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/33759165/	Circulating Levels of Thrombospondin-1 and Thrombospondin-2 in Patients with Common Brain Tumors.	causal interaction	4	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/24348828/	Correlation between TSP-1, TGF-? and PPAR-? expression levels and glioma microvascular density.	diagnostic usage	4	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/25621889/	EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas.	diagnostic usage	4	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/11132930/	Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma.	diagnostic usage	3	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/15662972/	Quantification of thrombospondin-1 secretion and expression of alphavbeta3 and alpha3beta1 integrins and syndecan-1 as cell-surface receptors for thrombospondin-1 in malignant glioma cells.	diagnostic usage	3	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/27167139/	Cytotoxic CD4(+) T cells are correlated with better prognosis in Han Chinese grade II and grade III glioma subjects and are suppressed by PD-1 signaling.	diagnostic usage	1	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/33759165/	Circulating Levels of Thrombospondin-1 and Thrombospondin-2 in Patients with Common Brain Tumors.	diagnostic usage	2	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/25621889/	EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas.	therapeutic application	1	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/11132930/	Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma.	therapeutic application	1	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/11396305/	Participation of thrombospondin-1 in the activation of latent transforming growth factor-beta in malignant glioma cells.	therapeutic application	1	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/11861403/	Overexpression of thrombospondin-1 reduces growth and vascular index but not perfusion in glioblastoma.	therapeutic application	1	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/24348828/	Correlation between TSP-1, TGF-? and PPAR-? expression levels and glioma microvascular density.	ongoing research	4	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/25621889/	EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas.	ongoing research	2	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/11132930/	Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma.	ongoing research	4	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/11396305/	Participation of thrombospondin-1 in the activation of latent transforming growth factor-beta in malignant glioma cells.	ongoing research	3	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/11745436/	Antisense-mediated reduction in thrombospondin-1 expression reduces cell motility in malignant glioma cells.	ongoing research	3	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/11861403/	Overexpression of thrombospondin-1 reduces growth and vascular index but not perfusion in glioblastoma.	ongoing research	3	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/15662972/	Quantification of thrombospondin-1 secretion and expression of alphavbeta3 and alpha3beta1 integrins and syndecan-1 as cell-surface receptors for thrombospondin-1 in malignant glioma cells.	ongoing research	4	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/11396305/	Participation of thrombospondin-1 in the activation of latent transforming growth factor-beta in malignant glioma cells.	unassigned	-	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/11745436/	Antisense-mediated reduction in thrombospondin-1 expression reduces cell motility in malignant glioma cells.	unassigned	-	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/11861403/	Overexpression of thrombospondin-1 reduces growth and vascular index but not perfusion in glioblastoma.	unassigned	-	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/24348828/	Correlation between TSP-1, TGF-? and PPAR-? expression levels and glioma microvascular density.	unassigned	-	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/15662972/	Quantification of thrombospondin-1 secretion and expression of alphavbeta3 and alpha3beta1 integrins and syndecan-1 as cell-surface receptors for thrombospondin-1 in malignant glioma cells.	unassigned	-	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/27167139/	Cytotoxic CD4(+) T cells are correlated with better prognosis in Han Chinese grade II and grade III glioma subjects and are suppressed by PD-1 signaling.	unassigned	-	
3.4.21.78	Glioma	https://pubmed.ncbi.nlm.nih.gov/33759165/	Circulating Levels of Thrombospondin-1 and Thrombospondin-2 in Patients with Common Brain Tumors.	unassigned	-	
3.4.21.78	Glomerulonephritis	https://pubmed.ncbi.nlm.nih.gov/10082755/	Differential expression of thrombospondin and cellular fibronectin during remodeling in proliferative glomerulonephritis.	causal interaction	1	
3.4.21.78	Glomerulonephritis	https://pubmed.ncbi.nlm.nih.gov/32921106/	Expression and clinical significance of thrombospondin-1 and plasminogen activator inhibitor-1 in patients with mesangial proliferative glomerulonephritis.	causal interaction	3	
3.4.21.78	Glomerulonephritis	https://pubmed.ncbi.nlm.nih.gov/32921106/	Expression and clinical significance of thrombospondin-1 and plasminogen activator inhibitor-1 in patients with mesangial proliferative glomerulonephritis.	diagnostic usage	3	
3.4.21.78	Glomerulonephritis	https://pubmed.ncbi.nlm.nih.gov/18596129/	PDE-5 inhibition impedes TSP-1 expression, TGF-beta activation and matrix accumulation in experimental glomerulonephritis.	therapeutic application	1	
3.4.21.78	Glomerulonephritis	https://pubmed.ncbi.nlm.nih.gov/32921106/	Expression and clinical significance of thrombospondin-1 and plasminogen activator inhibitor-1 in patients with mesangial proliferative glomerulonephritis.	therapeutic application	1	
3.4.21.78	Glomerulonephritis	https://pubmed.ncbi.nlm.nih.gov/18596129/	PDE-5 inhibition impedes TSP-1 expression, TGF-beta activation and matrix accumulation in experimental glomerulonephritis.	ongoing research	2	
3.4.21.78	Glomerulonephritis	https://pubmed.ncbi.nlm.nih.gov/10082755/	Differential expression of thrombospondin and cellular fibronectin during remodeling in proliferative glomerulonephritis.	ongoing research	4	
3.4.21.78	Glomerulonephritis	https://pubmed.ncbi.nlm.nih.gov/32921106/	Expression and clinical significance of thrombospondin-1 and plasminogen activator inhibitor-1 in patients with mesangial proliferative glomerulonephritis.	ongoing research	4	
3.4.21.78	Glomerulonephritis	https://pubmed.ncbi.nlm.nih.gov/18596129/	PDE-5 inhibition impedes TSP-1 expression, TGF-beta activation and matrix accumulation in experimental glomerulonephritis.	unassigned	-	
3.4.21.78	Glomerulonephritis	https://pubmed.ncbi.nlm.nih.gov/10082755/	Differential expression of thrombospondin and cellular fibronectin during remodeling in proliferative glomerulonephritis.	unassigned	-	
3.4.21.78	Glomerulonephritis, Membranoproliferative	https://pubmed.ncbi.nlm.nih.gov/25037634/	Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach.	causal interaction	4	
3.4.21.78	Glomerulonephritis, Membranoproliferative	https://pubmed.ncbi.nlm.nih.gov/25037634/	Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach.	unassigned	-	
3.4.21.78	Graft vs Host Disease	https://pubmed.ncbi.nlm.nih.gov/25928296/	Granzyme A Is Required for Regulatory T-Cell Mediated Prevention of Gastrointestinal Graft-versus-Host Disease.	causal interaction	3	
3.4.21.78	Graft vs Host Disease	https://pubmed.ncbi.nlm.nih.gov/25928296/	Granzyme A Is Required for Regulatory T-Cell Mediated Prevention of Gastrointestinal Graft-versus-Host Disease.	unassigned	-	
3.4.21.78	Granuloma	https://pubmed.ncbi.nlm.nih.gov/15947857/	[Granzymes A and B in pulmonary sarcoidosis (experimental study)]	causal interaction	3	
3.4.21.78	Granuloma	https://pubmed.ncbi.nlm.nih.gov/15947857/	[Granzymes A and B in pulmonary sarcoidosis (experimental study)]	diagnostic usage	4	
3.4.21.78	Granuloma	https://pubmed.ncbi.nlm.nih.gov/15947857/	[Granzymes A and B in pulmonary sarcoidosis (experimental study)]	therapeutic application	3	
3.4.21.78	Granuloma	https://pubmed.ncbi.nlm.nih.gov/15947857/	[Granzymes A and B in pulmonary sarcoidosis (experimental study)]	unassigned	-	
3.4.21.78	Granulomatosis with Polyangiitis	https://pubmed.ncbi.nlm.nih.gov/32286129/	Complement profile in microscopic polyangiitis and granulomatosis with polyangiitis: analysis using sera from a nationwide prospective cohort study.	causal interaction	2	
3.4.21.78	Granulomatosis with Polyangiitis	https://pubmed.ncbi.nlm.nih.gov/32286129/	Complement profile in microscopic polyangiitis and granulomatosis with polyangiitis: analysis using sera from a nationwide prospective cohort study.	diagnostic usage	3	
3.4.21.78	Granulomatosis with Polyangiitis	https://pubmed.ncbi.nlm.nih.gov/32286129/	Complement profile in microscopic polyangiitis and granulomatosis with polyangiitis: analysis using sera from a nationwide prospective cohort study.	ongoing research	1	
3.4.21.78	Granulomatosis with Polyangiitis	https://pubmed.ncbi.nlm.nih.gov/32286129/	Complement profile in microscopic polyangiitis and granulomatosis with polyangiitis: analysis using sera from a nationwide prospective cohort study.	unassigned	-	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/26352162/	TSP-1 Deficiency Alters Ocular Microbiota: Implications for Sjögren's Syndrome Pathogenesis.	causal interaction	3	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/21234123/	TSP-1 in lung fibrosis.	causal interaction	3	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/28364044/	High serum thrombospondin-1 concentration is associated with slower abdominal aortic aneurysm growth and deficiency promotes angiotensin-II induced aneurysm in mice.	causal interaction	4	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/28592701/	Thrombospondin-1 contributes to slower aortic aneurysm growth by inhibiting maladaptive remodeling of extracellular matrix.	causal interaction	4	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/22105716/	Thrombospondin-1 is a novel negative regulator of liver regeneration after partial hepatectomy via TGF-?1 activation in mice.	causal interaction	4	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/23094049/	Sustained beta-cell dysfunction but normalized islet mass in aged thrombospondin-1 deficient mice.	causal interaction	4	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/31891606/	Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).	causal interaction	4	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/33327743/	TSP-1 (Thrombospondin-1) Deficiency Protects ApoE-/- Mice Against Leptin-Induced Atherosclerosis.	causal interaction	4	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/19700744/	Sjögren's syndrome-like ocular surface disease in thrombospondin-1 deficient mice.	causal interaction	4	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/20581099/	Thrombospondin-1 Deficient Mice Are Not Protected from Bleomycin-Induced Pulmonary Fibrosis.	causal interaction	4	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/28733313/	Granzyme A-deficiency breaks immune tolerance and promotes Autoimmune Diabetes Through a Type I Interferon-Dependent Pathway.	causal interaction	4	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/30896397/	[H Factor Deficiency: A Case with an Atypical Presentation].	causal interaction	4	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/20581099/	Thrombospondin-1 Deficient Mice Are Not Protected from Bleomycin-Induced Pulmonary Fibrosis.	diagnostic usage	3	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/30896397/	[H Factor Deficiency: A Case with an Atypical Presentation].	diagnostic usage	4	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/28592701/	Thrombospondin-1 contributes to slower aortic aneurysm growth by inhibiting maladaptive remodeling of extracellular matrix.	therapeutic application	1	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/33327743/	TSP-1 (Thrombospondin-1) Deficiency Protects ApoE-/- Mice Against Leptin-Induced Atherosclerosis.	therapeutic application	2	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/20581099/	Thrombospondin-1 Deficient Mice Are Not Protected from Bleomycin-Induced Pulmonary Fibrosis.	therapeutic application	1	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/28733313/	Granzyme A-deficiency breaks immune tolerance and promotes Autoimmune Diabetes Through a Type I Interferon-Dependent Pathway.	therapeutic application	4	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/28592701/	Thrombospondin-1 contributes to slower aortic aneurysm growth by inhibiting maladaptive remodeling of extracellular matrix.	ongoing research	3	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/23094049/	Sustained beta-cell dysfunction but normalized islet mass in aged thrombospondin-1 deficient mice.	ongoing research	2	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/31891606/	Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).	ongoing research	4	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/33327743/	TSP-1 (Thrombospondin-1) Deficiency Protects ApoE-/- Mice Against Leptin-Induced Atherosclerosis.	ongoing research	3	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/20581099/	Thrombospondin-1 Deficient Mice Are Not Protected from Bleomycin-Induced Pulmonary Fibrosis.	ongoing research	4	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/28733313/	Granzyme A-deficiency breaks immune tolerance and promotes Autoimmune Diabetes Through a Type I Interferon-Dependent Pathway.	ongoing research	2	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/26352162/	TSP-1 Deficiency Alters Ocular Microbiota: Implications for Sjögren's Syndrome Pathogenesis.	unassigned	-	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/21234123/	TSP-1 in lung fibrosis.	unassigned	-	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/28364044/	High serum thrombospondin-1 concentration is associated with slower abdominal aortic aneurysm growth and deficiency promotes angiotensin-II induced aneurysm in mice.	unassigned	-	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/28592701/	Thrombospondin-1 contributes to slower aortic aneurysm growth by inhibiting maladaptive remodeling of extracellular matrix.	unassigned	-	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/22105716/	Thrombospondin-1 is a novel negative regulator of liver regeneration after partial hepatectomy via TGF-?1 activation in mice.	unassigned	-	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/23094049/	Sustained beta-cell dysfunction but normalized islet mass in aged thrombospondin-1 deficient mice.	unassigned	-	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/31891606/	Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).	unassigned	-	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/33327743/	TSP-1 (Thrombospondin-1) Deficiency Protects ApoE-/- Mice Against Leptin-Induced Atherosclerosis.	unassigned	-	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/19700744/	Sjögren's syndrome-like ocular surface disease in thrombospondin-1 deficient mice.	unassigned	-	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/28733313/	Granzyme A-deficiency breaks immune tolerance and promotes Autoimmune Diabetes Through a Type I Interferon-Dependent Pathway.	unassigned	-	
3.4.21.78	granzyme a deficiency	https://pubmed.ncbi.nlm.nih.gov/30896397/	[H Factor Deficiency: A Case with an Atypical Presentation].	unassigned	-	
3.4.21.78	Heart Diseases	https://pubmed.ncbi.nlm.nih.gov/22969907/	Investigation of thrombospondin-1 and transforming growth factor-? expression in the heart of aging mice.	causal interaction	3	
3.4.21.78	Heart Diseases	https://pubmed.ncbi.nlm.nih.gov/22969907/	Investigation of thrombospondin-1 and transforming growth factor-? expression in the heart of aging mice.	diagnostic usage	3	
3.4.21.78	Heart Diseases	https://pubmed.ncbi.nlm.nih.gov/22969907/	Investigation of thrombospondin-1 and transforming growth factor-? expression in the heart of aging mice.	unassigned	-	
3.4.21.78	Heart Failure	https://pubmed.ncbi.nlm.nih.gov/19715883/	Decreased expression of thrombospondin-1 in failing hearts may favor ventricular remodeling.	causal interaction	3	
3.4.21.78	Heart Failure	https://pubmed.ncbi.nlm.nih.gov/23074998/	Thrombospondins, potential drug targets for cardiovascular diseases.	causal interaction	3	
3.4.21.78	Heart Failure	https://pubmed.ncbi.nlm.nih.gov/19715883/	Decreased expression of thrombospondin-1 in failing hearts may favor ventricular remodeling.	therapeutic application	2	
3.4.21.78	Heart Failure	https://pubmed.ncbi.nlm.nih.gov/23074998/	Thrombospondins, potential drug targets for cardiovascular diseases.	therapeutic application	4	
3.4.21.78	Heart Failure	https://pubmed.ncbi.nlm.nih.gov/19715883/	Decreased expression of thrombospondin-1 in failing hearts may favor ventricular remodeling.	ongoing research	1	
3.4.21.78	Heart Failure	https://pubmed.ncbi.nlm.nih.gov/21501375/	MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure.	unassigned	-	
3.4.21.78	Heart Failure	https://pubmed.ncbi.nlm.nih.gov/19715883/	Decreased expression of thrombospondin-1 in failing hearts may favor ventricular remodeling.	unassigned	-	
3.4.21.78	Heart Failure	https://pubmed.ncbi.nlm.nih.gov/23074998/	Thrombospondins, potential drug targets for cardiovascular diseases.	unassigned	-	
3.4.21.78	HELLP Syndrome	https://pubmed.ncbi.nlm.nih.gov/22035632/	Circulating levels of thrombospondin-1 are decreased in HELLP syndrome.	causal interaction	3	
3.4.21.78	HELLP Syndrome	https://pubmed.ncbi.nlm.nih.gov/22035632/	Circulating levels of thrombospondin-1 are decreased in HELLP syndrome.	diagnostic usage	4	
3.4.21.78	HELLP Syndrome	https://pubmed.ncbi.nlm.nih.gov/22035632/	Circulating levels of thrombospondin-1 are decreased in HELLP syndrome.	therapeutic application	2	
3.4.21.78	HELLP Syndrome	https://pubmed.ncbi.nlm.nih.gov/22035632/	Circulating levels of thrombospondin-1 are decreased in HELLP syndrome.	unassigned	-	
3.4.21.78	Hemangioma	https://pubmed.ncbi.nlm.nih.gov/29927834/	Role of thrombospondin-1 and nuclear factor-kappa B signaling pathways in anti-angiogenesis of infantile hemangioma.	causal interaction	1	
3.4.21.78	Hemangioma	https://pubmed.ncbi.nlm.nih.gov/30067324/	[Expression and significance of the proteins in TSP-1 and NF-?B signal pathways of infantile capillary hemangioma].	causal interaction	2	
3.4.21.78	Hemangioma	https://pubmed.ncbi.nlm.nih.gov/30067324/	[Expression and significance of the proteins in TSP-1 and NF-?B signal pathways of infantile capillary hemangioma].	diagnostic usage	3	
3.4.21.78	Hemangioma	https://pubmed.ncbi.nlm.nih.gov/29927834/	Role of thrombospondin-1 and nuclear factor-kappa B signaling pathways in anti-angiogenesis of infantile hemangioma.	therapeutic application	4	
3.4.21.78	Hemangioma	https://pubmed.ncbi.nlm.nih.gov/30067324/	[Expression and significance of the proteins in TSP-1 and NF-?B signal pathways of infantile capillary hemangioma].	ongoing research	2	
3.4.21.78	Hemangioma	https://pubmed.ncbi.nlm.nih.gov/29927834/	Role of thrombospondin-1 and nuclear factor-kappa B signaling pathways in anti-angiogenesis of infantile hemangioma.	unassigned	-	
3.4.21.78	Hemangioma	https://pubmed.ncbi.nlm.nih.gov/30067324/	[Expression and significance of the proteins in TSP-1 and NF-?B signal pathways of infantile capillary hemangioma].	unassigned	-	
3.4.21.78	Hemorrhagic Fever with Renal Syndrome	https://pubmed.ncbi.nlm.nih.gov/18712840/	Serum thrombospondin-1 is altered in patients with hemorrhagic fever with renal syndrome.	causal interaction	4	
3.4.21.78	Hemorrhagic Fever with Renal Syndrome	https://pubmed.ncbi.nlm.nih.gov/18712840/	Serum thrombospondin-1 is altered in patients with hemorrhagic fever with renal syndrome.	diagnostic usage	4	
3.4.21.78	Hemorrhagic Fever with Renal Syndrome	https://pubmed.ncbi.nlm.nih.gov/18712840/	Serum thrombospondin-1 is altered in patients with hemorrhagic fever with renal syndrome.	unassigned	-	
3.4.21.78	Hemorrhagic Stroke	https://pubmed.ncbi.nlm.nih.gov/29214179/	The Roles of Thrombospondins in Hemorrhagic Stroke.	causal interaction	2	
3.4.21.78	Hemorrhagic Stroke	https://pubmed.ncbi.nlm.nih.gov/29214179/	The Roles of Thrombospondins in Hemorrhagic Stroke.	therapeutic application	2	
3.4.21.78	Hemorrhagic Stroke	https://pubmed.ncbi.nlm.nih.gov/29214179/	The Roles of Thrombospondins in Hemorrhagic Stroke.	unassigned	-	
3.4.21.78	Hepatitis C, Chronic	https://pubmed.ncbi.nlm.nih.gov/8657014/	Gene expression of perforin and granzyme A in the liver in chronic hepatitis C: comparison with peripheral blood mononuclear cells.	causal interaction	3	
3.4.21.78	Hepatitis C, Chronic	https://pubmed.ncbi.nlm.nih.gov/8657014/	Gene expression of perforin and granzyme A in the liver in chronic hepatitis C: comparison with peripheral blood mononuclear cells.	diagnostic usage	4	
3.4.21.78	Hepatitis C, Chronic	https://pubmed.ncbi.nlm.nih.gov/8657014/	Gene expression of perforin and granzyme A in the liver in chronic hepatitis C: comparison with peripheral blood mononuclear cells.	ongoing research	4	
3.4.21.78	Hepatitis C, Chronic	https://pubmed.ncbi.nlm.nih.gov/8657014/	Gene expression of perforin and granzyme A in the liver in chronic hepatitis C: comparison with peripheral blood mononuclear cells.	unassigned	-	
3.4.21.78	Herpes Simplex	https://pubmed.ncbi.nlm.nih.gov/10623769/	Granzyme A, a noncytolytic component of CD8(+) cell granules, restricts the spread of herpes simplex virus in the peripheral nervous systems of experimentally infected mice.	ongoing research	3	
3.4.21.78	Herpes Simplex	https://pubmed.ncbi.nlm.nih.gov/10623769/	Granzyme A, a noncytolytic component of CD8(+) cell granules, restricts the spread of herpes simplex virus in the peripheral nervous systems of experimentally infected mice.	unassigned	-	
3.4.21.78	HIV Infections	https://pubmed.ncbi.nlm.nih.gov/10449281/	Perforin is not co-expressed with granzyme A within cytotoxic granules in CD8 T lymphocytes present in lymphoid tissue during chronic HIV infection.	causal interaction	2	
3.4.21.78	HIV Infections	https://pubmed.ncbi.nlm.nih.gov/12001057/	Low levels of perforin expression in CD8+ T lymphocyte granules in lymphoid tissue during acute human immunodeficiency virus type 1 infection.	causal interaction	2	
3.4.21.78	HIV Infections	https://pubmed.ncbi.nlm.nih.gov/10449281/	Perforin is not co-expressed with granzyme A within cytotoxic granules in CD8 T lymphocytes present in lymphoid tissue during chronic HIV infection.	unassigned	-	
3.4.21.78	HIV Infections	https://pubmed.ncbi.nlm.nih.gov/12001057/	Low levels of perforin expression in CD8+ T lymphocyte granules in lymphoid tissue during acute human immunodeficiency virus type 1 infection.	unassigned	-	
3.4.21.78	Hypercalcemia	https://pubmed.ncbi.nlm.nih.gov/19661269/	Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease.	causal interaction	2	
3.4.21.78	Hypercalcemia	https://pubmed.ncbi.nlm.nih.gov/19661269/	Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease.	therapeutic application	1	
3.4.21.78	Hypercalcemia	https://pubmed.ncbi.nlm.nih.gov/19661269/	Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease.	unassigned	-	
3.4.21.78	Hyperglycemia	https://pubmed.ncbi.nlm.nih.gov/18959004/	The effect of cilostazol on expression of thrombospondin-1 in diabetic retinopathy.	causal interaction	4	
3.4.21.78	Hyperglycemia	https://pubmed.ncbi.nlm.nih.gov/20299182/	Thrombospondin-1: a proatherosclerotic protein augmented by hyperglycemia.	causal interaction	4	
3.4.21.78	Hyperglycemia	https://pubmed.ncbi.nlm.nih.gov/32626782/	Thrombospondin-1: A Key Protein That Induces Fibrosis in Diabetic Complications.	causal interaction	4	
3.4.21.78	Hyperglycemia	https://pubmed.ncbi.nlm.nih.gov/20299182/	Thrombospondin-1: a proatherosclerotic protein augmented by hyperglycemia.	diagnostic usage	3	
3.4.21.78	Hyperglycemia	https://pubmed.ncbi.nlm.nih.gov/18959004/	The effect of cilostazol on expression of thrombospondin-1 in diabetic retinopathy.	therapeutic application	4	
3.4.21.78	Hyperglycemia	https://pubmed.ncbi.nlm.nih.gov/20299182/	Thrombospondin-1: a proatherosclerotic protein augmented by hyperglycemia.	therapeutic application	3	
3.4.21.78	Hyperglycemia	https://pubmed.ncbi.nlm.nih.gov/20299182/	Thrombospondin-1: a proatherosclerotic protein augmented by hyperglycemia.	ongoing research	2	
3.4.21.78	Hyperglycemia	https://pubmed.ncbi.nlm.nih.gov/30478742/	Application of transcutaneous carbon dioxide improves capillary regression of skeletal muscle in hyperglycemia.	unassigned	-	
3.4.21.78	Hyperglycemia	https://pubmed.ncbi.nlm.nih.gov/18959004/	The effect of cilostazol on expression of thrombospondin-1 in diabetic retinopathy.	unassigned	-	
3.4.21.78	Hyperglycemia	https://pubmed.ncbi.nlm.nih.gov/32626782/	Thrombospondin-1: A Key Protein That Induces Fibrosis in Diabetic Complications.	unassigned	-	
3.4.21.78	Hypersensitivity	https://pubmed.ncbi.nlm.nih.gov/19194474/	The Angiogenesis Inhibitor Thrombospondin-1 Inhibits Acute Cutaneous Hypersensitivity Reactions.	causal interaction	2	
3.4.21.78	Hypersensitivity	https://pubmed.ncbi.nlm.nih.gov/19194474/	The Angiogenesis Inhibitor Thrombospondin-1 Inhibits Acute Cutaneous Hypersensitivity Reactions.	therapeutic application	1	
3.4.21.78	Hypersensitivity	https://pubmed.ncbi.nlm.nih.gov/31173926/	Thrombospondin-1 in ocular surface health and disease.	therapeutic application	2	
3.4.21.78	Hypersensitivity	https://pubmed.ncbi.nlm.nih.gov/32881993/	Thrombospondin-1 promotes haemostasis through modulation of cAMP signalling in blood platelets.	therapeutic application	1	
3.4.21.78	Hypersensitivity	https://pubmed.ncbi.nlm.nih.gov/33538796/	Thrombospondin-1 promotes hemostasis through modulation of cAMP signaling in blood platelets.	therapeutic application	1	
3.4.21.78	Hypersensitivity	https://pubmed.ncbi.nlm.nih.gov/19194474/	The Angiogenesis Inhibitor Thrombospondin-1 Inhibits Acute Cutaneous Hypersensitivity Reactions.	ongoing research	4	
3.4.21.78	Hypersensitivity	https://pubmed.ncbi.nlm.nih.gov/31173926/	Thrombospondin-1 in ocular surface health and disease.	unassigned	-	
3.4.21.78	Hypersensitivity	https://pubmed.ncbi.nlm.nih.gov/32881993/	Thrombospondin-1 promotes haemostasis through modulation of cAMP signalling in blood platelets.	unassigned	-	
3.4.21.78	Hypersensitivity	https://pubmed.ncbi.nlm.nih.gov/33538796/	Thrombospondin-1 promotes hemostasis through modulation of cAMP signaling in blood platelets.	unassigned	-	
3.4.21.78	Hypersensitivity	https://pubmed.ncbi.nlm.nih.gov/19194474/	The Angiogenesis Inhibitor Thrombospondin-1 Inhibits Acute Cutaneous Hypersensitivity Reactions.	unassigned	-	
3.4.21.78	Hypertension	https://pubmed.ncbi.nlm.nih.gov/31631975/	Thrombospondin-1 Serum Levels In Hypertensive Patients With Endothelial Dysfunction After One Year Of Treatment With Perindopril.	causal interaction	3	
3.4.21.78	Hypertension	https://pubmed.ncbi.nlm.nih.gov/31631975/	Thrombospondin-1 Serum Levels In Hypertensive Patients With Endothelial Dysfunction After One Year Of Treatment With Perindopril.	diagnostic usage	4	
3.4.21.78	Hypertension	https://pubmed.ncbi.nlm.nih.gov/31631975/	Thrombospondin-1 Serum Levels In Hypertensive Patients With Endothelial Dysfunction After One Year Of Treatment With Perindopril.	unassigned	-	
3.4.21.78	Hypertension, Pulmonary	https://pubmed.ncbi.nlm.nih.gov/20441584/	Thrombospondin-1 null mice are resistant to hypoxia-induced pulmonary hypertension.	causal interaction	4	
3.4.21.78	Hypertension, Pulmonary	https://pubmed.ncbi.nlm.nih.gov/20441584/	Thrombospondin-1 null mice are resistant to hypoxia-induced pulmonary hypertension.	unassigned	-	
3.4.21.78	Hypotension	https://pubmed.ncbi.nlm.nih.gov/18712840/	Serum thrombospondin-1 is altered in patients with hemorrhagic fever with renal syndrome.	causal interaction	4	
3.4.21.78	Hypotension	https://pubmed.ncbi.nlm.nih.gov/18712840/	Serum thrombospondin-1 is altered in patients with hemorrhagic fever with renal syndrome.	diagnostic usage	4	
3.4.21.78	Hypotension	https://pubmed.ncbi.nlm.nih.gov/18712840/	Serum thrombospondin-1 is altered in patients with hemorrhagic fever with renal syndrome.	unassigned	-	
3.4.21.78	Idiopathic Interstitial Pneumonias	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	causal interaction	4	
3.4.21.78	Idiopathic Interstitial Pneumonias	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	diagnostic usage	4	
3.4.21.78	Idiopathic Interstitial Pneumonias	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	ongoing research	3	
3.4.21.78	Idiopathic Interstitial Pneumonias	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	unassigned	-	
3.4.21.78	Idiopathic Pulmonary Fibrosis	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	causal interaction	4	
3.4.21.78	Idiopathic Pulmonary Fibrosis	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	diagnostic usage	4	
3.4.21.78	Idiopathic Pulmonary Fibrosis	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	ongoing research	3	
3.4.21.78	Idiopathic Pulmonary Fibrosis	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	unassigned	-	
3.4.21.78	Immunoglobulin G4-Related Disease	https://pubmed.ncbi.nlm.nih.gov/27358392/	Lesional CD4+ IFN-?+ cytotoxic T lymphocytes in IgG4-related dacryoadenitis and sialoadenitis.	causal interaction	4	
3.4.21.78	Immunoglobulin G4-Related Disease	https://pubmed.ncbi.nlm.nih.gov/27358392/	Lesional CD4+ IFN-?+ cytotoxic T lymphocytes in IgG4-related dacryoadenitis and sialoadenitis.	diagnostic usage	2	
3.4.21.78	Immunoglobulin G4-Related Disease	https://pubmed.ncbi.nlm.nih.gov/27358392/	Lesional CD4+ IFN-?+ cytotoxic T lymphocytes in IgG4-related dacryoadenitis and sialoadenitis.	ongoing research	3	
3.4.21.78	Immunoglobulin G4-Related Disease	https://pubmed.ncbi.nlm.nih.gov/26971690/	Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease.	unassigned	-	
3.4.21.78	Immunoglobulin G4-Related Disease	https://pubmed.ncbi.nlm.nih.gov/27358392/	Lesional CD4+ IFN-?+ cytotoxic T lymphocytes in IgG4-related dacryoadenitis and sialoadenitis.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/2668013/	Detection of perforin and granzyme A mRNA in infiltrating cells during infection of mice with lymphocytic choriomeningitis virus.	causal interaction	3	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/21248253/	A novel and divergent role of granzyme A and B in resistance to helminth infection.	causal interaction	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/27055232/	Granzyme A Is Expressed in Mouse Lungs during Mycobacterium tuberculosis Infection but Does Not Contribute to Protection In Vivo.	causal interaction	3	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/27136454/	Expression of perforin, granzyme A and Fas ligand mRNA in caecal tissues upon Eimeria tenella infection of naïve and immune chickens.	causal interaction	4	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/7927497/	Cutaneous leishmaniasis: co-ordinate expression of granzyme A and lymphokines by CD4+ T cells from susceptible mice.	causal interaction	3	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/10393860/	Human cytomegalovirus infection decreases expression of thrombospondin-1 independent of the tumor suppressor protein p53.	causal interaction	4	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/12011015/	Apoptosis in acute shigellosis is associated with increased production of Fas/Fas ligand, perforin, caspase-1, and caspase-3 but reduced production of Bcl-2 and interleukin-2.	causal interaction	3	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/15507626/	Perforin and Fas act together in the induction of apoptosis, and both are critical in the clearance of lymphocytic choriomeningitis virus infection.	causal interaction	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/16616140/	Stable RNA interference of host thrombospondin-1 blocks Trypanosoma cruzi infection.	causal interaction	3	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/18336597/	Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma.	causal interaction	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/20451619/	Identification and characterization of common carp (Cyprinus carpio L.) granzyme A/K, a cytotoxic cell granule-associated serine protease.	causal interaction	2	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/22808206/	Thrombospondin-1 interacts with Trypanosoma cruzi surface calreticulin to enhance cellular infection.	causal interaction	4	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/23422142/	The kinetics of CD4+ and CD8+ T-cell gene expression correlate with protection in Atlantic salmon (Salmo salar L) vaccinated against infectious pancreatic necrosis.	causal interaction	4	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/25492474/	Thrombospondin-1 restrains neutrophil granule serine protease function and regulates the innate immune response during Klebsiella pneumoniae infection.	causal interaction	4	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/28207896/	RNA-Seq analysis of chikungunya virus infection and identification of granzyme A as a major promoter of arthritic inflammation.	causal interaction	3	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/32664627/	Thrombospondin-1 Plays an Essential Role in Yes-Associated Protein Nuclear Translocation during the Early Phase of Trypanosoma cruzi Infection in Heart Endothelial Cells.	causal interaction	4	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/32912008/	Extracellular granzyme A in amniotic fluid is elevated in the presence of sterile intra-amniotic inflammation in preterm prelabor rupture of membranes.	causal interaction	2	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/33824208/	Thrombospondin-1 Restricts Interleukin-36?-Mediated Neutrophilic Inflammation during Pseudomonas aeruginosa Pulmonary Infection.	causal interaction	4	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/2668013/	Detection of perforin and granzyme A mRNA in infiltrating cells during infection of mice with lymphocytic choriomeningitis virus.	diagnostic usage	3	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/26051682/	Granzyme A as a potential biomarker of Mycobacterium tuberculosis infection and disease.	diagnostic usage	2	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/27055232/	Granzyme A Is Expressed in Mouse Lungs during Mycobacterium tuberculosis Infection but Does Not Contribute to Protection In Vivo.	diagnostic usage	2	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/27136454/	Expression of perforin, granzyme A and Fas ligand mRNA in caecal tissues upon Eimeria tenella infection of naïve and immune chickens.	diagnostic usage	4	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/7927497/	Cutaneous leishmaniasis: co-ordinate expression of granzyme A and lymphokines by CD4+ T cells from susceptible mice.	diagnostic usage	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/10393860/	Human cytomegalovirus infection decreases expression of thrombospondin-1 independent of the tumor suppressor protein p53.	diagnostic usage	3	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/12011015/	Apoptosis in acute shigellosis is associated with increased production of Fas/Fas ligand, perforin, caspase-1, and caspase-3 but reduced production of Bcl-2 and interleukin-2.	diagnostic usage	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/16616140/	Stable RNA interference of host thrombospondin-1 blocks Trypanosoma cruzi infection.	diagnostic usage	3	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/18336597/	Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma.	diagnostic usage	4	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/18570592/	Expression of cytotoxicity-associated genes in Marek's disease virus-infected chickens.	diagnostic usage	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/20163282/	Expression of activation and cytotoxic molecules by peripheral blood lymphocytes of patients with paracoccidioidomycosis.	diagnostic usage	3	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/20309955/	Intraarticular gene transfer of thrombospondin-1 suppresses the disease progression of experimental osteoarthritis.	diagnostic usage	3	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/23422142/	The kinetics of CD4+ and CD8+ T-cell gene expression correlate with protection in Atlantic salmon (Salmo salar L) vaccinated against infectious pancreatic necrosis.	diagnostic usage	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/26147698/	Differential Activation of Human Monocytes and Lymphocytes by Distinct Strains of Trypanosoma cruzi.	diagnostic usage	3	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/28207896/	RNA-Seq analysis of chikungunya virus infection and identification of granzyme A as a major promoter of arthritic inflammation.	diagnostic usage	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/12780694/	Circulating concentrations of soluble granzyme A and B increase during natural and experimental Plasmodium falciparum infections.	therapeutic application	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/15210827/	Abundant expression of granzyme A, but not perforin, in granules of CD8+ T cells in GALT: implications for immune control of HIV-1 infection.	therapeutic application	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/21248253/	A novel and divergent role of granzyme A and B in resistance to helminth infection.	therapeutic application	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/26051682/	Granzyme A as a potential biomarker of Mycobacterium tuberculosis infection and disease.	therapeutic application	4	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/27055232/	Granzyme A Is Expressed in Mouse Lungs during Mycobacterium tuberculosis Infection but Does Not Contribute to Protection In Vivo.	therapeutic application	2	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/8621589/	Expression of human recombinant granzyme A zymogen and its activation by the cysteine proteinase cathepsin C.	therapeutic application	2	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/10393860/	Human cytomegalovirus infection decreases expression of thrombospondin-1 independent of the tumor suppressor protein p53.	therapeutic application	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/10570179/	Granzymes are the essential downstream effector molecules for the control of primary virus infections by cytolytic leukocytes.	therapeutic application	2	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/10716374/	HIV virions and HIV infection in vitro are unaffected by human granzymes A and B.	therapeutic application	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/10820381/	Murine cytomegalovirus replication in salivary glands is controlled by both perforin and granzymes during acute infection.	therapeutic application	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/10950755/	Cytomegalovirus infection decreases expression of thrombospondin-1 and -2 in cultured human retinal glial cells: effects of antiviral agents.	therapeutic application	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/12011015/	Apoptosis in acute shigellosis is associated with increased production of Fas/Fas ligand, perforin, caspase-1, and caspase-3 but reduced production of Bcl-2 and interleukin-2.	therapeutic application	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/16616140/	Stable RNA interference of host thrombospondin-1 blocks Trypanosoma cruzi infection.	therapeutic application	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/18570592/	Expression of cytotoxicity-associated genes in Marek's disease virus-infected chickens.	therapeutic application	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/19838298/	Caspase-dependent inhibition of mousepox replication by gzmB.	therapeutic application	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/20309955/	Intraarticular gene transfer of thrombospondin-1 suppresses the disease progression of experimental osteoarthritis.	therapeutic application	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/22808206/	Thrombospondin-1 interacts with Trypanosoma cruzi surface calreticulin to enhance cellular infection.	therapeutic application	2	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/25492474/	Thrombospondin-1 restrains neutrophil granule serine protease function and regulates the innate immune response during Klebsiella pneumoniae infection.	therapeutic application	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/32664627/	Thrombospondin-1 Plays an Essential Role in Yes-Associated Protein Nuclear Translocation during the Early Phase of Trypanosoma cruzi Infection in Heart Endothelial Cells.	therapeutic application	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/33214610/	Ex vivo rectal explant model reveals potential opposing roles of Natural Killer cells and Marginal Zone-like B cells in HIV-1 infection.	therapeutic application	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/33824208/	Thrombospondin-1 Restricts Interleukin-36?-Mediated Neutrophilic Inflammation during Pseudomonas aeruginosa Pulmonary Infection.	therapeutic application	2	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/2668013/	Detection of perforin and granzyme A mRNA in infiltrating cells during infection of mice with lymphocytic choriomeningitis virus.	ongoing research	4	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/8650169/	Granzyme A is critical for recovery of mice from infection with the natural cytopathic viral pathogen, ectromelia.	ongoing research	2	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/12780694/	Circulating concentrations of soluble granzyme A and B increase during natural and experimental Plasmodium falciparum infections.	ongoing research	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/21248253/	A novel and divergent role of granzyme A and B in resistance to helminth infection.	ongoing research	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/26051682/	Granzyme A as a potential biomarker of Mycobacterium tuberculosis infection and disease.	ongoing research	4	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/27055232/	Granzyme A Is Expressed in Mouse Lungs during Mycobacterium tuberculosis Infection but Does Not Contribute to Protection In Vivo.	ongoing research	4	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/27136454/	Expression of perforin, granzyme A and Fas ligand mRNA in caecal tissues upon Eimeria tenella infection of naïve and immune chickens.	ongoing research	4	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/7927497/	Cutaneous leishmaniasis: co-ordinate expression of granzyme A and lymphokines by CD4+ T cells from susceptible mice.	ongoing research	4	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/8621589/	Expression of human recombinant granzyme A zymogen and its activation by the cysteine proteinase cathepsin C.	ongoing research	4	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/10393860/	Human cytomegalovirus infection decreases expression of thrombospondin-1 independent of the tumor suppressor protein p53.	ongoing research	4	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/10716374/	HIV virions and HIV infection in vitro are unaffected by human granzymes A and B.	ongoing research	2	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/10820381/	Murine cytomegalovirus replication in salivary glands is controlled by both perforin and granzymes during acute infection.	ongoing research	2	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/10950755/	Cytomegalovirus infection decreases expression of thrombospondin-1 and -2 in cultured human retinal glial cells: effects of antiviral agents.	ongoing research	3	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/11497079/	Control of murine cytomegalovirus replication in salivary glands during acute infection is independent of the Fas ligand/Fas system.	ongoing research	4	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/15507626/	Perforin and Fas act together in the induction of apoptosis, and both are critical in the clearance of lymphocytic choriomeningitis virus infection.	ongoing research	3	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/18336597/	Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma.	ongoing research	3	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/18570592/	Expression of cytotoxicity-associated genes in Marek's disease virus-infected chickens.	ongoing research	3	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/19838298/	Caspase-dependent inhibition of mousepox replication by gzmB.	ongoing research	3	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/20309955/	Intraarticular gene transfer of thrombospondin-1 suppresses the disease progression of experimental osteoarthritis.	ongoing research	3	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/22808206/	Thrombospondin-1 interacts with Trypanosoma cruzi surface calreticulin to enhance cellular infection.	ongoing research	2	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/25492474/	Thrombospondin-1 restrains neutrophil granule serine protease function and regulates the innate immune response during Klebsiella pneumoniae infection.	ongoing research	1	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/26147698/	Differential Activation of Human Monocytes and Lymphocytes by Distinct Strains of Trypanosoma cruzi.	ongoing research	2	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/32664627/	Thrombospondin-1 Plays an Essential Role in Yes-Associated Protein Nuclear Translocation during the Early Phase of Trypanosoma cruzi Infection in Heart Endothelial Cells.	ongoing research	4	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/8650169/	Granzyme A is critical for recovery of mice from infection with the natural cytopathic viral pathogen, ectromelia.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/12780694/	Circulating concentrations of soluble granzyme A and B increase during natural and experimental Plasmodium falciparum infections.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/15210827/	Abundant expression of granzyme A, but not perforin, in granules of CD8+ T cells in GALT: implications for immune control of HIV-1 infection.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/26051682/	Granzyme A as a potential biomarker of Mycobacterium tuberculosis infection and disease.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/31993061/	Granzyme A in Chikungunya and Other Arboviral Infections.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/8621589/	Expression of human recombinant granzyme A zymogen and its activation by the cysteine proteinase cathepsin C.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/10570179/	Granzymes are the essential downstream effector molecules for the control of primary virus infections by cytolytic leukocytes.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/10716374/	HIV virions and HIV infection in vitro are unaffected by human granzymes A and B.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/10820381/	Murine cytomegalovirus replication in salivary glands is controlled by both perforin and granzymes during acute infection.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/10950755/	Cytomegalovirus infection decreases expression of thrombospondin-1 and -2 in cultured human retinal glial cells: effects of antiviral agents.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/11497079/	Control of murine cytomegalovirus replication in salivary glands during acute infection is independent of the Fas ligand/Fas system.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/18570592/	Expression of cytotoxicity-associated genes in Marek's disease virus-infected chickens.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/19388169/	Binding of complement regulatory proteins to group A Streptococcus.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/19838298/	Caspase-dependent inhibition of mousepox replication by gzmB.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/20163282/	Expression of activation and cytotoxic molecules by peripheral blood lymphocytes of patients with paracoccidioidomycosis.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/20309955/	Intraarticular gene transfer of thrombospondin-1 suppresses the disease progression of experimental osteoarthritis.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/20795543/	Longevity of T-cell memory following acute viral infection.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/23164636/	Characterization of cytotoxicity-related gene expression in response to virulent Marek's disease virus infection in the bursa of Fabricius.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/26147698/	Differential Activation of Human Monocytes and Lymphocytes by Distinct Strains of Trypanosoma cruzi.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/33214610/	Ex vivo rectal explant model reveals potential opposing roles of Natural Killer cells and Marginal Zone-like B cells in HIV-1 infection.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/21248253/	A novel and divergent role of granzyme A and B in resistance to helminth infection.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/15507626/	Perforin and Fas act together in the induction of apoptosis, and both are critical in the clearance of lymphocytic choriomeningitis virus infection.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/20451619/	Identification and characterization of common carp (Cyprinus carpio L.) granzyme A/K, a cytotoxic cell granule-associated serine protease.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/22808206/	Thrombospondin-1 interacts with Trypanosoma cruzi surface calreticulin to enhance cellular infection.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/25492474/	Thrombospondin-1 restrains neutrophil granule serine protease function and regulates the innate immune response during Klebsiella pneumoniae infection.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/32664627/	Thrombospondin-1 Plays an Essential Role in Yes-Associated Protein Nuclear Translocation during the Early Phase of Trypanosoma cruzi Infection in Heart Endothelial Cells.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/32912008/	Extracellular granzyme A in amniotic fluid is elevated in the presence of sterile intra-amniotic inflammation in preterm prelabor rupture of membranes.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/33824208/	Thrombospondin-1 Restricts Interleukin-36?-Mediated Neutrophilic Inflammation during Pseudomonas aeruginosa Pulmonary Infection.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/2668013/	Detection of perforin and granzyme A mRNA in infiltrating cells during infection of mice with lymphocytic choriomeningitis virus.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/27136454/	Expression of perforin, granzyme A and Fas ligand mRNA in caecal tissues upon Eimeria tenella infection of naïve and immune chickens.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/7927497/	Cutaneous leishmaniasis: co-ordinate expression of granzyme A and lymphokines by CD4+ T cells from susceptible mice.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/18336597/	Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/23422142/	The kinetics of CD4+ and CD8+ T-cell gene expression correlate with protection in Atlantic salmon (Salmo salar L) vaccinated against infectious pancreatic necrosis.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/28207896/	RNA-Seq analysis of chikungunya virus infection and identification of granzyme A as a major promoter of arthritic inflammation.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/12011015/	Apoptosis in acute shigellosis is associated with increased production of Fas/Fas ligand, perforin, caspase-1, and caspase-3 but reduced production of Bcl-2 and interleukin-2.	unassigned	-	
3.4.21.78	Infections	https://pubmed.ncbi.nlm.nih.gov/16616140/	Stable RNA interference of host thrombospondin-1 blocks Trypanosoma cruzi infection.	unassigned	-	
3.4.21.78	Influenza, Human	https://pubmed.ncbi.nlm.nih.gov/23658773/	Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine.	diagnostic usage	1	
3.4.21.78	Influenza, Human	https://pubmed.ncbi.nlm.nih.gov/19404988/	Granzyme A expression reveals distinct cytolytic CTL subsets following influenza A virus infection.	therapeutic application	1	
3.4.21.78	Influenza, Human	https://pubmed.ncbi.nlm.nih.gov/19404988/	Granzyme A expression reveals distinct cytolytic CTL subsets following influenza A virus infection.	ongoing research	1	
3.4.21.78	Influenza, Human	https://pubmed.ncbi.nlm.nih.gov/14745033/	Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses.	ongoing research	1	
3.4.21.78	Influenza, Human	https://pubmed.ncbi.nlm.nih.gov/23658773/	Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine.	ongoing research	3	
3.4.21.78	Influenza, Human	https://pubmed.ncbi.nlm.nih.gov/19404988/	Granzyme A expression reveals distinct cytolytic CTL subsets following influenza A virus infection.	unassigned	-	
3.4.21.78	Influenza, Human	https://pubmed.ncbi.nlm.nih.gov/14745033/	Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses.	unassigned	-	
3.4.21.78	Influenza, Human	https://pubmed.ncbi.nlm.nih.gov/23658773/	Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine.	unassigned	-	
3.4.21.78	Insulin Resistance	https://pubmed.ncbi.nlm.nih.gov/27492207/	Thrombospondin 1 Suppresses Insulin Signaling in C2C12 Myotubes.	causal interaction	4	
3.4.21.78	Insulin Resistance	https://pubmed.ncbi.nlm.nih.gov/27492207/	Thrombospondin 1 Suppresses Insulin Signaling in C2C12 Myotubes.	therapeutic application	4	
3.4.21.78	Insulin Resistance	https://pubmed.ncbi.nlm.nih.gov/27492207/	Thrombospondin 1 Suppresses Insulin Signaling in C2C12 Myotubes.	unassigned	-	
3.4.21.78	Intracranial Aneurysm	https://pubmed.ncbi.nlm.nih.gov/32723034/	Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.	causal interaction	1	
3.4.21.78	Intracranial Aneurysm	https://pubmed.ncbi.nlm.nih.gov/32723034/	Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.	ongoing research	1	
3.4.21.78	Intracranial Aneurysm	https://pubmed.ncbi.nlm.nih.gov/32723034/	Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.	unassigned	-	
3.4.21.78	Intracranial Hemorrhages	https://pubmed.ncbi.nlm.nih.gov/32723034/	Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.	causal interaction	1	
3.4.21.78	Intracranial Hemorrhages	https://pubmed.ncbi.nlm.nih.gov/32723034/	Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.	ongoing research	1	
3.4.21.78	Intracranial Hemorrhages	https://pubmed.ncbi.nlm.nih.gov/32723034/	Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.	unassigned	-	
3.4.21.78	Ischemic Stroke	https://pubmed.ncbi.nlm.nih.gov/33853408/	Plasminogen deficiency causes reduced angiogenesis and behavioral recovery after stroke in mice.	causal interaction	4	
3.4.21.78	Ischemic Stroke	https://pubmed.ncbi.nlm.nih.gov/33853408/	Plasminogen deficiency causes reduced angiogenesis and behavioral recovery after stroke in mice.	therapeutic application	2	
3.4.21.78	Ischemic Stroke	https://pubmed.ncbi.nlm.nih.gov/33853408/	Plasminogen deficiency causes reduced angiogenesis and behavioral recovery after stroke in mice.	ongoing research	4	
3.4.21.78	Ischemic Stroke	https://pubmed.ncbi.nlm.nih.gov/33853408/	Plasminogen deficiency causes reduced angiogenesis and behavioral recovery after stroke in mice.	unassigned	-	
3.4.21.78	Keratitis	https://pubmed.ncbi.nlm.nih.gov/20847111/	Spontaneous bacterial keratitis in CD36 knockout mice.	therapeutic application	1	
3.4.21.78	Keratitis	https://pubmed.ncbi.nlm.nih.gov/31173926/	Thrombospondin-1 in ocular surface health and disease.	therapeutic application	2	
3.4.21.78	Keratitis	https://pubmed.ncbi.nlm.nih.gov/20847111/	Spontaneous bacterial keratitis in CD36 knockout mice.	ongoing research	2	
3.4.21.78	Keratitis	https://pubmed.ncbi.nlm.nih.gov/20847111/	Spontaneous bacterial keratitis in CD36 knockout mice.	unassigned	-	
3.4.21.78	Keratitis	https://pubmed.ncbi.nlm.nih.gov/31173926/	Thrombospondin-1 in ocular surface health and disease.	unassigned	-	
3.4.21.78	Keratoacanthoma	https://pubmed.ncbi.nlm.nih.gov/17198740/	The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.	causal interaction	4	
3.4.21.78	Keratoacanthoma	https://pubmed.ncbi.nlm.nih.gov/17198740/	The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.	diagnostic usage	1	
3.4.21.78	Keratoacanthoma	https://pubmed.ncbi.nlm.nih.gov/17198740/	The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.	ongoing research	1	
3.4.21.78	Keratoacanthoma	https://pubmed.ncbi.nlm.nih.gov/17198740/	The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.	unassigned	-	
3.4.21.78	Leiomyoma	https://pubmed.ncbi.nlm.nih.gov/18089612/	Thrombospondin-1 and thrombospondin-2 mRNA and TSP-1 and TSP-2 protein expression in uterine fibroids and correlation to the genes COL1A1 and COL3A1 and to the collagen cross-link hydroxyproline.	causal interaction	4	
3.4.21.78	Leiomyoma	https://pubmed.ncbi.nlm.nih.gov/23018248/	Expression of matricellular proteins in human uterine leiomyomas and normal myometrium.	causal interaction	4	
3.4.21.78	Leiomyoma	https://pubmed.ncbi.nlm.nih.gov/23018248/	Expression of matricellular proteins in human uterine leiomyomas and normal myometrium.	diagnostic usage	2	
3.4.21.78	Leiomyoma	https://pubmed.ncbi.nlm.nih.gov/18089612/	Thrombospondin-1 and thrombospondin-2 mRNA and TSP-1 and TSP-2 protein expression in uterine fibroids and correlation to the genes COL1A1 and COL3A1 and to the collagen cross-link hydroxyproline.	ongoing research	1	
3.4.21.78	Leiomyoma	https://pubmed.ncbi.nlm.nih.gov/18089612/	Thrombospondin-1 and thrombospondin-2 mRNA and TSP-1 and TSP-2 protein expression in uterine fibroids and correlation to the genes COL1A1 and COL3A1 and to the collagen cross-link hydroxyproline.	unassigned	-	
3.4.21.78	Leiomyoma	https://pubmed.ncbi.nlm.nih.gov/23018248/	Expression of matricellular proteins in human uterine leiomyomas and normal myometrium.	unassigned	-	
3.4.21.78	Leishmaniasis, Cutaneous	https://pubmed.ncbi.nlm.nih.gov/7927497/	Cutaneous leishmaniasis: co-ordinate expression of granzyme A and lymphokines by CD4+ T cells from susceptible mice.	causal interaction	3	
3.4.21.78	Leishmaniasis, Cutaneous	https://pubmed.ncbi.nlm.nih.gov/7927497/	Cutaneous leishmaniasis: co-ordinate expression of granzyme A and lymphokines by CD4+ T cells from susceptible mice.	diagnostic usage	1	
3.4.21.78	Leishmaniasis, Cutaneous	https://pubmed.ncbi.nlm.nih.gov/7927497/	Cutaneous leishmaniasis: co-ordinate expression of granzyme A and lymphokines by CD4+ T cells from susceptible mice.	ongoing research	4	
3.4.21.78	Leishmaniasis, Cutaneous	https://pubmed.ncbi.nlm.nih.gov/19646207/	Recruitment of CD8(+) T cells expressing granzyme A is associated with lesion progression in human cutaneous leishmaniasis.	unassigned	-	
3.4.21.78	Leishmaniasis, Cutaneous	https://pubmed.ncbi.nlm.nih.gov/7927497/	Cutaneous leishmaniasis: co-ordinate expression of granzyme A and lymphokines by CD4+ T cells from susceptible mice.	unassigned	-	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/2444461/	A secretable serine proteinase with highly restricted specificity from cytolytic T lymphocytes inactivates retrovirus-associated reverse transcriptase.	causal interaction	1	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/7869027/	Synergistic roles of granzymes A and B in mediating target cell death by rat basophilic leukemia mast cell tumors also expressing cytolysin/perforin.	causal interaction	1	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/14612980/	Thrombospondin-1 induces apoptosis in primary leukemia and cell lines mediated by CD36 and Caspase-3.	causal interaction	3	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/15784731/	Type 3 repeat/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/alphavbeta3 in promyelocytic leukemia NB4 cells.	causal interaction	1	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/15868907/	Thrombospondin-1 (TSP-1) and TSP-1-derived heparin-binding peptides induce promyelocytic leukemia cell differentiation and apoptosis.	causal interaction	1	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/1423596/	Cytotoxicity with target DNA breakdown by rat basophilic leukemia cells expressing both cytolysin and granzyme A.	diagnostic usage	3	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/12801528/	Adenovirus-mediated gene therapy with an antiangiogenic fragment of thrombospondin-1 inhibits human leukemia xenograft growth in nude mice.	diagnostic usage	1	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/14612980/	Thrombospondin-1 induces apoptosis in primary leukemia and cell lines mediated by CD36 and Caspase-3.	diagnostic usage	4	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/15567431/	Independent roles of perforin, granzymes, and Fas in the control of Friend retrovirus infection.	diagnostic usage	3	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/15868907/	Thrombospondin-1 (TSP-1) and TSP-1-derived heparin-binding peptides induce promyelocytic leukemia cell differentiation and apoptosis.	diagnostic usage	3	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/12958185/	Granzyme A mediates glucocorticoid-induced apoptosis in leukemia cells.	therapeutic application	1	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/12801528/	Adenovirus-mediated gene therapy with an antiangiogenic fragment of thrombospondin-1 inhibits human leukemia xenograft growth in nude mice.	therapeutic application	4	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/14612980/	Thrombospondin-1 induces apoptosis in primary leukemia and cell lines mediated by CD36 and Caspase-3.	therapeutic application	4	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/15567431/	Independent roles of perforin, granzymes, and Fas in the control of Friend retrovirus infection.	therapeutic application	1	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/15784731/	Type 3 repeat/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/alphavbeta3 in promyelocytic leukemia NB4 cells.	therapeutic application	3	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/1423596/	Cytotoxicity with target DNA breakdown by rat basophilic leukemia cells expressing both cytolysin and granzyme A.	ongoing research	2	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/12958185/	Granzyme A mediates glucocorticoid-induced apoptosis in leukemia cells.	ongoing research	3	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/7507956/	Cytotoxic lymphocyte granzymes trigger a target cell internal disintegration pathway leading to cytolysis and DNA breakdown.	ongoing research	2	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/7869027/	Synergistic roles of granzymes A and B in mediating target cell death by rat basophilic leukemia mast cell tumors also expressing cytolysin/perforin.	ongoing research	2	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/12801528/	Adenovirus-mediated gene therapy with an antiangiogenic fragment of thrombospondin-1 inhibits human leukemia xenograft growth in nude mice.	ongoing research	3	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/14612980/	Thrombospondin-1 induces apoptosis in primary leukemia and cell lines mediated by CD36 and Caspase-3.	ongoing research	4	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/15784731/	Type 3 repeat/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/alphavbeta3 in promyelocytic leukemia NB4 cells.	ongoing research	2	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/15868907/	Thrombospondin-1 (TSP-1) and TSP-1-derived heparin-binding peptides induce promyelocytic leukemia cell differentiation and apoptosis.	ongoing research	3	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/19324018/	All-trans retinoic acid induces Thrombospondin-1 expression in acute promyelocytic leukemia cells though down-regulation of its transcription repressor, c-MYC oncoprotein.	ongoing research	4	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/1423596/	Cytotoxicity with target DNA breakdown by rat basophilic leukemia cells expressing both cytolysin and granzyme A.	unassigned	-	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/12958185/	Granzyme A mediates glucocorticoid-induced apoptosis in leukemia cells.	unassigned	-	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/7507956/	Cytotoxic lymphocyte granzymes trigger a target cell internal disintegration pathway leading to cytolysis and DNA breakdown.	unassigned	-	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/12801528/	Adenovirus-mediated gene therapy with an antiangiogenic fragment of thrombospondin-1 inhibits human leukemia xenograft growth in nude mice.	unassigned	-	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/15567431/	Independent roles of perforin, granzymes, and Fas in the control of Friend retrovirus infection.	unassigned	-	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/19324018/	All-trans retinoic acid induces Thrombospondin-1 expression in acute promyelocytic leukemia cells though down-regulation of its transcription repressor, c-MYC oncoprotein.	unassigned	-	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/2444461/	A secretable serine proteinase with highly restricted specificity from cytolytic T lymphocytes inactivates retrovirus-associated reverse transcriptase.	unassigned	-	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/7869027/	Synergistic roles of granzymes A and B in mediating target cell death by rat basophilic leukemia mast cell tumors also expressing cytolysin/perforin.	unassigned	-	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/15784731/	Type 3 repeat/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/alphavbeta3 in promyelocytic leukemia NB4 cells.	unassigned	-	
3.4.21.78	Leukemia	https://pubmed.ncbi.nlm.nih.gov/15868907/	Thrombospondin-1 (TSP-1) and TSP-1-derived heparin-binding peptides induce promyelocytic leukemia cell differentiation and apoptosis.	unassigned	-	
3.4.21.78	Leukemia, Promyelocytic, Acute	https://pubmed.ncbi.nlm.nih.gov/19324018/	All-trans retinoic acid induces Thrombospondin-1 expression in acute promyelocytic leukemia cells though down-regulation of its transcription repressor, c-MYC oncoprotein.	ongoing research	4	
3.4.21.78	Leukemia, Promyelocytic, Acute	https://pubmed.ncbi.nlm.nih.gov/19324018/	All-trans retinoic acid induces Thrombospondin-1 expression in acute promyelocytic leukemia cells though down-regulation of its transcription repressor, c-MYC oncoprotein.	unassigned	-	
3.4.21.78	Leukopenia	https://pubmed.ncbi.nlm.nih.gov/29998369/	Decreased serum thrombospondin-1 and elevation of its autoantibody are associated with multiple exacerbated clinical manifestations in systemic lupus erythematosus.	therapeutic application	1	
3.4.21.78	Leukopenia	https://pubmed.ncbi.nlm.nih.gov/29998369/	Decreased serum thrombospondin-1 and elevation of its autoantibody are associated with multiple exacerbated clinical manifestations in systemic lupus erythematosus.	unassigned	-	
3.4.21.78	Liver Cirrhosis	https://pubmed.ncbi.nlm.nih.gov/31891606/	Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).	causal interaction	4	
3.4.21.78	Liver Cirrhosis	https://pubmed.ncbi.nlm.nih.gov/31891606/	Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).	ongoing research	4	
3.4.21.78	Liver Cirrhosis	https://pubmed.ncbi.nlm.nih.gov/31891606/	Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).	unassigned	-	
3.4.21.78	Liver Diseases	https://pubmed.ncbi.nlm.nih.gov/31891606/	Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).	causal interaction	4	
3.4.21.78	Liver Diseases	https://pubmed.ncbi.nlm.nih.gov/25866938/	Effect of LSKL peptide on thrombospondin 1-mediated transforming growth factor ? signal activation and liver regeneration after hepatectomy in an experimental model.	diagnostic usage	4	
3.4.21.78	Liver Diseases	https://pubmed.ncbi.nlm.nih.gov/31891606/	Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).	ongoing research	4	
3.4.21.78	Liver Diseases	https://pubmed.ncbi.nlm.nih.gov/25866938/	Effect of LSKL peptide on thrombospondin 1-mediated transforming growth factor ? signal activation and liver regeneration after hepatectomy in an experimental model.	unassigned	-	
3.4.21.78	Liver Diseases	https://pubmed.ncbi.nlm.nih.gov/31891606/	Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).	unassigned	-	
3.4.21.78	Liver Failure, Acute	https://pubmed.ncbi.nlm.nih.gov/31734229/	Thrombospondin-1 Exacerbates Acute Liver Failure and Hepatic Encephalopathy Pathology in Mice by Activating Transforming Growth Factor ?1.	causal interaction	1	
3.4.21.78	Liver Failure, Acute	https://pubmed.ncbi.nlm.nih.gov/31734229/	Thrombospondin-1 Exacerbates Acute Liver Failure and Hepatic Encephalopathy Pathology in Mice by Activating Transforming Growth Factor ?1.	therapeutic application	1	
3.4.21.78	Liver Failure, Acute	https://pubmed.ncbi.nlm.nih.gov/31734229/	Thrombospondin-1 Exacerbates Acute Liver Failure and Hepatic Encephalopathy Pathology in Mice by Activating Transforming Growth Factor ?1.	ongoing research	4	
3.4.21.78	Liver Failure, Acute	https://pubmed.ncbi.nlm.nih.gov/31734229/	Thrombospondin-1 Exacerbates Acute Liver Failure and Hepatic Encephalopathy Pathology in Mice by Activating Transforming Growth Factor ?1.	unassigned	-	
3.4.21.78	Lung Diseases	https://pubmed.ncbi.nlm.nih.gov/18559365/	Granzyme K: a novel mediator in acute airway inflammation.	therapeutic application	1	
3.4.21.78	Lung Diseases	https://pubmed.ncbi.nlm.nih.gov/18559365/	Granzyme K: a novel mediator in acute airway inflammation.	ongoing research	2	
3.4.21.78	Lung Diseases	https://pubmed.ncbi.nlm.nih.gov/18559365/	Granzyme K: a novel mediator in acute airway inflammation.	unassigned	-	
3.4.21.78	Lung Diseases, Interstitial	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	causal interaction	4	
3.4.21.78	Lung Diseases, Interstitial	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	diagnostic usage	4	
3.4.21.78	Lung Diseases, Interstitial	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	ongoing research	3	
3.4.21.78	Lung Diseases, Interstitial	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	unassigned	-	
3.4.21.78	Lung Injury	https://pubmed.ncbi.nlm.nih.gov/18579356/	A TSP-1 synthetic peptide inhibits bleomycin-induced lung fibrosis in mice.	unassigned	-	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20950544/	[Expression of thrombospondin-1 and CD44 in human lung cancer tissues and their prognostic significance.]	causal interaction	4	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24018559/	Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors.	causal interaction	3	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26653811/	[Changes in serum protease and cytokine in patients with silicosis, tuberculosis, and lung cancer].	causal interaction	4	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31446985/	Identification and validation of novel circulating biomarkers for early diagnosis of lung cancer.	causal interaction	3	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/34501309/	Decreased Thrombospondin-1 and Bone Morphogenetic Protein-4 Serum Levels as Potential Indices of Advanced Stage Lung Cancer.	causal interaction	4	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19471115/	Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.	diagnostic usage	2	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20950544/	[Expression of thrombospondin-1 and CD44 in human lung cancer tissues and their prognostic significance.]	diagnostic usage	3	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24788022/	Net platelet angiogenic activity (NPAA) correlates with progression and prognosis of non-small cell lung cancer.	diagnostic usage	4	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26653811/	[Changes in serum protease and cytokine in patients with silicosis, tuberculosis, and lung cancer].	diagnostic usage	4	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31446985/	Identification and validation of novel circulating biomarkers for early diagnosis of lung cancer.	diagnostic usage	4	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/34501309/	Decreased Thrombospondin-1 and Bone Morphogenetic Protein-4 Serum Levels as Potential Indices of Advanced Stage Lung Cancer.	diagnostic usage	4	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19471115/	Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.	therapeutic application	1	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24018559/	Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors.	therapeutic application	2	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24788022/	Net platelet angiogenic activity (NPAA) correlates with progression and prognosis of non-small cell lung cancer.	therapeutic application	1	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26653811/	[Changes in serum protease and cytokine in patients with silicosis, tuberculosis, and lung cancer].	therapeutic application	1	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31446985/	Identification and validation of novel circulating biomarkers for early diagnosis of lung cancer.	therapeutic application	1	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20950544/	[Expression of thrombospondin-1 and CD44 in human lung cancer tissues and their prognostic significance.]	ongoing research	4	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24018559/	Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors.	ongoing research	2	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24788022/	Net platelet angiogenic activity (NPAA) correlates with progression and prognosis of non-small cell lung cancer.	ongoing research	2	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26653811/	[Changes in serum protease and cytokine in patients with silicosis, tuberculosis, and lung cancer].	ongoing research	2	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/34501309/	Decreased Thrombospondin-1 and Bone Morphogenetic Protein-4 Serum Levels as Potential Indices of Advanced Stage Lung Cancer.	ongoing research	1	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19471115/	Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.	unassigned	-	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24788022/	Net platelet angiogenic activity (NPAA) correlates with progression and prognosis of non-small cell lung cancer.	unassigned	-	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24018559/	Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors.	unassigned	-	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20950544/	[Expression of thrombospondin-1 and CD44 in human lung cancer tissues and their prognostic significance.]	unassigned	-	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/34501309/	Decreased Thrombospondin-1 and Bone Morphogenetic Protein-4 Serum Levels as Potential Indices of Advanced Stage Lung Cancer.	unassigned	-	
3.4.21.78	Lung Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31446985/	Identification and validation of novel circulating biomarkers for early diagnosis of lung cancer.	unassigned	-	
3.4.21.78	Lupus Erythematosus, Systemic	https://pubmed.ncbi.nlm.nih.gov/32709480/	The role of thrombospondin-1 in the pathogenesis of antiphospholipid syndrome.	diagnostic usage	2	
3.4.21.78	Lupus Erythematosus, Systemic	https://pubmed.ncbi.nlm.nih.gov/29998369/	Decreased serum thrombospondin-1 and elevation of its autoantibody are associated with multiple exacerbated clinical manifestations in systemic lupus erythematosus.	therapeutic application	1	
3.4.21.78	Lupus Erythematosus, Systemic	https://pubmed.ncbi.nlm.nih.gov/32709480/	The role of thrombospondin-1 in the pathogenesis of antiphospholipid syndrome.	ongoing research	3	
3.4.21.78	Lupus Erythematosus, Systemic	https://pubmed.ncbi.nlm.nih.gov/29998369/	Decreased serum thrombospondin-1 and elevation of its autoantibody are associated with multiple exacerbated clinical manifestations in systemic lupus erythematosus.	unassigned	-	
3.4.21.78	Lupus Erythematosus, Systemic	https://pubmed.ncbi.nlm.nih.gov/32709480/	The role of thrombospondin-1 in the pathogenesis of antiphospholipid syndrome.	unassigned	-	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/10375104/	Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.	causal interaction	4	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/12429967/	Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma.	causal interaction	3	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/17709727/	Association of angiogenesis markers with lymph node metastasis in early colorectal cancer.	causal interaction	4	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/17912439/	Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer.	causal interaction	3	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	causal interaction	4	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/19906510/	The alteration of Id-1 and TSP-1 expression in mucoepidermoid carcinoma associated with its clinical features and prognosis.	causal interaction	1	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/23614916/	Thrombospondin-1 is highly expressed in desmoplastic components of invasive ductal carcinoma of the breast and associated with lymph node metastasis.	causal interaction	4	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/31750826/	[The poor prognosis is correlated with the high expression of vascular endothelial growth factor (VEGF) and low expression of thrombospondin 1 (TSP-1) in patients with breast cancer].	causal interaction	4	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/10375104/	Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.	diagnostic usage	4	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/12429967/	Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma.	diagnostic usage	3	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/17709727/	Association of angiogenesis markers with lymph node metastasis in early colorectal cancer.	diagnostic usage	4	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/17912439/	Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer.	diagnostic usage	4	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	diagnostic usage	3	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/19906510/	The alteration of Id-1 and TSP-1 expression in mucoepidermoid carcinoma associated with its clinical features and prognosis.	diagnostic usage	4	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/23614916/	Thrombospondin-1 is highly expressed in desmoplastic components of invasive ductal carcinoma of the breast and associated with lymph node metastasis.	diagnostic usage	4	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/31750826/	[The poor prognosis is correlated with the high expression of vascular endothelial growth factor (VEGF) and low expression of thrombospondin 1 (TSP-1) in patients with breast cancer].	diagnostic usage	4	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/10375104/	Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.	therapeutic application	1	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/17709727/	Association of angiogenesis markers with lymph node metastasis in early colorectal cancer.	therapeutic application	1	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	therapeutic application	1	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/23614916/	Thrombospondin-1 is highly expressed in desmoplastic components of invasive ductal carcinoma of the breast and associated with lymph node metastasis.	therapeutic application	1	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/10375104/	Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.	ongoing research	3	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/12429967/	Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma.	ongoing research	4	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/17709727/	Association of angiogenesis markers with lymph node metastasis in early colorectal cancer.	ongoing research	3	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/17912439/	Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer.	ongoing research	4	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/19906510/	The alteration of Id-1 and TSP-1 expression in mucoepidermoid carcinoma associated with its clinical features and prognosis.	ongoing research	2	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/23614916/	Thrombospondin-1 is highly expressed in desmoplastic components of invasive ductal carcinoma of the breast and associated with lymph node metastasis.	ongoing research	4	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/31750826/	[The poor prognosis is correlated with the high expression of vascular endothelial growth factor (VEGF) and low expression of thrombospondin 1 (TSP-1) in patients with breast cancer].	ongoing research	4	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/12429967/	Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma.	unassigned	-	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/17912439/	Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer.	unassigned	-	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/19906510/	The alteration of Id-1 and TSP-1 expression in mucoepidermoid carcinoma associated with its clinical features and prognosis.	unassigned	-	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/31750826/	[The poor prognosis is correlated with the high expression of vascular endothelial growth factor (VEGF) and low expression of thrombospondin 1 (TSP-1) in patients with breast cancer].	unassigned	-	
3.4.21.78	Lymphatic Metastasis	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	unassigned	-	
3.4.21.78	Lymphocytic Choriomeningitis	https://pubmed.ncbi.nlm.nih.gov/2668013/	Detection of perforin and granzyme A mRNA in infiltrating cells during infection of mice with lymphocytic choriomeningitis virus.	causal interaction	3	
3.4.21.78	Lymphocytic Choriomeningitis	https://pubmed.ncbi.nlm.nih.gov/15507626/	Perforin and Fas act together in the induction of apoptosis, and both are critical in the clearance of lymphocytic choriomeningitis virus infection.	causal interaction	1	
3.4.21.78	Lymphocytic Choriomeningitis	https://pubmed.ncbi.nlm.nih.gov/2668013/	Detection of perforin and granzyme A mRNA in infiltrating cells during infection of mice with lymphocytic choriomeningitis virus.	diagnostic usage	3	
3.4.21.78	Lymphocytic Choriomeningitis	https://pubmed.ncbi.nlm.nih.gov/3260181/	Induction of T cell serine proteinase 1 (TSP-1)-specific mRNA in mouse T lymphocytes.	diagnostic usage	4	
3.4.21.78	Lymphocytic Choriomeningitis	https://pubmed.ncbi.nlm.nih.gov/2668013/	Detection of perforin and granzyme A mRNA in infiltrating cells during infection of mice with lymphocytic choriomeningitis virus.	ongoing research	4	
3.4.21.78	Lymphocytic Choriomeningitis	https://pubmed.ncbi.nlm.nih.gov/15507626/	Perforin and Fas act together in the induction of apoptosis, and both are critical in the clearance of lymphocytic choriomeningitis virus infection.	ongoing research	3	
3.4.21.78	Lymphocytic Choriomeningitis	https://pubmed.ncbi.nlm.nih.gov/3260181/	Induction of T cell serine proteinase 1 (TSP-1)-specific mRNA in mouse T lymphocytes.	unassigned	-	
3.4.21.78	Lymphocytic Choriomeningitis	https://pubmed.ncbi.nlm.nih.gov/15507626/	Perforin and Fas act together in the induction of apoptosis, and both are critical in the clearance of lymphocytic choriomeningitis virus infection.	unassigned	-	
3.4.21.78	Lymphocytic Choriomeningitis	https://pubmed.ncbi.nlm.nih.gov/2668013/	Detection of perforin and granzyme A mRNA in infiltrating cells during infection of mice with lymphocytic choriomeningitis virus.	unassigned	-	
3.4.21.78	Lymphoma	https://pubmed.ncbi.nlm.nih.gov/15239400/	NK/T-cell lymphoma associated with Epstein-Barr virus in a patient infected with human immunodeficiency virus: an autopsy case.	diagnostic usage	1	
3.4.21.78	Lymphoma	https://pubmed.ncbi.nlm.nih.gov/15239400/	NK/T-cell lymphoma associated with Epstein-Barr virus in a patient infected with human immunodeficiency virus: an autopsy case.	therapeutic application	1	
3.4.21.78	Lymphoma	https://pubmed.ncbi.nlm.nih.gov/17706282/	Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas.	therapeutic application	1	
3.4.21.78	Lymphoma	https://pubmed.ncbi.nlm.nih.gov/1989498/	The enzymatic activity of human cytotoxic T-lymphocyte granzyme A and cytolysis mediated by cytotoxic T-lymphocytes are potently inhibited by a synthetic antiprotease, FUT-175.	ongoing research	1	
3.4.21.78	Lymphoma	https://pubmed.ncbi.nlm.nih.gov/15239400/	NK/T-cell lymphoma associated with Epstein-Barr virus in a patient infected with human immunodeficiency virus: an autopsy case.	ongoing research	3	
3.4.21.78	Lymphoma	https://pubmed.ncbi.nlm.nih.gov/17706282/	Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas.	ongoing research	4	
3.4.21.78	Lymphoma	https://pubmed.ncbi.nlm.nih.gov/1989498/	The enzymatic activity of human cytotoxic T-lymphocyte granzyme A and cytolysis mediated by cytotoxic T-lymphocytes are potently inhibited by a synthetic antiprotease, FUT-175.	unassigned	-	
3.4.21.78	Lymphoma	https://pubmed.ncbi.nlm.nih.gov/15239400/	NK/T-cell lymphoma associated with Epstein-Barr virus in a patient infected with human immunodeficiency virus: an autopsy case.	unassigned	-	
3.4.21.78	Lymphoma	https://pubmed.ncbi.nlm.nih.gov/17706282/	Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas.	unassigned	-	
3.4.21.78	Lymphoma, B-Cell	https://pubmed.ncbi.nlm.nih.gov/22789925/	Immune mediators in vitreous fluids from patients with vitreoretinal B-cell lymphoma.	unassigned	-	
3.4.21.78	Lymphoma, Non-Hodgkin	https://pubmed.ncbi.nlm.nih.gov/8934921/	Sjögren's syndrome: immunobiology of exocrine gland dysfunction.	unassigned	-	
3.4.21.78	Lymphoma, T-Cell, Cutaneous	https://pubmed.ncbi.nlm.nih.gov/31712778/	Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47.	causal interaction	1	
3.4.21.78	Lymphoma, T-Cell, Cutaneous	https://pubmed.ncbi.nlm.nih.gov/31712778/	Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47.	ongoing research	4	
3.4.21.78	Lymphoma, T-Cell, Cutaneous	https://pubmed.ncbi.nlm.nih.gov/31712778/	Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47.	unassigned	-	
3.4.21.78	Lymphoproliferative Disorders	https://pubmed.ncbi.nlm.nih.gov/10892713/	The clinicopathologic spectrum of cytotoxic lymphomas of the skin.	unassigned	-	
3.4.21.78	Macular Degeneration	https://pubmed.ncbi.nlm.nih.gov/27116510/	Effect of Risk Alleles in CFH, C3, and VEGFA on the Response to Intravitreal Bevacizumab in Tunisian Patients with Neovascular Age-related Macular Degeneration.	diagnostic usage	3	
3.4.21.78	Macular Degeneration	https://pubmed.ncbi.nlm.nih.gov/27116510/	Effect of Risk Alleles in CFH, C3, and VEGFA on the Response to Intravitreal Bevacizumab in Tunisian Patients with Neovascular Age-related Macular Degeneration.	ongoing research	3	
3.4.21.78	Macular Degeneration	https://pubmed.ncbi.nlm.nih.gov/27116510/	Effect of Risk Alleles in CFH, C3, and VEGFA on the Response to Intravitreal Bevacizumab in Tunisian Patients with Neovascular Age-related Macular Degeneration.	unassigned	-	
3.4.21.78	Medulloblastoma	https://pubmed.ncbi.nlm.nih.gov/20876797/	Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma.	causal interaction	3	
3.4.21.78	Medulloblastoma	https://pubmed.ncbi.nlm.nih.gov/20876797/	Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma.	diagnostic usage	4	
3.4.21.78	Medulloblastoma	https://pubmed.ncbi.nlm.nih.gov/20876797/	Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma.	therapeutic application	1	
3.4.21.78	Medulloblastoma	https://pubmed.ncbi.nlm.nih.gov/20876797/	Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma.	ongoing research	3	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/11438469/	Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.	causal interaction	4	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/27349907/	Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide.	causal interaction	1	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/33032882/	Novel application of adipose-derived mesenchymal stem cells via producing antiangiogenic factor TSP-1 in lung metastatic melanoma animal model.	causal interaction	3	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/9618039/	Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma.	causal interaction	4	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/12874006/	Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts.	causal interaction	3	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/14511656/	Restoration of thrombospondin 1 expression in tumor cells harbouring mutant ras oncogene by treatment with low doses of doxycycline.	causal interaction	3	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/15375381/	Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model.	causal interaction	4	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/18171979/	Interference of macrophage migration inhibitory factor expression in a mouse melanoma inhibits tumor establishment by up-regulating thrombospondin-1.	causal interaction	4	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/18836566/	Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell growth.	causal interaction	1	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/23846726/	Thrombospondin-1 is a putative target gene of Runx2 and Runx3.	causal interaction	3	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/25256553/	Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2.	causal interaction	2	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/27756886/	Properdistatin inhibits angiogenesis and improves vascular function in human melanoma xenografts with low thrombospondin-1 expression.	causal interaction	1	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/11438469/	Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.	diagnostic usage	4	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/27349907/	Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide.	diagnostic usage	3	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/9618039/	Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma.	diagnostic usage	4	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/12874006/	Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts.	diagnostic usage	3	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/14511656/	Restoration of thrombospondin 1 expression in tumor cells harbouring mutant ras oncogene by treatment with low doses of doxycycline.	diagnostic usage	2	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/15840100/	The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.	diagnostic usage	1	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/23846726/	Thrombospondin-1 is a putative target gene of Runx2 and Runx3.	diagnostic usage	3	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/25256553/	Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2.	diagnostic usage	3	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/11438469/	Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.	therapeutic application	2	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/27349907/	Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide.	therapeutic application	4	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/33032882/	Novel application of adipose-derived mesenchymal stem cells via producing antiangiogenic factor TSP-1 in lung metastatic melanoma animal model.	therapeutic application	4	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/8601718/	Human microvascular endothelial cells adhere to thrombospondin-1 via an RGD/CSVTCG domain independent mechanism.	therapeutic application	1	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/12874006/	Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts.	therapeutic application	4	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/15375381/	Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model.	therapeutic application	4	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/15840100/	The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.	therapeutic application	1	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/18171979/	Interference of macrophage migration inhibitory factor expression in a mouse melanoma inhibits tumor establishment by up-regulating thrombospondin-1.	therapeutic application	1	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/18836566/	Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell growth.	therapeutic application	2	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/25256553/	Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2.	therapeutic application	1	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/27756886/	Properdistatin inhibits angiogenesis and improves vascular function in human melanoma xenografts with low thrombospondin-1 expression.	therapeutic application	2	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/27349907/	Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide.	ongoing research	1	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/33032882/	Novel application of adipose-derived mesenchymal stem cells via producing antiangiogenic factor TSP-1 in lung metastatic melanoma animal model.	ongoing research	2	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/8601718/	Human microvascular endothelial cells adhere to thrombospondin-1 via an RGD/CSVTCG domain independent mechanism.	ongoing research	1	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/9618039/	Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma.	ongoing research	4	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/12874006/	Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts.	ongoing research	3	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/14511656/	Restoration of thrombospondin 1 expression in tumor cells harbouring mutant ras oncogene by treatment with low doses of doxycycline.	ongoing research	2	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/15375381/	Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model.	ongoing research	4	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/15840100/	The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.	ongoing research	4	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/18171979/	Interference of macrophage migration inhibitory factor expression in a mouse melanoma inhibits tumor establishment by up-regulating thrombospondin-1.	ongoing research	2	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/23846726/	Thrombospondin-1 is a putative target gene of Runx2 and Runx3.	ongoing research	1	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/25256553/	Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2.	ongoing research	4	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/27756886/	Properdistatin inhibits angiogenesis and improves vascular function in human melanoma xenografts with low thrombospondin-1 expression.	ongoing research	4	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/8601718/	Human microvascular endothelial cells adhere to thrombospondin-1 via an RGD/CSVTCG domain independent mechanism.	unassigned	-	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/9032471/	Identification of cell adhesive active sites in the N-terminal domain of thrombospondin-1.	unassigned	-	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/15840100/	The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.	unassigned	-	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/33032882/	Novel application of adipose-derived mesenchymal stem cells via producing antiangiogenic factor TSP-1 in lung metastatic melanoma animal model.	unassigned	-	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/15375381/	Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model.	unassigned	-	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/18171979/	Interference of macrophage migration inhibitory factor expression in a mouse melanoma inhibits tumor establishment by up-regulating thrombospondin-1.	unassigned	-	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/18836566/	Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell growth.	unassigned	-	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/27756886/	Properdistatin inhibits angiogenesis and improves vascular function in human melanoma xenografts with low thrombospondin-1 expression.	unassigned	-	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/9618039/	Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma.	unassigned	-	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/14511656/	Restoration of thrombospondin 1 expression in tumor cells harbouring mutant ras oncogene by treatment with low doses of doxycycline.	unassigned	-	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/23846726/	Thrombospondin-1 is a putative target gene of Runx2 and Runx3.	unassigned	-	
3.4.21.78	Melanoma	https://pubmed.ncbi.nlm.nih.gov/11438469/	Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.	unassigned	-	
3.4.21.78	Melanoma, Experimental	https://pubmed.ncbi.nlm.nih.gov/27349907/	Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide.	causal interaction	1	
3.4.21.78	Melanoma, Experimental	https://pubmed.ncbi.nlm.nih.gov/27349907/	Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide.	diagnostic usage	3	
3.4.21.78	Melanoma, Experimental	https://pubmed.ncbi.nlm.nih.gov/27349907/	Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide.	therapeutic application	4	
3.4.21.78	Melanoma, Experimental	https://pubmed.ncbi.nlm.nih.gov/27349907/	Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide.	ongoing research	1	
3.4.21.78	Meningioma	https://pubmed.ncbi.nlm.nih.gov/33759165/	Circulating Levels of Thrombospondin-1 and Thrombospondin-2 in Patients with Common Brain Tumors.	causal interaction	4	
3.4.21.78	Meningioma	https://pubmed.ncbi.nlm.nih.gov/33759165/	Circulating Levels of Thrombospondin-1 and Thrombospondin-2 in Patients with Common Brain Tumors.	diagnostic usage	2	
3.4.21.78	Meningioma	https://pubmed.ncbi.nlm.nih.gov/33759165/	Circulating Levels of Thrombospondin-1 and Thrombospondin-2 in Patients with Common Brain Tumors.	unassigned	-	
3.4.21.78	Meningitis	https://pubmed.ncbi.nlm.nih.gov/20675593/	Escherichia coli K1 promotes the ligation of CD47 with thrombospondin-1 to prevent the maturation of dendritic cells in the pathogenesis of neonatal meningitis.	therapeutic application	1	
3.4.21.78	Meningitis	https://pubmed.ncbi.nlm.nih.gov/20675593/	Escherichia coli K1 promotes the ligation of CD47 with thrombospondin-1 to prevent the maturation of dendritic cells in the pathogenesis of neonatal meningitis.	ongoing research	4	
3.4.21.78	Meningitis	https://pubmed.ncbi.nlm.nih.gov/20675593/	Escherichia coli K1 promotes the ligation of CD47 with thrombospondin-1 to prevent the maturation of dendritic cells in the pathogenesis of neonatal meningitis.	unassigned	-	
3.4.21.78	Mesothelioma	https://pubmed.ncbi.nlm.nih.gov/10375104/	Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.	causal interaction	4	
3.4.21.78	Mesothelioma	https://pubmed.ncbi.nlm.nih.gov/10375104/	Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.	diagnostic usage	4	
3.4.21.78	Mesothelioma	https://pubmed.ncbi.nlm.nih.gov/10375104/	Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.	therapeutic application	1	
3.4.21.78	Mesothelioma	https://pubmed.ncbi.nlm.nih.gov/10375104/	Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.	ongoing research	3	
3.4.21.78	Mesothelioma, Malignant	https://pubmed.ncbi.nlm.nih.gov/10375104/	Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.	causal interaction	4	
3.4.21.78	Mesothelioma, Malignant	https://pubmed.ncbi.nlm.nih.gov/33197421/	Exploration of identifying novel serum biomarkers for malignant mesothelioma using iTRAQ combined with 2D-LC-MS/MS.	causal interaction	3	
3.4.21.78	Mesothelioma, Malignant	https://pubmed.ncbi.nlm.nih.gov/10375104/	Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.	diagnostic usage	4	
3.4.21.78	Mesothelioma, Malignant	https://pubmed.ncbi.nlm.nih.gov/33197421/	Exploration of identifying novel serum biomarkers for malignant mesothelioma using iTRAQ combined with 2D-LC-MS/MS.	diagnostic usage	4	
3.4.21.78	Mesothelioma, Malignant	https://pubmed.ncbi.nlm.nih.gov/10375104/	Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.	therapeutic application	1	
3.4.21.78	Mesothelioma, Malignant	https://pubmed.ncbi.nlm.nih.gov/10375104/	Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.	ongoing research	3	
3.4.21.78	Mesothelioma, Malignant	https://pubmed.ncbi.nlm.nih.gov/33197421/	Exploration of identifying novel serum biomarkers for malignant mesothelioma using iTRAQ combined with 2D-LC-MS/MS.	ongoing research	2	
3.4.21.78	Mesothelioma, Malignant	https://pubmed.ncbi.nlm.nih.gov/33197421/	Exploration of identifying novel serum biomarkers for malignant mesothelioma using iTRAQ combined with 2D-LC-MS/MS.	unassigned	-	
3.4.21.78	Metabolic Diseases	https://pubmed.ncbi.nlm.nih.gov/24575376/	The role of thrombospondin (TSP)-1 in obesity and diabetes.	causal interaction	1	
3.4.21.78	Metabolic Diseases	https://pubmed.ncbi.nlm.nih.gov/27492207/	Thrombospondin 1 Suppresses Insulin Signaling in C2C12 Myotubes.	causal interaction	4	
3.4.21.78	Metabolic Diseases	https://pubmed.ncbi.nlm.nih.gov/27492207/	Thrombospondin 1 Suppresses Insulin Signaling in C2C12 Myotubes.	therapeutic application	4	
3.4.21.78	Metabolic Diseases	https://pubmed.ncbi.nlm.nih.gov/24575376/	The role of thrombospondin (TSP)-1 in obesity and diabetes.	ongoing research	2	
3.4.21.78	Metabolic Diseases	https://pubmed.ncbi.nlm.nih.gov/24575376/	The role of thrombospondin (TSP)-1 in obesity and diabetes.	unassigned	-	
3.4.21.78	Metabolic Diseases	https://pubmed.ncbi.nlm.nih.gov/27492207/	Thrombospondin 1 Suppresses Insulin Signaling in C2C12 Myotubes.	unassigned	-	
3.4.21.78	Microscopic Polyangiitis	https://pubmed.ncbi.nlm.nih.gov/32286129/	Complement profile in microscopic polyangiitis and granulomatosis with polyangiitis: analysis using sera from a nationwide prospective cohort study.	causal interaction	2	
3.4.21.78	Microscopic Polyangiitis	https://pubmed.ncbi.nlm.nih.gov/32286129/	Complement profile in microscopic polyangiitis and granulomatosis with polyangiitis: analysis using sera from a nationwide prospective cohort study.	diagnostic usage	3	
3.4.21.78	Microscopic Polyangiitis	https://pubmed.ncbi.nlm.nih.gov/32286129/	Complement profile in microscopic polyangiitis and granulomatosis with polyangiitis: analysis using sera from a nationwide prospective cohort study.	ongoing research	1	
3.4.21.78	Microscopic Polyangiitis	https://pubmed.ncbi.nlm.nih.gov/32286129/	Complement profile in microscopic polyangiitis and granulomatosis with polyangiitis: analysis using sera from a nationwide prospective cohort study.	unassigned	-	
3.4.21.78	Mucocutaneous Lymph Node Syndrome	https://pubmed.ncbi.nlm.nih.gov/27055423/	[Predicting value of thrombospondin-2 for coronary artery dilatation in patients with Kawasaki disease].	diagnostic usage	1	
3.4.21.78	Mucocutaneous Lymph Node Syndrome	https://pubmed.ncbi.nlm.nih.gov/27055423/	[Predicting value of thrombospondin-2 for coronary artery dilatation in patients with Kawasaki disease].	unassigned	-	
3.4.21.78	Muscular Diseases	https://pubmed.ncbi.nlm.nih.gov/20467328/	Role of thrombospondin 1 in macrophage inflammation in dysferlin myopathy.	unassigned	-	
3.4.21.78	Mycosis Fungoides	https://pubmed.ncbi.nlm.nih.gov/9345072/	Granzyme A mRNA expression in mycosis fungoides progression.	ongoing research	1	
3.4.21.78	Mycosis Fungoides	https://pubmed.ncbi.nlm.nih.gov/9345072/	Granzyme A mRNA expression in mycosis fungoides progression.	unassigned	-	
3.4.21.78	Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/22750995/	Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction.	causal interaction	3	
3.4.21.78	Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/19715883/	Decreased expression of thrombospondin-1 in failing hearts may favor ventricular remodeling.	causal interaction	3	
3.4.21.78	Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/21883885/	A functional variant in the thrombospondin-1 gene and the risk of small for gestational age infants.	causal interaction	1	
3.4.21.78	Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/23074998/	Thrombospondins, potential drug targets for cardiovascular diseases.	causal interaction	3	
3.4.21.78	Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/29336258/	Association of Thrombospondin-1 (N700S) and Thrombospondin-4 (A387P) Gene Polymorphisms with the Incidence of Acute Myocardial Infarction in Egyptians.	causal interaction	1	
3.4.21.78	Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/22750995/	Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction.	diagnostic usage	4	
3.4.21.78	Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/21883885/	A functional variant in the thrombospondin-1 gene and the risk of small for gestational age infants.	diagnostic usage	3	
3.4.21.78	Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/29336258/	Association of Thrombospondin-1 (N700S) and Thrombospondin-4 (A387P) Gene Polymorphisms with the Incidence of Acute Myocardial Infarction in Egyptians.	diagnostic usage	1	
3.4.21.78	Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/22750995/	Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction.	therapeutic application	4	
3.4.21.78	Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/19715883/	Decreased expression of thrombospondin-1 in failing hearts may favor ventricular remodeling.	therapeutic application	2	
3.4.21.78	Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/23074998/	Thrombospondins, potential drug targets for cardiovascular diseases.	therapeutic application	4	
3.4.21.78	Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/22750995/	Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction.	ongoing research	3	
3.4.21.78	Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/19715883/	Decreased expression of thrombospondin-1 in failing hearts may favor ventricular remodeling.	ongoing research	1	
3.4.21.78	Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/29336258/	Association of Thrombospondin-1 (N700S) and Thrombospondin-4 (A387P) Gene Polymorphisms with the Incidence of Acute Myocardial Infarction in Egyptians.	ongoing research	2	
3.4.21.78	Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/15140581/	Genetic association analysis of myocardial infarction with thrombospondin-1 N700S variant in a Chinese population.	unassigned	-	
3.4.21.78	Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/18178577/	Polymorphisms in thrombospondin genes and myocardial infarction: a case-control study and a meta-analysis of available evidence.	unassigned	-	
3.4.21.78	Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/19715883/	Decreased expression of thrombospondin-1 in failing hearts may favor ventricular remodeling.	unassigned	-	
3.4.21.78	Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/23074998/	Thrombospondins, potential drug targets for cardiovascular diseases.	unassigned	-	
3.4.21.78	Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/21883885/	A functional variant in the thrombospondin-1 gene and the risk of small for gestational age infants.	unassigned	-	
3.4.21.78	Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/29336258/	Association of Thrombospondin-1 (N700S) and Thrombospondin-4 (A387P) Gene Polymorphisms with the Incidence of Acute Myocardial Infarction in Egyptians.	unassigned	-	
3.4.21.78	Myocardial Ischemia	https://pubmed.ncbi.nlm.nih.gov/22750995/	Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction.	causal interaction	3	
3.4.21.78	Myocardial Ischemia	https://pubmed.ncbi.nlm.nih.gov/22750995/	Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction.	diagnostic usage	4	
3.4.21.78	Myocardial Ischemia	https://pubmed.ncbi.nlm.nih.gov/22750995/	Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction.	therapeutic application	4	
3.4.21.78	Myocardial Ischemia	https://pubmed.ncbi.nlm.nih.gov/22750995/	Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction.	ongoing research	3	
3.4.21.78	Myositis	https://pubmed.ncbi.nlm.nih.gov/7919969/	Immunohistochemical analysis of perforin and granzyme A in inflammatory myopathies.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/26668367/	Lung inflammation promotes metastasis through neutrophil protease-mediated degradation of Tsp-1.	causal interaction	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/8593167/	The role of thrombospondin-1 in tumor progression and angiogenesis.	causal interaction	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/8661169/	Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer.	causal interaction	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/10375104/	Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.	causal interaction	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/11216860/	Expression of thrombospondin-1 in human hepatocarcinoma cell lines and its regulation by transcription factor Jun/AP-1.	causal interaction	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	causal interaction	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/11920636/	Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.	causal interaction	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/12213285/	Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein.	causal interaction	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/12219015/	Fibroblasts promote breast cancer cell invasion by upregulating tumor matrix metalloproteinase-9 production.	causal interaction	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/12429967/	Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma.	causal interaction	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/12439745/	Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice.	causal interaction	2	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	causal interaction	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/14751520/	Thrombospondin-1 treatment prevents growth of dormant lung micrometastases after surgical resection and curative radiation therapy of the primary tumor in human melanoma xenografts.	causal interaction	1	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/16166434/	Expression of thrombospondin-1 in resected colorectal liver metastases predicts poor prognosis.	causal interaction	2	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/16465407/	Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance.	causal interaction	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/16650813/	IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway.	causal interaction	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/16705174/	Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling.	causal interaction	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/17106256/	Cyclin D1 functions in cell migration.	causal interaction	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/17709727/	Association of angiogenesis markers with lymph node metastasis in early colorectal cancer.	causal interaction	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/17827686/	Induction of Egr-1 is associated with anti-metastatic and anti-invasive ability of beta-lapachone in human hepatocarcinoma cells.	causal interaction	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/17912439/	Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer.	causal interaction	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/18409060/	The effect of thrombospondin-1 on breast cancer metastasis.	causal interaction	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	causal interaction	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/19747478/	Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: Exploring the functional significance in tumor cell invasion.	causal interaction	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/19906510/	The alteration of Id-1 and TSP-1 expression in mucoepidermoid carcinoma associated with its clinical features and prognosis.	causal interaction	1	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/20498063/	B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.	causal interaction	1	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/21479427/	Thrombospondin-2 inhibits tumor cell invasion through the modulation of MMP-9 and uPA in pancreatic cancer cells.	causal interaction	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/22700773/	Thrombospondin-1 (TSP-1) Analogs ABT-510 and ABT-898 Inhibit Prolactinoma Growth and Recover Active Pituitary Transforming Growth Factor-?1 (TGF-?1).	causal interaction	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/23614916/	Thrombospondin-1 is highly expressed in desmoplastic components of invasive ductal carcinoma of the breast and associated with lymph node metastasis.	causal interaction	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/23633432/	Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1.	causal interaction	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/25256553/	Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2.	causal interaction	2	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/26273699/	Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro.	causal interaction	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/28274095/	Sphingosylphosphorylcholine Induces Thrombospondin-1 Secretion in MCF10A Cells via ERK2.	causal interaction	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/31750826/	[The poor prognosis is correlated with the high expression of vascular endothelial growth factor (VEGF) and low expression of thrombospondin 1 (TSP-1) in patients with breast cancer].	causal interaction	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/32243929/	Postoperative administration of ketorolac averts morphine-induced angiogenesis and metastasis in triple-negative breast cancer.	causal interaction	1	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/33629064/	Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma.	causal interaction	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/33816691/	Platelet TSP-1 controls prostate cancer-induced osteoclast differentiation and bone marrow-derived cell mobilization through TGF?-1.	causal interaction	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/10375104/	Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.	diagnostic usage	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/11216860/	Expression of thrombospondin-1 in human hepatocarcinoma cell lines and its regulation by transcription factor Jun/AP-1.	diagnostic usage	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	diagnostic usage	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/12219015/	Fibroblasts promote breast cancer cell invasion by upregulating tumor matrix metalloproteinase-9 production.	diagnostic usage	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/12429967/	Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma.	diagnostic usage	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/12439745/	Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice.	diagnostic usage	1	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	diagnostic usage	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/16166434/	Expression of thrombospondin-1 in resected colorectal liver metastases predicts poor prognosis.	diagnostic usage	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/16465407/	Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance.	diagnostic usage	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/17709727/	Association of angiogenesis markers with lymph node metastasis in early colorectal cancer.	diagnostic usage	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/17912439/	Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer.	diagnostic usage	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	diagnostic usage	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/19747478/	Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: Exploring the functional significance in tumor cell invasion.	diagnostic usage	1	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/19906510/	The alteration of Id-1 and TSP-1 expression in mucoepidermoid carcinoma associated with its clinical features and prognosis.	diagnostic usage	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/23614916/	Thrombospondin-1 is highly expressed in desmoplastic components of invasive ductal carcinoma of the breast and associated with lymph node metastasis.	diagnostic usage	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/23633432/	Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1.	diagnostic usage	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/25256553/	Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2.	diagnostic usage	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/28274095/	Sphingosylphosphorylcholine Induces Thrombospondin-1 Secretion in MCF10A Cells via ERK2.	diagnostic usage	2	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/31750826/	[The poor prognosis is correlated with the high expression of vascular endothelial growth factor (VEGF) and low expression of thrombospondin 1 (TSP-1) in patients with breast cancer].	diagnostic usage	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/33629064/	Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma.	diagnostic usage	1	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/19581582/	Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1.	therapeutic application	2	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/26668367/	Lung inflammation promotes metastasis through neutrophil protease-mediated degradation of Tsp-1.	therapeutic application	2	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/8661169/	Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer.	therapeutic application	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/10375104/	Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.	therapeutic application	1	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	therapeutic application	2	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/12219015/	Fibroblasts promote breast cancer cell invasion by upregulating tumor matrix metalloproteinase-9 production.	therapeutic application	1	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/12439745/	Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice.	therapeutic application	1	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/14501775/	Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts.	therapeutic application	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/14751520/	Thrombospondin-1 treatment prevents growth of dormant lung micrometastases after surgical resection and curative radiation therapy of the primary tumor in human melanoma xenografts.	therapeutic application	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/17709727/	Association of angiogenesis markers with lymph node metastasis in early colorectal cancer.	therapeutic application	1	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/17827686/	Induction of Egr-1 is associated with anti-metastatic and anti-invasive ability of beta-lapachone in human hepatocarcinoma cells.	therapeutic application	1	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/18409060/	The effect of thrombospondin-1 on breast cancer metastasis.	therapeutic application	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	therapeutic application	1	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/21479427/	Thrombospondin-2 inhibits tumor cell invasion through the modulation of MMP-9 and uPA in pancreatic cancer cells.	therapeutic application	1	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/22700773/	Thrombospondin-1 (TSP-1) Analogs ABT-510 and ABT-898 Inhibit Prolactinoma Growth and Recover Active Pituitary Transforming Growth Factor-?1 (TGF-?1).	therapeutic application	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/23614916/	Thrombospondin-1 is highly expressed in desmoplastic components of invasive ductal carcinoma of the breast and associated with lymph node metastasis.	therapeutic application	1	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/23633432/	Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1.	therapeutic application	1	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/25256553/	Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2.	therapeutic application	1	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/26273699/	Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro.	therapeutic application	1	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/28274095/	Sphingosylphosphorylcholine Induces Thrombospondin-1 Secretion in MCF10A Cells via ERK2.	therapeutic application	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/31410189/	CD36 tango in cancer: signaling pathways and functions.	therapeutic application	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/33629064/	Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma.	therapeutic application	1	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/33816691/	Platelet TSP-1 controls prostate cancer-induced osteoclast differentiation and bone marrow-derived cell mobilization through TGF?-1.	therapeutic application	1	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/8661169/	Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer.	ongoing research	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/10375104/	Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.	ongoing research	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/11216860/	Expression of thrombospondin-1 in human hepatocarcinoma cell lines and its regulation by transcription factor Jun/AP-1.	ongoing research	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	ongoing research	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/11920636/	Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.	ongoing research	2	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/12219015/	Fibroblasts promote breast cancer cell invasion by upregulating tumor matrix metalloproteinase-9 production.	ongoing research	2	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/12429967/	Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma.	ongoing research	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/12439745/	Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice.	ongoing research	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	ongoing research	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/14501775/	Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts.	ongoing research	2	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/14751520/	Thrombospondin-1 treatment prevents growth of dormant lung micrometastases after surgical resection and curative radiation therapy of the primary tumor in human melanoma xenografts.	ongoing research	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/15095410/	Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1.	ongoing research	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/16166434/	Expression of thrombospondin-1 in resected colorectal liver metastases predicts poor prognosis.	ongoing research	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/16465407/	Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance.	ongoing research	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/16650813/	IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway.	ongoing research	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/17709727/	Association of angiogenesis markers with lymph node metastasis in early colorectal cancer.	ongoing research	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/17912439/	Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer.	ongoing research	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/19747478/	Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: Exploring the functional significance in tumor cell invasion.	ongoing research	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/19906510/	The alteration of Id-1 and TSP-1 expression in mucoepidermoid carcinoma associated with its clinical features and prognosis.	ongoing research	2	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/20498063/	B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.	ongoing research	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/21479427/	Thrombospondin-2 inhibits tumor cell invasion through the modulation of MMP-9 and uPA in pancreatic cancer cells.	ongoing research	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/23614916/	Thrombospondin-1 is highly expressed in desmoplastic components of invasive ductal carcinoma of the breast and associated with lymph node metastasis.	ongoing research	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/25256553/	Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2.	ongoing research	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/26273699/	Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro.	ongoing research	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/31750826/	[The poor prognosis is correlated with the high expression of vascular endothelial growth factor (VEGF) and low expression of thrombospondin 1 (TSP-1) in patients with breast cancer].	ongoing research	4	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/33629064/	Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma.	ongoing research	3	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/33816691/	Platelet TSP-1 controls prostate cancer-induced osteoclast differentiation and bone marrow-derived cell mobilization through TGF?-1.	ongoing research	2	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/19581582/	Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/14501775/	Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/15095410/	Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/31410189/	CD36 tango in cancer: signaling pathways and functions.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/26668367/	Lung inflammation promotes metastasis through neutrophil protease-mediated degradation of Tsp-1.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/8593167/	The role of thrombospondin-1 in tumor progression and angiogenesis.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/8661169/	Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/11920636/	Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/12213285/	Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/14751520/	Thrombospondin-1 treatment prevents growth of dormant lung micrometastases after surgical resection and curative radiation therapy of the primary tumor in human melanoma xenografts.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/16650813/	IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/16705174/	Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/17106256/	Cyclin D1 functions in cell migration.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/17827686/	Induction of Egr-1 is associated with anti-metastatic and anti-invasive ability of beta-lapachone in human hepatocarcinoma cells.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/18409060/	The effect of thrombospondin-1 on breast cancer metastasis.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/20498063/	B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/21479427/	Thrombospondin-2 inhibits tumor cell invasion through the modulation of MMP-9 and uPA in pancreatic cancer cells.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/22700773/	Thrombospondin-1 (TSP-1) Analogs ABT-510 and ABT-898 Inhibit Prolactinoma Growth and Recover Active Pituitary Transforming Growth Factor-?1 (TGF-?1).	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/26273699/	Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/32243929/	Postoperative administration of ketorolac averts morphine-induced angiogenesis and metastasis in triple-negative breast cancer.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/33816691/	Platelet TSP-1 controls prostate cancer-induced osteoclast differentiation and bone marrow-derived cell mobilization through TGF?-1.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/11216860/	Expression of thrombospondin-1 in human hepatocarcinoma cell lines and its regulation by transcription factor Jun/AP-1.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/12429967/	Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/16166434/	Expression of thrombospondin-1 in resected colorectal liver metastases predicts poor prognosis.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/16465407/	Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/17912439/	Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/19747478/	Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: Exploring the functional significance in tumor cell invasion.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/19906510/	The alteration of Id-1 and TSP-1 expression in mucoepidermoid carcinoma associated with its clinical features and prognosis.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/31750826/	[The poor prognosis is correlated with the high expression of vascular endothelial growth factor (VEGF) and low expression of thrombospondin 1 (TSP-1) in patients with breast cancer].	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/23633432/	Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1.	unassigned	-	
3.4.21.78	Neoplasm Metastasis	https://pubmed.ncbi.nlm.nih.gov/28274095/	Sphingosylphosphorylcholine Induces Thrombospondin-1 Secretion in MCF10A Cells via ERK2.	unassigned	-	
3.4.21.78	Neoplasm Micrometastasis	https://pubmed.ncbi.nlm.nih.gov/12874006/	Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts.	causal interaction	3	
3.4.21.78	Neoplasm Micrometastasis	https://pubmed.ncbi.nlm.nih.gov/14751520/	Thrombospondin-1 treatment prevents growth of dormant lung micrometastases after surgical resection and curative radiation therapy of the primary tumor in human melanoma xenografts.	causal interaction	1	
3.4.21.78	Neoplasm Micrometastasis	https://pubmed.ncbi.nlm.nih.gov/12874006/	Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts.	diagnostic usage	3	
3.4.21.78	Neoplasm Micrometastasis	https://pubmed.ncbi.nlm.nih.gov/12874006/	Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts.	therapeutic application	4	
3.4.21.78	Neoplasm Micrometastasis	https://pubmed.ncbi.nlm.nih.gov/14751520/	Thrombospondin-1 treatment prevents growth of dormant lung micrometastases after surgical resection and curative radiation therapy of the primary tumor in human melanoma xenografts.	therapeutic application	4	
3.4.21.78	Neoplasm Micrometastasis	https://pubmed.ncbi.nlm.nih.gov/12874006/	Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts.	ongoing research	3	
3.4.21.78	Neoplasm Micrometastasis	https://pubmed.ncbi.nlm.nih.gov/14751520/	Thrombospondin-1 treatment prevents growth of dormant lung micrometastases after surgical resection and curative radiation therapy of the primary tumor in human melanoma xenografts.	ongoing research	4	
3.4.21.78	Neoplasm Micrometastasis	https://pubmed.ncbi.nlm.nih.gov/14751520/	Thrombospondin-1 treatment prevents growth of dormant lung micrometastases after surgical resection and curative radiation therapy of the primary tumor in human melanoma xenografts.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/2179951/	Genes encoding tumor necrosis factor alpha and granzyme A are expressed during development of autoimmune diabetes.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15707585/	The tumor suppressor PTEN inhibits EGF-induced TSP-1 and TIMP-1 expression in FTC-133 thyroid carcinoma cells.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15743540/	Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1.	causal interaction	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18555217/	Differential involvement of TGF-beta1 in mediating the motogenic effects of TSP-1 on endothelial cells, fibroblasts and oral tumour cells.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25358253/	Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32194708/	TSP-1 as a novel biological marker of tumor vasculature normalization in colon carcinoma induced by Endostar.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32600280/	Role of TSP-1 as prognostic marker in various cancers: a systematic review and meta-analysis.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/7813805/	Accelerated beta-cell destruction in adoptively transferred autoimmune diabetes correlates with an increased expression of the genes coding for TNF-alpha and granzyme A in the intra-islet infiltrates.	causal interaction	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/8593167/	The role of thrombospondin-1 in tumor progression and angiogenesis.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/8661169/	Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/8677265/	Expression of thrombospondin-1 in cancer: a role in tumor progression.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/8980608/	Adhesive proteins and the hematogenous spread of cancer.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9288157/	Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9302563/	Histopathology and clinical assessment correlate with the cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) receptor of thrombospondin-1 in breast tumors.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9515819/	Molecular mediators of angiogenesis in bladder cancer.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9600434/	Thrombospondin-1 and its CSVTCG-specific receptor in wound healing and cancer.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9618039/	Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9695745/	The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9828214/	Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9833775/	Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10051595/	Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10328956/	Retinoic acid alters the mechanism of attachment of malignant astrocytoma and neuroblastoma cells to thrombospondin-1.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10375104/	Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10393860/	Human cytomegalovirus infection decreases expression of thrombospondin-1 independent of the tumor suppressor protein p53.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10433937/	Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10502735/	Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10611308/	Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10719053/	Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11036248/	Thrombospondin-1 expression in oral squamous cell carcinomas: correlations with tumor vascularity, clinicopathological features and survival.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11132930/	Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11150912/	Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis.	causal interaction	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11216860/	Expression of thrombospondin-1 in human hepatocarcinoma cell lines and its regulation by transcription factor Jun/AP-1.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11228532/	The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11253112/	Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11410779/	Expression of thrombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11438469/	Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11445843/	Thrombospondin-1 and -2 messenger RNA expression in normal and neoplastic endometrial tissues: correlation with angiogenesis and prognosis.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11520937/	The role of thrombospondin-1 in tumor progression.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11531279/	Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11555600/	Thrombospondin-1 and -2 messenger RNA expression in invasive cervical cancer: correlation with angiogenesis and prognosis.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11712798/	Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11746276/	Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11856116/	Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11861403/	Overexpression of thrombospondin-1 reduces growth and vascular index but not perfusion in glioblastoma.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11877681/	p53 accumulation in favorable-histology Wilms tumor is associated with angiogenesis and clinically aggressive disease.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11882904/	Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11920636/	Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11927969/	The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11955611/	Up-regulation of thrombospondin-1 gene by epidermal growth factor and transforming growth factor beta in human cancer cells--transcriptional activation and messenger RNA stabilization.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12003665/	Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12006528/	Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12213285/	Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12219015/	Fibroblasts promote breast cancer cell invasion by upregulating tumor matrix metalloproteinase-9 production.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12429155/	Reduced thrombospondin-1 at presentation predicts disease progression in superficial bladder cancer.	causal interaction	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12429967/	Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12439745/	Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice.	causal interaction	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12443715/	Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12461058/	Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12492491/	Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12570805/	Thrombospondins as anti-angiogenic therapeutic agents.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12584168/	Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12719977/	Expression of thrombospondin-1 is correlated with microvessel density in gastric carcinoma.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12720300/	Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12814189/	Evidence of a bi-phasic effect of thrombospondin-1 on angiogenesis.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12825818/	Cell density regulates thrombospondin-1 production in malignant glioma cells.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12874006/	Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12912908/	Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12963968/	Clinical significance of thrombospondin-1 expression in relation to vascular endothelial growth factor and interleukin-10 expression at the deepest invasive tumor site of advanced colorectal carcinoma.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14511656/	Restoration of thrombospondin 1 expression in tumor cells harbouring mutant ras oncogene by treatment with low doses of doxycycline.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14555767/	Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14559817/	Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14658007/	Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14751520/	Thrombospondin-1 treatment prevents growth of dormant lung micrometastases after surgical resection and curative radiation therapy of the primary tumor in human melanoma xenografts.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14996710/	Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15094119/	Tumor progression: the effects of thrombospondin-1 and -2.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15172186/	Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15277228/	Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15375381/	Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15503824/	Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: relationship to platelet alpha-granule content and primary activation.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15526350/	Hepatocyte growth factor (HGF) downregulates thrombospondin 1 (TSP-1) expression in thyroid papillary carcinoma cells.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15583827/	Expression of thrombospondin-1 in prostate-derived cell lines.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15662972/	Quantification of thrombospondin-1 secretion and expression of alphavbeta3 and alpha3beta1 integrins and syndecan-1 as cell-surface receptors for thrombospondin-1 in malignant glioma cells.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15784731/	Type 3 repeat/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/alphavbeta3 in promyelocytic leukemia NB4 cells.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15833768/	Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15838828/	Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15908066/	Extraction of RNA from archival tissues and measurement of thrombospondin-1 mRNA in normal, dysplastic, and malignant oral tissues.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15963261/	Characterization of integrin beta6 and thrombospondin-1 double-null mice.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16009408/	Immunohistochemical expression of thrombospondin-1 in invasive vulvar squamous cell carcinoma.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16076702/	Thrombospondins, metallo proteases and thrombospondin receptors messenger RNA and protein expression in different tumour sublines of the Dunning prostate cancer model.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16166434/	Expression of thrombospondin-1 in resected colorectal liver metastases predicts poor prognosis.	causal interaction	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16227405/	Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16394085/	Pituitary tumor-transforming gene regulates multiple downstream angiogenic genes in thyroid cancer.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16406676/	Regulation of tumor angiogenesis by thrombospondin-1.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16418571/	Halofuginone Inhibits Tumor Growth in the Polyoma Middle T Antigen Mouse via a Thrombospondin-1 Independent Mechanism.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16465407/	Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16650813/	IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16732887/	Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16847352/	Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17056717/	Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.	causal interaction	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17106256/	Cyclin D1 functions in cell migration.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17198740/	The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17234749/	Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17283240/	Changes in thrombospondin-1 levels in the endothelial cells of the anterior pituitary during estrogen-induced prolactin-secreting pituitary tumors.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17709727/	Association of angiogenesis markers with lymph node metastasis in early colorectal cancer.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17912439/	Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17912446/	Effects of alpha-difluoromethylornithine on thrombospondin-1 production by human breast cancer cells.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18067717/	[Relationship between changes of serum concentrations of antiangiogenic factors and disease progression in patients of pancreatic carcinoma]	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18171979/	Interference of macrophage migration inhibitory factor expression in a mouse melanoma inhibits tumor establishment by up-regulating thrombospondin-1.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18193162/	Thrombospondins: from structure to therapeutics : Thrombospondins in cancer.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18222489/	Collagen-binding domains of gelatinase A and thrombospondin-derived peptides impede endocytic clearance of active gelatinase A and promote HT1080 fibrosarcoma cell invasion.	causal interaction	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18228414/	Purification and analysis of thrombospondin-1.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18336597/	Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18409060/	The effect of thrombospondin-1 on breast cancer metastasis.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18413367/	A novel role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18420342/	Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18443598/	Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib.	causal interaction	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18661355/	Thrombospondin-1 in differentiated thyroid cancer: Dr. Jekyll and Mr. Hyde.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19002766/	Carrageenan inhibits granzyme A-induced detachment of and interleukin-8 release from alveolar epithelial A549 cells.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19024308/	[Correlation between the expression of thrombospondin-1 and the angiogenesis in mucoepidermoid carcinoma]	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19080117/	Correlation between the expression of thrombospondin-1 and neovascularization in mucoepidermoid carcinoma.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19250552/	Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19259612/	Fascin overexpression correlates with positive thrombospondin-1 and syndecan-1 expressions and a more aggressive clinical course in patients with gallbladder cancer.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19391135/	Estrogen regulation of thrombospondin-1 in human breast cancer cells.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19447890/	Elongation factor ELL (Eleven-Nineteen Lysine-rich Leukemia) acts as a transcription factor for direct thrombospondin-1 regulation.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19509293/	Thrombospondin-1 is a transcriptional repression target of PRMT6.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19570906/	Regulation of thrombospondin-1 by natural and synthetic progestins in human breast cancer cells.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19594546/	c-Ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19634159/	The role of angiocidin in sarcomas.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19690133/	Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19747478/	Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: Exploring the functional significance in tumor cell invasion.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19762163/	Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19805200/	Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20204299/	Correlation between pathological data and the RNA expression of p53 or p53-targeted genes in primary invasive ductal breast carcinomas: a preliminary study.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20458281/	Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20492458/	Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20498063/	B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20631908/	Thrombospondin-1 (TSP-1) Stimulates Expression of Integrin alpha6 in Human Breast Carcinoma Cells: A Downstream Modulator of TSP-1-Induced Cellular Adhesion.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20714802/	CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20736295/	Regional control of tumor growth.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20876797/	Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21068403/	Human eosinophils exert TNF-? and granzyme A-mediated tumoricidal activity toward colon carcinoma cells.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21107877/	Expression of thrombospondin-1 and Ski are prognostic factors in advanced gastric cancer.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21290245/	Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model.	causal interaction	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21407216/	Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21479427/	Thrombospondin-2 inhibits tumor cell invasion through the modulation of MMP-9 and uPA in pancreatic cancer cells.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21697041/	The expression levels of thrombospondin-1 in dermatofibroma and dermatofibrosarcoma protuberans.	causal interaction	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22207555/	Thrombospondin-1 expression in breast cancer: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22700773/	Thrombospondin-1 (TSP-1) Analogs ABT-510 and ABT-898 Inhibit Prolactinoma Growth and Recover Active Pituitary Transforming Growth Factor-?1 (TGF-?1).	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23085760/	The novel tumor suppressor NOL7 post-transcriptionally regulates thrombospondin-1 expression.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23380452/	PRMT6 overexpression upregulates TSP-1 and downregulates MMPs: Its implication in motility and invasion.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23389639/	The pharmacological bases of the antiangiogenic activity of paclitaxel.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23614916/	Thrombospondin-1 is highly expressed in desmoplastic components of invasive ductal carcinoma of the breast and associated with lymph node metastasis.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23633432/	Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23695365/	Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23749112/	Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23757408/	Thrombospondin-1 regulates adiposity and metabolic dysfunction in diet-induced obesity enhancing adipose inflammation and stimulating adipocyte proliferation.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23846726/	Thrombospondin-1 is a putative target gene of Runx2 and Runx3.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23851682/	Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24127010/	A novel cancer therapeutic using thrombospondin 1 in dendritic cells.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24590059/	Immunosurveillance by Antiangiogenesis: Tumor Growth Arrest by T Cell-Derived Thrombospondin-1.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24729221/	Recurrent low-dose chemotherapy to inhibit and oxygenate head and neck tumors.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25621889/	EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25943461/	Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26273699/	Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26461935/	Thrombospondin-1 in a Murine Model of Colorectal Carcinogenesis.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26578962/	Original insights on thrombospondin-1-related antireceptor strategies in cancer.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26676551/	Quercetin inhibits angiogenesis through thrombospondin-1 upregulation to antagonize human prostate cancer PC-3 cell growth in vitro and in vivo.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26756218/	Thrombospondin-1 might be a therapeutic target to suppress RB cells by regulating the DNA double-strand breaks repair.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26852677/	Development of a Cancer Treatment with the Concomitant Use of Low-Intensity Ultrasound: Entering the Age of Simultaneous Diagnosis and Treatment.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26962158/	Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27349907/	Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27422280/	Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27756886/	Properdistatin inhibits angiogenesis and improves vascular function in human melanoma xenografts with low thrombospondin-1 expression.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27757299/	Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27878431/	Aqueous immune mediators in malignant uveal melanomas in comparison to benign pigmented intraocular tumors.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/28207087/	Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: Relationship to platelet a-granule content and primary activation.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/28614657/	General Strategy for Direct Cytosolic Protein Delivery via Protein-Nanoparticle Co-engineering.	causal interaction	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/28810809/	Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/29200966/	Microencapsulation of low-passage poorly-differentiated human mucoepidermoid carcinoma cells by alginate microcapsules: in vitro profiling of angiogenesis-related molecules.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/29441713/	Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/29927834/	Role of thrombospondin-1 and nuclear factor-kappa B signaling pathways in anti-angiogenesis of infantile hemangioma.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/30076136/	Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGF?1 Axis.	causal interaction	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/30593119/	[Relationship between thrombospondin-1 and the occurrence and development of oral and maxillofacial malignancy].	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31016850/	TSP-1 is downregulated and inversely correlates with miR-449c expression in Cushing's disease.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31222746/	Silencing of PTGS2 exerts promoting effects on angiogenesis endothelial progenitor cells in mice with ischemic stroke via repression of the NF-?B signaling pathway.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31237113/	High immune cytolytic activity in tumor-free tongue tissue confers better prognosis in patients with squamous cell carcinoma of the oral tongue.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31418132/	Combination of metronomic administration and target delivery strategies to improve the anti-angiogenic and anti-tumor effects of triptolide.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31462506/	Glycolipid Stimulation of Invariant NKT Cells Expands a Unique Tissue-Resident Population of Precursors to Mature NK Cells Endowed with Oncolytic and Antimetastatic Properties.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31712778/	Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32845506/	Thrombospondin in Tumor Microenvironment.	causal interaction	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/33001862/	Protein tyrosine phosphatase non-receptor type 2 controls colorectal cancer development.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/33629064/	Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/33816691/	Platelet TSP-1 controls prostate cancer-induced osteoclast differentiation and bone marrow-derived cell mobilization through TGF?-1.	causal interaction	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/33968059/	Endometrial Cancer Suppresses CD8+ T Cell-Mediated Cytotoxicity in Postmenopausal Women.	causal interaction	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/34215227/	CD36 promotes vasculogenic mimicry in melanoma by mediating adhesion to the extracellular matrix.	causal interaction	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15743540/	Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18555217/	Differential involvement of TGF-beta1 in mediating the motogenic effects of TSP-1 on endothelial cells, fibroblasts and oral tumour cells.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32194708/	TSP-1 as a novel biological marker of tumor vasculature normalization in colon carcinoma induced by Endostar.	diagnostic usage	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32600280/	Role of TSP-1 as prognostic marker in various cancers: a systematic review and meta-analysis.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/1350566/	Murine Thy-1+ dendritic epidermal T cell lines express granule-associated perforin and a family of granzyme molecules.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/1423596/	Cytotoxicity with target DNA breakdown by rat basophilic leukemia cells expressing both cytolysin and granzyme A.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/7813805/	Accelerated beta-cell destruction in adoptively transferred autoimmune diabetes correlates with an increased expression of the genes coding for TNF-alpha and granzyme A in the intra-islet infiltrates.	diagnostic usage	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/8677265/	Expression of thrombospondin-1 in cancer: a role in tumor progression.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/8959642/	Peripheral T cell activation in long-term renal transplant patients: concordant upregulation of adhesion molecules and cytokine gene transcription.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9288157/	Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9302563/	Histopathology and clinical assessment correlate with the cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) receptor of thrombospondin-1 in breast tumors.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9515819/	Molecular mediators of angiogenesis in bladder cancer.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9600434/	Thrombospondin-1 and its CSVTCG-specific receptor in wound healing and cancer.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9603160/	The cellular basis of cardiac allograft rejection: VIII. Mechanisms underlying delayed allograft rejection in PVG C6-deficient rats.	diagnostic usage	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9618039/	Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9695745/	The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9828214/	Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9833775/	Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10375104/	Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10393860/	Human cytomegalovirus infection decreases expression of thrombospondin-1 independent of the tumor suppressor protein p53.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10433937/	Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10502735/	Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10611308/	Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10719053/	Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11036248/	Thrombospondin-1 expression in oral squamous cell carcinomas: correlations with tumor vascularity, clinicopathological features and survival.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11069717/	Cationic lipid gene transfer of an IL-2 transgene leads to activation of natural killer cells in a SCID mouse human tumor xenograft.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11132930/	Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11150912/	Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11205922/	Independent association of angiogenesis index with outcome in prostate cancer.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11216860/	Expression of thrombospondin-1 in human hepatocarcinoma cell lines and its regulation by transcription factor Jun/AP-1.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11228532/	The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11253112/	Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11410779/	Expression of thrombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11438469/	Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11445843/	Thrombospondin-1 and -2 messenger RNA expression in normal and neoplastic endometrial tissues: correlation with angiogenesis and prognosis.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11531279/	Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11555600/	Thrombospondin-1 and -2 messenger RNA expression in invasive cervical cancer: correlation with angiogenesis and prognosis.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11712798/	Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11856116/	Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11877681/	p53 accumulation in favorable-histology Wilms tumor is associated with angiogenesis and clinically aggressive disease.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11882904/	Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11927969/	The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11955611/	Up-regulation of thrombospondin-1 gene by epidermal growth factor and transforming growth factor beta in human cancer cells--transcriptional activation and messenger RNA stabilization.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11955648/	Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12006528/	Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12219015/	Fibroblasts promote breast cancer cell invasion by upregulating tumor matrix metalloproteinase-9 production.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12429155/	Reduced thrombospondin-1 at presentation predicts disease progression in superficial bladder cancer.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12429967/	Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12439745/	Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice.	diagnostic usage	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12443715/	Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12461058/	Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast.	diagnostic usage	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12584168/	Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model.	diagnostic usage	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12719977/	Expression of thrombospondin-1 is correlated with microvessel density in gastric carcinoma.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12814189/	Evidence of a bi-phasic effect of thrombospondin-1 on angiogenesis.	diagnostic usage	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12847210/	Cutting edge: granzymes A and B are not essential for perforin-mediated tumor rejection.	diagnostic usage	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12874006/	Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12963968/	Clinical significance of thrombospondin-1 expression in relation to vascular endothelial growth factor and interleukin-10 expression at the deepest invasive tumor site of advanced colorectal carcinoma.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14511656/	Restoration of thrombospondin 1 expression in tumor cells harbouring mutant ras oncogene by treatment with low doses of doxycycline.	diagnostic usage	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14559817/	Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14996710/	Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15172186/	Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15180634/	The expression of thrombospondin-1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15321749/	[Inhibition of fibrosarcoma growth in mice by antibody against B cell epitope on mouse Toll-like receptor-2 extracellular domain]	diagnostic usage	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15503824/	Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: relationship to platelet alpha-granule content and primary activation.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15519514/	Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15526350/	Hepatocyte growth factor (HGF) downregulates thrombospondin 1 (TSP-1) expression in thyroid papillary carcinoma cells.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15583827/	Expression of thrombospondin-1 in prostate-derived cell lines.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15623630/	Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15662972/	Quantification of thrombospondin-1 secretion and expression of alphavbeta3 and alpha3beta1 integrins and syndecan-1 as cell-surface receptors for thrombospondin-1 in malignant glioma cells.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15831915/	Thrombospondin 1 acts as a strong promoter of transforming growth factor beta effects via two distinct mechanisms in hepatic stellate cells.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15833768/	Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15838828/	Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15840100/	The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.	diagnostic usage	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16009408/	Immunohistochemical expression of thrombospondin-1 in invasive vulvar squamous cell carcinoma.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16076702/	Thrombospondins, metallo proteases and thrombospondin receptors messenger RNA and protein expression in different tumour sublines of the Dunning prostate cancer model.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16166434/	Expression of thrombospondin-1 in resected colorectal liver metastases predicts poor prognosis.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16394085/	Pituitary tumor-transforming gene regulates multiple downstream angiogenic genes in thyroid cancer.	diagnostic usage	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16465407/	Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16515598/	Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16618977/	Thrombospondin 1 mRNA as a Candidate for a Marker to Detect Thyroid-derived Fibroblasts in Fine Needle Aspiration Biopsy of the Thyroid.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16677501/	[Mechanism of reversion of myocardial interstitial fibrosis in diabetic cardiomyopathy by valsartan]	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16732887/	Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17198740/	The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.	diagnostic usage	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17409099/	Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17692904/	Effect of oral anticoagulant therapy on thrombospondin-1 and von Willebrand factor in patients with stable heart failure.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17709727/	Association of angiogenesis markers with lymph node metastasis in early colorectal cancer.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17912439/	Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17931108/	Functional Characterization of BK Virus-Specific CD4(+) T Cells with Cytotoxic Potential in Seropositive Adults.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18067717/	[Relationship between changes of serum concentrations of antiangiogenic factors and disease progression in patients of pancreatic carcinoma]	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18321763/	Thrombospondin-1 enhances human thyroid carcinoma cell invasion through urokinase activity.	diagnostic usage	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18336597/	Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19024308/	[Correlation between the expression of thrombospondin-1 and the angiogenesis in mucoepidermoid carcinoma]	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19080117/	Correlation between the expression of thrombospondin-1 and neovascularization in mucoepidermoid carcinoma.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19110305/	Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study.	diagnostic usage	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19634159/	The role of angiocidin in sarcomas.	diagnostic usage	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19690133/	Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19747478/	Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: Exploring the functional significance in tumor cell invasion.	diagnostic usage	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19762163/	Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas.	diagnostic usage	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19805200/	Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20204299/	Correlation between pathological data and the RNA expression of p53 or p53-targeted genes in primary invasive ductal breast carcinomas: a preliminary study.	diagnostic usage	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20458281/	Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20736295/	Regional control of tumor growth.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20876797/	Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21107877/	Expression of thrombospondin-1 and Ski are prognostic factors in advanced gastric cancer.	diagnostic usage	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21407216/	Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22207555/	Thrombospondin-1 expression in breast cancer: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23380452/	PRMT6 overexpression upregulates TSP-1 and downregulates MMPs: Its implication in motility and invasion.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23614916/	Thrombospondin-1 is highly expressed in desmoplastic components of invasive ductal carcinoma of the breast and associated with lymph node metastasis.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23633432/	Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23749112/	Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23846726/	Thrombospondin-1 is a putative target gene of Runx2 and Runx3.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24788022/	Net platelet angiogenic activity (NPAA) correlates with progression and prognosis of non-small cell lung cancer.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25621889/	EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25943461/	Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.	diagnostic usage	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25970326/	Association of platelet activation markers with cancer-associated venous thromboembolism.	diagnostic usage	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26676551/	Quercetin inhibits angiogenesis through thrombospondin-1 upregulation to antagonize human prostate cancer PC-3 cell growth in vitro and in vivo.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26756218/	Thrombospondin-1 might be a therapeutic target to suppress RB cells by regulating the DNA double-strand breaks repair.	diagnostic usage	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26961119/	Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients.	diagnostic usage	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27349907/	Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27422280/	Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27757299/	Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27878431/	Aqueous immune mediators in malignant uveal melanomas in comparison to benign pigmented intraocular tumors.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/28207087/	Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: Relationship to platelet a-granule content and primary activation.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/28493520/	HBV-specific CD4+ cytotoxic T cells in hepatocellular carcinoma are less cytolytic toward tumor cells and suppress CD8+ T cell-mediated antitumor immunity.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/29200966/	Microencapsulation of low-passage poorly-differentiated human mucoepidermoid carcinoma cells by alginate microcapsules: in vitro profiling of angiogenesis-related molecules.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/29441713/	Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/29590229/	Association of Oxytocin with Glucose Intolerance and Inflammation Biomarkers in Metabolic Syndrome Patients with and without Prediabetes.	diagnostic usage	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/30963401/	Tumor Heterogeneity Correlates with Less Immune Response and Worse Survival in Breast Cancer Patients.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31016850/	TSP-1 is downregulated and inversely correlates with miR-449c expression in Cushing's disease.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31222746/	Silencing of PTGS2 exerts promoting effects on angiogenesis endothelial progenitor cells in mice with ischemic stroke via repression of the NF-?B signaling pathway.	diagnostic usage	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31235729/	Circulating pro- and anti-angiogenic factors in multi-stage liver disease and hepatocellular carcinoma progression.	diagnostic usage	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31237113/	High immune cytolytic activity in tumor-free tongue tissue confers better prognosis in patients with squamous cell carcinoma of the oral tongue.	diagnostic usage	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/33001862/	Protein tyrosine phosphatase non-receptor type 2 controls colorectal cancer development.	diagnostic usage	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/33629064/	Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma.	diagnostic usage	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/34215227/	CD36 promotes vasculogenic mimicry in melanoma by mediating adhesion to the extracellular matrix.	diagnostic usage	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19219378/	The N-terminal domain of thrombospondin-1: a key for the dual effect of TSP-1 in angiogenesis and cancer progression?	therapeutic application	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19581582/	Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1.	therapeutic application	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32194708/	TSP-1 as a novel biological marker of tumor vasculature normalization in colon carcinoma induced by Endostar.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32600280/	Role of TSP-1 as prognostic marker in various cancers: a systematic review and meta-analysis.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/8661169/	Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/8677265/	Expression of thrombospondin-1 in cancer: a role in tumor progression.	therapeutic application	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9302563/	Histopathology and clinical assessment correlate with the cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) receptor of thrombospondin-1 in breast tumors.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9600434/	Thrombospondin-1 and its CSVTCG-specific receptor in wound healing and cancer.	therapeutic application	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9833775/	Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10375104/	Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10393860/	Human cytomegalovirus infection decreases expression of thrombospondin-1 independent of the tumor suppressor protein p53.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10433937/	Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10502735/	Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10611308/	Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10719053/	Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11036248/	Thrombospondin-1 expression in oral squamous cell carcinomas: correlations with tumor vascularity, clinicopathological features and survival.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11132930/	Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11228532/	The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11253112/	Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	therapeutic application	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11410779/	Expression of thrombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer.	therapeutic application	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11438469/	Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.	therapeutic application	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11531279/	Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11746276/	Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11856116/	Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11861403/	Overexpression of thrombospondin-1 reduces growth and vascular index but not perfusion in glioblastoma.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11877681/	p53 accumulation in favorable-histology Wilms tumor is associated with angiogenesis and clinically aggressive disease.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11882904/	Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12219015/	Fibroblasts promote breast cancer cell invasion by upregulating tumor matrix metalloproteinase-9 production.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12429155/	Reduced thrombospondin-1 at presentation predicts disease progression in superficial bladder cancer.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12439745/	Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12443715/	Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer.	therapeutic application	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12461058/	Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12492491/	Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells.	therapeutic application	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12584168/	Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12719977/	Expression of thrombospondin-1 is correlated with microvessel density in gastric carcinoma.	therapeutic application	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12720300/	Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12847210/	Cutting edge: granzymes A and B are not essential for perforin-mediated tumor rejection.	therapeutic application	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12874006/	Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14501775/	Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts.	therapeutic application	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14555767/	Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14559817/	Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14658007/	Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.	therapeutic application	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14751520/	Thrombospondin-1 treatment prevents growth of dormant lung micrometastases after surgical resection and curative radiation therapy of the primary tumor in human melanoma xenografts.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14996710/	Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression.	therapeutic application	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15172186/	Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15321749/	[Inhibition of fibrosarcoma growth in mice by antibody against B cell epitope on mouse Toll-like receptor-2 extracellular domain]	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15375381/	Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15784731/	Type 3 repeat/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/alphavbeta3 in promyelocytic leukemia NB4 cells.	therapeutic application	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15838828/	Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15840100/	The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16009408/	Immunohistochemical expression of thrombospondin-1 in invasive vulvar squamous cell carcinoma.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16227405/	Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1.	therapeutic application	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16286245/	TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16406676/	Regulation of tumor angiogenesis by thrombospondin-1.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16418571/	Halofuginone Inhibits Tumor Growth in the Polyoma Middle T Antigen Mouse via a Thrombospondin-1 Independent Mechanism.	therapeutic application	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16732887/	Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17395736/	Thrombopoietic cells and the bone marrow vascular niche.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17431618/	Interleukin-4 impairs granzyme-mediated cytotoxicity of Simian virus 40 large tumor antigen-specific CTL in BALB/c mice.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17706282/	Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17709727/	Association of angiogenesis markers with lymph node metastasis in early colorectal cancer.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17912446/	Effects of alpha-difluoromethylornithine on thrombospondin-1 production by human breast cancer cells.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17931108/	Functional Characterization of BK Virus-Specific CD4(+) T Cells with Cytotoxic Potential in Seropositive Adults.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18171979/	Interference of macrophage migration inhibitory factor expression in a mouse melanoma inhibits tumor establishment by up-regulating thrombospondin-1.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18222489/	Collagen-binding domains of gelatinase A and thrombospondin-derived peptides impede endocytic clearance of active gelatinase A and promote HT1080 fibrosarcoma cell invasion.	therapeutic application	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18313158/	Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18409060/	The effect of thrombospondin-1 on breast cancer metastasis.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18413367/	A novel role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18420342/	Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18661355/	Thrombospondin-1 in differentiated thyroid cancer: Dr. Jekyll and Mr. Hyde.	therapeutic application	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18726995/	Thrombospondin-1-induced apoptosis of brain microvascular endothelial cells can be mediated by TNF-R1.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19079608/	Modulation of macrophage activation state protects tissue from necrosis during critical limb ischemia in thrombospondin-1-deficient mice.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19080117/	Correlation between the expression of thrombospondin-1 and neovascularization in mucoepidermoid carcinoma.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19110305/	Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19391135/	Estrogen regulation of thrombospondin-1 in human breast cancer cells.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19447890/	Elongation factor ELL (Eleven-Nineteen Lysine-rich Leukemia) acts as a transcription factor for direct thrombospondin-1 regulation.	therapeutic application	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19509293/	Thrombospondin-1 is a transcriptional repression target of PRMT6.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19570906/	Regulation of thrombospondin-1 by natural and synthetic progestins in human breast cancer cells.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19690133/	Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19805200/	Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20458281/	Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20631908/	Thrombospondin-1 (TSP-1) Stimulates Expression of Integrin alpha6 in Human Breast Carcinoma Cells: A Downstream Modulator of TSP-1-Induced Cellular Adhesion.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20714802/	CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo.	therapeutic application	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20876797/	Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21068403/	Human eosinophils exert TNF-? and granzyme A-mediated tumoricidal activity toward colon carcinoma cells.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21407216/	Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21479427/	Thrombospondin-2 inhibits tumor cell invasion through the modulation of MMP-9 and uPA in pancreatic cancer cells.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22207555/	Thrombospondin-1 expression in breast cancer: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.	therapeutic application	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22700773/	Thrombospondin-1 (TSP-1) Analogs ABT-510 and ABT-898 Inhibit Prolactinoma Growth and Recover Active Pituitary Transforming Growth Factor-?1 (TGF-?1).	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23380452/	PRMT6 overexpression upregulates TSP-1 and downregulates MMPs: Its implication in motility and invasion.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23614916/	Thrombospondin-1 is highly expressed in desmoplastic components of invasive ductal carcinoma of the breast and associated with lymph node metastasis.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23633432/	Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23851682/	Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24127010/	A novel cancer therapeutic using thrombospondin 1 in dendritic cells.	therapeutic application	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24729221/	Recurrent low-dose chemotherapy to inhibit and oxygenate head and neck tumors.	therapeutic application	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24788022/	Net platelet angiogenic activity (NPAA) correlates with progression and prognosis of non-small cell lung cancer.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25365482/	EBAG9 modulates host immune defense against tumor formation and metastasis by regulating cytotoxic activity of T lymphocytes.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25621889/	EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25970326/	Association of platelet activation markers with cancer-associated venous thromboembolism.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26273699/	Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26756218/	Thrombospondin-1 might be a therapeutic target to suppress RB cells by regulating the DNA double-strand breaks repair.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26852677/	Development of a Cancer Treatment with the Concomitant Use of Low-Intensity Ultrasound: Entering the Age of Simultaneous Diagnosis and Treatment.	therapeutic application	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27349907/	Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27756886/	Properdistatin inhibits angiogenesis and improves vascular function in human melanoma xenografts with low thrombospondin-1 expression.	therapeutic application	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27757299/	Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27878431/	Aqueous immune mediators in malignant uveal melanomas in comparison to benign pigmented intraocular tumors.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/28045898/	Transcriptional and Post-Transcriptional Regulation of Thrombospondin-1 Expression: A Computational Model.	therapeutic application	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/28614657/	General Strategy for Direct Cytosolic Protein Delivery via Protein-Nanoparticle Co-engineering.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/29441713/	Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/29927834/	Role of thrombospondin-1 and nuclear factor-kappa B signaling pathways in anti-angiogenesis of infantile hemangioma.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/30076136/	Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGF?1 Axis.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/30593119/	[Relationship between thrombospondin-1 and the occurrence and development of oral and maxillofacial malignancy].	therapeutic application	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31160686/	AAV-mediated expression of 3TSR inhibits tumor and metastatic lesion development and extends survival in a murine model of epithelial ovarian carcinoma.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31222746/	Silencing of PTGS2 exerts promoting effects on angiogenesis endothelial progenitor cells in mice with ischemic stroke via repression of the NF-?B signaling pathway.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31293597/	Granzyme A Stimulates pDCs to Promote Adaptive Immunity via Induction of Type I IFN.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31410189/	CD36 tango in cancer: signaling pathways and functions.	therapeutic application	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31418132/	Combination of metronomic administration and target delivery strategies to improve the anti-angiogenic and anti-tumor effects of triptolide.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32679628/	Decrease in immune function and the role of mitogen-activated protein kinase (MAPK) overactivation in apoptosis during T lymphocytes activation induced by zearalenone, deoxynivalenol, and their combinations.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/33001862/	Protein tyrosine phosphatase non-receptor type 2 controls colorectal cancer development.	therapeutic application	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/33629064/	Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/33816691/	Platelet TSP-1 controls prostate cancer-induced osteoclast differentiation and bone marrow-derived cell mobilization through TGF?-1.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/34045231/	Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing.	therapeutic application	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/34215227/	CD36 promotes vasculogenic mimicry in melanoma by mediating adhesion to the extracellular matrix.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/34466000/	Potential Role of Pleural Fluid Cytokine Profile in Myelomatous Pleural Effusions.	therapeutic application	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/2179951/	Genes encoding tumor necrosis factor alpha and granzyme A are expressed during development of autoimmune diabetes.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15743540/	Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18555217/	Differential involvement of TGF-beta1 in mediating the motogenic effects of TSP-1 on endothelial cells, fibroblasts and oral tumour cells.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25358253/	Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/1350566/	Murine Thy-1+ dendritic epidermal T cell lines express granule-associated perforin and a family of granzyme molecules.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/1423596/	Cytotoxicity with target DNA breakdown by rat basophilic leukemia cells expressing both cytolysin and granzyme A.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/7507956/	Cytotoxic lymphocyte granzymes trigger a target cell internal disintegration pathway leading to cytolysis and DNA breakdown.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/7813805/	Accelerated beta-cell destruction in adoptively transferred autoimmune diabetes correlates with an increased expression of the genes coding for TNF-alpha and granzyme A in the intra-islet infiltrates.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/8661169/	Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/8959642/	Peripheral T cell activation in long-term renal transplant patients: concordant upregulation of adhesion molecules and cytokine gene transcription.	ongoing research	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9288157/	Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9302563/	Histopathology and clinical assessment correlate with the cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) receptor of thrombospondin-1 in breast tumors.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9515819/	Molecular mediators of angiogenesis in bladder cancer.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9600434/	Thrombospondin-1 and its CSVTCG-specific receptor in wound healing and cancer.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9618039/	Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9695745/	The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9833775/	Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10051595/	Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization.	ongoing research	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10328956/	Retinoic acid alters the mechanism of attachment of malignant astrocytoma and neuroblastoma cells to thrombospondin-1.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10375104/	Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10393860/	Human cytomegalovirus infection decreases expression of thrombospondin-1 independent of the tumor suppressor protein p53.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10433937/	Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10502735/	Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10719053/	Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10914744/	Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor.	ongoing research	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11036248/	Thrombospondin-1 expression in oral squamous cell carcinomas: correlations with tumor vascularity, clinicopathological features and survival.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11069717/	Cationic lipid gene transfer of an IL-2 transgene leads to activation of natural killer cells in a SCID mouse human tumor xenograft.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11132930/	Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11169436/	Granzyme A and B-deficient killer lymphocytes are defective in eliciting DNA fragmentation but retain potent in vivo anti-tumor capacity.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11205922/	Independent association of angiogenesis index with outcome in prostate cancer.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11216860/	Expression of thrombospondin-1 in human hepatocarcinoma cell lines and its regulation by transcription factor Jun/AP-1.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11228532/	The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11253112/	Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11410779/	Expression of thrombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11531279/	Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11555600/	Thrombospondin-1 and -2 messenger RNA expression in invasive cervical cancer: correlation with angiogenesis and prognosis.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11712798/	Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11856116/	Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11861403/	Overexpression of thrombospondin-1 reduces growth and vascular index but not perfusion in glioblastoma.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11882904/	Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11920636/	Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11927969/	The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11955611/	Up-regulation of thrombospondin-1 gene by epidermal growth factor and transforming growth factor beta in human cancer cells--transcriptional activation and messenger RNA stabilization.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11955648/	Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12006528/	Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12219015/	Fibroblasts promote breast cancer cell invasion by upregulating tumor matrix metalloproteinase-9 production.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12429967/	Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12439745/	Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12443715/	Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12461058/	Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12492491/	Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12584168/	Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12719977/	Expression of thrombospondin-1 is correlated with microvessel density in gastric carcinoma.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12720300/	Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12825818/	Cell density regulates thrombospondin-1 production in malignant glioma cells.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12847210/	Cutting edge: granzymes A and B are not essential for perforin-mediated tumor rejection.	ongoing research	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12874006/	Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12912908/	Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12947001/	Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12963968/	Clinical significance of thrombospondin-1 expression in relation to vascular endothelial growth factor and interleukin-10 expression at the deepest invasive tumor site of advanced colorectal carcinoma.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14501775/	Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14511656/	Restoration of thrombospondin 1 expression in tumor cells harbouring mutant ras oncogene by treatment with low doses of doxycycline.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14555767/	Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14559817/	Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14751520/	Thrombospondin-1 treatment prevents growth of dormant lung micrometastases after surgical resection and curative radiation therapy of the primary tumor in human melanoma xenografts.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14996710/	Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15095410/	Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15172186/	Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15180634/	The expression of thrombospondin-1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15321749/	[Inhibition of fibrosarcoma growth in mice by antibody against B cell epitope on mouse Toll-like receptor-2 extracellular domain]	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15375381/	Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15503824/	Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: relationship to platelet alpha-granule content and primary activation.	ongoing research	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15519514/	Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers.	ongoing research	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15526350/	Hepatocyte growth factor (HGF) downregulates thrombospondin 1 (TSP-1) expression in thyroid papillary carcinoma cells.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15583827/	Expression of thrombospondin-1 in prostate-derived cell lines.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15623630/	Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15662972/	Quantification of thrombospondin-1 secretion and expression of alphavbeta3 and alpha3beta1 integrins and syndecan-1 as cell-surface receptors for thrombospondin-1 in malignant glioma cells.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15784731/	Type 3 repeat/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/alphavbeta3 in promyelocytic leukemia NB4 cells.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15831915/	Thrombospondin 1 acts as a strong promoter of transforming growth factor beta effects via two distinct mechanisms in hepatic stellate cells.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15833768/	Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15838828/	Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15840100/	The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16009408/	Immunohistochemical expression of thrombospondin-1 in invasive vulvar squamous cell carcinoma.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16076702/	Thrombospondins, metallo proteases and thrombospondin receptors messenger RNA and protein expression in different tumour sublines of the Dunning prostate cancer model.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16166434/	Expression of thrombospondin-1 in resected colorectal liver metastases predicts poor prognosis.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16204059/	Oncogenes and Angiogenesis: down-regulation of thrombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16227405/	Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16394085/	Pituitary tumor-transforming gene regulates multiple downstream angiogenic genes in thyroid cancer.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16397274/	Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16418571/	Halofuginone Inhibits Tumor Growth in the Polyoma Middle T Antigen Mouse via a Thrombospondin-1 Independent Mechanism.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16465407/	Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16467081/	Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16515598/	Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16618977/	Thrombospondin 1 mRNA as a Candidate for a Marker to Detect Thyroid-derived Fibroblasts in Fine Needle Aspiration Biopsy of the Thyroid.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16650813/	IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16677501/	[Mechanism of reversion of myocardial interstitial fibrosis in diabetic cardiomyopathy by valsartan]	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16732887/	Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17198740/	The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.	ongoing research	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17283240/	Changes in thrombospondin-1 levels in the endothelial cells of the anterior pituitary during estrogen-induced prolactin-secreting pituitary tumors.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17409099/	Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17706282/	Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17709727/	Association of angiogenesis markers with lymph node metastasis in early colorectal cancer.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17912439/	Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18067717/	[Relationship between changes of serum concentrations of antiangiogenic factors and disease progression in patients of pancreatic carcinoma]	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18171979/	Interference of macrophage migration inhibitory factor expression in a mouse melanoma inhibits tumor establishment by up-regulating thrombospondin-1.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18313158/	Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18321763/	Thrombospondin-1 enhances human thyroid carcinoma cell invasion through urokinase activity.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18336597/	Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18413367/	A novel role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19024308/	[Correlation between the expression of thrombospondin-1 and the angiogenesis in mucoepidermoid carcinoma]	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19080117/	Correlation between the expression of thrombospondin-1 and neovascularization in mucoepidermoid carcinoma.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19110305/	Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study.	ongoing research	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19259612/	Fascin overexpression correlates with positive thrombospondin-1 and syndecan-1 expressions and a more aggressive clinical course in patients with gallbladder cancer.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19324018/	All-trans retinoic acid induces Thrombospondin-1 expression in acute promyelocytic leukemia cells though down-regulation of its transcription repressor, c-MYC oncoprotein.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19391135/	Estrogen regulation of thrombospondin-1 in human breast cancer cells.	ongoing research	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19509293/	Thrombospondin-1 is a transcriptional repression target of PRMT6.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19570906/	Regulation of thrombospondin-1 by natural and synthetic progestins in human breast cancer cells.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19594546/	c-Ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma.	ongoing research	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19634159/	The role of angiocidin in sarcomas.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19690133/	Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19747478/	Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: Exploring the functional significance in tumor cell invasion.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19762163/	Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19805200/	Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20458281/	Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20498063/	B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20552567/	Improved therapeutic responses for liposomal doxorubicin targeted via thrombospondin peptidomimetics versus untargeted doxorubicin.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20631908/	Thrombospondin-1 (TSP-1) Stimulates Expression of Integrin alpha6 in Human Breast Carcinoma Cells: A Downstream Modulator of TSP-1-Induced Cellular Adhesion.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20736295/	Regional control of tumor growth.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20876797/	Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21107877/	Expression of thrombospondin-1 and Ski are prognostic factors in advanced gastric cancer.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21443538/	Aberrant Expression of Chemokine Receptor CCR4 in Human Gastric Cancer Contributes to Tumor-Induced Immunosuppression.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21479427/	Thrombospondin-2 inhibits tumor cell invasion through the modulation of MMP-9 and uPA in pancreatic cancer cells.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21765615/	Thrombospondin-1: multiple paths to inflammation.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22207555/	Thrombospondin-1 expression in breast cancer: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22808089/	Context dependent role of the CD36--thrombospondin--histidine-rich glycoprotein axis in tumor angiogenesis and growth.	ongoing research	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23117884/	Production of gastrointestinal tumors in mice by modulating latent TGF-?1 activation.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23380452/	PRMT6 overexpression upregulates TSP-1 and downregulates MMPs: Its implication in motility and invasion.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23389639/	The pharmacological bases of the antiangiogenic activity of paclitaxel.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23614916/	Thrombospondin-1 is highly expressed in desmoplastic components of invasive ductal carcinoma of the breast and associated with lymph node metastasis.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23695365/	Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23749112/	Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23757408/	Thrombospondin-1 regulates adiposity and metabolic dysfunction in diet-induced obesity enhancing adipose inflammation and stimulating adipocyte proliferation.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23846726/	Thrombospondin-1 is a putative target gene of Runx2 and Runx3.	ongoing research	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24127010/	A novel cancer therapeutic using thrombospondin 1 in dendritic cells.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24590059/	Immunosurveillance by Antiangiogenesis: Tumor Growth Arrest by T Cell-Derived Thrombospondin-1.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24788022/	Net platelet angiogenic activity (NPAA) correlates with progression and prognosis of non-small cell lung cancer.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25365482/	EBAG9 modulates host immune defense against tumor formation and metastasis by regulating cytotoxic activity of T lymphocytes.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25621889/	EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25943461/	Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26273699/	Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26461935/	Thrombospondin-1 in a Murine Model of Colorectal Carcinogenesis.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26756218/	Thrombospondin-1 might be a therapeutic target to suppress RB cells by regulating the DNA double-strand breaks repair.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26962158/	Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment.	ongoing research	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27349907/	Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide.	ongoing research	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27756886/	Properdistatin inhibits angiogenesis and improves vascular function in human melanoma xenografts with low thrombospondin-1 expression.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27878431/	Aqueous immune mediators in malignant uveal melanomas in comparison to benign pigmented intraocular tumors.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/28045898/	Transcriptional and Post-Transcriptional Regulation of Thrombospondin-1 Expression: A Computational Model.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/28207087/	Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: Relationship to platelet a-granule content and primary activation.	ongoing research	1	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/29200966/	Microencapsulation of low-passage poorly-differentiated human mucoepidermoid carcinoma cells by alginate microcapsules: in vitro profiling of angiogenesis-related molecules.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/29441713/	Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/30963401/	Tumor Heterogeneity Correlates with Less Immune Response and Worse Survival in Breast Cancer Patients.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31016850/	TSP-1 is downregulated and inversely correlates with miR-449c expression in Cushing's disease.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31160686/	AAV-mediated expression of 3TSR inhibits tumor and metastatic lesion development and extends survival in a murine model of epithelial ovarian carcinoma.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31222746/	Silencing of PTGS2 exerts promoting effects on angiogenesis endothelial progenitor cells in mice with ischemic stroke via repression of the NF-?B signaling pathway.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31237113/	High immune cytolytic activity in tumor-free tongue tissue confers better prognosis in patients with squamous cell carcinoma of the oral tongue.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31712778/	Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/33001862/	Protein tyrosine phosphatase non-receptor type 2 controls colorectal cancer development.	ongoing research	4	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/33629064/	Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/33816691/	Platelet TSP-1 controls prostate cancer-induced osteoclast differentiation and bone marrow-derived cell mobilization through TGF?-1.	ongoing research	2	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/34045231/	Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing.	ongoing research	3	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18834408/	Regulation of tumor dormancy as a function of tumor-mediated paracrine regulation of stromal Tsp-1 and VEGF expression.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19219378/	The N-terminal domain of thrombospondin-1: a key for the dual effect of TSP-1 in angiogenesis and cancer progression?	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19581582/	Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/1350566/	Murine Thy-1+ dendritic epidermal T cell lines express granule-associated perforin and a family of granzyme molecules.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/1423596/	Cytotoxicity with target DNA breakdown by rat basophilic leukemia cells expressing both cytolysin and granzyme A.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/7507956/	Cytotoxic lymphocyte granzymes trigger a target cell internal disintegration pathway leading to cytolysis and DNA breakdown.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/8959642/	Peripheral T cell activation in long-term renal transplant patients: concordant upregulation of adhesion molecules and cytokine gene transcription.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9603160/	The cellular basis of cardiac allograft rejection: VIII. Mechanisms underlying delayed allograft rejection in PVG C6-deficient rats.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10914744/	Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11069717/	Cationic lipid gene transfer of an IL-2 transgene leads to activation of natural killer cells in a SCID mouse human tumor xenograft.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11157717/	Association of thrombospondin-1 and cardiac allograft vasculopathy in human cardiac allografts.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11169436/	Granzyme A and B-deficient killer lymphocytes are defective in eliciting DNA fragmentation but retain potent in vivo anti-tumor capacity.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11205922/	Independent association of angiogenesis index with outcome in prostate cancer.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11955648/	Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12428227/	Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12847210/	Cutting edge: granzymes A and B are not essential for perforin-mediated tumor rejection.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12947001/	Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14501775/	Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15095410/	Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15180634/	The expression of thrombospondin-1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15321749/	[Inhibition of fibrosarcoma growth in mice by antibody against B cell epitope on mouse Toll-like receptor-2 extracellular domain]	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15519514/	Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15623630/	Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15831915/	Thrombospondin 1 acts as a strong promoter of transforming growth factor beta effects via two distinct mechanisms in hepatic stellate cells.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15840100/	The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16204059/	Oncogenes and Angiogenesis: down-regulation of thrombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16286245/	TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16397274/	Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16467081/	Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16515598/	Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16618977/	Thrombospondin 1 mRNA as a Candidate for a Marker to Detect Thyroid-derived Fibroblasts in Fine Needle Aspiration Biopsy of the Thyroid.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16677501/	[Mechanism of reversion of myocardial interstitial fibrosis in diabetic cardiomyopathy by valsartan]	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17395736/	Thrombopoietic cells and the bone marrow vascular niche.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17409099/	Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17431618/	Interleukin-4 impairs granzyme-mediated cytotoxicity of Simian virus 40 large tumor antigen-specific CTL in BALB/c mice.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17603295/	Inhibition of trichostatin A-induced antiangiogenesis by small-interfering RNA for thrombospondin-1.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17639047/	Effects of a phytoestrogen-containing soy extract on the growth-inhibitory activity of ICI 182 780 in an experimental model of estrogen-dependent breast cancer.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17692904/	Effect of oral anticoagulant therapy on thrombospondin-1 and von Willebrand factor in patients with stable heart failure.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17706282/	Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17931108/	Functional Characterization of BK Virus-Specific CD4(+) T Cells with Cytotoxic Potential in Seropositive Adults.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18313158/	Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18321763/	Thrombospondin-1 enhances human thyroid carcinoma cell invasion through urokinase activity.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18726995/	Thrombospondin-1-induced apoptosis of brain microvascular endothelial cells can be mediated by TNF-R1.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19079608/	Modulation of macrophage activation state protects tissue from necrosis during critical limb ischemia in thrombospondin-1-deficient mice.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19110305/	Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19324018/	All-trans retinoic acid induces Thrombospondin-1 expression in acute promyelocytic leukemia cells though down-regulation of its transcription repressor, c-MYC oncoprotein.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20552567/	Improved therapeutic responses for liposomal doxorubicin targeted via thrombospondin peptidomimetics versus untargeted doxorubicin.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21443538/	Aberrant Expression of Chemokine Receptor CCR4 in Human Gastric Cancer Contributes to Tumor-Induced Immunosuppression.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21765615/	Thrombospondin-1: multiple paths to inflammation.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22587436/	Anti-angiogenesis effect of 3'-sulfoquinovosyl-1'-monoacylglycerol via upregulation of thrombospondin 1.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22808089/	Context dependent role of the CD36--thrombospondin--histidine-rich glycoprotein axis in tumor angiogenesis and growth.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23117884/	Production of gastrointestinal tumors in mice by modulating latent TGF-?1 activation.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24041868/	Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24788022/	Net platelet angiogenic activity (NPAA) correlates with progression and prognosis of non-small cell lung cancer.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25365482/	EBAG9 modulates host immune defense against tumor formation and metastasis by regulating cytotoxic activity of T lymphocytes.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25970326/	Association of platelet activation markers with cancer-associated venous thromboembolism.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26561569/	Triple costimulation via CD80, 4-1BB, and CD83 ligand elicits the long-term growth of V?9V?2 T cells in low levels of IL-2.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26961119/	Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/28045898/	Transcriptional and Post-Transcriptional Regulation of Thrombospondin-1 Expression: A Computational Model.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/28493520/	HBV-specific CD4+ cytotoxic T cells in hepatocellular carcinoma are less cytolytic toward tumor cells and suppress CD8+ T cell-mediated antitumor immunity.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/29590229/	Association of Oxytocin with Glucose Intolerance and Inflammation Biomarkers in Metabolic Syndrome Patients with and without Prediabetes.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/30963401/	Tumor Heterogeneity Correlates with Less Immune Response and Worse Survival in Breast Cancer Patients.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31160686/	AAV-mediated expression of 3TSR inhibits tumor and metastatic lesion development and extends survival in a murine model of epithelial ovarian carcinoma.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31200779/	Multiplex quantitative analysis of stroma-mediated cancer cell invasion, matrix remodeling, and drug response in a 3D co-culture model of pancreatic tumor spheroids and stellate cells.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31235729/	Circulating pro- and anti-angiogenic factors in multi-stage liver disease and hepatocellular carcinoma progression.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31293597/	Granzyme A Stimulates pDCs to Promote Adaptive Immunity via Induction of Type I IFN.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31410189/	CD36 tango in cancer: signaling pathways and functions.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32679628/	Decrease in immune function and the role of mitogen-activated protein kinase (MAPK) overactivation in apoptosis during T lymphocytes activation induced by zearalenone, deoxynivalenol, and their combinations.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/34045231/	Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/34466000/	Potential Role of Pleural Fluid Cytokine Profile in Myelomatous Pleural Effusions.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/2179951/	Genes encoding tumor necrosis factor alpha and granzyme A are expressed during development of autoimmune diabetes.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15707585/	The tumor suppressor PTEN inhibits EGF-induced TSP-1 and TIMP-1 expression in FTC-133 thyroid carcinoma cells.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25358253/	Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/8593167/	The role of thrombospondin-1 in tumor progression and angiogenesis.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/8661169/	Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/8980608/	Adhesive proteins and the hematogenous spread of cancer.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10051595/	Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10328956/	Retinoic acid alters the mechanism of attachment of malignant astrocytoma and neuroblastoma cells to thrombospondin-1.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11520937/	The role of thrombospondin-1 in tumor progression.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11746276/	Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11861403/	Overexpression of thrombospondin-1 reduces growth and vascular index but not perfusion in glioblastoma.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11920636/	Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12003665/	Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12213285/	Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12492491/	Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12570805/	Thrombospondins as anti-angiogenic therapeutic agents.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12720300/	Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12825818/	Cell density regulates thrombospondin-1 production in malignant glioma cells.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12912908/	Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14555767/	Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14658007/	Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14751520/	Thrombospondin-1 treatment prevents growth of dormant lung micrometastases after surgical resection and curative radiation therapy of the primary tumor in human melanoma xenografts.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15094119/	Tumor progression: the effects of thrombospondin-1 and -2.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15277228/	Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15375381/	Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15784731/	Type 3 repeat/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/alphavbeta3 in promyelocytic leukemia NB4 cells.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15908066/	Extraction of RNA from archival tissues and measurement of thrombospondin-1 mRNA in normal, dysplastic, and malignant oral tissues.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15963261/	Characterization of integrin beta6 and thrombospondin-1 double-null mice.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16227405/	Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16406676/	Regulation of tumor angiogenesis by thrombospondin-1.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16418571/	Halofuginone Inhibits Tumor Growth in the Polyoma Middle T Antigen Mouse via a Thrombospondin-1 Independent Mechanism.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16650813/	IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16847352/	Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17056717/	Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17106256/	Cyclin D1 functions in cell migration.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17234749/	Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17283240/	Changes in thrombospondin-1 levels in the endothelial cells of the anterior pituitary during estrogen-induced prolactin-secreting pituitary tumors.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17912446/	Effects of alpha-difluoromethylornithine on thrombospondin-1 production by human breast cancer cells.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18171979/	Interference of macrophage migration inhibitory factor expression in a mouse melanoma inhibits tumor establishment by up-regulating thrombospondin-1.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18193162/	Thrombospondins: from structure to therapeutics : Thrombospondins in cancer.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18222489/	Collagen-binding domains of gelatinase A and thrombospondin-derived peptides impede endocytic clearance of active gelatinase A and promote HT1080 fibrosarcoma cell invasion.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18228414/	Purification and analysis of thrombospondin-1.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18409060/	The effect of thrombospondin-1 on breast cancer metastasis.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18413367/	A novel role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18420342/	Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18443598/	Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18661355/	Thrombospondin-1 in differentiated thyroid cancer: Dr. Jekyll and Mr. Hyde.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19002766/	Carrageenan inhibits granzyme A-induced detachment of and interleukin-8 release from alveolar epithelial A549 cells.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19250552/	Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19259612/	Fascin overexpression correlates with positive thrombospondin-1 and syndecan-1 expressions and a more aggressive clinical course in patients with gallbladder cancer.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19391135/	Estrogen regulation of thrombospondin-1 in human breast cancer cells.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19447890/	Elongation factor ELL (Eleven-Nineteen Lysine-rich Leukemia) acts as a transcription factor for direct thrombospondin-1 regulation.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19509293/	Thrombospondin-1 is a transcriptional repression target of PRMT6.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19570906/	Regulation of thrombospondin-1 by natural and synthetic progestins in human breast cancer cells.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19594546/	c-Ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20492458/	Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20498063/	B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20631908/	Thrombospondin-1 (TSP-1) Stimulates Expression of Integrin alpha6 in Human Breast Carcinoma Cells: A Downstream Modulator of TSP-1-Induced Cellular Adhesion.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20714802/	CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21068403/	Human eosinophils exert TNF-? and granzyme A-mediated tumoricidal activity toward colon carcinoma cells.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21290245/	Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21479427/	Thrombospondin-2 inhibits tumor cell invasion through the modulation of MMP-9 and uPA in pancreatic cancer cells.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21697041/	The expression levels of thrombospondin-1 in dermatofibroma and dermatofibrosarcoma protuberans.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22700773/	Thrombospondin-1 (TSP-1) Analogs ABT-510 and ABT-898 Inhibit Prolactinoma Growth and Recover Active Pituitary Transforming Growth Factor-?1 (TGF-?1).	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23085760/	The novel tumor suppressor NOL7 post-transcriptionally regulates thrombospondin-1 expression.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23389639/	The pharmacological bases of the antiangiogenic activity of paclitaxel.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23695365/	Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23757408/	Thrombospondin-1 regulates adiposity and metabolic dysfunction in diet-induced obesity enhancing adipose inflammation and stimulating adipocyte proliferation.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23851682/	Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24127010/	A novel cancer therapeutic using thrombospondin 1 in dendritic cells.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24590059/	Immunosurveillance by Antiangiogenesis: Tumor Growth Arrest by T Cell-Derived Thrombospondin-1.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24729221/	Recurrent low-dose chemotherapy to inhibit and oxygenate head and neck tumors.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26273699/	Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26461935/	Thrombospondin-1 in a Murine Model of Colorectal Carcinogenesis.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26578962/	Original insights on thrombospondin-1-related antireceptor strategies in cancer.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26852677/	Development of a Cancer Treatment with the Concomitant Use of Low-Intensity Ultrasound: Entering the Age of Simultaneous Diagnosis and Treatment.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26962158/	Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27756886/	Properdistatin inhibits angiogenesis and improves vascular function in human melanoma xenografts with low thrombospondin-1 expression.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/28614657/	General Strategy for Direct Cytosolic Protein Delivery via Protein-Nanoparticle Co-engineering.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/28810809/	Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/29927834/	Role of thrombospondin-1 and nuclear factor-kappa B signaling pathways in anti-angiogenesis of infantile hemangioma.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/30076136/	Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGF?1 Axis.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/30593119/	[Relationship between thrombospondin-1 and the occurrence and development of oral and maxillofacial malignancy].	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31418132/	Combination of metronomic administration and target delivery strategies to improve the anti-angiogenic and anti-tumor effects of triptolide.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31462506/	Glycolipid Stimulation of Invariant NKT Cells Expands a Unique Tissue-Resident Population of Precursors to Mature NK Cells Endowed with Oncolytic and Antimetastatic Properties.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31712778/	Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32845506/	Thrombospondin in Tumor Microenvironment.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/33816691/	Platelet TSP-1 controls prostate cancer-induced osteoclast differentiation and bone marrow-derived cell mobilization through TGF?-1.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/33968059/	Endometrial Cancer Suppresses CD8+ T Cell-Mediated Cytotoxicity in Postmenopausal Women.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15743540/	Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18555217/	Differential involvement of TGF-beta1 in mediating the motogenic effects of TSP-1 on endothelial cells, fibroblasts and oral tumour cells.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/7813805/	Accelerated beta-cell destruction in adoptively transferred autoimmune diabetes correlates with an increased expression of the genes coding for TNF-alpha and granzyme A in the intra-islet infiltrates.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9288157/	Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9515819/	Molecular mediators of angiogenesis in bladder cancer.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9618039/	Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9695745/	The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9828214/	Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11150912/	Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11216860/	Expression of thrombospondin-1 in human hepatocarcinoma cell lines and its regulation by transcription factor Jun/AP-1.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11445843/	Thrombospondin-1 and -2 messenger RNA expression in normal and neoplastic endometrial tissues: correlation with angiogenesis and prognosis.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11555600/	Thrombospondin-1 and -2 messenger RNA expression in invasive cervical cancer: correlation with angiogenesis and prognosis.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11712798/	Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11927969/	The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11955611/	Up-regulation of thrombospondin-1 gene by epidermal growth factor and transforming growth factor beta in human cancer cells--transcriptional activation and messenger RNA stabilization.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12006528/	Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12429967/	Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12814189/	Evidence of a bi-phasic effect of thrombospondin-1 on angiogenesis.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12927044/	Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12963968/	Clinical significance of thrombospondin-1 expression in relation to vascular endothelial growth factor and interleukin-10 expression at the deepest invasive tumor site of advanced colorectal carcinoma.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/14511656/	Restoration of thrombospondin 1 expression in tumor cells harbouring mutant ras oncogene by treatment with low doses of doxycycline.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15503824/	Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: relationship to platelet alpha-granule content and primary activation.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15526350/	Hepatocyte growth factor (HGF) downregulates thrombospondin 1 (TSP-1) expression in thyroid papillary carcinoma cells.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15583827/	Expression of thrombospondin-1 in prostate-derived cell lines.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15662972/	Quantification of thrombospondin-1 secretion and expression of alphavbeta3 and alpha3beta1 integrins and syndecan-1 as cell-surface receptors for thrombospondin-1 in malignant glioma cells.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15833768/	Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16076702/	Thrombospondins, metallo proteases and thrombospondin receptors messenger RNA and protein expression in different tumour sublines of the Dunning prostate cancer model.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16166434/	Expression of thrombospondin-1 in resected colorectal liver metastases predicts poor prognosis.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16394085/	Pituitary tumor-transforming gene regulates multiple downstream angiogenic genes in thyroid cancer.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16465407/	Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17198740/	The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/17912439/	Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18067717/	[Relationship between changes of serum concentrations of antiangiogenic factors and disease progression in patients of pancreatic carcinoma]	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18336597/	Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19024308/	[Correlation between the expression of thrombospondin-1 and the angiogenesis in mucoepidermoid carcinoma]	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19634159/	The role of angiocidin in sarcomas.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19747478/	Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: Exploring the functional significance in tumor cell invasion.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19762163/	Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20204299/	Correlation between pathological data and the RNA expression of p53 or p53-targeted genes in primary invasive ductal breast carcinomas: a preliminary study.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20736295/	Regional control of tumor growth.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21107877/	Expression of thrombospondin-1 and Ski are prognostic factors in advanced gastric cancer.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23749112/	Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23846726/	Thrombospondin-1 is a putative target gene of Runx2 and Runx3.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25943461/	Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26676551/	Quercetin inhibits angiogenesis through thrombospondin-1 upregulation to antagonize human prostate cancer PC-3 cell growth in vitro and in vivo.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27422280/	Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/28207087/	Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: Relationship to platelet a-granule content and primary activation.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/29200966/	Microencapsulation of low-passage poorly-differentiated human mucoepidermoid carcinoma cells by alginate microcapsules: in vitro profiling of angiogenesis-related molecules.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31016850/	TSP-1 is downregulated and inversely correlates with miR-449c expression in Cushing's disease.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31237113/	High immune cytolytic activity in tumor-free tongue tissue confers better prognosis in patients with squamous cell carcinoma of the oral tongue.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32194708/	TSP-1 as a novel biological marker of tumor vasculature normalization in colon carcinoma induced by Endostar.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32600280/	Role of TSP-1 as prognostic marker in various cancers: a systematic review and meta-analysis.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/8677265/	Expression of thrombospondin-1 in cancer: a role in tumor progression.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10611308/	Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11438469/	Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11877681/	p53 accumulation in favorable-histology Wilms tumor is associated with angiogenesis and clinically aggressive disease.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12429155/	Reduced thrombospondin-1 at presentation predicts disease progression in superficial bladder cancer.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19383251/	Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21407216/	Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23633432/	Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27757299/	Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma.	unassigned	-	
3.4.21.78	Neoplasms	https://pubmed.ncbi.nlm.nih.gov/34215227/	CD36 promotes vasculogenic mimicry in melanoma by mediating adhesion to the extracellular matrix.	unassigned	-	
3.4.21.78	Neoplasms, Glandular and Epithelial	https://pubmed.ncbi.nlm.nih.gov/10482694/	Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer.	causal interaction	2	
3.4.21.78	Neoplasms, Glandular and Epithelial	https://pubmed.ncbi.nlm.nih.gov/10482694/	Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer.	diagnostic usage	3	
3.4.21.78	Neoplasms, Glandular and Epithelial	https://pubmed.ncbi.nlm.nih.gov/10482694/	Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer.	therapeutic application	1	
3.4.21.78	Neoplasms, Glandular and Epithelial	https://pubmed.ncbi.nlm.nih.gov/10482694/	Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer.	ongoing research	4	
3.4.21.78	Nephritis	https://pubmed.ncbi.nlm.nih.gov/23554717/	TSP-1 promotes glomerular mesangial cell proliferation and extracellular matrix secretion in Thy-1 nephritis rats.	causal interaction	1	
3.4.21.78	Nephritis	https://pubmed.ncbi.nlm.nih.gov/23554717/	TSP-1 promotes glomerular mesangial cell proliferation and extracellular matrix secretion in Thy-1 nephritis rats.	ongoing research	4	
3.4.21.78	Nephritis	https://pubmed.ncbi.nlm.nih.gov/23554717/	TSP-1 promotes glomerular mesangial cell proliferation and extracellular matrix secretion in Thy-1 nephritis rats.	unassigned	-	
3.4.21.78	Nephrosclerosis	https://pubmed.ncbi.nlm.nih.gov/11961406/	Sustained expression of thrombospondin-1 is associated with the development of glomerular and tubulointerstitial fibrosis in the remnant kidney model.	causal interaction	3	
3.4.21.78	Nephrosclerosis	https://pubmed.ncbi.nlm.nih.gov/19799194/	[Molecular factors of angiogenesis in renal tissue of patients with chronic glomerulonephritis: association with nephrosclerosis and anemia]	diagnostic usage	2	
3.4.21.78	Nephrosclerosis	https://pubmed.ncbi.nlm.nih.gov/11961406/	Sustained expression of thrombospondin-1 is associated with the development of glomerular and tubulointerstitial fibrosis in the remnant kidney model.	ongoing research	4	
3.4.21.78	Nephrosclerosis	https://pubmed.ncbi.nlm.nih.gov/19799194/	[Molecular factors of angiogenesis in renal tissue of patients with chronic glomerulonephritis: association with nephrosclerosis and anemia]	ongoing research	2	
3.4.21.78	Nephrosclerosis	https://pubmed.ncbi.nlm.nih.gov/19799194/	[Molecular factors of angiogenesis in renal tissue of patients with chronic glomerulonephritis: association with nephrosclerosis and anemia]	unassigned	-	
3.4.21.78	Nephrosclerosis	https://pubmed.ncbi.nlm.nih.gov/11961406/	Sustained expression of thrombospondin-1 is associated with the development of glomerular and tubulointerstitial fibrosis in the remnant kidney model.	unassigned	-	
3.4.21.78	Neuroblastoma	https://pubmed.ncbi.nlm.nih.gov/10328956/	Retinoic acid alters the mechanism of attachment of malignant astrocytoma and neuroblastoma cells to thrombospondin-1.	causal interaction	1	
3.4.21.78	Neuroblastoma	https://pubmed.ncbi.nlm.nih.gov/14559817/	Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma.	causal interaction	4	
3.4.21.78	Neuroblastoma	https://pubmed.ncbi.nlm.nih.gov/14559817/	Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma.	diagnostic usage	3	
3.4.21.78	Neuroblastoma	https://pubmed.ncbi.nlm.nih.gov/27756784/	TGF?R1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.	diagnostic usage	4	
3.4.21.78	Neuroblastoma	https://pubmed.ncbi.nlm.nih.gov/14559817/	Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma.	therapeutic application	1	
3.4.21.78	Neuroblastoma	https://pubmed.ncbi.nlm.nih.gov/27756784/	TGF?R1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.	therapeutic application	1	
3.4.21.78	Neuroblastoma	https://pubmed.ncbi.nlm.nih.gov/10328956/	Retinoic acid alters the mechanism of attachment of malignant astrocytoma and neuroblastoma cells to thrombospondin-1.	ongoing research	4	
3.4.21.78	Neuroblastoma	https://pubmed.ncbi.nlm.nih.gov/14559817/	Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma.	ongoing research	4	
3.4.21.78	Neuroblastoma	https://pubmed.ncbi.nlm.nih.gov/27756784/	TGF?R1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.	ongoing research	3	
3.4.21.78	Neuroblastoma	https://pubmed.ncbi.nlm.nih.gov/29531828/	Thrombospondin-1 protects against A?-induced mitochondrial fragmentation and dysfunction in hippocampal cells.	ongoing research	4	
3.4.21.78	Neuroblastoma	https://pubmed.ncbi.nlm.nih.gov/27756784/	TGF?R1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.	unassigned	-	
3.4.21.78	Neuroblastoma	https://pubmed.ncbi.nlm.nih.gov/29531828/	Thrombospondin-1 protects against A?-induced mitochondrial fragmentation and dysfunction in hippocampal cells.	unassigned	-	
3.4.21.78	Neuroblastoma	https://pubmed.ncbi.nlm.nih.gov/10328956/	Retinoic acid alters the mechanism of attachment of malignant astrocytoma and neuroblastoma cells to thrombospondin-1.	unassigned	-	
3.4.21.78	Neuroinflammatory Diseases	https://pubmed.ncbi.nlm.nih.gov/30340642/	New insights into meningitic Escherichia coli infection of brain microvascular endothelial cells from quantitative proteomics analysis.	causal interaction	2	
3.4.21.78	Neuroinflammatory Diseases	https://pubmed.ncbi.nlm.nih.gov/30340642/	New insights into meningitic Escherichia coli infection of brain microvascular endothelial cells from quantitative proteomics analysis.	therapeutic application	1	
3.4.21.78	Neuroinflammatory Diseases	https://pubmed.ncbi.nlm.nih.gov/30340642/	New insights into meningitic Escherichia coli infection of brain microvascular endothelial cells from quantitative proteomics analysis.	unassigned	-	
3.4.21.78	Obesity	https://pubmed.ncbi.nlm.nih.gov/23528972/	Regulation of thrombospondin-1 expression in alternatively activated macrophages and adipocytes: role of cellular cross talk and omega-3 fatty acids.	causal interaction	3	
3.4.21.78	Obesity	https://pubmed.ncbi.nlm.nih.gov/23757408/	Thrombospondin-1 regulates adiposity and metabolic dysfunction in diet-induced obesity enhancing adipose inflammation and stimulating adipocyte proliferation.	causal interaction	4	
3.4.21.78	Obesity	https://pubmed.ncbi.nlm.nih.gov/24575376/	The role of thrombospondin (TSP)-1 in obesity and diabetes.	causal interaction	1	
3.4.21.78	Obesity	https://pubmed.ncbi.nlm.nih.gov/26391700/	Serum levels of TSP-1, NF-?B and TGF-?1 in polycystic ovarian syndrome (PCOS) patients in northern China suggest PCOS is associated with chronic inflammation.	causal interaction	4	
3.4.21.78	Obesity	https://pubmed.ncbi.nlm.nih.gov/26391700/	Serum levels of TSP-1, NF-?B and TGF-?1 in polycystic ovarian syndrome (PCOS) patients in northern China suggest PCOS is associated with chronic inflammation.	diagnostic usage	2	
3.4.21.78	Obesity	https://pubmed.ncbi.nlm.nih.gov/23757408/	Thrombospondin-1 regulates adiposity and metabolic dysfunction in diet-induced obesity enhancing adipose inflammation and stimulating adipocyte proliferation.	ongoing research	2	
3.4.21.78	Obesity	https://pubmed.ncbi.nlm.nih.gov/24575376/	The role of thrombospondin (TSP)-1 in obesity and diabetes.	ongoing research	2	
3.4.21.78	Obesity	https://pubmed.ncbi.nlm.nih.gov/23528972/	Regulation of thrombospondin-1 expression in alternatively activated macrophages and adipocytes: role of cellular cross talk and omega-3 fatty acids.	unassigned	-	
3.4.21.78	Obesity	https://pubmed.ncbi.nlm.nih.gov/23757408/	Thrombospondin-1 regulates adiposity and metabolic dysfunction in diet-induced obesity enhancing adipose inflammation and stimulating adipocyte proliferation.	unassigned	-	
3.4.21.78	Obesity	https://pubmed.ncbi.nlm.nih.gov/24575376/	The role of thrombospondin (TSP)-1 in obesity and diabetes.	unassigned	-	
3.4.21.78	Obesity	https://pubmed.ncbi.nlm.nih.gov/26391700/	Serum levels of TSP-1, NF-?B and TGF-?1 in polycystic ovarian syndrome (PCOS) patients in northern China suggest PCOS is associated with chronic inflammation.	unassigned	-	
3.4.21.78	Oligodendroglioma	https://pubmed.ncbi.nlm.nih.gov/25621889/	EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas.	causal interaction	4	
3.4.21.78	Oligodendroglioma	https://pubmed.ncbi.nlm.nih.gov/25621889/	EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas.	diagnostic usage	4	
3.4.21.78	Oligodendroglioma	https://pubmed.ncbi.nlm.nih.gov/25621889/	EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas.	therapeutic application	1	
3.4.21.78	Oligodendroglioma	https://pubmed.ncbi.nlm.nih.gov/25621889/	EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas.	ongoing research	2	
3.4.21.78	Osteoarthritis	https://pubmed.ncbi.nlm.nih.gov/7536415/	Demonstration of granzyme A and perforin messenger RNA in the synovium of patients with rheumatoid arthritis.	causal interaction	4	
3.4.21.78	Osteoarthritis	https://pubmed.ncbi.nlm.nih.gov/10834862/	Expression of thrombospondin-1 and its receptor CD36 in human osteoarthritic cartilage.	causal interaction	3	
3.4.21.78	Osteoarthritis	https://pubmed.ncbi.nlm.nih.gov/7536415/	Demonstration of granzyme A and perforin messenger RNA in the synovium of patients with rheumatoid arthritis.	diagnostic usage	1	
3.4.21.78	Osteoarthritis	https://pubmed.ncbi.nlm.nih.gov/20309955/	Intraarticular gene transfer of thrombospondin-1 suppresses the disease progression of experimental osteoarthritis.	diagnostic usage	3	
3.4.21.78	Osteoarthritis	https://pubmed.ncbi.nlm.nih.gov/20309955/	Intraarticular gene transfer of thrombospondin-1 suppresses the disease progression of experimental osteoarthritis.	therapeutic application	1	
3.4.21.78	Osteoarthritis	https://pubmed.ncbi.nlm.nih.gov/7536415/	Demonstration of granzyme A and perforin messenger RNA in the synovium of patients with rheumatoid arthritis.	ongoing research	2	
3.4.21.78	Osteoarthritis	https://pubmed.ncbi.nlm.nih.gov/20309955/	Intraarticular gene transfer of thrombospondin-1 suppresses the disease progression of experimental osteoarthritis.	ongoing research	3	
3.4.21.78	Osteoarthritis	https://pubmed.ncbi.nlm.nih.gov/28668542/	CD56(+)/CD16(-) Natural Killer cells expressing the inflammatory protease granzyme A are enriched in synovial fluid from patients with osteoarthritis.	unassigned	-	
3.4.21.78	Osteoarthritis	https://pubmed.ncbi.nlm.nih.gov/20309955/	Intraarticular gene transfer of thrombospondin-1 suppresses the disease progression of experimental osteoarthritis.	unassigned	-	
3.4.21.78	Osteoarthritis	https://pubmed.ncbi.nlm.nih.gov/10834862/	Expression of thrombospondin-1 and its receptor CD36 in human osteoarthritic cartilage.	unassigned	-	
3.4.21.78	Osteoarthritis	https://pubmed.ncbi.nlm.nih.gov/7536415/	Demonstration of granzyme A and perforin messenger RNA in the synovium of patients with rheumatoid arthritis.	unassigned	-	
3.4.21.78	Osteosarcoma	https://pubmed.ncbi.nlm.nih.gov/11955611/	Up-regulation of thrombospondin-1 gene by epidermal growth factor and transforming growth factor beta in human cancer cells--transcriptional activation and messenger RNA stabilization.	causal interaction	4	
3.4.21.78	Osteosarcoma	https://pubmed.ncbi.nlm.nih.gov/12054567/	Adhesion of osteosarcoma cells to the 70-kDa core region of thrombospondin-1 is mediated by the alpha 4 beta 1 integrin.	causal interaction	4	
3.4.21.78	Osteosarcoma	https://pubmed.ncbi.nlm.nih.gov/10703939/	Platelet-osteosarcoma cell interaction is mediated through a specific fibrinogen-binding sequence located within the N-terminal domain of thrombospondin 1.	diagnostic usage	1	
3.4.21.78	Osteosarcoma	https://pubmed.ncbi.nlm.nih.gov/11955611/	Up-regulation of thrombospondin-1 gene by epidermal growth factor and transforming growth factor beta in human cancer cells--transcriptional activation and messenger RNA stabilization.	diagnostic usage	3	
3.4.21.78	Osteosarcoma	https://pubmed.ncbi.nlm.nih.gov/10703939/	Platelet-osteosarcoma cell interaction is mediated through a specific fibrinogen-binding sequence located within the N-terminal domain of thrombospondin 1.	therapeutic application	1	
3.4.21.78	Osteosarcoma	https://pubmed.ncbi.nlm.nih.gov/12054567/	Adhesion of osteosarcoma cells to the 70-kDa core region of thrombospondin-1 is mediated by the alpha 4 beta 1 integrin.	therapeutic application	3	
3.4.21.78	Osteosarcoma	https://pubmed.ncbi.nlm.nih.gov/10703939/	Platelet-osteosarcoma cell interaction is mediated through a specific fibrinogen-binding sequence located within the N-terminal domain of thrombospondin 1.	ongoing research	4	
3.4.21.78	Osteosarcoma	https://pubmed.ncbi.nlm.nih.gov/11955611/	Up-regulation of thrombospondin-1 gene by epidermal growth factor and transforming growth factor beta in human cancer cells--transcriptional activation and messenger RNA stabilization.	ongoing research	4	
3.4.21.78	Osteosarcoma	https://pubmed.ncbi.nlm.nih.gov/9032471/	Identification of cell adhesive active sites in the N-terminal domain of thrombospondin-1.	unassigned	-	
3.4.21.78	Osteosarcoma	https://pubmed.ncbi.nlm.nih.gov/10703939/	Platelet-osteosarcoma cell interaction is mediated through a specific fibrinogen-binding sequence located within the N-terminal domain of thrombospondin 1.	unassigned	-	
3.4.21.78	Osteosarcoma	https://pubmed.ncbi.nlm.nih.gov/12054567/	Adhesion of osteosarcoma cells to the 70-kDa core region of thrombospondin-1 is mediated by the alpha 4 beta 1 integrin.	unassigned	-	
3.4.21.78	Osteosarcoma	https://pubmed.ncbi.nlm.nih.gov/11955611/	Up-regulation of thrombospondin-1 gene by epidermal growth factor and transforming growth factor beta in human cancer cells--transcriptional activation and messenger RNA stabilization.	unassigned	-	
3.4.21.78	Otitis Media	https://pubmed.ncbi.nlm.nih.gov/30896397/	[H Factor Deficiency: A Case with an Atypical Presentation].	causal interaction	4	
3.4.21.78	Otitis Media	https://pubmed.ncbi.nlm.nih.gov/30896397/	[H Factor Deficiency: A Case with an Atypical Presentation].	diagnostic usage	4	
3.4.21.78	Otitis Media	https://pubmed.ncbi.nlm.nih.gov/30896397/	[H Factor Deficiency: A Case with an Atypical Presentation].	unassigned	-	
3.4.21.78	Ovarian Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22136730/	Alteration of HGF and TSP-1 expression in ovarian carcinoma associated with clinical features.	causal interaction	4	
3.4.21.78	Ovarian Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25943461/	Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.	causal interaction	3	
3.4.21.78	Ovarian Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22136730/	Alteration of HGF and TSP-1 expression in ovarian carcinoma associated with clinical features.	diagnostic usage	4	
3.4.21.78	Ovarian Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25943461/	Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.	diagnostic usage	2	
3.4.21.78	Ovarian Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22136730/	Alteration of HGF and TSP-1 expression in ovarian carcinoma associated with clinical features.	ongoing research	3	
3.4.21.78	Ovarian Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25943461/	Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.	ongoing research	4	
3.4.21.78	Ovarian Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22136730/	Alteration of HGF and TSP-1 expression in ovarian carcinoma associated with clinical features.	unassigned	-	
3.4.21.78	Ovarian Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25943461/	Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.	unassigned	-	
3.4.21.78	Pancreatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9695745/	The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.	causal interaction	4	
3.4.21.78	Pancreatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10482694/	Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer.	causal interaction	2	
3.4.21.78	Pancreatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11882904/	Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production.	causal interaction	4	
3.4.21.78	Pancreatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12429967/	Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma.	causal interaction	3	
3.4.21.78	Pancreatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19805200/	Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer.	causal interaction	4	
3.4.21.78	Pancreatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22631643/	Knockdown of radixin by RNA interference suppresses the growth of human pancreatic cancer cells in vitro and in vivo.	causal interaction	4	
3.4.21.78	Pancreatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9695745/	The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.	diagnostic usage	3	
3.4.21.78	Pancreatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10482694/	Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer.	diagnostic usage	3	
3.4.21.78	Pancreatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11882904/	Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production.	diagnostic usage	4	
3.4.21.78	Pancreatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12429967/	Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma.	diagnostic usage	3	
3.4.21.78	Pancreatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19805200/	Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer.	diagnostic usage	3	
3.4.21.78	Pancreatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10482694/	Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer.	therapeutic application	1	
3.4.21.78	Pancreatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11882904/	Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production.	therapeutic application	1	
3.4.21.78	Pancreatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19805200/	Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer.	therapeutic application	1	
3.4.21.78	Pancreatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22631643/	Knockdown of radixin by RNA interference suppresses the growth of human pancreatic cancer cells in vitro and in vivo.	therapeutic application	1	
3.4.21.78	Pancreatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9695745/	The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.	ongoing research	4	
3.4.21.78	Pancreatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/10482694/	Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer.	ongoing research	4	
3.4.21.78	Pancreatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11882904/	Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production.	ongoing research	4	
3.4.21.78	Pancreatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12429967/	Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma.	ongoing research	4	
3.4.21.78	Pancreatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19805200/	Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer.	ongoing research	3	
3.4.21.78	Pancreatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22631643/	Knockdown of radixin by RNA interference suppresses the growth of human pancreatic cancer cells in vitro and in vivo.	unassigned	-	
3.4.21.78	Pancreatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9695745/	The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.	unassigned	-	
3.4.21.78	Pancreatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12429967/	Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma.	unassigned	-	
3.4.21.78	Pancreatitis, Acute Necrotizing	https://pubmed.ncbi.nlm.nih.gov/23409078/	Eomesodermin of atlantic salmon: an important regulator of cytolytic gene and interferon gamma expression in spleen lymphocytes.	causal interaction	1	
3.4.21.78	Pancreatitis, Acute Necrotizing	https://pubmed.ncbi.nlm.nih.gov/23409078/	Eomesodermin of atlantic salmon: an important regulator of cytolytic gene and interferon gamma expression in spleen lymphocytes.	diagnostic usage	1	
3.4.21.78	Pancreatitis, Acute Necrotizing	https://pubmed.ncbi.nlm.nih.gov/23409078/	Eomesodermin of atlantic salmon: an important regulator of cytolytic gene and interferon gamma expression in spleen lymphocytes.	unassigned	-	
3.4.21.78	Papillomavirus Infections	https://pubmed.ncbi.nlm.nih.gov/18336597/	Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma.	causal interaction	1	
3.4.21.78	Papillomavirus Infections	https://pubmed.ncbi.nlm.nih.gov/18336597/	Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma.	diagnostic usage	4	
3.4.21.78	Papillomavirus Infections	https://pubmed.ncbi.nlm.nih.gov/18336597/	Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma.	ongoing research	3	
3.4.21.78	Papillomavirus Infections	https://pubmed.ncbi.nlm.nih.gov/18336597/	Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma.	unassigned	-	
3.4.21.78	Paralysis	https://pubmed.ncbi.nlm.nih.gov/20628203/	Angiotensin II sustains brain inflammation in mice via TGF-beta.	causal interaction	3	
3.4.21.78	Paralysis	https://pubmed.ncbi.nlm.nih.gov/20628203/	Angiotensin II sustains brain inflammation in mice via TGF-beta.	therapeutic application	4	
3.4.21.78	Paralysis	https://pubmed.ncbi.nlm.nih.gov/20628203/	Angiotensin II sustains brain inflammation in mice via TGF-beta.	unassigned	-	
3.4.21.78	Penile Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18336597/	Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma.	causal interaction	1	
3.4.21.78	Penile Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18336597/	Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma.	diagnostic usage	4	
3.4.21.78	Penile Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18336597/	Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma.	ongoing research	3	
3.4.21.78	Penile Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18336597/	Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma.	unassigned	-	
3.4.21.78	Periodontitis	https://pubmed.ncbi.nlm.nih.gov/34015597/	Targeting TSP-1 decreased periodontitis by attenuating extracellular matrix degradation and alveolar bone destruction.	causal interaction	4	
3.4.21.78	Periodontitis	https://pubmed.ncbi.nlm.nih.gov/25501558/	Thrombospondin-1 production is enhanced by Porphyromonas gingivalis lipopolysaccharide in THP-1 cells.	causal interaction	4	
3.4.21.78	Periodontitis	https://pubmed.ncbi.nlm.nih.gov/28634844/	Thrombospondin-1 Production Regulates the Inflammatory Cytokine Secretion in THP-1 Cells Through NF-?B Signaling Pathway.	causal interaction	4	
3.4.21.78	Periodontitis	https://pubmed.ncbi.nlm.nih.gov/25501558/	Thrombospondin-1 production is enhanced by Porphyromonas gingivalis lipopolysaccharide in THP-1 cells.	diagnostic usage	3	
3.4.21.78	Periodontitis	https://pubmed.ncbi.nlm.nih.gov/34015597/	Targeting TSP-1 decreased periodontitis by attenuating extracellular matrix degradation and alveolar bone destruction.	therapeutic application	3	
3.4.21.78	Periodontitis	https://pubmed.ncbi.nlm.nih.gov/25501558/	Thrombospondin-1 production is enhanced by Porphyromonas gingivalis lipopolysaccharide in THP-1 cells.	therapeutic application	1	
3.4.21.78	Periodontitis	https://pubmed.ncbi.nlm.nih.gov/34015597/	Targeting TSP-1 decreased periodontitis by attenuating extracellular matrix degradation and alveolar bone destruction.	ongoing research	1	
3.4.21.78	Periodontitis	https://pubmed.ncbi.nlm.nih.gov/25501558/	Thrombospondin-1 production is enhanced by Porphyromonas gingivalis lipopolysaccharide in THP-1 cells.	ongoing research	4	
3.4.21.78	Periodontitis	https://pubmed.ncbi.nlm.nih.gov/28634844/	Thrombospondin-1 Production Regulates the Inflammatory Cytokine Secretion in THP-1 Cells Through NF-?B Signaling Pathway.	ongoing research	3	
3.4.21.78	Periodontitis	https://pubmed.ncbi.nlm.nih.gov/34015597/	Targeting TSP-1 decreased periodontitis by attenuating extracellular matrix degradation and alveolar bone destruction.	unassigned	-	
3.4.21.78	Periodontitis	https://pubmed.ncbi.nlm.nih.gov/28634844/	Thrombospondin-1 Production Regulates the Inflammatory Cytokine Secretion in THP-1 Cells Through NF-?B Signaling Pathway.	unassigned	-	
3.4.21.78	Peripheral Arterial Disease	https://pubmed.ncbi.nlm.nih.gov/29441713/	Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.	causal interaction	4	
3.4.21.78	Peripheral Arterial Disease	https://pubmed.ncbi.nlm.nih.gov/29441713/	Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.	diagnostic usage	4	
3.4.21.78	Peripheral Arterial Disease	https://pubmed.ncbi.nlm.nih.gov/28045898/	Transcriptional and Post-Transcriptional Regulation of Thrombospondin-1 Expression: A Computational Model.	therapeutic application	2	
3.4.21.78	Peripheral Arterial Disease	https://pubmed.ncbi.nlm.nih.gov/29441713/	Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.	therapeutic application	4	
3.4.21.78	Peripheral Arterial Disease	https://pubmed.ncbi.nlm.nih.gov/28045898/	Transcriptional and Post-Transcriptional Regulation of Thrombospondin-1 Expression: A Computational Model.	ongoing research	3	
3.4.21.78	Peripheral Arterial Disease	https://pubmed.ncbi.nlm.nih.gov/29441713/	Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.	ongoing research	4	
3.4.21.78	Peripheral Arterial Disease	https://pubmed.ncbi.nlm.nih.gov/28045898/	Transcriptional and Post-Transcriptional Regulation of Thrombospondin-1 Expression: A Computational Model.	unassigned	-	
3.4.21.78	Peritoneal Fibrosis	https://pubmed.ncbi.nlm.nih.gov/31236971/	Blockade of thrombospondin-1 ameliorates high glucose-induced peritoneal fibrosis through downregulation of TGF-?1/Smad3 signaling pathway.	causal interaction	1	
3.4.21.78	Peritoneal Fibrosis	https://pubmed.ncbi.nlm.nih.gov/31236971/	Blockade of thrombospondin-1 ameliorates high glucose-induced peritoneal fibrosis through downregulation of TGF-?1/Smad3 signaling pathway.	therapeutic application	1	
3.4.21.78	Peritoneal Fibrosis	https://pubmed.ncbi.nlm.nih.gov/31236971/	Blockade of thrombospondin-1 ameliorates high glucose-induced peritoneal fibrosis through downregulation of TGF-?1/Smad3 signaling pathway.	ongoing research	3	
3.4.21.78	Peritoneal Fibrosis	https://pubmed.ncbi.nlm.nih.gov/31236971/	Blockade of thrombospondin-1 ameliorates high glucose-induced peritoneal fibrosis through downregulation of TGF-?1/Smad3 signaling pathway.	unassigned	-	
3.4.21.78	Persistent Infection	https://pubmed.ncbi.nlm.nih.gov/16051854/	CD8+ T-cell dysfunction due to cytolytic granule deficiency in persistent Friend retrovirus infection.	causal interaction	4	
3.4.21.78	Persistent Infection	https://pubmed.ncbi.nlm.nih.gov/16051854/	CD8+ T-cell dysfunction due to cytolytic granule deficiency in persistent Friend retrovirus infection.	diagnostic usage	2	
3.4.21.78	Persistent Infection	https://pubmed.ncbi.nlm.nih.gov/16051854/	CD8+ T-cell dysfunction due to cytolytic granule deficiency in persistent Friend retrovirus infection.	unassigned	-	
3.4.21.78	Pituitary ACTH Hypersecretion	https://pubmed.ncbi.nlm.nih.gov/31016850/	TSP-1 is downregulated and inversely correlates with miR-449c expression in Cushing's disease.	causal interaction	4	
3.4.21.78	Pituitary ACTH Hypersecretion	https://pubmed.ncbi.nlm.nih.gov/31016850/	TSP-1 is downregulated and inversely correlates with miR-449c expression in Cushing's disease.	diagnostic usage	4	
3.4.21.78	Pituitary ACTH Hypersecretion	https://pubmed.ncbi.nlm.nih.gov/31016850/	TSP-1 is downregulated and inversely correlates with miR-449c expression in Cushing's disease.	ongoing research	4	
3.4.21.78	Pituitary ACTH Hypersecretion	https://pubmed.ncbi.nlm.nih.gov/31016850/	TSP-1 is downregulated and inversely correlates with miR-449c expression in Cushing's disease.	unassigned	-	
3.4.21.78	Pituitary Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31016850/	TSP-1 is downregulated and inversely correlates with miR-449c expression in Cushing's disease.	causal interaction	4	
3.4.21.78	Pituitary Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31016850/	TSP-1 is downregulated and inversely correlates with miR-449c expression in Cushing's disease.	diagnostic usage	4	
3.4.21.78	Pituitary Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31016850/	TSP-1 is downregulated and inversely correlates with miR-449c expression in Cushing's disease.	ongoing research	4	
3.4.21.78	Pituitary Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15347840/	Regulation of VEGF-A, VEGFR-I, thrombospondin-1, -2, and -3 expression in a human pituitary cell line (HP75) by TGFbeta1, bFGF, and EGF.	unassigned	-	
3.4.21.78	Pituitary Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31016850/	TSP-1 is downregulated and inversely correlates with miR-449c expression in Cushing's disease.	unassigned	-	
3.4.21.78	Pleural Effusion	https://pubmed.ncbi.nlm.nih.gov/34466000/	Potential Role of Pleural Fluid Cytokine Profile in Myelomatous Pleural Effusions.	therapeutic application	1	
3.4.21.78	Pleural Effusion	https://pubmed.ncbi.nlm.nih.gov/34466000/	Potential Role of Pleural Fluid Cytokine Profile in Myelomatous Pleural Effusions.	unassigned	-	
3.4.21.78	Pneumonia	https://pubmed.ncbi.nlm.nih.gov/26668367/	Lung inflammation promotes metastasis through neutrophil protease-mediated degradation of Tsp-1.	causal interaction	3	
3.4.21.78	Pneumonia	https://pubmed.ncbi.nlm.nih.gov/26668367/	Lung inflammation promotes metastasis through neutrophil protease-mediated degradation of Tsp-1.	therapeutic application	2	
3.4.21.78	Pneumonia	https://pubmed.ncbi.nlm.nih.gov/27343190/	Granzyme A impairs host defense during Streptococcus pneumoniae pneumonia.	unassigned	-	
3.4.21.78	Pneumonia	https://pubmed.ncbi.nlm.nih.gov/26668367/	Lung inflammation promotes metastasis through neutrophil protease-mediated degradation of Tsp-1.	unassigned	-	
3.4.21.78	Pneumovirus Infections	https://pubmed.ncbi.nlm.nih.gov/20018616/	Granzyme A- and B-cluster deficiency delays acute lung injury in pneumovirus-infected mice.	causal interaction	3	
3.4.21.78	Pneumovirus Infections	https://pubmed.ncbi.nlm.nih.gov/20018616/	Granzyme A- and B-cluster deficiency delays acute lung injury in pneumovirus-infected mice.	therapeutic application	2	
3.4.21.78	Pneumovirus Infections	https://pubmed.ncbi.nlm.nih.gov/20018616/	Granzyme A- and B-cluster deficiency delays acute lung injury in pneumovirus-infected mice.	unassigned	-	
3.4.21.78	Polycystic Ovary Syndrome	https://pubmed.ncbi.nlm.nih.gov/26391700/	Serum levels of TSP-1, NF-?B and TGF-?1 in polycystic ovarian syndrome (PCOS) patients in northern China suggest PCOS is associated with chronic inflammation.	causal interaction	4	
3.4.21.78	Polycystic Ovary Syndrome	https://pubmed.ncbi.nlm.nih.gov/26391700/	Serum levels of TSP-1, NF-?B and TGF-?1 in polycystic ovarian syndrome (PCOS) patients in northern China suggest PCOS is associated with chronic inflammation.	diagnostic usage	2	
3.4.21.78	Polycystic Ovary Syndrome	https://pubmed.ncbi.nlm.nih.gov/26391700/	Serum levels of TSP-1, NF-?B and TGF-?1 in polycystic ovarian syndrome (PCOS) patients in northern China suggest PCOS is associated with chronic inflammation.	unassigned	-	
3.4.21.78	Polymyositis	https://pubmed.ncbi.nlm.nih.gov/8268727/	Degradative activity of granzyme A on skeletal muscle proteins in vitro: a possible molecular mechanism for muscle fiber damage in polymyositis.	ongoing research	3	
3.4.21.78	Polymyositis	https://pubmed.ncbi.nlm.nih.gov/8268727/	Degradative activity of granzyme A on skeletal muscle proteins in vitro: a possible molecular mechanism for muscle fiber damage in polymyositis.	unassigned	-	
3.4.21.78	Pre-Eclampsia	https://pubmed.ncbi.nlm.nih.gov/22035632/	Circulating levels of thrombospondin-1 are decreased in HELLP syndrome.	causal interaction	3	
3.4.21.78	Pre-Eclampsia	https://pubmed.ncbi.nlm.nih.gov/29471751/	Maternal serum thrombospondin-1 is significantly altered in cases with established preeclampsia.	causal interaction	4	
3.4.21.78	Pre-Eclampsia	https://pubmed.ncbi.nlm.nih.gov/22035632/	Circulating levels of thrombospondin-1 are decreased in HELLP syndrome.	diagnostic usage	4	
3.4.21.78	Pre-Eclampsia	https://pubmed.ncbi.nlm.nih.gov/29471751/	Maternal serum thrombospondin-1 is significantly altered in cases with established preeclampsia.	diagnostic usage	4	
3.4.21.78	Pre-Eclampsia	https://pubmed.ncbi.nlm.nih.gov/22035632/	Circulating levels of thrombospondin-1 are decreased in HELLP syndrome.	therapeutic application	2	
3.4.21.78	Pre-Eclampsia	https://pubmed.ncbi.nlm.nih.gov/29471751/	Maternal serum thrombospondin-1 is significantly altered in cases with established preeclampsia.	ongoing research	1	
3.4.21.78	Pre-Eclampsia	https://pubmed.ncbi.nlm.nih.gov/29471751/	Maternal serum thrombospondin-1 is significantly altered in cases with established preeclampsia.	unassigned	-	
3.4.21.78	Pre-Eclampsia	https://pubmed.ncbi.nlm.nih.gov/22035632/	Circulating levels of thrombospondin-1 are decreased in HELLP syndrome.	unassigned	-	
3.4.21.78	Precursor Cell Lymphoblastic Leukemia-Lymphoma	https://pubmed.ncbi.nlm.nih.gov/17310274/	Glucocorticoid-induced granzyme A expression can be used as a marker of glucocorticoid sensitivity for acute lymphoblastic leukemia therapy.	diagnostic usage	4	
3.4.21.78	Precursor Cell Lymphoblastic Leukemia-Lymphoma	https://pubmed.ncbi.nlm.nih.gov/17310274/	Glucocorticoid-induced granzyme A expression can be used as a marker of glucocorticoid sensitivity for acute lymphoblastic leukemia therapy.	therapeutic application	3	
3.4.21.78	Precursor Cell Lymphoblastic Leukemia-Lymphoma	https://pubmed.ncbi.nlm.nih.gov/17310274/	Glucocorticoid-induced granzyme A expression can be used as a marker of glucocorticoid sensitivity for acute lymphoblastic leukemia therapy.	unassigned	-	
3.4.21.78	Primary Myelofibrosis	https://pubmed.ncbi.nlm.nih.gov/20625903/	Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF) - a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia.	diagnostic usage	3	
3.4.21.78	Primary Myelofibrosis	https://pubmed.ncbi.nlm.nih.gov/20944070/	Thrombospondin-1 is not the major activator of TGF-{beta}1 in thrombopoietin-induced myelofibrosis.	therapeutic application	1	
3.4.21.78	Primary Myelofibrosis	https://pubmed.ncbi.nlm.nih.gov/20625903/	Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF) - a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia.	ongoing research	3	
3.4.21.78	Primary Myelofibrosis	https://pubmed.ncbi.nlm.nih.gov/20944070/	Thrombospondin-1 is not the major activator of TGF-{beta}1 in thrombopoietin-induced myelofibrosis.	ongoing research	4	
3.4.21.78	Primary Myelofibrosis	https://pubmed.ncbi.nlm.nih.gov/20625903/	Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF) - a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia.	unassigned	-	
3.4.21.78	Primary Myelofibrosis	https://pubmed.ncbi.nlm.nih.gov/20944070/	Thrombospondin-1 is not the major activator of TGF-{beta}1 in thrombopoietin-induced myelofibrosis.	unassigned	-	
3.4.21.78	Prolactinoma	https://pubmed.ncbi.nlm.nih.gov/22700773/	Thrombospondin-1 (TSP-1) Analogs ABT-510 and ABT-898 Inhibit Prolactinoma Growth and Recover Active Pituitary Transforming Growth Factor-?1 (TGF-?1).	causal interaction	4	
3.4.21.78	Prolactinoma	https://pubmed.ncbi.nlm.nih.gov/22700773/	Thrombospondin-1 (TSP-1) Analogs ABT-510 and ABT-898 Inhibit Prolactinoma Growth and Recover Active Pituitary Transforming Growth Factor-?1 (TGF-?1).	therapeutic application	4	
3.4.21.78	Prolactinoma	https://pubmed.ncbi.nlm.nih.gov/22700773/	Thrombospondin-1 (TSP-1) Analogs ABT-510 and ABT-898 Inhibit Prolactinoma Growth and Recover Active Pituitary Transforming Growth Factor-?1 (TGF-?1).	unassigned	-	
3.4.21.78	Prostatic Diseases	https://pubmed.ncbi.nlm.nih.gov/17192876/	Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease.	causal interaction	1	
3.4.21.78	Prostatic Diseases	https://pubmed.ncbi.nlm.nih.gov/17192876/	Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease.	diagnostic usage	4	
3.4.21.78	Prostatic Diseases	https://pubmed.ncbi.nlm.nih.gov/17192876/	Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease.	ongoing research	3	
3.4.21.78	Prostatic Diseases	https://pubmed.ncbi.nlm.nih.gov/17192876/	Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease.	unassigned	-	
3.4.21.78	Prostatic Hyperplasia	https://pubmed.ncbi.nlm.nih.gov/11856116/	Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.	causal interaction	4	
3.4.21.78	Prostatic Hyperplasia	https://pubmed.ncbi.nlm.nih.gov/11856116/	Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.	diagnostic usage	4	
3.4.21.78	Prostatic Hyperplasia	https://pubmed.ncbi.nlm.nih.gov/11856116/	Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.	therapeutic application	1	
3.4.21.78	Prostatic Hyperplasia	https://pubmed.ncbi.nlm.nih.gov/11856116/	Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.	ongoing research	4	
3.4.21.78	Prostatic Intraepithelial Neoplasia	https://pubmed.ncbi.nlm.nih.gov/15180634/	The expression of thrombospondin-1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer.	diagnostic usage	4	
3.4.21.78	Prostatic Intraepithelial Neoplasia	https://pubmed.ncbi.nlm.nih.gov/15180634/	The expression of thrombospondin-1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer.	ongoing research	4	
3.4.21.78	Prostatic Intraepithelial Neoplasia	https://pubmed.ncbi.nlm.nih.gov/15180634/	The expression of thrombospondin-1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer.	unassigned	-	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11228532/	The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts.	causal interaction	4	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11856116/	Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.	causal interaction	4	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15583827/	Expression of thrombospondin-1 in prostate-derived cell lines.	causal interaction	4	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19747478/	Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: Exploring the functional significance in tumor cell invasion.	causal interaction	4	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20458281/	Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation.	causal interaction	3	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23749112/	Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.	causal interaction	3	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26676551/	Quercetin inhibits angiogenesis through thrombospondin-1 upregulation to antagonize human prostate cancer PC-3 cell growth in vitro and in vivo.	causal interaction	3	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11228532/	The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts.	diagnostic usage	4	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11856116/	Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.	diagnostic usage	4	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15583827/	Expression of thrombospondin-1 in prostate-derived cell lines.	diagnostic usage	3	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19747478/	Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: Exploring the functional significance in tumor cell invasion.	diagnostic usage	1	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20458281/	Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation.	diagnostic usage	3	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23749112/	Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.	diagnostic usage	3	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26676551/	Quercetin inhibits angiogenesis through thrombospondin-1 upregulation to antagonize human prostate cancer PC-3 cell growth in vitro and in vivo.	diagnostic usage	3	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11228532/	The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts.	therapeutic application	4	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11856116/	Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.	therapeutic application	1	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20458281/	Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation.	therapeutic application	1	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11228532/	The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts.	ongoing research	3	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11856116/	Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.	ongoing research	4	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15583827/	Expression of thrombospondin-1 in prostate-derived cell lines.	ongoing research	4	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19747478/	Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: Exploring the functional significance in tumor cell invasion.	ongoing research	4	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20458281/	Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation.	ongoing research	2	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23749112/	Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.	ongoing research	2	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15583827/	Expression of thrombospondin-1 in prostate-derived cell lines.	unassigned	-	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/19747478/	Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: Exploring the functional significance in tumor cell invasion.	unassigned	-	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23749112/	Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.	unassigned	-	
3.4.21.78	Prostatic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26676551/	Quercetin inhibits angiogenesis through thrombospondin-1 upregulation to antagonize human prostate cancer PC-3 cell growth in vitro and in vivo.	unassigned	-	
3.4.21.78	Proteinuria	https://pubmed.ncbi.nlm.nih.gov/16316526/	[Localized expressing tendency of nuclear transcription factor kappa-B, pro-fibrosis genetic factors and fibronectin mRNA in renal tissues in proteinuria overload nephrotic young rats]	causal interaction	3	
3.4.21.78	Proteinuria	https://pubmed.ncbi.nlm.nih.gov/18676351/	Correlation of enhanced thrombospondin-1 expression, TGF-beta signalling and proteinuria in human type-2 diabetic nephropathy.	causal interaction	4	
3.4.21.78	Proteinuria	https://pubmed.ncbi.nlm.nih.gov/16316526/	[Localized expressing tendency of nuclear transcription factor kappa-B, pro-fibrosis genetic factors and fibronectin mRNA in renal tissues in proteinuria overload nephrotic young rats]	diagnostic usage	3	
3.4.21.78	Proteinuria	https://pubmed.ncbi.nlm.nih.gov/18676351/	Correlation of enhanced thrombospondin-1 expression, TGF-beta signalling and proteinuria in human type-2 diabetic nephropathy.	therapeutic application	2	
3.4.21.78	Proteinuria	https://pubmed.ncbi.nlm.nih.gov/16316526/	[Localized expressing tendency of nuclear transcription factor kappa-B, pro-fibrosis genetic factors and fibronectin mRNA in renal tissues in proteinuria overload nephrotic young rats]	ongoing research	2	
3.4.21.78	Proteinuria	https://pubmed.ncbi.nlm.nih.gov/18676351/	Correlation of enhanced thrombospondin-1 expression, TGF-beta signalling and proteinuria in human type-2 diabetic nephropathy.	unassigned	-	
3.4.21.78	Proteinuria	https://pubmed.ncbi.nlm.nih.gov/16316526/	[Localized expressing tendency of nuclear transcription factor kappa-B, pro-fibrosis genetic factors and fibronectin mRNA in renal tissues in proteinuria overload nephrotic young rats]	unassigned	-	
3.4.21.78	Pseudolymphoma	https://pubmed.ncbi.nlm.nih.gov/23030305/	Expression of apoptosis associated proteins Survivin, Livin and Thrombospondin-1 in Burkitt lymphoma.	diagnostic usage	2	
3.4.21.78	Pseudolymphoma	https://pubmed.ncbi.nlm.nih.gov/23030305/	Expression of apoptosis associated proteins Survivin, Livin and Thrombospondin-1 in Burkitt lymphoma.	unassigned	-	
3.4.21.78	Psoriasis	https://pubmed.ncbi.nlm.nih.gov/31214201/	Thrombospondin-1/CD47 Interaction Regulates Th17 and Treg Differentiation in Psoriasis.	diagnostic usage	3	
3.4.21.78	Psoriasis	https://pubmed.ncbi.nlm.nih.gov/31214201/	Thrombospondin-1/CD47 Interaction Regulates Th17 and Treg Differentiation in Psoriasis.	ongoing research	4	
3.4.21.78	Psoriasis	https://pubmed.ncbi.nlm.nih.gov/31214201/	Thrombospondin-1/CD47 Interaction Regulates Th17 and Treg Differentiation in Psoriasis.	unassigned	-	
3.4.21.78	Pterygium	https://pubmed.ncbi.nlm.nih.gov/33661363/	Thrombospondin 1 polymorphism associated with decreased expression and increased risk of pterygium.	causal interaction	4	
3.4.21.78	Pterygium	https://pubmed.ncbi.nlm.nih.gov/33661363/	Thrombospondin 1 polymorphism associated with decreased expression and increased risk of pterygium.	unassigned	-	
3.4.21.78	Pulmonary Arterial Hypertension	https://pubmed.ncbi.nlm.nih.gov/31631975/	Thrombospondin-1 Serum Levels In Hypertensive Patients With Endothelial Dysfunction After One Year Of Treatment With Perindopril.	causal interaction	3	
3.4.21.78	Pulmonary Arterial Hypertension	https://pubmed.ncbi.nlm.nih.gov/31631975/	Thrombospondin-1 Serum Levels In Hypertensive Patients With Endothelial Dysfunction After One Year Of Treatment With Perindopril.	diagnostic usage	4	
3.4.21.78	Pulmonary Arterial Hypertension	https://pubmed.ncbi.nlm.nih.gov/31631975/	Thrombospondin-1 Serum Levels In Hypertensive Patients With Endothelial Dysfunction After One Year Of Treatment With Perindopril.	unassigned	-	
3.4.21.78	Pulmonary Disease, Chronic Obstructive	https://pubmed.ncbi.nlm.nih.gov/17138956/	Increased granzyme A expression in type II pneumocytes of patients with severe chronic obstructive pulmonary disease.	causal interaction	4	
3.4.21.78	Pulmonary Disease, Chronic Obstructive	https://pubmed.ncbi.nlm.nih.gov/20638828/	Involvement of type II pneumocytes in the pathogenesis of chronic obstructive pulmonary disease.	causal interaction	3	
3.4.21.78	Pulmonary Disease, Chronic Obstructive	https://pubmed.ncbi.nlm.nih.gov/17138956/	Increased granzyme A expression in type II pneumocytes of patients with severe chronic obstructive pulmonary disease.	ongoing research	2	
3.4.21.78	Pulmonary Disease, Chronic Obstructive	https://pubmed.ncbi.nlm.nih.gov/17138956/	Increased granzyme A expression in type II pneumocytes of patients with severe chronic obstructive pulmonary disease.	unassigned	-	
3.4.21.78	Pulmonary Disease, Chronic Obstructive	https://pubmed.ncbi.nlm.nih.gov/20638828/	Involvement of type II pneumocytes in the pathogenesis of chronic obstructive pulmonary disease.	unassigned	-	
3.4.21.78	Pulmonary Fibrosis	https://pubmed.ncbi.nlm.nih.gov/29495147/	[The roles of TSP-1 and its receptor CD47 in pathogenesis of paraquat-induced pulmonary fibrosis in rats].	causal interaction	2	
3.4.21.78	Pulmonary Fibrosis	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	causal interaction	4	
3.4.21.78	Pulmonary Fibrosis	https://pubmed.ncbi.nlm.nih.gov/20581099/	Thrombospondin-1 Deficient Mice Are Not Protected from Bleomycin-Induced Pulmonary Fibrosis.	causal interaction	4	
3.4.21.78	Pulmonary Fibrosis	https://pubmed.ncbi.nlm.nih.gov/21234123/	TSP-1 in lung fibrosis.	causal interaction	3	
3.4.21.78	Pulmonary Fibrosis	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	diagnostic usage	4	
3.4.21.78	Pulmonary Fibrosis	https://pubmed.ncbi.nlm.nih.gov/20581099/	Thrombospondin-1 Deficient Mice Are Not Protected from Bleomycin-Induced Pulmonary Fibrosis.	diagnostic usage	3	
3.4.21.78	Pulmonary Fibrosis	https://pubmed.ncbi.nlm.nih.gov/30419666/	[The Role of TSP-1-CD47 in ROS-mediated Pulmonary Fibrosis Induced by Paraquat].	diagnostic usage	3	
3.4.21.78	Pulmonary Fibrosis	https://pubmed.ncbi.nlm.nih.gov/20581099/	Thrombospondin-1 Deficient Mice Are Not Protected from Bleomycin-Induced Pulmonary Fibrosis.	therapeutic application	1	
3.4.21.78	Pulmonary Fibrosis	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	ongoing research	3	
3.4.21.78	Pulmonary Fibrosis	https://pubmed.ncbi.nlm.nih.gov/20581099/	Thrombospondin-1 Deficient Mice Are Not Protected from Bleomycin-Induced Pulmonary Fibrosis.	ongoing research	4	
3.4.21.78	Pulmonary Fibrosis	https://pubmed.ncbi.nlm.nih.gov/30419666/	[The Role of TSP-1-CD47 in ROS-mediated Pulmonary Fibrosis Induced by Paraquat].	ongoing research	4	
3.4.21.78	Pulmonary Fibrosis	https://pubmed.ncbi.nlm.nih.gov/30419666/	[The Role of TSP-1-CD47 in ROS-mediated Pulmonary Fibrosis Induced by Paraquat].	unassigned	-	
3.4.21.78	Pulmonary Fibrosis	https://pubmed.ncbi.nlm.nih.gov/29495147/	[The roles of TSP-1 and its receptor CD47 in pathogenesis of paraquat-induced pulmonary fibrosis in rats].	unassigned	-	
3.4.21.78	Pulmonary Fibrosis	https://pubmed.ncbi.nlm.nih.gov/21234123/	TSP-1 in lung fibrosis.	unassigned	-	
3.4.21.78	Pulmonary Fibrosis	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	unassigned	-	
3.4.21.78	Purpura, Thrombotic Thrombocytopenic	https://pubmed.ncbi.nlm.nih.gov/16204318/	Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13.	causal interaction	3	
3.4.21.78	Purpura, Thrombotic Thrombocytopenic	https://pubmed.ncbi.nlm.nih.gov/21496552/	Postoperative thrombotic thrombocytopenic purpura in an infant: case report and literature review.	causal interaction	1	
3.4.21.78	Purpura, Thrombotic Thrombocytopenic	https://pubmed.ncbi.nlm.nih.gov/16204318/	Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13.	therapeutic application	1	
3.4.21.78	Purpura, Thrombotic Thrombocytopenic	https://pubmed.ncbi.nlm.nih.gov/16204318/	Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13.	ongoing research	4	
3.4.21.78	Purpura, Thrombotic Thrombocytopenic	https://pubmed.ncbi.nlm.nih.gov/16204318/	Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13.	unassigned	-	
3.4.21.78	Purpura, Thrombotic Thrombocytopenic	https://pubmed.ncbi.nlm.nih.gov/21496552/	Postoperative thrombotic thrombocytopenic purpura in an infant: case report and literature review.	unassigned	-	
3.4.21.78	Renal Insufficiency	https://pubmed.ncbi.nlm.nih.gov/16294224/	Identification of thrombospondin 1 (TSP-1) as a novel mediator of cell injury in kidney ischemia.	causal interaction	4	
3.4.21.78	Renal Insufficiency	https://pubmed.ncbi.nlm.nih.gov/16294224/	Identification of thrombospondin 1 (TSP-1) as a novel mediator of cell injury in kidney ischemia.	ongoing research	2	
3.4.21.78	Renal Insufficiency	https://pubmed.ncbi.nlm.nih.gov/16294224/	Identification of thrombospondin 1 (TSP-1) as a novel mediator of cell injury in kidney ischemia.	unassigned	-	
3.4.21.78	Renal Insufficiency, Chronic	https://pubmed.ncbi.nlm.nih.gov/24356144/	[Role of thrombospondin-1 in the development of kidney diseases].	causal interaction	4	
3.4.21.78	Renal Insufficiency, Chronic	https://pubmed.ncbi.nlm.nih.gov/24356144/	[Role of thrombospondin-1 in the development of kidney diseases].	therapeutic application	4	
3.4.21.78	Renal Insufficiency, Chronic	https://pubmed.ncbi.nlm.nih.gov/22418977/	Thrombospondin-1 plays a profibrotic and pro-inflammatory role during ureteric obstruction.	ongoing research	4	
3.4.21.78	Renal Insufficiency, Chronic	https://pubmed.ncbi.nlm.nih.gov/22418977/	Thrombospondin-1 plays a profibrotic and pro-inflammatory role during ureteric obstruction.	unassigned	-	
3.4.21.78	Renal Insufficiency, Chronic	https://pubmed.ncbi.nlm.nih.gov/24356144/	[Role of thrombospondin-1 in the development of kidney diseases].	unassigned	-	
3.4.21.78	Retinal Degeneration	https://pubmed.ncbi.nlm.nih.gov/25693608/	Enhanced functional integration of human photoreceptor precursors into human and rodent retina in an <i>ex vivo</i> retinal explant model system.	therapeutic application	3	
3.4.21.78	Retinal Degeneration	https://pubmed.ncbi.nlm.nih.gov/25693608/	Enhanced functional integration of human photoreceptor precursors into human and rodent retina in an <i>ex vivo</i> retinal explant model system.	unassigned	-	
3.4.21.78	Retinal Neovascularization	https://pubmed.ncbi.nlm.nih.gov/24071704/	[Expression and significance of thrombonspondin-1 in oxygen-induced retinopathy in mice.]	causal interaction	3	
3.4.21.78	Retinal Neovascularization	https://pubmed.ncbi.nlm.nih.gov/24071704/	[Expression and significance of thrombonspondin-1 in oxygen-induced retinopathy in mice.]	unassigned	-	
3.4.21.78	Retinoblastoma	https://pubmed.ncbi.nlm.nih.gov/17596205/	Novel antiangiogenic pathway of thrombospondin-1 mediated by suppression of the cell cycle.	causal interaction	1	
3.4.21.78	Retinoblastoma	https://pubmed.ncbi.nlm.nih.gov/26756218/	Thrombospondin-1 might be a therapeutic target to suppress RB cells by regulating the DNA double-strand breaks repair.	causal interaction	4	
3.4.21.78	Retinoblastoma	https://pubmed.ncbi.nlm.nih.gov/26756218/	Thrombospondin-1 might be a therapeutic target to suppress RB cells by regulating the DNA double-strand breaks repair.	diagnostic usage	1	
3.4.21.78	Retinoblastoma	https://pubmed.ncbi.nlm.nih.gov/26756218/	Thrombospondin-1 might be a therapeutic target to suppress RB cells by regulating the DNA double-strand breaks repair.	therapeutic application	4	
3.4.21.78	Retinoblastoma	https://pubmed.ncbi.nlm.nih.gov/26756218/	Thrombospondin-1 might be a therapeutic target to suppress RB cells by regulating the DNA double-strand breaks repair.	ongoing research	4	
3.4.21.78	Retinoblastoma	https://pubmed.ncbi.nlm.nih.gov/17596205/	Novel antiangiogenic pathway of thrombospondin-1 mediated by suppression of the cell cycle.	unassigned	-	
3.4.21.78	Retinopathy of Prematurity	https://pubmed.ncbi.nlm.nih.gov/10892887/	Inhibition of retinal angiogenesis by peptides derived from thrombospondin-1.	diagnostic usage	3	
3.4.21.78	Retinopathy of Prematurity	https://pubmed.ncbi.nlm.nih.gov/10892887/	Inhibition of retinal angiogenesis by peptides derived from thrombospondin-1.	ongoing research	3	
3.4.21.78	Retinopathy of Prematurity	https://pubmed.ncbi.nlm.nih.gov/10892887/	Inhibition of retinal angiogenesis by peptides derived from thrombospondin-1.	unassigned	-	
3.4.21.78	Sarcoidosis	https://pubmed.ncbi.nlm.nih.gov/15947857/	[Granzymes A and B in pulmonary sarcoidosis (experimental study)]	causal interaction	3	
3.4.21.78	Sarcoidosis	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	causal interaction	4	
3.4.21.78	Sarcoidosis	https://pubmed.ncbi.nlm.nih.gov/15947857/	[Granzymes A and B in pulmonary sarcoidosis (experimental study)]	diagnostic usage	4	
3.4.21.78	Sarcoidosis	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	diagnostic usage	4	
3.4.21.78	Sarcoidosis	https://pubmed.ncbi.nlm.nih.gov/15947857/	[Granzymes A and B in pulmonary sarcoidosis (experimental study)]	therapeutic application	3	
3.4.21.78	Sarcoidosis	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	ongoing research	3	
3.4.21.78	Sarcoidosis	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	unassigned	-	
3.4.21.78	Sarcoidosis	https://pubmed.ncbi.nlm.nih.gov/15947857/	[Granzymes A and B in pulmonary sarcoidosis (experimental study)]	unassigned	-	
3.4.21.78	Sarcoidosis, Pulmonary	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	causal interaction	4	
3.4.21.78	Sarcoidosis, Pulmonary	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	diagnostic usage	4	
3.4.21.78	Sarcoidosis, Pulmonary	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	ongoing research	3	
3.4.21.78	Sarcoidosis, Pulmonary	https://pubmed.ncbi.nlm.nih.gov/18640828/	High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.	unassigned	-	
3.4.21.78	Sarcoma	https://pubmed.ncbi.nlm.nih.gov/19634159/	The role of angiocidin in sarcomas.	causal interaction	4	
3.4.21.78	Sarcoma	https://pubmed.ncbi.nlm.nih.gov/8258716/	Human granzyme B degrades aggrecan proteoglycan in matrix synthesized by chondrocytes.	diagnostic usage	1	
3.4.21.78	Sarcoma	https://pubmed.ncbi.nlm.nih.gov/19634159/	The role of angiocidin in sarcomas.	diagnostic usage	2	
3.4.21.78	Sarcoma	https://pubmed.ncbi.nlm.nih.gov/19634159/	The role of angiocidin in sarcomas.	ongoing research	3	
3.4.21.78	Sarcoma	https://pubmed.ncbi.nlm.nih.gov/8258716/	Human granzyme B degrades aggrecan proteoglycan in matrix synthesized by chondrocytes.	unassigned	-	
3.4.21.78	Sarcoma	https://pubmed.ncbi.nlm.nih.gov/19634159/	The role of angiocidin in sarcomas.	unassigned	-	
3.4.21.78	Seizures	https://pubmed.ncbi.nlm.nih.gov/30386206/	A Purinergic P2 Receptor Family-Mediated Increase in Thrombospondin-1 Bolsters Synaptic Density and Epileptic Seizure Activity in the Amygdala-Kindling Rat Model.	causal interaction	2	
3.4.21.78	Seizures	https://pubmed.ncbi.nlm.nih.gov/31005663/	P2Y4/TSP-1/TGF-?1/pSmad2/3 pathway contributes to acute generalized seizures induced by kainic acid.	causal interaction	3	
3.4.21.78	Seizures	https://pubmed.ncbi.nlm.nih.gov/31664678/	Role of Elevated Thrombospondin-1 in Kainic Acid-Induced Status Epilepticus.	causal interaction	4	
3.4.21.78	Seizures	https://pubmed.ncbi.nlm.nih.gov/30386206/	A Purinergic P2 Receptor Family-Mediated Increase in Thrombospondin-1 Bolsters Synaptic Density and Epileptic Seizure Activity in the Amygdala-Kindling Rat Model.	diagnostic usage	2	
3.4.21.78	Seizures	https://pubmed.ncbi.nlm.nih.gov/33372257/	Circulating Levels of Thrombospondin-1 and Thrombospondin-2 in Patients with Temporal Lobe Epilepsy Before and After Surgery.	diagnostic usage	4	
3.4.21.78	Seizures	https://pubmed.ncbi.nlm.nih.gov/30386206/	A Purinergic P2 Receptor Family-Mediated Increase in Thrombospondin-1 Bolsters Synaptic Density and Epileptic Seizure Activity in the Amygdala-Kindling Rat Model.	therapeutic application	1	
3.4.21.78	Seizures	https://pubmed.ncbi.nlm.nih.gov/31005663/	P2Y4/TSP-1/TGF-?1/pSmad2/3 pathway contributes to acute generalized seizures induced by kainic acid.	therapeutic application	3	
3.4.21.78	Seizures	https://pubmed.ncbi.nlm.nih.gov/31664678/	Role of Elevated Thrombospondin-1 in Kainic Acid-Induced Status Epilepticus.	therapeutic application	1	
3.4.21.78	Seizures	https://pubmed.ncbi.nlm.nih.gov/30386206/	A Purinergic P2 Receptor Family-Mediated Increase in Thrombospondin-1 Bolsters Synaptic Density and Epileptic Seizure Activity in the Amygdala-Kindling Rat Model.	ongoing research	4	
3.4.21.78	Seizures	https://pubmed.ncbi.nlm.nih.gov/33372257/	Circulating Levels of Thrombospondin-1 and Thrombospondin-2 in Patients with Temporal Lobe Epilepsy Before and After Surgery.	unassigned	-	
3.4.21.78	Seizures	https://pubmed.ncbi.nlm.nih.gov/31005663/	P2Y4/TSP-1/TGF-?1/pSmad2/3 pathway contributes to acute generalized seizures induced by kainic acid.	unassigned	-	
3.4.21.78	Seizures	https://pubmed.ncbi.nlm.nih.gov/31664678/	Role of Elevated Thrombospondin-1 in Kainic Acid-Induced Status Epilepticus.	unassigned	-	
3.4.21.78	Sepsis	https://pubmed.ncbi.nlm.nih.gov/20362398/	Reduction of plasma granzyme A correlates with severity of sepsis in burn patients.	causal interaction	4	
3.4.21.78	Sepsis	https://pubmed.ncbi.nlm.nih.gov/33664861/	Granzyme A inhibition reduces inflammation and increases survival during abdominal sepsis.	causal interaction	4	
3.4.21.78	Sepsis	https://pubmed.ncbi.nlm.nih.gov/21573017/	Thrombospondin-1 contributes to mortality in murine sepsis through effects on innate immunity.	causal interaction	1	
3.4.21.78	Sepsis	https://pubmed.ncbi.nlm.nih.gov/25574201/	Curcumin protects against lipopolysaccharide-induced vasoconstriction dysfunction via inhibition of thrombospondin-1 and transforming growth factor-?1.	causal interaction	3	
3.4.21.78	Sepsis	https://pubmed.ncbi.nlm.nih.gov/28124196/	Baseline thrombospondin-1 concentrations are not associated with mortality in septic patients: a single-center cohort study on the intensive care unit.	causal interaction	3	
3.4.21.78	Sepsis	https://pubmed.ncbi.nlm.nih.gov/10619826/	Upregulation of two death pathways of perforin/granzyme and FasL/Fas in septic acute respiratory distress syndrome.	diagnostic usage	3	
3.4.21.78	Sepsis	https://pubmed.ncbi.nlm.nih.gov/25574201/	Curcumin protects against lipopolysaccharide-induced vasoconstriction dysfunction via inhibition of thrombospondin-1 and transforming growth factor-?1.	diagnostic usage	1	
3.4.21.78	Sepsis	https://pubmed.ncbi.nlm.nih.gov/28124196/	Baseline thrombospondin-1 concentrations are not associated with mortality in septic patients: a single-center cohort study on the intensive care unit.	diagnostic usage	4	
3.4.21.78	Sepsis	https://pubmed.ncbi.nlm.nih.gov/33088624/	Heparin-binding protein as a novel biomarker for sepsis-related acute kidney injury.	diagnostic usage	3	
3.4.21.78	Sepsis	https://pubmed.ncbi.nlm.nih.gov/10619826/	Upregulation of two death pathways of perforin/granzyme and FasL/Fas in septic acute respiratory distress syndrome.	therapeutic application	2	
3.4.21.78	Sepsis	https://pubmed.ncbi.nlm.nih.gov/21573017/	Thrombospondin-1 contributes to mortality in murine sepsis through effects on innate immunity.	ongoing research	2	
3.4.21.78	Sepsis	https://pubmed.ncbi.nlm.nih.gov/28124196/	Baseline thrombospondin-1 concentrations are not associated with mortality in septic patients: a single-center cohort study on the intensive care unit.	ongoing research	4	
3.4.21.78	Sepsis	https://pubmed.ncbi.nlm.nih.gov/31957847/	LncRNA NEAT1 facilitates the progression of sepsis through up-regulating TSP-1 via sponging miR-370-3p.	unassigned	-	
3.4.21.78	Sepsis	https://pubmed.ncbi.nlm.nih.gov/10619826/	Upregulation of two death pathways of perforin/granzyme and FasL/Fas in septic acute respiratory distress syndrome.	unassigned	-	
3.4.21.78	Sepsis	https://pubmed.ncbi.nlm.nih.gov/32496420/	Adipose-Derived Inflammatory and Coagulant Mediators in Patients with Sepsis.	unassigned	-	
3.4.21.78	Sepsis	https://pubmed.ncbi.nlm.nih.gov/33088624/	Heparin-binding protein as a novel biomarker for sepsis-related acute kidney injury.	unassigned	-	
3.4.21.78	Sepsis	https://pubmed.ncbi.nlm.nih.gov/20362398/	Reduction of plasma granzyme A correlates with severity of sepsis in burn patients.	unassigned	-	
3.4.21.78	Sepsis	https://pubmed.ncbi.nlm.nih.gov/33664861/	Granzyme A inhibition reduces inflammation and increases survival during abdominal sepsis.	unassigned	-	
3.4.21.78	Sepsis	https://pubmed.ncbi.nlm.nih.gov/21573017/	Thrombospondin-1 contributes to mortality in murine sepsis through effects on innate immunity.	unassigned	-	
3.4.21.78	Sepsis	https://pubmed.ncbi.nlm.nih.gov/25574201/	Curcumin protects against lipopolysaccharide-induced vasoconstriction dysfunction via inhibition of thrombospondin-1 and transforming growth factor-?1.	unassigned	-	
3.4.21.78	Sepsis	https://pubmed.ncbi.nlm.nih.gov/28124196/	Baseline thrombospondin-1 concentrations are not associated with mortality in septic patients: a single-center cohort study on the intensive care unit.	unassigned	-	
3.4.21.78	Severe Combined Immunodeficiency	https://pubmed.ncbi.nlm.nih.gov/18413367/	A novel role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer.	causal interaction	1	
3.4.21.78	Severe Combined Immunodeficiency	https://pubmed.ncbi.nlm.nih.gov/18413367/	A novel role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer.	therapeutic application	1	
3.4.21.78	Severe Combined Immunodeficiency	https://pubmed.ncbi.nlm.nih.gov/18413367/	A novel role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer.	ongoing research	2	
3.4.21.78	Severe Combined Immunodeficiency	https://pubmed.ncbi.nlm.nih.gov/18413367/	A novel role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer.	unassigned	-	
3.4.21.78	Silicosis	https://pubmed.ncbi.nlm.nih.gov/26653811/	[Changes in serum protease and cytokine in patients with silicosis, tuberculosis, and lung cancer].	causal interaction	4	
3.4.21.78	Silicosis	https://pubmed.ncbi.nlm.nih.gov/26653808/	[Comparative analysis of serum proteomic profiles between patients with silicosis and chronic bronchitis].	diagnostic usage	4	
3.4.21.78	Silicosis	https://pubmed.ncbi.nlm.nih.gov/26653811/	[Changes in serum protease and cytokine in patients with silicosis, tuberculosis, and lung cancer].	diagnostic usage	4	
3.4.21.78	Silicosis	https://pubmed.ncbi.nlm.nih.gov/26653811/	[Changes in serum protease and cytokine in patients with silicosis, tuberculosis, and lung cancer].	therapeutic application	1	
3.4.21.78	Silicosis	https://pubmed.ncbi.nlm.nih.gov/26653811/	[Changes in serum protease and cytokine in patients with silicosis, tuberculosis, and lung cancer].	ongoing research	2	
3.4.21.78	Silicosis	https://pubmed.ncbi.nlm.nih.gov/26653808/	[Comparative analysis of serum proteomic profiles between patients with silicosis and chronic bronchitis].	unassigned	-	
3.4.21.78	Spinal Cord Injuries	https://pubmed.ncbi.nlm.nih.gov/19278574/	TSP-1 expression changes in diabetic rats with spinal cord injury.	causal interaction	2	
3.4.21.78	Spinal Cord Injuries	https://pubmed.ncbi.nlm.nih.gov/19719963/	Protection of erythropoietin on experimental spinal cord injury by reducing the expression of thrombospondin-1 and transforming growth factor-beta.	therapeutic application	3	
3.4.21.78	Spinal Cord Injuries	https://pubmed.ncbi.nlm.nih.gov/19278574/	TSP-1 expression changes in diabetic rats with spinal cord injury.	ongoing research	1	
3.4.21.78	Spinal Cord Injuries	https://pubmed.ncbi.nlm.nih.gov/19342245/	The role of thrombospondin-1 and transforming growth factor-beta after spinal cord injury in the rat.	ongoing research	4	
3.4.21.78	Spinal Cord Injuries	https://pubmed.ncbi.nlm.nih.gov/19342245/	The role of thrombospondin-1 and transforming growth factor-beta after spinal cord injury in the rat.	unassigned	-	
3.4.21.78	Spinal Cord Injuries	https://pubmed.ncbi.nlm.nih.gov/19719963/	Protection of erythropoietin on experimental spinal cord injury by reducing the expression of thrombospondin-1 and transforming growth factor-beta.	unassigned	-	
3.4.21.78	Spinal Cord Injuries	https://pubmed.ncbi.nlm.nih.gov/19278574/	TSP-1 expression changes in diabetic rats with spinal cord injury.	unassigned	-	
3.4.21.78	Squamous Cell Carcinoma of Head and Neck	https://pubmed.ncbi.nlm.nih.gov/11036248/	Thrombospondin-1 expression in oral squamous cell carcinomas: correlations with tumor vascularity, clinicopathological features and survival.	causal interaction	4	
3.4.21.78	Squamous Cell Carcinoma of Head and Neck	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	causal interaction	4	
3.4.21.78	Squamous Cell Carcinoma of Head and Neck	https://pubmed.ncbi.nlm.nih.gov/11036248/	Thrombospondin-1 expression in oral squamous cell carcinomas: correlations with tumor vascularity, clinicopathological features and survival.	diagnostic usage	4	
3.4.21.78	Squamous Cell Carcinoma of Head and Neck	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	diagnostic usage	3	
3.4.21.78	Squamous Cell Carcinoma of Head and Neck	https://pubmed.ncbi.nlm.nih.gov/11036248/	Thrombospondin-1 expression in oral squamous cell carcinomas: correlations with tumor vascularity, clinicopathological features and survival.	therapeutic application	4	
3.4.21.78	Squamous Cell Carcinoma of Head and Neck	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	therapeutic application	2	
3.4.21.78	Squamous Cell Carcinoma of Head and Neck	https://pubmed.ncbi.nlm.nih.gov/20008890/	c-MYC depletion potentiates cisplatin-induced apoptosis in head and neck squamous cell carcinoma: involvement of TSP-1 up-regulation.	ongoing research	2	
3.4.21.78	Squamous Cell Carcinoma of Head and Neck	https://pubmed.ncbi.nlm.nih.gov/11036248/	Thrombospondin-1 expression in oral squamous cell carcinomas: correlations with tumor vascularity, clinicopathological features and survival.	ongoing research	3	
3.4.21.78	Squamous Cell Carcinoma of Head and Neck	https://pubmed.ncbi.nlm.nih.gov/11332689/	The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.	ongoing research	4	
3.4.21.78	Squamous Cell Carcinoma of Head and Neck	https://pubmed.ncbi.nlm.nih.gov/20008890/	c-MYC depletion potentiates cisplatin-induced apoptosis in head and neck squamous cell carcinoma: involvement of TSP-1 up-regulation.	unassigned	-	
3.4.21.78	ST Elevation Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/22750995/	Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction.	causal interaction	3	
3.4.21.78	ST Elevation Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/29611169/	Increased plasma cathepsin S and trombospondin-1 in patients with acute ST segment elevation myocardial infarction.	causal interaction	4	
3.4.21.78	ST Elevation Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/22750995/	Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction.	diagnostic usage	4	
3.4.21.78	ST Elevation Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/29611169/	Increased plasma cathepsin S and trombospondin-1 in patients with acute ST segment elevation myocardial infarction.	diagnostic usage	3	
3.4.21.78	ST Elevation Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/22750995/	Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction.	therapeutic application	4	
3.4.21.78	ST Elevation Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/29611169/	Increased plasma cathepsin S and trombospondin-1 in patients with acute ST segment elevation myocardial infarction.	therapeutic application	2	
3.4.21.78	ST Elevation Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/22750995/	Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction.	ongoing research	3	
3.4.21.78	ST Elevation Myocardial Infarction	https://pubmed.ncbi.nlm.nih.gov/29611169/	Increased plasma cathepsin S and trombospondin-1 in patients with acute ST segment elevation myocardial infarction.	unassigned	-	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/30405822/	Intervenolin suppresses gastric cancer cell growth through the induction of TSP-1 secretion from fibroblast-like stromal cells.	causal interaction	1	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12443715/	Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer.	causal interaction	4	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12719977/	Expression of thrombospondin-1 is correlated with microvessel density in gastric carcinoma.	causal interaction	4	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16650813/	IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway.	causal interaction	3	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21107877/	Expression of thrombospondin-1 and Ski are prognostic factors in advanced gastric cancer.	causal interaction	3	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26523612/	Effects of caffeic acid phenethyl ester on matrix molecules and angiogenetic and anti-angiogenetic factors in gastric cancer cells cultured on different substrates.	causal interaction	3	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12443715/	Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer.	diagnostic usage	3	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12719977/	Expression of thrombospondin-1 is correlated with microvessel density in gastric carcinoma.	diagnostic usage	4	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21107877/	Expression of thrombospondin-1 and Ski are prognostic factors in advanced gastric cancer.	diagnostic usage	1	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26523612/	Effects of caffeic acid phenethyl ester on matrix molecules and angiogenetic and anti-angiogenetic factors in gastric cancer cells cultured on different substrates.	diagnostic usage	1	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12443715/	Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer.	therapeutic application	2	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12719977/	Expression of thrombospondin-1 is correlated with microvessel density in gastric carcinoma.	therapeutic application	3	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/30321186/	Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer.	therapeutic application	1	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/30405822/	Intervenolin suppresses gastric cancer cell growth through the induction of TSP-1 secretion from fibroblast-like stromal cells.	ongoing research	4	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12443715/	Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer.	ongoing research	4	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12719977/	Expression of thrombospondin-1 is correlated with microvessel density in gastric carcinoma.	ongoing research	4	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16650813/	IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway.	ongoing research	4	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21107877/	Expression of thrombospondin-1 and Ski are prognostic factors in advanced gastric cancer.	ongoing research	4	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22729516/	An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.	ongoing research	3	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26523612/	Effects of caffeic acid phenethyl ester on matrix molecules and angiogenetic and anti-angiogenetic factors in gastric cancer cells cultured on different substrates.	ongoing research	2	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/30321186/	Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer.	ongoing research	1	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/22729516/	An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.	unassigned	-	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/30321186/	Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer.	unassigned	-	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/32573272/	Effect of geldanamycin on the expression of the matrix molecules and angiogenetic factors in a gastric cancer cell line.	unassigned	-	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/30405822/	Intervenolin suppresses gastric cancer cell growth through the induction of TSP-1 secretion from fibroblast-like stromal cells.	unassigned	-	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16650813/	IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway.	unassigned	-	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/21107877/	Expression of thrombospondin-1 and Ski are prognostic factors in advanced gastric cancer.	unassigned	-	
3.4.21.78	Stomach Neoplasms	https://pubmed.ncbi.nlm.nih.gov/26523612/	Effects of caffeic acid phenethyl ester on matrix molecules and angiogenetic and anti-angiogenetic factors in gastric cancer cells cultured on different substrates.	unassigned	-	
3.4.21.78	Stroke	https://pubmed.ncbi.nlm.nih.gov/14961162/	Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1).	causal interaction	3	
3.4.21.78	Stroke	https://pubmed.ncbi.nlm.nih.gov/32941082/	An evaluation of the ability of thrombospondin-1 to predict stroke outcomes and mortality after ischemic stroke.	causal interaction	4	
3.4.21.78	Stroke	https://pubmed.ncbi.nlm.nih.gov/14961162/	Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1).	diagnostic usage	1	
3.4.21.78	Stroke	https://pubmed.ncbi.nlm.nih.gov/32941082/	An evaluation of the ability of thrombospondin-1 to predict stroke outcomes and mortality after ischemic stroke.	diagnostic usage	2	
3.4.21.78	Stroke	https://pubmed.ncbi.nlm.nih.gov/14961162/	Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1).	therapeutic application	1	
3.4.21.78	Stroke	https://pubmed.ncbi.nlm.nih.gov/14961162/	Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1).	ongoing research	3	
3.4.21.78	Stroke	https://pubmed.ncbi.nlm.nih.gov/18594557/	Thrombospondins 1 and 2 are necessary for synaptic plasticity and functional recovery after stroke.	unassigned	-	
3.4.21.78	Stroke	https://pubmed.ncbi.nlm.nih.gov/32941082/	An evaluation of the ability of thrombospondin-1 to predict stroke outcomes and mortality after ischemic stroke.	unassigned	-	
3.4.21.78	Subarachnoid Hemorrhage	https://pubmed.ncbi.nlm.nih.gov/27653877/	Elevated cerebrospinal fluid levels of thrombospondin-1 correlate with adverse clinical outcome in patients with aneurysmal subarachnoid hemorrhage.	causal interaction	4	
3.4.21.78	Subarachnoid Hemorrhage	https://pubmed.ncbi.nlm.nih.gov/27653877/	Elevated cerebrospinal fluid levels of thrombospondin-1 correlate with adverse clinical outcome in patients with aneurysmal subarachnoid hemorrhage.	diagnostic usage	4	
3.4.21.78	Subarachnoid Hemorrhage	https://pubmed.ncbi.nlm.nih.gov/27653877/	Elevated cerebrospinal fluid levels of thrombospondin-1 correlate with adverse clinical outcome in patients with aneurysmal subarachnoid hemorrhage.	ongoing research	3	
3.4.21.78	Subarachnoid Hemorrhage	https://pubmed.ncbi.nlm.nih.gov/27653877/	Elevated cerebrospinal fluid levels of thrombospondin-1 correlate with adverse clinical outcome in patients with aneurysmal subarachnoid hemorrhage.	unassigned	-	
3.4.21.78	Synovitis	https://pubmed.ncbi.nlm.nih.gov/15641039/	Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis.	causal interaction	4	
3.4.21.78	Synovitis	https://pubmed.ncbi.nlm.nih.gov/15641039/	Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis.	therapeutic application	4	
3.4.21.78	Synovitis	https://pubmed.ncbi.nlm.nih.gov/15641039/	Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis.	ongoing research	4	
3.4.21.78	Synovitis	https://pubmed.ncbi.nlm.nih.gov/15641039/	Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis.	unassigned	-	
3.4.21.78	TDP-43 Proteinopathies	https://pubmed.ncbi.nlm.nih.gov/27735996/	Defective synthesis and release of astrocytic thrombospondin-1 mediates the neuronal TDP-43 proteinopathy, resulting in defects in neuronal integrity associated with chronic traumatic encephalopathy: in vitro studies.	causal interaction	3	
3.4.21.78	TDP-43 Proteinopathies	https://pubmed.ncbi.nlm.nih.gov/27735996/	Defective synthesis and release of astrocytic thrombospondin-1 mediates the neuronal TDP-43 proteinopathy, resulting in defects in neuronal integrity associated with chronic traumatic encephalopathy: in vitro studies.	therapeutic application	4	
3.4.21.78	TDP-43 Proteinopathies	https://pubmed.ncbi.nlm.nih.gov/27735996/	Defective synthesis and release of astrocytic thrombospondin-1 mediates the neuronal TDP-43 proteinopathy, resulting in defects in neuronal integrity associated with chronic traumatic encephalopathy: in vitro studies.	unassigned	-	
3.4.21.78	Telangiectasia, Hereditary Hemorrhagic	https://pubmed.ncbi.nlm.nih.gov/32723034/	Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.	causal interaction	1	
3.4.21.78	Telangiectasia, Hereditary Hemorrhagic	https://pubmed.ncbi.nlm.nih.gov/32723034/	Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.	ongoing research	1	
3.4.21.78	Telangiectasia, Hereditary Hemorrhagic	https://pubmed.ncbi.nlm.nih.gov/32723034/	Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.	unassigned	-	
3.4.21.78	Telangiectasis	https://pubmed.ncbi.nlm.nih.gov/32723034/	Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.	causal interaction	1	
3.4.21.78	Telangiectasis	https://pubmed.ncbi.nlm.nih.gov/32723034/	Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.	ongoing research	1	
3.4.21.78	Telangiectasis	https://pubmed.ncbi.nlm.nih.gov/32723034/	Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.	unassigned	-	
3.4.21.78	Thrombasthenia	https://pubmed.ncbi.nlm.nih.gov/11964147/	Association of thrombospondin-1 with the actin cytoskeleton of human thrombin-activated platelets through an alphaIIbbeta3- or CD36-independent mechanism.	ongoing research	2	
3.4.21.78	Thrombasthenia	https://pubmed.ncbi.nlm.nih.gov/11964147/	Association of thrombospondin-1 with the actin cytoskeleton of human thrombin-activated platelets through an alphaIIbbeta3- or CD36-independent mechanism.	unassigned	-	
3.4.21.78	Thrombocytopenia	https://pubmed.ncbi.nlm.nih.gov/26155102/	Evaluation of complement regulatory components in patients with atypical hemolytic uremic syndrome.	diagnostic usage	1	
3.4.21.78	Thrombocytopenia	https://pubmed.ncbi.nlm.nih.gov/29998369/	Decreased serum thrombospondin-1 and elevation of its autoantibody are associated with multiple exacerbated clinical manifestations in systemic lupus erythematosus.	therapeutic application	1	
3.4.21.78	Thrombocytopenia	https://pubmed.ncbi.nlm.nih.gov/26155102/	Evaluation of complement regulatory components in patients with atypical hemolytic uremic syndrome.	ongoing research	2	
3.4.21.78	Thrombocytopenia	https://pubmed.ncbi.nlm.nih.gov/26155102/	Evaluation of complement regulatory components in patients with atypical hemolytic uremic syndrome.	unassigned	-	
3.4.21.78	Thrombocytopenia	https://pubmed.ncbi.nlm.nih.gov/29998369/	Decreased serum thrombospondin-1 and elevation of its autoantibody are associated with multiple exacerbated clinical manifestations in systemic lupus erythematosus.	unassigned	-	
3.4.21.78	Thrombosis	https://pubmed.ncbi.nlm.nih.gov/16204318/	Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13.	causal interaction	3	
3.4.21.78	Thrombosis	https://pubmed.ncbi.nlm.nih.gov/17583726/	Vascular response to intra-arterial injury in the thrombospondin-1 null mouse.	causal interaction	4	
3.4.21.78	Thrombosis	https://pubmed.ncbi.nlm.nih.gov/30419595/	Neutrophil-Mediated Proteolysis of Thrombospondin-1 Promotes Platelet Adhesion and String Formation.	causal interaction	1	
3.4.21.78	Thrombosis	https://pubmed.ncbi.nlm.nih.gov/33232198/	Towards the Therapeutic Use of Thrombospondin 1/CD47 Targeting TAX2 Peptide as an Antithrombotic Agent.	causal interaction	3	
3.4.21.78	Thrombosis	https://pubmed.ncbi.nlm.nih.gov/8245406/	Differential expression of SPARC and thrombospondin 1 in wound repair: immunolocalization and in situ hybridization.	diagnostic usage	1	
3.4.21.78	Thrombosis	https://pubmed.ncbi.nlm.nih.gov/16204318/	Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13.	therapeutic application	1	
3.4.21.78	Thrombosis	https://pubmed.ncbi.nlm.nih.gov/30905589/	Whole-exome sequencing detects mutations in pediatric patients with atypical hemolytic uremic syndrome in Taiwan.	therapeutic application	1	
3.4.21.78	Thrombosis	https://pubmed.ncbi.nlm.nih.gov/32881993/	Thrombospondin-1 promotes haemostasis through modulation of cAMP signalling in blood platelets.	therapeutic application	1	
3.4.21.78	Thrombosis	https://pubmed.ncbi.nlm.nih.gov/33538796/	Thrombospondin-1 promotes hemostasis through modulation of cAMP signaling in blood platelets.	therapeutic application	1	
3.4.21.78	Thrombosis	https://pubmed.ncbi.nlm.nih.gov/16204318/	Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13.	ongoing research	4	
3.4.21.78	Thrombosis	https://pubmed.ncbi.nlm.nih.gov/17583726/	Vascular response to intra-arterial injury in the thrombospondin-1 null mouse.	ongoing research	2	
3.4.21.78	Thrombosis	https://pubmed.ncbi.nlm.nih.gov/8245406/	Differential expression of SPARC and thrombospondin 1 in wound repair: immunolocalization and in situ hybridization.	unassigned	-	
3.4.21.78	Thrombosis	https://pubmed.ncbi.nlm.nih.gov/18178577/	Polymorphisms in thrombospondin genes and myocardial infarction: a case-control study and a meta-analysis of available evidence.	unassigned	-	
3.4.21.78	Thrombosis	https://pubmed.ncbi.nlm.nih.gov/30905589/	Whole-exome sequencing detects mutations in pediatric patients with atypical hemolytic uremic syndrome in Taiwan.	unassigned	-	
3.4.21.78	Thrombosis	https://pubmed.ncbi.nlm.nih.gov/32881993/	Thrombospondin-1 promotes haemostasis through modulation of cAMP signalling in blood platelets.	unassigned	-	
3.4.21.78	Thrombosis	https://pubmed.ncbi.nlm.nih.gov/33538796/	Thrombospondin-1 promotes hemostasis through modulation of cAMP signaling in blood platelets.	unassigned	-	
3.4.21.78	Thrombosis	https://pubmed.ncbi.nlm.nih.gov/16204318/	Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13.	unassigned	-	
3.4.21.78	Thrombosis	https://pubmed.ncbi.nlm.nih.gov/17583726/	Vascular response to intra-arterial injury in the thrombospondin-1 null mouse.	unassigned	-	
3.4.21.78	Thrombosis	https://pubmed.ncbi.nlm.nih.gov/30419595/	Neutrophil-Mediated Proteolysis of Thrombospondin-1 Promotes Platelet Adhesion and String Formation.	unassigned	-	
3.4.21.78	Thrombosis	https://pubmed.ncbi.nlm.nih.gov/33232198/	Towards the Therapeutic Use of Thrombospondin 1/CD47 Targeting TAX2 Peptide as an Antithrombotic Agent.	unassigned	-	
3.4.21.78	Thymoma	https://pubmed.ncbi.nlm.nih.gov/31462506/	Glycolipid Stimulation of Invariant NKT Cells Expands a Unique Tissue-Resident Population of Precursors to Mature NK Cells Endowed with Oncolytic and Antimetastatic Properties.	causal interaction	1	
3.4.21.78	Thymoma	https://pubmed.ncbi.nlm.nih.gov/31462506/	Glycolipid Stimulation of Invariant NKT Cells Expands a Unique Tissue-Resident Population of Precursors to Mature NK Cells Endowed with Oncolytic and Antimetastatic Properties.	unassigned	-	
3.4.21.78	Thyroid Cancer, Papillary	https://pubmed.ncbi.nlm.nih.gov/17409099/	Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion.	diagnostic usage	3	
3.4.21.78	Thyroid Cancer, Papillary	https://pubmed.ncbi.nlm.nih.gov/17409099/	Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion.	ongoing research	4	
3.4.21.78	Thyroid Cancer, Papillary	https://pubmed.ncbi.nlm.nih.gov/17409099/	Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion.	unassigned	-	
3.4.21.78	Thyroid Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15707585/	The tumor suppressor PTEN inhibits EGF-induced TSP-1 and TIMP-1 expression in FTC-133 thyroid carcinoma cells.	causal interaction	1	
3.4.21.78	Thyroid Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16394085/	Pituitary tumor-transforming gene regulates multiple downstream angiogenic genes in thyroid cancer.	causal interaction	4	
3.4.21.78	Thyroid Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18661355/	Thrombospondin-1 in differentiated thyroid cancer: Dr. Jekyll and Mr. Hyde.	causal interaction	4	
3.4.21.78	Thyroid Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20498063/	B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.	causal interaction	1	
3.4.21.78	Thyroid Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24348463/	Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment.	causal interaction	3	
3.4.21.78	Thyroid Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16394085/	Pituitary tumor-transforming gene regulates multiple downstream angiogenic genes in thyroid cancer.	diagnostic usage	1	
3.4.21.78	Thyroid Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18661355/	Thrombospondin-1 in differentiated thyroid cancer: Dr. Jekyll and Mr. Hyde.	therapeutic application	2	
3.4.21.78	Thyroid Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16394085/	Pituitary tumor-transforming gene regulates multiple downstream angiogenic genes in thyroid cancer.	ongoing research	3	
3.4.21.78	Thyroid Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20498063/	B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.	ongoing research	4	
3.4.21.78	Thyroid Neoplasms	https://pubmed.ncbi.nlm.nih.gov/15707585/	The tumor suppressor PTEN inhibits EGF-induced TSP-1 and TIMP-1 expression in FTC-133 thyroid carcinoma cells.	unassigned	-	
3.4.21.78	Thyroid Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18661355/	Thrombospondin-1 in differentiated thyroid cancer: Dr. Jekyll and Mr. Hyde.	unassigned	-	
3.4.21.78	Thyroid Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20498063/	B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.	unassigned	-	
3.4.21.78	Thyroid Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24348463/	Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment.	unassigned	-	
3.4.21.78	Thyroid Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16394085/	Pituitary tumor-transforming gene regulates multiple downstream angiogenic genes in thyroid cancer.	unassigned	-	
3.4.21.78	Thyroiditis	https://pubmed.ncbi.nlm.nih.gov/30896397/	[H Factor Deficiency: A Case with an Atypical Presentation].	causal interaction	4	
3.4.21.78	Thyroiditis	https://pubmed.ncbi.nlm.nih.gov/30896397/	[H Factor Deficiency: A Case with an Atypical Presentation].	diagnostic usage	4	
3.4.21.78	Thyroiditis	https://pubmed.ncbi.nlm.nih.gov/30896397/	[H Factor Deficiency: A Case with an Atypical Presentation].	unassigned	-	
3.4.21.78	Trauma, Nervous System	https://pubmed.ncbi.nlm.nih.gov/22776902/	Trauma-induced expression of astrocytic thrombospondin-1 is regulated by P2 receptors coupled to protein kinase cascades.	unassigned	-	
3.4.21.78	Tuberculosis	https://pubmed.ncbi.nlm.nih.gov/27055232/	Granzyme A Is Expressed in Mouse Lungs during Mycobacterium tuberculosis Infection but Does Not Contribute to Protection In Vivo.	causal interaction	3	
3.4.21.78	Tuberculosis	https://pubmed.ncbi.nlm.nih.gov/19014932/	Regulatory role of 1, 25-dihydroxyvitamin D3 and vitamin D receptor gene variants on intracellular granzyme A expression in pulmonary tuberculosis.	causal interaction	3	
3.4.21.78	Tuberculosis	https://pubmed.ncbi.nlm.nih.gov/26653811/	[Changes in serum protease and cytokine in patients with silicosis, tuberculosis, and lung cancer].	causal interaction	4	
3.4.21.78	Tuberculosis	https://pubmed.ncbi.nlm.nih.gov/26051682/	Granzyme A as a potential biomarker of Mycobacterium tuberculosis infection and disease.	diagnostic usage	2	
3.4.21.78	Tuberculosis	https://pubmed.ncbi.nlm.nih.gov/27055232/	Granzyme A Is Expressed in Mouse Lungs during Mycobacterium tuberculosis Infection but Does Not Contribute to Protection In Vivo.	diagnostic usage	2	
3.4.21.78	Tuberculosis	https://pubmed.ncbi.nlm.nih.gov/26653811/	[Changes in serum protease and cytokine in patients with silicosis, tuberculosis, and lung cancer].	diagnostic usage	4	
3.4.21.78	Tuberculosis	https://pubmed.ncbi.nlm.nih.gov/26051682/	Granzyme A as a potential biomarker of Mycobacterium tuberculosis infection and disease.	therapeutic application	4	
3.4.21.78	Tuberculosis	https://pubmed.ncbi.nlm.nih.gov/27055232/	Granzyme A Is Expressed in Mouse Lungs during Mycobacterium tuberculosis Infection but Does Not Contribute to Protection In Vivo.	therapeutic application	2	
3.4.21.78	Tuberculosis	https://pubmed.ncbi.nlm.nih.gov/26653811/	[Changes in serum protease and cytokine in patients with silicosis, tuberculosis, and lung cancer].	therapeutic application	1	
3.4.21.78	Tuberculosis	https://pubmed.ncbi.nlm.nih.gov/26051682/	Granzyme A as a potential biomarker of Mycobacterium tuberculosis infection and disease.	ongoing research	4	
3.4.21.78	Tuberculosis	https://pubmed.ncbi.nlm.nih.gov/27055232/	Granzyme A Is Expressed in Mouse Lungs during Mycobacterium tuberculosis Infection but Does Not Contribute to Protection In Vivo.	ongoing research	4	
3.4.21.78	Tuberculosis	https://pubmed.ncbi.nlm.nih.gov/19014932/	Regulatory role of 1, 25-dihydroxyvitamin D3 and vitamin D receptor gene variants on intracellular granzyme A expression in pulmonary tuberculosis.	ongoing research	4	
3.4.21.78	Tuberculosis	https://pubmed.ncbi.nlm.nih.gov/26653811/	[Changes in serum protease and cytokine in patients with silicosis, tuberculosis, and lung cancer].	ongoing research	2	
3.4.21.78	Tuberculosis	https://pubmed.ncbi.nlm.nih.gov/26051682/	Granzyme A as a potential biomarker of Mycobacterium tuberculosis infection and disease.	unassigned	-	
3.4.21.78	Tuberculosis	https://pubmed.ncbi.nlm.nih.gov/19014932/	Regulatory role of 1, 25-dihydroxyvitamin D3 and vitamin D receptor gene variants on intracellular granzyme A expression in pulmonary tuberculosis.	unassigned	-	
3.4.21.78	Tuberculosis, Bovine	https://pubmed.ncbi.nlm.nih.gov/22359547/	Transcriptional profiling of disease-induced host responses in bovine tuberculosis and the identification of potential diagnostic biomarkers.	diagnostic usage	2	
3.4.21.78	Tuberculosis, Bovine	https://pubmed.ncbi.nlm.nih.gov/22359547/	Transcriptional profiling of disease-induced host responses in bovine tuberculosis and the identification of potential diagnostic biomarkers.	therapeutic application	1	
3.4.21.78	Tuberculosis, Bovine	https://pubmed.ncbi.nlm.nih.gov/22359547/	Transcriptional profiling of disease-induced host responses in bovine tuberculosis and the identification of potential diagnostic biomarkers.	unassigned	-	
3.4.21.78	Tuberculosis, Pulmonary	https://pubmed.ncbi.nlm.nih.gov/19014932/	Regulatory role of 1, 25-dihydroxyvitamin D3 and vitamin D receptor gene variants on intracellular granzyme A expression in pulmonary tuberculosis.	causal interaction	3	
3.4.21.78	Tuberculosis, Pulmonary	https://pubmed.ncbi.nlm.nih.gov/19014932/	Regulatory role of 1, 25-dihydroxyvitamin D3 and vitamin D receptor gene variants on intracellular granzyme A expression in pulmonary tuberculosis.	ongoing research	4	
3.4.21.78	Tuberculosis, Pulmonary	https://pubmed.ncbi.nlm.nih.gov/19014932/	Regulatory role of 1, 25-dihydroxyvitamin D3 and vitamin D receptor gene variants on intracellular granzyme A expression in pulmonary tuberculosis.	unassigned	-	
3.4.21.78	Typhoid Fever	https://pubmed.ncbi.nlm.nih.gov/28749963/	Expression of intra- and extracellular granzymes in patients with typhoid fever.	ongoing research	1	
3.4.21.78	Typhoid Fever	https://pubmed.ncbi.nlm.nih.gov/28749963/	Expression of intra- and extracellular granzymes in patients with typhoid fever.	unassigned	-	
3.4.21.78	Ureteral Obstruction	https://pubmed.ncbi.nlm.nih.gov/21860248/	Thrombospondin-1 Short Hairpin RNA Suppresses Tubulointerstitial Fibrosis in the Kidney of Ureteral Obstruction by Ameliorating Peritubular Capillary Injury.	diagnostic usage	1	
3.4.21.78	Ureteral Obstruction	https://pubmed.ncbi.nlm.nih.gov/21860248/	Thrombospondin-1 Short Hairpin RNA Suppresses Tubulointerstitial Fibrosis in the Kidney of Ureteral Obstruction by Ameliorating Peritubular Capillary Injury.	ongoing research	1	
3.4.21.78	Ureteral Obstruction	https://pubmed.ncbi.nlm.nih.gov/22418977/	Thrombospondin-1 plays a profibrotic and pro-inflammatory role during ureteric obstruction.	ongoing research	4	
3.4.21.78	Ureteral Obstruction	https://pubmed.ncbi.nlm.nih.gov/21860248/	Thrombospondin-1 Short Hairpin RNA Suppresses Tubulointerstitial Fibrosis in the Kidney of Ureteral Obstruction by Ameliorating Peritubular Capillary Injury.	unassigned	-	
3.4.21.78	Ureteral Obstruction	https://pubmed.ncbi.nlm.nih.gov/22418977/	Thrombospondin-1 plays a profibrotic and pro-inflammatory role during ureteric obstruction.	unassigned	-	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9515819/	Molecular mediators of angiogenesis in bladder cancer.	causal interaction	4	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11371931/	The role of hypoxia and p53 in the regulation of angiogenesis in bladder cancer.	causal interaction	3	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12429155/	Reduced thrombospondin-1 at presentation predicts disease progression in superficial bladder cancer.	causal interaction	2	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16732887/	Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.	causal interaction	4	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27729991/	Role of angiogenesis in urothelial bladder carcinoma.	causal interaction	1	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31092423/	The Pathological Significance and Prognostic Roles of Thrombospondin-1, and -2, and 4N1K-peptide in Bladder Cancer.	causal interaction	4	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9515819/	Molecular mediators of angiogenesis in bladder cancer.	diagnostic usage	3	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11371931/	The role of hypoxia and p53 in the regulation of angiogenesis in bladder cancer.	diagnostic usage	3	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12429155/	Reduced thrombospondin-1 at presentation predicts disease progression in superficial bladder cancer.	diagnostic usage	3	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16732887/	Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.	diagnostic usage	4	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24367787/	TSP-1-1223 A/G Polymorphism as a Potential Predictor of the Recurrence Risk of Bladder Cancer in a Chinese Population.	diagnostic usage	4	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25150583/	Effects of TSP-1-696 C/T polymorphism on bladder cancer susceptibility and clinicopathologic features.	diagnostic usage	3	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27729991/	Role of angiogenesis in urothelial bladder carcinoma.	diagnostic usage	4	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31092423/	The Pathological Significance and Prognostic Roles of Thrombospondin-1, and -2, and 4N1K-peptide in Bladder Cancer.	diagnostic usage	3	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12429155/	Reduced thrombospondin-1 at presentation predicts disease progression in superficial bladder cancer.	therapeutic application	1	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16732887/	Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.	therapeutic application	1	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25150583/	Effects of TSP-1-696 C/T polymorphism on bladder cancer susceptibility and clinicopathologic features.	therapeutic application	1	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9515819/	Molecular mediators of angiogenesis in bladder cancer.	ongoing research	4	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/16732887/	Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.	ongoing research	4	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25150583/	Effects of TSP-1-696 C/T polymorphism on bladder cancer susceptibility and clinicopathologic features.	ongoing research	4	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31092423/	The Pathological Significance and Prognostic Roles of Thrombospondin-1, and -2, and 4N1K-peptide in Bladder Cancer.	ongoing research	3	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/24367787/	TSP-1-1223 A/G Polymorphism as a Potential Predictor of the Recurrence Risk of Bladder Cancer in a Chinese Population.	unassigned	-	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/25150583/	Effects of TSP-1-696 C/T polymorphism on bladder cancer susceptibility and clinicopathologic features.	unassigned	-	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/29349903/	GP73 promotes invasion and metastasis of bladder cancer by regulating the epithelial-mesenchymal transition through the TGF-?1/Smad2 signalling pathway.	unassigned	-	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/9515819/	Molecular mediators of angiogenesis in bladder cancer.	unassigned	-	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11371931/	The role of hypoxia and p53 in the regulation of angiogenesis in bladder cancer.	unassigned	-	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/27729991/	Role of angiogenesis in urothelial bladder carcinoma.	unassigned	-	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/31092423/	The Pathological Significance and Prognostic Roles of Thrombospondin-1, and -2, and 4N1K-peptide in Bladder Cancer.	unassigned	-	
3.4.21.78	Urinary Bladder Neoplasms	https://pubmed.ncbi.nlm.nih.gov/12429155/	Reduced thrombospondin-1 at presentation predicts disease progression in superficial bladder cancer.	unassigned	-	
3.4.21.78	Urologic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23749112/	Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.	causal interaction	3	
3.4.21.78	Urologic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23749112/	Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.	diagnostic usage	3	
3.4.21.78	Urologic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23749112/	Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.	ongoing research	2	
3.4.21.78	Urologic Neoplasms	https://pubmed.ncbi.nlm.nih.gov/23749112/	Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.	unassigned	-	
3.4.21.78	Urticaria	https://pubmed.ncbi.nlm.nih.gov/23995607/	Endostatin and Thrombospondin-1 levels are increased in the sera of patients with chronic spontaneous urticaria.	causal interaction	2	
3.4.21.78	Urticaria	https://pubmed.ncbi.nlm.nih.gov/23995607/	Endostatin and Thrombospondin-1 levels are increased in the sera of patients with chronic spontaneous urticaria.	diagnostic usage	3	
3.4.21.78	Urticaria	https://pubmed.ncbi.nlm.nih.gov/23995607/	Endostatin and Thrombospondin-1 levels are increased in the sera of patients with chronic spontaneous urticaria.	therapeutic application	1	
3.4.21.78	Urticaria	https://pubmed.ncbi.nlm.nih.gov/23995607/	Endostatin and Thrombospondin-1 levels are increased in the sera of patients with chronic spontaneous urticaria.	unassigned	-	
3.4.21.78	Uterine Cervical Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11555600/	Thrombospondin-1 and -2 messenger RNA expression in invasive cervical cancer: correlation with angiogenesis and prognosis.	causal interaction	4	
3.4.21.78	Uterine Cervical Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18413367/	A novel role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer.	causal interaction	1	
3.4.21.78	Uterine Cervical Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11555600/	Thrombospondin-1 and -2 messenger RNA expression in invasive cervical cancer: correlation with angiogenesis and prognosis.	diagnostic usage	4	
3.4.21.78	Uterine Cervical Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18413367/	A novel role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer.	therapeutic application	1	
3.4.21.78	Uterine Cervical Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11555600/	Thrombospondin-1 and -2 messenger RNA expression in invasive cervical cancer: correlation with angiogenesis and prognosis.	ongoing research	3	
3.4.21.78	Uterine Cervical Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18413367/	A novel role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer.	ongoing research	2	
3.4.21.78	Uterine Cervical Neoplasms	https://pubmed.ncbi.nlm.nih.gov/18413367/	A novel role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer.	unassigned	-	
3.4.21.78	Uterine Cervical Neoplasms	https://pubmed.ncbi.nlm.nih.gov/11555600/	Thrombospondin-1 and -2 messenger RNA expression in invasive cervical cancer: correlation with angiogenesis and prognosis.	unassigned	-	
3.4.21.78	Uveitis	https://pubmed.ncbi.nlm.nih.gov/22803005/	Environmental conditioning in the control of macrophage thrombospondin-1 production.	unassigned	-	
3.4.21.78	Vaccinia	https://pubmed.ncbi.nlm.nih.gov/8621589/	Expression of human recombinant granzyme A zymogen and its activation by the cysteine proteinase cathepsin C.	therapeutic application	2	
3.4.21.78	Vaccinia	https://pubmed.ncbi.nlm.nih.gov/8621589/	Expression of human recombinant granzyme A zymogen and its activation by the cysteine proteinase cathepsin C.	ongoing research	4	
3.4.21.78	Vaccinia	https://pubmed.ncbi.nlm.nih.gov/8621589/	Expression of human recombinant granzyme A zymogen and its activation by the cysteine proteinase cathepsin C.	unassigned	-	
3.4.21.78	Vaccinia	https://pubmed.ncbi.nlm.nih.gov/15749916/	Differential regulation of granzyme and perforin in effector and memory T cells following smallpox immunization.	unassigned	-	
3.4.21.78	Vascular Diseases	https://pubmed.ncbi.nlm.nih.gov/32348623/	Thrombospondin-5 and fluvastatin promote angiogenesis and are protective against endothelial cell apoptosis.	causal interaction	1	
3.4.21.78	Vascular Diseases	https://pubmed.ncbi.nlm.nih.gov/32348623/	Thrombospondin-5 and fluvastatin promote angiogenesis and are protective against endothelial cell apoptosis.	therapeutic application	1	
3.4.21.78	Vascular Diseases	https://pubmed.ncbi.nlm.nih.gov/32348623/	Thrombospondin-5 and fluvastatin promote angiogenesis and are protective against endothelial cell apoptosis.	unassigned	-	
3.4.21.78	Vascular System Injuries	https://pubmed.ncbi.nlm.nih.gov/17583726/	Vascular response to intra-arterial injury in the thrombospondin-1 null mouse.	causal interaction	4	
3.4.21.78	Vascular System Injuries	https://pubmed.ncbi.nlm.nih.gov/31647293/	Thrombospondins Differentially Regulate Proteins Involved in Arterial Remodeling.	causal interaction	1	
3.4.21.78	Vascular System Injuries	https://pubmed.ncbi.nlm.nih.gov/32881993/	Thrombospondin-1 promotes haemostasis through modulation of cAMP signalling in blood platelets.	therapeutic application	1	
3.4.21.78	Vascular System Injuries	https://pubmed.ncbi.nlm.nih.gov/33538796/	Thrombospondin-1 promotes hemostasis through modulation of cAMP signaling in blood platelets.	therapeutic application	1	
3.4.21.78	Vascular System Injuries	https://pubmed.ncbi.nlm.nih.gov/17583726/	Vascular response to intra-arterial injury in the thrombospondin-1 null mouse.	ongoing research	2	
3.4.21.78	Vascular System Injuries	https://pubmed.ncbi.nlm.nih.gov/32881993/	Thrombospondin-1 promotes haemostasis through modulation of cAMP signalling in blood platelets.	unassigned	-	
3.4.21.78	Vascular System Injuries	https://pubmed.ncbi.nlm.nih.gov/33538796/	Thrombospondin-1 promotes hemostasis through modulation of cAMP signaling in blood platelets.	unassigned	-	
3.4.21.78	Vascular System Injuries	https://pubmed.ncbi.nlm.nih.gov/17583726/	Vascular response to intra-arterial injury in the thrombospondin-1 null mouse.	unassigned	-	
3.4.21.78	Vascular System Injuries	https://pubmed.ncbi.nlm.nih.gov/31647293/	Thrombospondins Differentially Regulate Proteins Involved in Arterial Remodeling.	unassigned	-	
3.4.21.78	Vasculitis	https://pubmed.ncbi.nlm.nih.gov/19508384/	Endothelial-derived thrombospondin-1 promotes macrophage recruitment and apoptotic cell clearance.	diagnostic usage	4	
3.4.21.78	Vasculitis	https://pubmed.ncbi.nlm.nih.gov/19508384/	Endothelial-derived thrombospondin-1 promotes macrophage recruitment and apoptotic cell clearance.	ongoing research	2	
3.4.21.78	Vasculitis	https://pubmed.ncbi.nlm.nih.gov/19508384/	Endothelial-derived thrombospondin-1 promotes macrophage recruitment and apoptotic cell clearance.	unassigned	-	
3.4.21.78	Ventricular Fibrillation	https://pubmed.ncbi.nlm.nih.gov/22750995/	Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction.	causal interaction	3	
3.4.21.78	Ventricular Fibrillation	https://pubmed.ncbi.nlm.nih.gov/22750995/	Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction.	diagnostic usage	4	
3.4.21.78	Ventricular Fibrillation	https://pubmed.ncbi.nlm.nih.gov/22750995/	Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction.	therapeutic application	4	
3.4.21.78	Ventricular Fibrillation	https://pubmed.ncbi.nlm.nih.gov/22750995/	Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction.	ongoing research	3	
3.4.21.78	Virus Diseases	https://pubmed.ncbi.nlm.nih.gov/8929545/	Granzymes: a variety of serine protease specificities encoded by genetically distinct subfamilies.	causal interaction	3	
3.4.21.78	Virus Diseases	https://pubmed.ncbi.nlm.nih.gov/10998317/	Nucleolin as the earliest target molecule of autoantibodies produced in MRL/lpr lupus-prone mice.	causal interaction	4	
3.4.21.78	Virus Diseases	https://pubmed.ncbi.nlm.nih.gov/24590059/	Immunosurveillance by Antiangiogenesis: Tumor Growth Arrest by T Cell-Derived Thrombospondin-1.	causal interaction	1	
3.4.21.78	Virus Diseases	https://pubmed.ncbi.nlm.nih.gov/34323115/	Low Dose Hyperoxia Primes Airways for Fibrosis in Mice after Influenza A Infection.	causal interaction	4	
3.4.21.78	Virus Diseases	https://pubmed.ncbi.nlm.nih.gov/34323115/	Low Dose Hyperoxia Primes Airways for Fibrosis in Mice after Influenza A Infection.	diagnostic usage	3	
3.4.21.78	Virus Diseases	https://pubmed.ncbi.nlm.nih.gov/19404988/	Granzyme A expression reveals distinct cytolytic CTL subsets following influenza A virus infection.	therapeutic application	1	
3.4.21.78	Virus Diseases	https://pubmed.ncbi.nlm.nih.gov/8929545/	Granzymes: a variety of serine protease specificities encoded by genetically distinct subfamilies.	therapeutic application	4	
3.4.21.78	Virus Diseases	https://pubmed.ncbi.nlm.nih.gov/34323115/	Low Dose Hyperoxia Primes Airways for Fibrosis in Mice after Influenza A Infection.	therapeutic application	1	
3.4.21.78	Virus Diseases	https://pubmed.ncbi.nlm.nih.gov/19404988/	Granzyme A expression reveals distinct cytolytic CTL subsets following influenza A virus infection.	ongoing research	1	
3.4.21.78	Virus Diseases	https://pubmed.ncbi.nlm.nih.gov/24590059/	Immunosurveillance by Antiangiogenesis: Tumor Growth Arrest by T Cell-Derived Thrombospondin-1.	ongoing research	2	
3.4.21.78	Virus Diseases	https://pubmed.ncbi.nlm.nih.gov/19404988/	Granzyme A expression reveals distinct cytolytic CTL subsets following influenza A virus infection.	unassigned	-	
3.4.21.78	Virus Diseases	https://pubmed.ncbi.nlm.nih.gov/8929545/	Granzymes: a variety of serine protease specificities encoded by genetically distinct subfamilies.	unassigned	-	
3.4.21.78	Virus Diseases	https://pubmed.ncbi.nlm.nih.gov/10998317/	Nucleolin as the earliest target molecule of autoantibodies produced in MRL/lpr lupus-prone mice.	unassigned	-	
3.4.21.78	Virus Diseases	https://pubmed.ncbi.nlm.nih.gov/24590059/	Immunosurveillance by Antiangiogenesis: Tumor Growth Arrest by T Cell-Derived Thrombospondin-1.	unassigned	-	
3.4.21.78	Virus Diseases	https://pubmed.ncbi.nlm.nih.gov/34323115/	Low Dose Hyperoxia Primes Airways for Fibrosis in Mice after Influenza A Infection.	unassigned	-	
3.4.21.78	Vulvar Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20734389/	Differential hypermethylation of genes in vulvar cancer and lichen sclerosus coexisting or not with vulvar cancer.	diagnostic usage	4	
3.4.21.78	Vulvar Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20734389/	Differential hypermethylation of genes in vulvar cancer and lichen sclerosus coexisting or not with vulvar cancer.	ongoing research	3	
3.4.21.78	Vulvar Neoplasms	https://pubmed.ncbi.nlm.nih.gov/20734389/	Differential hypermethylation of genes in vulvar cancer and lichen sclerosus coexisting or not with vulvar cancer.	unassigned	-	
3.4.21.78	Whooping Cough	https://pubmed.ncbi.nlm.nih.gov/18571589/	The role of G proteins in thromospondin-1-induced vascular smooth muscle cell migration.	therapeutic application	1	
3.4.21.78	Whooping Cough	https://pubmed.ncbi.nlm.nih.gov/33118159/	Lysophosphatidic acid induces thrombospondin-1 production in primary cultured rat cortical astrocytes.	therapeutic application	2	
3.4.21.78	Whooping Cough	https://pubmed.ncbi.nlm.nih.gov/16204059/	Oncogenes and Angiogenesis: down-regulation of thrombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras.	ongoing research	3	
3.4.21.78	Whooping Cough	https://pubmed.ncbi.nlm.nih.gov/18571589/	The role of G proteins in thromospondin-1-induced vascular smooth muscle cell migration.	ongoing research	2	
3.4.21.78	Whooping Cough	https://pubmed.ncbi.nlm.nih.gov/16204059/	Oncogenes and Angiogenesis: down-regulation of thrombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras.	unassigned	-	
3.4.21.78	Whooping Cough	https://pubmed.ncbi.nlm.nih.gov/18571589/	The role of G proteins in thromospondin-1-induced vascular smooth muscle cell migration.	unassigned	-	
3.4.21.78	Whooping Cough	https://pubmed.ncbi.nlm.nih.gov/33118159/	Lysophosphatidic acid induces thrombospondin-1 production in primary cultured rat cortical astrocytes.	unassigned	-	
3.4.21.78	Wilms Tumor	https://pubmed.ncbi.nlm.nih.gov/21040752/	Suppression of tumorigenicity of rhabdoid tumor derived G401 cells by the multivalent HB-19 pseudopeptide that targets surface nucleolin.	therapeutic application	1	
3.4.21.78	Wilms Tumor	https://pubmed.ncbi.nlm.nih.gov/21040752/	Suppression of tumorigenicity of rhabdoid tumor derived G401 cells by the multivalent HB-19 pseudopeptide that targets surface nucleolin.	unassigned	-